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Abstract 
 
Autism spectrum disorder (ASD) is a class of complex neurodevelopmental 
disabilities that are characterized by the presence and severity of stereotyped behaviors, 
impaired communication, and abnormal social interactions. The incidence of autism has 
rapidly increased to 1 in 88 children in the United States, making ASD one of the most 
significant medical and social burdens of our time. However, drugs are often used to treat 
autism-related conditions, including anxiety, hyperactivity, epilepsy, and obsessive-
compulsive behaviors, and therapies for treating the core symptoms of autism are limited. 
Moreover, molecular diagnostics are not available for the reproducible identification of 
ASD; as yet, the disorder is diagnosed based on standardized behavioral assessments. 
Much research into ASD has focused on genetic, behavioral, and neurological aspects of 
the illness. However, primary roles for environmental risk factors and peripheral 
disruptions, such as immune dysregulation and gastrointestinal distress, have gained 
significant attention.  
The work described in this thesis uncovers molecular mechanisms involved in the 
pathogenesis of autism-related endophenotypes in a mouse model of a primary autism 
risk factor, maternal immune activation (MIA). MIA is founded upon the strong 
epidemiological link between maternal infection and increased autism risk in the 
offspring. This risk factor can be translated to a mouse model with face and construct 
validity for autism, wherein pregnant mice injected with the immunogenic, double-
stranded RNA poly(I:C) yield offspring with the core behavioral and neuropathological 
features of autism. Specifically, we report that MIA critically alters placental immune 
 v 
status and endocrine function, reflecting a key pathway by which fetal development may 
be disrupted to manifest in ASD-related phenotypes. We identify signature changes to the 
fetal brain transcriptome in response to multiple modes of MIA, highlighting a 
converging pathway involved in the development of autism-related behaviors and 
neuropathologies. We characterize peripheral, neural, and enteric immune alterations in 
MIA offspring and uncover an immune contribution to autism-related behavioral 
abnormalities. Finally we demonstrate that a microbe-based therapeutic can ameliorate 
intestinal pathology, metabolic function, and autism-related behaviors in MIA mice, 
which supports a role for the gut-immune-brain axis in ASD.   
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 Autism spectrum disorder (ASD) is a devastating neurodevelopmental ailment 
that encompasses five distinct conditions: autism, Asperger’s syndrome, Rett syndrome, 
childhood disintegrative disorder and pervasive developmental disorder not otherwise 
specified (PDD-NOS). The disorders are diagnosed based on the presence and severity of 
three core symptoms: impairments in reciprocal social interactions, abnormal 
development and use of language, and repetitive, stereotyped behaviors or insistence on 
sameness. However, ASD is co-morbid with several other neurological symptoms, 
including intellectual disability, epilepsy, anxiety and mood disorders, as well as other 
peripheral symptoms, such as hyperserotonemia, immune dysregulation, and 
gastrointestinal abnormalities. The prevalence of autism has risen to 1 in 88 children in 
the United States, with males being more susceptible than females. The causes of autism 
are largely unknown, but are believed to originate from a combination of genetic and 
environmental risk factors. Several rare, single gene mutations have been associated with 
autism, including those affecting genes like SHANK3, CNTNAP2 and MET, and 
environmental risk factors, such as the use of the teratogens valproic acid and 
thalidomide during pregnancy and the focus of my doctoral research, maternal immune 
activation (MIA), have been shown to increase the risk for features of autism in the 
offspring.  
 Maternal infection is a principal non-genetic cause of autism. Several large 
epidemiological studies have linked maternal infection during pregnancy with elevated 
risk for autism in the offspring. After the 1964 Rubella pandemic, 8-13% of children born 
to infected mothers developed features of autism, representing an over 200-fold increase 
in incidence of autism at the time. In a recent seminal study that included all children 
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born in Denmark from 1980 to 2005, a very significant association was found between 
autism and maternal viral infection during the first trimester of pregnancy. A similar 
association was found in another large study that included all residents of Stockholm 
County, Sweden from 2001-2007, where an analysis of over 4000 autism cases found a 
significant association between autism and maternal hospitalization for infection. By 
modeling this primary autism risk factor in mice, we are able to recapitulate the core 
behavioral and neuropathological of features of autism with face and construct validity. 
Studying these mice, which display clinically relevant features of autism, offers the 
unique potential to uncover the molecular mechanisms involved the pathogenesis of 
autism endophenotypes, and to further use this information toward the development of 
novel treatments for core behaviors and symptoms relevant to human autism.  
 The doctoral research presented in the following chapters can be broadly 
classified under three primary questions in the field of autism research: i) what causes 
autism?, ii) how is autism related to its co-morbid conditions?, iii) how can autism be 
treated? In Chapters 6-8, we trace the early molecular responses that mediate the effects 
of MIA on fetal development. In Chapters 4, 8 and 9 we characterize the later-life 
consequences of MIA on brain and behavior. In Chapters 11 and 12, we highlight 
immune dysregulation and gastrointestinal dysfunction as conditions that are highly co-
morbid with autism, and we address the question of whether these co-morbidities 
contribute to the pathogenesis of autism-related endophenotypes. Finally in Chapter 12 
we present data demonstrating that a microbe-based treatment ameliorates autism-related 
gastrointestinal disruptions, metabolome changes and behavior in MIA offspring.  
 Chapter 2 introduces autism as a complex neurodevelopmental disability and 
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provides a detailed overview of genetic, environmental and lesion models for autism, in 
addition to background on how features of autism are modeled in rodents. This content 
was published in 2011 in Autism Spectrum Disorders (Oxford University Press, Eds. 
Amaral DG, Dawson G, Geschwind DH). Chapter 3 discusses maternal infection as a risk 
factor for autism and schizophrenia, along with the several different animal models of 
maternal infection that are used to recapitulate features of autism and schizophrenia in 
rodents. This text was published in 2010 in Maternal Influences on Fetal 
Neurodevelopment: Clinical and Research Aspects (Humana Press, Eds. Zimmerman 
AW, Connors SJ).  
 Chapter 4 introduces the animal model of maternal infection that is used as a basis 
for the majority of my doctoral research. We show that offspring of poly(I:C)-injected 
mothers exhibit the three core diagnostic features of human autism: deficient 
communication, decreased social interaction and increased stereotyped behavior. This 
validates this poly(I:C) paradigm as a mouse model with face and construct validity for 
autism. The content was published in Brain, Behavior and Immunity in 2012.  
 Chapter 5 highlights the placenta as a key regulator of maternal-fetal interactions 
during pregnancy and reviews literature supporting a role for placental dysfunction in 
altering neurodevelopment. This serves as a preface to Chapter 6, in which we 
demonstrate that the cytokine IL-6, found to be a critical mediator of the effects of MIA 
on the development of autism-related behaviors in the offspring, regulates placental 
immune status and endocrine function. Interestingly, IL-6 action is necessary to drive the 
direct transfer of the MIA response to fetally-derived cells in the placenta. The review 
was published in Developmental Neurobiology in 2012 and the primary research article 
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was published in Brain, Behavior and Immunity in 2011.  
 Chapter 7 addresses the role of MIA on gene expression in the fetal brain and 
uncovers a converging molecular pathway common among three different modes of MIA. 
This transcriptome signature involves activation of crystalline family genes, which may 
trigger further molecular responses leading to impaired neurodevelopment in MIA 
offspring. This work was published in 2012 in Translational Psychiatry. Chapter 8 
provides further evidence of early life alterations in brain development in MIA offspring, 
demonstrating that MIA neonates experience global changes in brain cytokines. Cytokine 
alterations are also observed at different time points and different brain regions in MIA 
versus control offspring. These results were published in 2012 in Brain, Behavior and 
Immunity. Chapter 9 reflects earlier work demonstrating alterations in hippocampal 
synaptic strength and plasticity in MIA versus controls, which correspond to alterations 
in nonspatial information processing. This work appeared in Brain, Behavior and 
Immunity in 2010. 
  In Chapter 10, we discuss increasing evidence supporting a role for immune 
dysregulation in ASD. We review the striking abnormalities observed in the neural, 
peripheral and enteric immune systems of autistic individuals, and explore how these 
changes could impact brain function. This serves as a preface to Chapter 11, wherein we 
report that MIA offspring, in addition to displaying the core behavioral and 
neuropathological features of autism, also exhibit autism-related immune abnormalities 
that suggest a pro-inflammatory-like state. Importantly, we explore whether these 
immune abnormalities contribute toward the development or persistence of autism-
related behaviors in MIA offspring, by utilizing bone marrow transplants to reconstitute 
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immunity in immunologically-abnormal mice. Importantly, we provide evidence 
supporting the notion that immune changes in autism can contribute to primary 
behavioral features of the disorder. This work was published in PNAS in 2012, and the 
review in Chapter 10 is now in press in Autism Open Access. 
 In Chapter 12, we explore the use of a probiotic treatment, known to impact 
immune parameters in other disease models, to correct immune abnormalities in MIA 
offspring. Remarkably, we find that treatment with the human commensal Bacteroides 
fragilis corrects autism-related behaviors in MIA offspring. Surprisingly, however, this 
beneficial effect is not mediated by changes in immune status. This led us to uncover an 
autism-related gastrointestinal phenotype in MIA offspring, characterized by increased 
intestinal permeability and altered gut cytokine levels, in addition to a metabolic 
phenotype in MIA offspring involving global serum metabolome changes. Overall, we 
find that microbial treatment alters the composition of the gut microbiome in MIA 
offspring, which is associated with improvements in gastrointestinal physiology, changes 
in the systemic metabolome and amelioration of autism-related behaviors. This provides 
compelling evidence for a probiotic-based treatment for symptoms relevant to human 
autism. This work has been submitted for publication. 
 Finally, the appendices include preliminary research findings that are relevant to 
much of the research discussed in the primary chapters. Appendix A reflects experiments 
that explore the prenatal programming of placental hematopoietic stem cells as a basis for 
the persistent immune abnormalities observed in MIA offspring, as described in Chapter 
11. Appendix B demonstrates that MIA leads to induction of the cytokine IL-6 in the fetal 
brain, and that basal levels of many brain cytokines depend on maternal IL-6 signaling.  
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Appendix C provides additional immune characterization of adult MIA offspring that was 
not included in the publication from Chapter 11. Appendix D assesses intestinal 
permeability and behavioral changes in a mouse model of early postnatal colitis, 
demonstrating that increased intestinal permeability itself is not sufficient to drive the 
autism-related changes in behavior reported in Chapter 12. In Appendix E, we provide 
preliminary data supporting a role for the commensal microbiota itself to contribute to 
communicative and sensorimotor behavior in wild-type mice. Lastly, in Appendix F, we 
explore a potential gene x environment interaction between two autism-related 
susceptibility factors: MHCI polymorphisms and maternal infection.  
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Abstract 
 
A variety of features of autism have been reproduced in rodents, including several 
hallmarks of abnormal behavior such as neophobia, deficits in social interactions, 
communication, stereotyped and repetitive motor behaviors, enhanced anxiety, abnormal 
pain sensitivity and eye blink conditioning, disturbed sleep patterns, seizures, and deficits 
in sensorimotor gating. There is also neuropathology that is frequently seen in autism 
such as a spatially restricted Purkinje cell deficit, as well as characteristic neurochemical 
changes (serotonin) and alterations in the immune status in the brain and periphery. 
Several known environmental risk factors for autism have been successfully established 
in rodents, including maternal infection and valproate administration, and genetic models 
are being produced that attempt to mimic some of the genetic variants associated with 
autism. There are also a few lesion models. This chapter critically reviews these various 
types of models, highlighting those with face and/or construct validity, and noting the 
potential for investigation of pathogenesis and therapies. 
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Points of interest 
 
• A number of abnormal behaviors found in autism can be produced in rodent 
models. None of these behaviors are specific for autism, however. 
 
• Human disorders caused by single-gene mutations that exhibit features of autism 
provide proof-of-principle for the role of genetics in autism. Similarly, studies 
showing that maternal thalidomide, valproate, or infection can increase the risk 
for features of autism in the offspring provide proof-of-principle for the role of 
environmental factors. Both the environmental and genetic factors can be very 
effectively modeled in mice. 
 
• Certain neuropathologies that are relatively common in autism can be 
reproduced in rodent models. 
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Introduction 
Animal models of many neurological diseases (Alzheimer’s, Parkinson’s, Huntington’s, 
multiple sclerosis) have proven enormously useful for determining the roles of genes and 
environment, for understanding pathogenesis, and for testing potential therapeutic 
approaches. There is some skepticism, however, concerning models of psychiatric or 
mental illnesses (e.g., autism, schizophrenia, depression). After all, can cognitive 
abnormalities or language deficits be detected in animals? However, to give up on this 
approach would deny the application of powerful genetic and molecular tools to these 
critical illnesses. Moreover, animal models need not be perfect mimics of human diseases 
to be valuable. This is clear from the extensive and productive use of genetic mouse 
models for Huntington’s and other neurodegenerative diseases, which do not exhibit the 
severe loss of particular types of neurons that characterize these disorders. The power of 
animal models is in the examination of key features of a disease, and the relevance of an 
animal model should be judged by how well it reflects one or more features of that 
disease, which may include genetics, neuropathology, behavior, etiology, 
electrophysiology, or molecular changes. 
Autism is a particularly difficult case for animal studies because it has a 
heterogeneous behavioral phenotype, the susceptibility genes have not been firmly 
identified, and it does not have a pathognomonic histology that allows definitive 
diagnosis. Nonetheless, autism does have generally agreed upon features that are 
distinctive, such as a deficit of Purkinje cells (PCs), decreased hippocampal γ-
aminobutyric acid (GABA-A) receptors, and elevated levels of brain-derived 
neurotrophic factor (BDNF) and platelet serotonin (5-HT) (Palmen et al., 2004; Pardo & 
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Eberhart, 2007; Amaral et al., 2008). There is also striking evidence for immune 
dysregulation in the autistic brain and cerebrospinal fl uid (Pardo et al., 2006; Arion et 
al., 2007; Chez et al., 2007; Pardo & Eberhart, 2007; Morgan et al., 2010). Moreover, 
some of the characteristic behavioral features of autism can be assayed in animals, such 
as neophobia, abnormal social interactions, stereotyped and repetitive motor behaviors, 
communication deficits (ultrasonic vocalizations; USVs), enhanced anxiety, abnormal 
pain sensitivity, disturbed sleep patterns, abnormal eye blink conditioning, and deficits in 
sensorimotor gating (prepulse inhibition; PPI) (Silverman et al., 2010). 
Although autism has a strong genetic basis, it is not a monogenic disorder, and 
thus it is not possible to establish an immediately relevant genetic mouse model, as was 
done with Huntington’s disease. Nonetheless, there are several genetic changes that do 
entail an elevated risk for autism, and mouse models of these changes share some 
features with the human disorder. There are also several human disorders caused by 
single gene mutations that display autistic features and mouse mutants of these mutations 
display behavior or neuropathology relevant to autism. In addition, models based on 
autism etiology are valuable, and there are several known environmental risk factors that 
are being successfully modeled in rodents. Finally, there are brain lesion models of 
interest. Therefore, even at this early stage of analysis, it is clear that various models can 
be used to study how particular genes influence certain autism endophenotypes, and how 
known environmental risk factors influence such endophenotypes. It will also be 
interesting to determine how a particular genotype influences the response to an 
environmental risk factor, and vice versa. There are currently very few examples of such 
gene-environment interactions in mouse models. This chapter discusses current genetic, 
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environmental risk factor and lesion models. Several other authors have reviewed various 
aspects of animal models related to autism (Murcia et al., 2005; Tordjman et al., 2007; 
Moy & Nadler, 2008). 
 
Environmental manipulations 
Thalidomide and valproic acid 
Prenatal or early postnatal drug exposure can increase autism risk. Comorbidity of 
Moebius syndrome and autism support a correlation between autism and the use of the 
prostaglandin misoprostol, a drug historically administered for labor induction or 
abortion (Miller et al., 2004). Case studies of fetal alcohol syndrome also suggest that 
prenatal exposure to ethanol increases risk for autism (Nanson, 1992). Perhaps most 
clearly associated with autism, however, are the teratogens thalidomide (Stromland et al., 
1994) and valproic acid (VPA; valproate) (Christianson et al., 1994). Not only can these 
drugs cause an array of birth defects, they also increase the incidence of autism when 
administered early in human pregnancy (Miyazaki et al., 2005). 
The use of thalidomide led to the discovery of a window of vulnerability for the 
development of autism (Fig. 52.1). During the 1950s and 60s, thalidomide treatment of 
morning sickness resulted in thousands of offspring with severe malformations. Since the 
timing of drug exposure leads to specific types of craniofacial defects, the defects seen in 
the autistic offspring could be used to determine when these offspring were exposed. In 
this way, vulnerability to autism was pinpointed to days 20 to 24 of gestation, the time of 
neural tube closure and formation of motor nuclei and cranial nerves. Importantly, there 
is some evidence that idiopathic autism cases may also exhibit abnormalities in the 
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cranial nerve nuclei and other neuropathologies that originate during fetal brain 
development (Schneider & Przewlocki, 2005; Palmen et al., 2004). 
A few laboratories have translated maternal thalidomide exposure into rodent 
models. Exposure of rats to thalidomide on embryonic day 9 (E9) yields adult offspring 
with hyperserotonemia in the plasma (as in autism), hippocampus, and frontal cortex 
(Narita et al., 2002), with altered distribution of serotonergic neurons in the raphe nuclei 
(Miyazaki et al., 2005). These offspring also display hyperactivity in the open field and 
decreased learning in the radial maze (Narita et al., 2010). Exposure on E15 inhibits 
vasculogenesis and alters cortical and hippocampal morphology (Fan et al., 2008). 
Furthermore, daily maternal injection of rats from  E7 to E18 yields adult offspring with 
altered learning and memory as measured by increased errors and latency in the 
Cincinnati water maze (Vorhees et al., 2001). Clearly, much more could be done with this 
model to establish its relevance for autism.  
Because VPA retains its teratogenicity in rodents, its administration during the 
time of neural tube closure has proven useful as a rodent model. VPA was fi rst 
introduced in the 1960s as an anticonvulsant and later as a mood-stabilizing drug for 
treatment of epilepsy and bipolar disorder (Markram et al., 2007). Like thalidomide, use 
of VPA during early human pregnancy significantly elevates the incidence of autism and 
the development of craniofacial defects in exposed offspring. Both case and 
epidemiological studies have confirmed the association between fetal valproate syndrome 
and autism (Hyman et al., 2006; Fan et al., 2008). Although women who are prescribed 
VPA for treatment of epilepsy often take the drug throughout pregnancy, it is unclear 
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whether brain regions other than the brain stem are vulnerable to VPA insult at later 
stages of development (Rinaldi et al., 2007a). 
In animal studies, a single injection of VPA in a pregnant rat results in striking 
neuropathology and behavioral abnormalities. Offspring of rats injected with VPA show 
brain defects resembling those sometimes found in autism, including reduced number of 
motor nuclei and PCs (Schneider & Przewlocki, 2005), hyperserotonemia, and 
disorganized migration of 5-HT neurons in the dorsal raphe nuclei (Miyazaki et al., 
2005). Fetuses from VPA-injected mothers display hypoplasia of the cortical plate, 
abnormal migration of dopaminergic and serotonergic neurons, and abnormal pons 
pathology (Kuwagata et al., 2009). VPA is a histone deacetylase inhibitor that is thought 
to impede neuronal differentiation and migration by interfering with the sonic hedgehog 
signaling pathway. 
Interestingly, offspring of rats injected with VPA on E12.5 develop behavioral 
abnormalities that appear before puberty, a feature that distinguishes this model from 
behavioral changes seen in schizophrenia (Schneider & Przewlocki, 2005). VPA 
offspring display lower sensitivity to pain and higher sensitivity to nonpainful sensory 
stimuli, which parallels reported changes in endogenous opioid systems in some autistic 
patients. These offspring also exhibit impaired sensorimotor gating as measured by 
acoustic PPI, elevated anxiety as evidenced by decreased open field exploration, 
increased stereotypic/ repetitive activity, decreased social interaction,  impaired reversal 
learning, and altered eyeblink conditioning patterns, and enhanced fear memory 
processing, all of which are consistent with results in autistic children (Stanton et al., 
2007; Murawski et al., 2008; Markram et al., 2008; Dufour-Rainfray et al., 2010; Roullet 
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et al., 2010) (Table 52.1). A sexual dimorphism has been reported for some of these 
parameters, with abnormalities seen only in male offspring, which is also consistent with 
the very significant male bias in autism (Schneider et al., 2008). It will also be interesting 
to look for communication deficits (USVs) in this model. 
Electrophysiological studies indicate that offspring of VPA treated mothers 
exhibit abnormal microcircuit connectivity in the neocortex and amygdala. Exposure to 
VPA results in overexpression of CaMKII and the NR2A and NR2B NMDA receptor 
subunits in the neocortex (Rinaldi et al., 2007b). These observations are consistent with 
observed increases in NMDA receptor-mediated synaptic transmission and enhanced 
postsynaptic long-term potentiation in neocortical pyramidal neurons. Adult VPA 
offspring also show increased connection probability of layer 5 pyramidal cells but 
decreased excitability and decreased putative pyramidal cell synaptic contacts (Rinaldi et 
al., 2008). These results relate to MRI studies showing impaired long-range functional 
connectivity in autistic individuals (Just et al., 2004).  
Recordings from neurons in the lateral amygdaloid nucleus demonstrate hyper-
reactivity to electrical stimulation, elevated long-term potentiation and impaired stimulus 
inhibition that may contribute to the deficient fear extinction and high anxiety seen in 
VPA offspring (Markram et al., 2008). These results suggest molecular and synaptic 
alterations in VPA mice that are relevant for the alterations in amygdala morphology 
observed in autism (Amaral et al., 2008). Dysfunction in the amygdala may contribute to 
the decreased social interaction and/or abnormal fear processing characteristic of autistic 
pathology (Markram et al., 2008). While deficits in social play and exploration have been 
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reported in VPA rodent offspring (Schneider et al., 2008), an important gap in the 
behavioral analysis of social interaction is in the analysis of social preference and USVs.  
Although the mechanisms underlying the effects of prenatal VPA on fetal brain 
development are largely unknown, neural inflammation and gene regulation could be 
involved. Immunological alterations have been reported in offspring of VPA-treated 
mice, (Schneider et al., 2008; Bennett et al., 2000), and in vitro studies indicate that VPA 
promotes astrocyte proliferation, inhibits microglial and macrophage activation, and 
induces microglial apoptosis (Peng et al., 2005; Dragunow et al., 2006). This is consistent 
with the finding that VPA can regulate epigenetic modifi cations through three 
mechanisms: inhibiting histone deacetylases, enhancing histone acetylation, and 
promoting demethylase activity (Chen et al., 2007). The ability of VPA to alter HOX 
gene expression is particular interest, as HOXa1 is expressed during the time of neural 
tube closure and regulates development of the facial nucleus and superior olive (c.f., 
Finnell et al., 2002). Moreover, VPA treatment may actually promote neurogenesis of 
GABAergic neurons and facilitate neurite outgrowth (Dragunow et al., 2006). These 
neuroprotective effects occur after chronic VPA treatment rather than the acute exposure 
administered in the maternal VPA model, however (Hao et al., 2004; Ren et al., 2004). 
Although maternal VPA and thalidomide exposure are responsible for only a 
small fraction of autism cases, the extremely high risk for autism in the offspring 
provides proof-of-principle for environmental influences on autism incidence. Moreover, 
the similarities in neuropathology and behavior between the rodent models and human 
autism support the utility of environment-based models for defining relevant pathways of 
developmental dysregulation. It will be important to extend the VPA model to mice 
 18 
carrying genetic variants associated with increased risk for autism, which would provide 
a test of the gene x environment paradigm. Interestingly, prenatal VPA exposure has been 
linked to altered expression of neuroligin3, a genetic susceptibility factor for autism 
(Kolozsi et al., 2009). 
 
Maternal Infection 
Maternal infection is an environmental risk factor for the development of several 
neuropsychiatric disorders in the offspring. As is the case for schizophrenia (Patterson, 
2007; Brown & Derkits, 2020), maternal viral infection is linked to higher incidence of 
autism by clinical, epidemiological, and case studies. Early evidence for this came from 
the 1964 rubella pandemic, in which the incidence of autistic features was increased more 
than 200-fold in the offspring of infected mothers (Chess, 1977). Case studies have 
linked autism to several other prenatal viral infections, including varicella, rubeola, and 
cytomegalovirus (Ciaranello & Ciaranello, 1995). Bacterial and protozoan infections 
have also been associated with autism (Nicolson et al., 2007; Bransfield et al., 2008). The 
most compelling evidence linking maternal infection with autism comes from a very 
large study utilizing the Danish Medical Birth Register. An examination of over 10,000 
autism cases found a very significant association with maternal viral infection in the first 
trimester (Atladottir et al., 2010). In sum, the diversity of micro-organisms implicated in 
autism, along with the fact that several of these infections do not involve direct 
transmission into the fetus, suggests that the maternal immune response, rather than 
microbial pathogenesis, is responsible for increasing the risk for autism in the offspring 
(Fig. 52.2). Animal models of maternal infection further support the idea that maternal 
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immune activation (MIA) and the production of pro-inflammatory cytokines are what 
unite the various types of maternal infection as risk factors for autism. There are three 
primary rodent models for MIA: maternal influenza infection, poly(I:C) injection, and 
lipopolysaccharide (LPS) injection. 
Pregnant mice intranasally infected with influenza yield offspring with behavioral 
and neuropathological abnormalities that parallel those seen in autism. Abnormal 
behaviors include heightened anxiety during open-field exploration, deficient PPI, 
decreased novel object exploration, and reduced social interaction (Shi et al., 2003). 
These offspring display spatially selective PC loss in lobules VI and VII (Fig. 52.3) (Shi 
et al., 2009), which is a common neuropathology in autism (Palmen et al., 2004; Amaral 
et al., 2008). There is also macrocephaly, delayed cerebellar granule cell migration, 
reduced Reelin immunoreactivity in the cortex, thinning of the neocortex and 
hippocampus, and altered expression of neuronal nitric oxide synthase and synaptosome-
associated protein-25 (Fatemi et al., 2002; Shi et al., 2009). Infection on E16 or E18 
causes altered expression of several genes associated with autism, white matter thinning 
in the corpus callosum, widespread brain atrophy, and altered levels of cerebellar 5-HT 
but not dopamine (Fatemi et al., 2008, 2009; Winter et al., 2008). 
Because maternal influenza infection is largely confined to the respiratory tract, it 
is unlikely that these neurological defects are caused by direct viral infection of the fetus. 
There are, however, conflicting reports as to whether viral mRNA or protein is present in 
fetal tissues (Aronsson et al., 2002; Shi et al., 2005). Nonetheless, the fact that 
stimulating the maternal immune system with poly(I:C) (mimicking viral infection) and 
LPS (mimicking bacterial infection) causes neuropathogical and behavioral defects in the 
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offspring similar to those seen with maternal influenza infection supports the idea that 
MIA is the causative event, as no pathogen is required. Poly(I:C) is a synthetic, double-
stranded RNA that generates an antiviral immune response in the absence of virus. 
Depending on the dosage, mode of injection (intraperitoneal or intravenous) and timing 
of maternal poly(I:C) administration, offspring display deficits in PPI, latent inhibition, 
open field exploration, working memory, social interaction and USVs, while reversal 
learning and amphetamine-induced locomotion are enhanced (Shi et al., 2003; 
Zuckerman et al., 2003, 2005; Lee et al., 2007; Meyer et al., 2007; Smith et al., 2007; 
Winter et al., 2009; Malkova & Patterson, 2010). A single poly(I:C) injection also causes 
histopathological changes similar to those seen in autism, including increased GABAA 
receptor, spatially-restricted reduction in PCs, and delayed myelination, and decreased 
cortical neurogenesis (Nyffeler et al., 2006; Shi et al., 2009; Makinodan et al, 2008; De 
Miranda et al., 2010). A cardinal pathology in schizophrenia, enlarged lateral ventricles, 
is also observed (Li et al., 2009; Piontkewitz, Assaf, & Weiner, 2009). In addition, there 
is evidence of physiological abnormalities in the hippocampus. In slices from adult 
offspring of poly(I:C)-treated mothers, oscillations in CA1 are less rhythmic than in 
controls, and CA1 pyramidal neurons display reduced frequency and increased amplitude 
of miniature excitatory postsynaptic currents. Differing results have been reported 
regarding a deficit in long term potentiation (Ito et al, 2010; Oh-Nishi et al., 2010). 
Interestingly, the specific component of the temporoammonic pathway that mediates 
object-related information displays significantly increased sensitivity to dopamine (Lowe 
et al., 2009; Ito et al., 2010). There are a few studies describing abnormal dopamine 
levels in autism (Previc, 2007), and a variety of changes in dopamine are found in the 
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maternal poly(I:C) model (Zuckerman et al., 2003; Ozawa et al., 2006; Meyer et al., 
2008a). However, whether dysregulation of the dopaminergic system is an important 
feature of autism is unknown. Dopamine pathology is very important in schizophrenia, 
where maternal infection is also a risk factor. Another finding consistent with both 
schizophrenia and autism is a disruption in long-range synchrony of neuronal firing. 
Adult MIA offspring display significant reduction in medial prefrontal cortex-
hippocampal EEG coherence (Dickerson, Wolff & Bilkey, 2010). 
Further supporting the role of MIA in altering fetal brain development is the use 
of maternal LPS injection to simulate bacterial infection. Although poly(I:C) and LPS act 
through different toll-like receptors, their effects on the behavior and brain pathology in 
offspring often overlap. For example, a single injection of LPS in a pregnant rat yields 
offspring with elevated anxiety, aberrant social behavior, reduced play behavior and 
USVs, reduced PPI, enhanced amphetamine-induced locomotion, and abnormal learning 
and memory (Borrell et al., 2002; Fortier et al., 2004; Golan et al., 2005; Hava et al., 
2006; Basta-Kaim et al., 2010; Baharnoori et al., 2010; Hao et al., 2010; Kirsten et al., 
2010), many of which parallel behaviors seen in autism. There is also evidence of 
hyperactivity in the hypothalamus-pituitary-adrenal axis in the LPS offspring, and some 
of the abnormal behaviors can be reversed by anti-psychotic drug treatment (Basta-Kaim 
et al., 2010), as is the case for the poly(I:C) offspring. Recall that maternal infection is a 
risk factor for schizophrenia as well as autism. 
Histological findings include smaller, more densely packed neurons in the 
hippocampus, increased numbers of pyknotic cells in the cortex, fewer tyrosine 
hydroxylase-positive (TH+) neurons in the substantia nigra, and increased TH+ cells in 
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the nucleus accumbens (Golan et al., 2005; Ling et al., 2004; Borrell et al., 2002). Further 
studies indicate that changes in dendritic length, dendritic branching, spine structure, and 
spine density in the medial prefrontal cortex and hippocampus, suggesting dysregulated 
neuronal connections formed during embryogenesis (Baharnoori et al., 2008). Some of 
these effects, including increased cell density and limited dendritic arbors in the 
hippocampus, have been found in MRI and post mortem brain studies in autism (Amaral 
et al., 2008). Electrophysiological recordings reveal reduced synaptic input to CA1 of the 
hippocampus, heightened excitability of pyramidal neurons, enhanced postsynaptic 
glutamatergic response, and impaired NMDA-induced synaptic plasticity (Lowe et al., 
2008; Lante et al., 2008). Interestingly, many of these effects are prevented by 
pretreatment of pregnant rats with N-acetyl-cysteine (Lante et al., 2008), which increases 
calcium influx when binding to glutamate receptors in combination with the transmitter. 
Brain imaging studies of the hippocampus and of particular neurotransmitter systems in 
autism have yielded inconsistent results, so no definite statement can be made about their 
exact roles in autism (Palmen et al., 2004). 
In addition to the behavioral deficits and neuropathology, the MIA models also 
share with autism dysregulation of immune status in the brain. Post mortem brain and 
cerebrospinal fluid samples from autistic individuals exhibit marked astrogliosis, 
microglial activation, dysregulation of immune-related genes, and high levels of pro-
inflammatory cytokines and chemokines (Vargas et al., 2005; Garbettet al., 2008; Chez et 
al., 2007; Tetreault et al., 2009; Patterson, 2009). Although LPS itself does not cross the 
placental barrier, maternal LPS injections yield offspring with MHC II induction along 
with increased GFAP and microglial staining in various adult (Borrell 2002; Ling et al., 
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2004) and fetal (Paintlia et al., 2004) brain regions. While several cytokines are elevated 
in the placenta and amniotic fluid after MIA, mRNA transcripts for a number of 
cytokines are also elevated in the fetal brain following maternal LPS or poly(I:C) 
(Urakubo et al., 2001; Cai et al., 2000; Paintlia et al., 2004; Liverman et al., 2006; Golan 
et al., 2005; Meyer et al., 2008b; Elovitz et al., 2006; E. Hsiao & P.H. Patterson, 
unpublished). The importance of cytokines as soluble mediators of the effects of MIA on 
fetal brain development was demonstrated using cytokine knockout (KO) mice and mice 
injected with recombinant cytokines or cytokine-neutralizing antibodies. Interleukin (IL)-
6 is necessary and sufficient for mediating the effects of MIA on the development of 
neurological, behavioral, and transcriptional changes in poly(I:C)-exposed offspring (Fig. 
52.2; Samuelsson et al., 2006; Smith et al., 2007). In a converse approach, overexpression 
of the anti-inflammatory cytokine IL-10 suppresses the effects of maternal poly(I:C) on 
the fetus (Meyer et al., 2008c). Perturbation of IL-10, IL-1, or TNFa can also 
significantly influence the outcome of MIA in the LPS MIA model (Girard et al., 2010; 
reviewed in Patterson, 2011). 
How cytokines induced by MIA alter the course of fetal brain development is 
largely unknown. The most obvious possibility is by direct action on the developing 
brain, as both cytokines and chemokines are key modulators of astrogliosis, neurogenesis, 
microglial activation, and synaptic pruning (Bauer et al., 2007; Deverman & Patterson, 
2009), and some maternal cytokines have been reported to cross the placenta (Dahlgren et 
al., 2006; Zaretsky et al., 2004). A second possibility is that MIA alters the endocrine 
function and/or the immunological state of the placenta. In fact, poly(I:C) MIA increases 
maternally-derived IL-6 protein as well as IL-6 mRNA in the placenta. Such placentas 
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exhibit increases in CD69+ decidual macrophages, granulocytes and uterine NK cells, 
indicating elevated early immune activation. Moreover, maternally-derived IL-6 mediates 
activation of the JAK/STAT3 pathway in the placenta, which parallels an IL-6-dependent 
disruption of the growth hormone-insulin-like growth factor axis (E. Hsiao & P. H. 
Patterson, unpublished data). Such endocrine changes could affect the development of the 
fetal brain and immune system, with permanent consequences. It is notable that a greater 
occurrence of placental trophoblast inclusions is observed in placental tissue from births 
of children who develop autism spectrum disorder compared to non-ASD controls 
(Anderson et al., 2007). Moreover, chorioamnionitis and other obstetric complications are 
significantly associated with socialization and communication deficitis in autistic infants 
(Limperopoulos, 2008).  
In this context, it is of interest that several studies have reported that the sera of 
some mothers of autistic children contain antibodies that bind fetal human, monkey, or 
rat brain antigens (Zimmerman et al., 2007; Braunschweig et al., 2008; Martin et al., 
2008). Most relevant to this review is the further finding that injection of such maternal 
sera into pregnant mice (Dalton et al., 2003) or purified maternal IgG into pregnant 
Rhesus monkeys (Martin et al., 2008) yields offspring with several behavioral 
abnormalities, including hyperactivity and stereotopies in the case of the monkeys. That 
something is different about the immune system of in the mothers of autistic offspring is 
further supported by the observation that these mothers are more likely to have a history 
of autoimmune disease or asthma (e.g., Altadottir et al., 2009). There is also evidence that 
the peripheral immune system of autistic subjects is abnormal (Pardo & Eberhart, 2007; 
Enstrom, Van de Water, & Ashwood, 2009). In that light it is interesting that, compared 
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to controls, CD4+ T cells from the spleen and mesenteric lymph nodes of adult mouse 
MIA offspring display significantly elevated IL-6 and IL-17 responses to in vitro 
stimulation (Hsiao et al., 2010; Mandal et al., 2010). Furthermore, adult MIA offspring 
display reduced T cell responses to CNS-specific antigens, despite elevated proliferation 
of nonspecific T cells (Cardon et al., 2009).  
Although it is commonly stated that autism can result from an environmental 
stimulus acting on a susceptible genetic background, there is little support for this 
hypothesis thus far. Thus, it is of interest that mice heterozygous for the tuberous 
sclerosis 2 (TSC2) gene display a social interaction deficit only when they are born to 
mothers treated with poly(I:C) (Ehninger et al., 2010). That is, this deficit is most severe 
when the MIA environmental risk factor is combined with a genetic defect that, in 
humans, also carries a very high risk for ASD. In addition, there is an excess of TSC-
ASD individuals born during the peak influenza season, an association that is not seen for 
TSC individuals not displaying ASD symptoms (Ehninger et al., 2010).  
 
Postnatal Vaccination 
Although there is currently no convincing evidence that postnatal vaccination is a 
cause of autism, the occasional coincidence in the timing of routine childhood 
immunizations with the appearance of autistic symptoms continues to fuel public 
concern. The measles-mumps-rubella (MMR) vaccine is of particular interest because of 
the use of live, attenuated virus, but there are currently no rodent models for the effects of 
MMR on neural development. Moreover, many epidemiological studies have failed to 
substantiate a connection between MMR vaccination and autism (DeStefano, 2007). 
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There has been investigation of the effects of thimerosal-containing vaccines 
(TCVs) on neurodevelopment in rodents. Increased mercury burden from this sodium 
ethylmercurithiosalicylate preservative is of concern because of known neurotoxic 
properties of methylmercurials. One study reported that immunogenetic factors can 
render mice susceptible to thimerosal-induced neurotoxicity (Hornig et al., 2004). The 
autoimmune-prone SJL/J (H-2s) strain developed neuropathology and abnormal 
behavior. However, a recent study failed to replicate the histological and behavioral 
results (Berman et al., 2008). This latter paper is consistent with several epidemiological 
studies failing to support a link between thimerosal and autism (Andrews et al., 2004; 
Schechter & Grether, 2008; Gerber & Offit, 2008 Price et al., 2010). 
 
Terbutaline 
The b2 adrenergic receptor is expressed early in fetal brain development, and its 
activation affects cell proliferation and differentiation. Terbutaline is a selective b2 
adrenergic receptor agonist that is used to relax uterine smooth muscle to prevent 
premature labor and birth. A study of dizygotic twins found an increased rate of 
concordance for autism if the mother was given terbutaline for 2 weeks (Conners et al., 
2005). Further implicating the  b2 adrenergic receptor is the finding that certain 
functional variants of this gene are associated with increased risk for autism (Cheslack-
Postava et al., 2007). In modeling this risk factor in rats, neonates are given subcutaneous 
injections of terbutaline daily, from postnatal days 2 through 5, a time meant to mimic the 
stage of human brain development at which the drug is given. A significant deficit in PCs 
was found, but no mention of any spatial restriction of this change was made. 
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Histological changes were reported in the hippocampus and somatosensory cortex as 
well, including microglial activation in cortex and cerebellum (Rhodes et al., 2004; 
Zerrate et al., 2007). Also of interest in terms of autism is a finding of increased 5-HT 
turnover (Slotkin & Seidler, 2007). Behavioral analysis of this model is somewhat 
disappointing thus far, with female-specific hyperactivity and no change in PPI (Zerrate 
et al., 2007). 
 
Genetic Manipulations 
 
X-Linked and Autosomal Lesions 
Fmr1 Knockout Mice 
Fragile X Syndrome (FXS) is an X-linked condition that is the leading genetic 
cause of mental retardation (Hatton et al., 2006). It is caused by the loss of expression of 
FMRP, an mRNA-binding protein that is highly expressed in hippocampal and cortical 
synapses, where it regulates translation of its target mRNAs and thus plays a key role in 
protein synthesis-dependent functions (Bassell & Warren, 2008). It is estimated that 90% 
of FXS patients present some autistic-like behaviors, and that 15% to 33% meet the full 
diagnostic criteria of autism (Cohen et al., 1988; Bailey et al., 1998). Overall, FXS 
accounts for about 5% of the autistic population (Li et al., 1993). Fmr1 KO mice display 
some anatomical features of FXS, such as macro-orchidism and abnormal dendritic 
development and morphology (The Dutch-Belgian Fragile X Consortium, 1994), and 
spines are altered in idiopathic autism (Zoghbi, 2003). These mice also display some core 
behavioral features relevant to autism, including impaired social interaction 
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(McNaughton et al., 2008) and repetitive behaviors. Whether they display learning and 
memory deficits is unclear (Dobkin et al., 2000; Frankland et al., 2004), and whether they 
show other autism-related symptoms such as anxiety and hyperactivity depends on the 
genetic background (Bernardet & Crusio, 2006). The observations that both cognitive 
performance and behaviors relevant to autistic traits are affected by genetic background is 
of interest given the genetic variability in humans and the phenotypic heterogeneity in 
FXS. Although overall resemblance to autism is partial, the presence of two core features 
of autism indicates that molecular investigation of Fmr1 KO mice may further our 
understanding of the genetic etiology of FXS and autistic traits. 
The signaling pathways for metabotropic glutamate receptor 5 (mGluR-5) and 
PAK, a kinase involved in actin remodeling and regulation of synapse structure, represent 
two plausible therapeutic targets for FXS and autism. A 50% reduction of mGluR-5 
expression in Fmr1 KO mice normalizes dendrite morphology, seizure susceptibility, and 
inhibitory avoidance extinction (Dolen et al., 2007) (Table 52.2). This supports the 
mGluR theory, which posits that upregulation of group 1 mGluR leads to exaggerated 
protein synthesis-dependent functions, such as long-term depression, and therefore 
underlies the neuropathology and behavioral traits associated with FXS (Bear, Huber, & 
Warren, 2004). Interestingly, postnatal inhibition of PAK in the forebrain of Fmr1 KO 
mice normalizes dendrite morphology and restores locomotion, repetitive behavior, and 
anxiety (Hayashi et al., 2007). In addition, in a Drosophila model, treatment with mGluR 
antagonists or protein synthesis inhibitors in adulthood can partially restore deficits in 
courtship behavior and improve memory (McBride et al., 2005; Bolduc et al., 2008). Two 
small, open label human trials based on these findings yielded promising results (Berry-
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Kravis et al., 2008, 2009; Paribello et al., 2010), supporting the use of FXS animal 
models for preclinical purposes.  
 
Methyl-CpG-Binding Protein-Null, Mutant, and Overexpressing Mice 
Rett syndrome is another X-linked disorder that causes mental retardation, 
primarily affecting females. It is estimated that 95% of Rett syndrome cases are caused 
by mutations in the methyl-CpG-binding protein (MECP2) gene (Chahrour & Zoghbi, 
2007), leading to deficiency in this global transcriptional regulator, whose targets include 
BDNF. During the regression phase of the disease, affected girls display autistic-like 
behaviors, such as stereotypies as well as reduced social contact and communication. 
Association between MECP2 variants and autism have also been reported (Loat et al., 
2008). Both MECP2-null mice, and mice in which MECP2 is deleted in mature neurons 
only, exhibit a neurological phenotype consistent with Rett, including hypoactivity, 
ataxic gait, tremor, limb-clasping, and reduced brain size with smaller neuronal cell 
bodies in cortex and hippocampus (Chen et al., 2001; Guy et al., 2001). BDNF levels are 
also reduced in comparison to wild-type (WT) animals, and deletion or over-expression 
of Bdnf in the Mecp2 mutant brain either accelerates or delays the onset of the symptoms, 
suggesting a functional interaction between MeCP2 and BDNF in vivo (Chang et al., 
2006). Male mice that carry the truncating mutation, Mecp2308/y, a common variant 
observed in Rett patients, display a milder Rett-like phenotype (Shahbazian et al., 2002). 
Increased synaptic transmission and impaired LTP induction is observed in the mutant 
mice, whereas spine morphology, BDNF levels, and synaptic biochemical composition 
are not altered. Behavioral deficits in these mice include enhanced anxiety in the open 
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field, reduced nest-building, and aberrant social interactions. Genetic background 
modifies performance in the Morris water maze, latent inhibition, and long-term memory 
tasks (Moretti et al., 2005; Moretti et al., 2006). Mice over-expressing MeCP2 also 
develop a progressive neurological disorder with, surprisingly, an enhancement in 
synaptic plasticity, motor and contextual learning skills between age 10 and 20 weeks, 
and, at an older age, hypoactivity, seizures, and abnormal forelimb-clasping, all of which 
are reminiscent of human Rett syndrome (Collins et al., 2004). These results with the 
various MeCP2 mouse models indicate that this gene must be tightly regulated under 
normal conditions. These mice should aid in the search for genes that are regulated by 
MeCP2 (Chahrour et al., 2008) and possibly the various behavioral abnormalities. These 
mice are also providing reason for optimism regarding the testing of potential treatments 
for Rett Syndrome. In a conditional KO model, it was shown that restoring MeCP2 
expression in immature or even in mature mice results in reversal of the disease 
phenotype, as measured by behavioral and electrophysiological tests (Guy et al., 2007). 
Thus, despite the fact that MeCP2 function was disrupted during fetal and postnatal 
development, the disease symptoms can be reversed. In one test of a potential treatment, 
administration of an active peptide fragment of insulin-like growth factor 1 to MeCP2 
mutant mice extends life span, improves locomotor, heart and breathing functions, and 
stabilizes a measure of cortical plasticity (Tropea et al., 2009). Such results provide 
proof-of-principle that these mice can be used to screen candidate treatments of autism-
related disorders.  
 
Angelman and Prader-Willi Syndromes 
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Loss of function of maternal or paternal genes in the imprinted chromosomal 
region 15q11-q13 causes Angelman Syndrome and Prader-Willi Syndrome (PWS), 
respectively. Although clinically distinct, both syndromes are behavioral disorders 
presenting with some autistic traits as well as other diverse symptoms (Veltman et al., 
2005). Linkage studies have also associated the 15q11-q13 locus with autism, and 
maternal duplications of this region account for rare cases of autism (Wassink & Piven, 
2000). 70% of Angelman Syndrome patients carry large maternal deletions of 15q11-q13, 
and display a severe phenotype; yet, mutations in a single gene, UBE3A, are sufficient to 
cause major clinical manifestations of the syndrome. By contrast, PWS is clearly a 
multigenic syndrome involving 10 imprinted genes, whose individual significance in the 
etiology of the disorder is not yet fully clarified (Nicholls & Knepper, 2001). UBE3A 
encodes E6-AP, an enzyme that has ubiquitin protein ligase and transcriptional 
coactivator activities (Nawaz et al., 1999). Two different KO mouse strains with 
maternally inherited mutations in Ube3a display a phenotype consistent with human 
Angelman Syndrome: motor dysfunction, propensity for seizures, defective learning and 
memory, and abnormal electroencephalograms (Jiang et al., 1998; Miura et al., 2002). 
These mice also display deficits in hippocampal LTP and decreased hippocampal 
CaMKII activity, which may contribute to learning problems in Angelman Syndrome 
(Weeber et al., 2003). When crossed to mice carrying a mutation in CaMKII that prevents 
its autophosphorylation, the double mutants no longer exhibit the Angelman Syndrome 
phenotype (van Woerden et al., 2007). This suggests that increased inhibitory 
autophosphorylation may provide a molecular basis for deficits in LTP, motor 
coordination, and seizure propensity. Studies of another Angelman Syndrome mouse 
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model, the Ube3aYFP knock-in (KI) reporter mouse, reveal that E6-AP is found in 
synapses and the nucleus (Dindot et al., 2008). These mice display decreased spine 
density, an interesting finding because altered spine morphology is observed in Rett and 
FXS patients, as well as in Fmr1 KO mice (Kaufmann & Moser, 2000). Thus, the 
neuropathology in this KI suggests that E6-AP could play a role in spine development 
and synaptic plasticity. It is relevant that loss of UBE3A activity or its overexpression in 
Drosophila reduces dendritic branching and affects dendrite morphogenesis (Lu et al., 
2009). It remains to be determined whether similar neuropathology is present in the KO 
mouse lines and Angelman Syndrome patients and whether it contributes to cognitive 
dysfunction and behavioral abnormalities.  
More recently, mutant mice carrying a large maternal deletion from Ube3a to 
Gabrb3 were generated (Jiang et al. 2010). Similar to the Ube3a KO mice, these mutants 
display increased spontaneous seizure activity, abnormal electroencephalograms, as well 
as impairments in learning and memory. Additional behavioral tests reveal that they 
display anxiety traits in the light-dark box, but no difference in pain sensitivity or in PPI. 
Mutant newborn pups emit more USVs than control mice. This latter observation is of 
interest, since Angelman syndrome patients show a happy disposition that is currently 
interpreted as increased signaling behavior. Relevance to autism is also possible, as 
increased USVs have been reported in Mecp2 mutant and BTBR pups. However, one 
would expect to see fewer USVs in an autism model, given the deficits in communication 
in ASD. Comparative studies of the various mouse models of Angelman Syndrome 
should yield new insights into the contribution of additional, maternally imprinted genes 
of this region, or biallelically expressed genes such as Gabrb3 or Atp10a. Mouse models 
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for PWS with deletion of the corresponding murine imprinted locus have been generated, 
but early postnatal lethality has precluded behavioral characterization (Yang et al., 1998). 
Among the mice engineered to carry a mutation in one candidate gene of the imprinted 
region, Necdin (Ndn), paternally-deficient mice display some behavioral traits 
reminiscent of PWS, such as skin-scraping, improved performance in Morris water maze, 
and reduced numbers of hypothalamic oxytocin and LHRH-producing neurons 
(Muscatelli et al., 2000). Serotonergic alterations are also observed in these mice and are 
linked to respiratory deficiency (Zanella et al., 2008). All these findings might be relevant 
to autism, because repetitive self-injury, enhanced visual-spatial skills, oxytocin 
abnormalities, and alterations in serotonin levels have been described in autism. As with 
Angelman Syndrome mice, Necdin mutant mice require further behavioral 
characterization. 
 
Pten Mutant Mice 
Phosphatase and tensin homolog on chromosome 10, PTEN, is a tumor 
suppressor that negatively regulates phosphatidylinositol 3-kinase PI3K/Akt signaling, a 
pathway that promotes cell growth, proliferation, and survival. Germline mutations in 
PTEN cause Cowden and Bannayan–Riley–Ruvalcaba syndromes (CS and BRRS, 
respectively). CS and BRRS are characterized by benign and malignant tumors in 
multiple organs as well as brain disorders such as macrocephaly, mental retardation, and 
seizure. Association between these syndromes—particularly CS—and autism has 
occasionally been reported (Zori et al., 1998; Goffin et al., 2001; Pilarski & Eng, 2004). 
Moreover, genetic screening identified PTEN mutations in a subset of autistic individuals 
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who display macrocephaly (Butler et al., 2005; Buxbaum et al., 2007), an anatomical 
anomaly also present in 15% to 20% of autistic patients (Lainhart et al., 2006). Of 
particular interest is the mouse strain Nse-cre-PtenloxP/loxP, in which a Pten deletion is 
restricted to differentiated neurons in the cerebral cortex and hippocampus (Kwon et al., 
2006) These mutants develop forebrain macrocephaly resulting from neuronal 
hypertrophy in the cortex and hippocampus. In addition, analysis of the hippocampus 
shows increased dendritic and axonal growth, ectopic positioning of axons and dendrites 
of granule neurons and elevated synapse number. 
Abnormalities in Pten-deleted neurons correlate with enhanced levels of 
phosphorylated Akt and its downstream effectors, mTOR and S6. Components of the 
mTOR/S6K/S6 pathway are present in dendrites, where they are involved in the 
regulation of protein synthesis. Protein synthesis in dendrites is believed to modulate 
synapse morphology and function and thus is involved in synapse plasticity. These mice 
display behaviors reminiscent of autism, such as deficits in social interaction, 
exaggerated responses to sensory stimuli, decreased PPI (but only at one prepulse 
stimulus intensity), anxiety-like behavior in the open field, and learning deficits in the 
Morris water maze. However, no impairments in fear conditioning, elevated plus maze, 
or motor activity are observed. Increased spine density and social deficits are also 
observed in the Fmr1 KO. In this context, it is relevant that ribosomal S6 kinase (S6K1), 
a component of the mTOR/PI3K signaling cascade, was recently identified as a major 
FMRP kinase (Narayanan et al., 2008). Because the phosphorylation status of FMRP may 
govern translational regulation of its target mRNAs, upstream modulators of the 
mTOR/PI3K pathway such as PTEN may modulate synaptic function by affecting FMRP 
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phosphorylation status (Bassell & Warren, 2008). Thus, FMRP phosphorylation may be 
affected in CS, BRRS, and also tuberous sclerosis (TSC), another human disorder 
associated with autism, caused by mutations in the TSC1/2 complex. Indeed, hamartin 
and tuberin, the gene products of TSC1 and TSC2, can inhibit mTOR (Yates, 2006). 
Moreover, mTOR signaling is dysregulated in the FMRP-deficient mouse (Sharma et al., 
2010). Taken together, these data support the hypothesis that synaptic alteration may 
underlie autistic-like behaviors (Zoghbi, 2003) and highlight the mTOR pathway as a key 
regulator of synaptic function. In addition, as in the case of the MeCP2 mice, the 
Tsc2+/mouse model responds to treatment in adulthood. Brief administration of the 
mTOR inhibitor rapamycin rescues synaptic plasticity and the behavioral deficits in the 
TSC model (Ehninger et al., 2009). Moreover, early phase clinical trials suggest that 
cognitive features of TSC may be reversible in adult humans (De Vries, 2010).  
 
Autism Candidate Genes 
Neuroligins 3 and 4 
Recent findings in autism genetics have revealed several, rare causal variants that 
are associated with ASD (Betancur, Sakurai & Buxbaum, 2009). Neuroligins (NLGNs) 
constitute a family of transmembrane postsynaptic proteins, which, together with their 
presynaptic and intracellular binding partners, the β-neurexins and SHANK3, 
respectively, play a key role in synaptic maturation and transmission. NLGN-3 and -4 
were identified in two X-chromosome loci previously associated with autism spectrum 
disorders (ASDs) (Jamain et al., 2003). Thus far, one missense mutation in NLGN-3 and 
four missense and two nonsense mutations in NLGN-4 have been identified in a very 
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small number of individuals with ASDs (Jamain et al., 2003; Laumonnier et al., 2004; 
Yan et al., 2005), supporting the hypothesis that synaptic dysfunction is important in 
ASDs. Mutations in neurexin and SHANK3 are also found in ASD probands, but whether 
they are involved in ASD etiology is controversial (Sudhof, 2008). There is currently no 
KO for Shank3, but a KO for Shank1, the closest relative to Shank3, was recently 
created. These mutants display morphological alterations in hippocampal neurons that are 
associated with a reduction in basal synaptic transmission, but no change in several other 
electrophysiological parameters (LTP, LTD, and L-LTP). Behaviorally, Shank1 KO mice 
exhibit increased anxiety, impaired contextual fear memory, and, surprisingly, enhanced 
performance in a spatial learning task but impaired memory retention of that task (Hung 
et al., 2008). Additional behavioral tasks relevant to the three core symptoms have yet to 
be reported. 
Results with NLGN-3 and -4 mutant mice confirm the functional significance of 
NLGNs in synaptic function. A NLGN-3 KI mouse was engineered with a point mutation 
in the endogenous mouse gene that is identical to the relevant human NLGN3 gene 
(Tabuchi et al., 2007). These mice display increased inhibitory synaptic transmission 
without a change in excitatory transmission, a phenotype not observed in NLGN-3 KO 
mice, emphasizing the disparity between missense and nonsense mutations. It will be 
ofinterest to characterize the behavior of the KO mice to check for differential 
phenotypes. The augmentation in inhibitory synaptic transmission in the NLGN-3 KI 
mice is accompanied by a deficit in social interaction and, as observed in the Shank1 KO, 
enhanced spatial learning ability. These results are surprising because (1) a loss, rather 
than a gain of inhibition in different neural systems was hypothesized to contribute to 
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ASDs (Hussman, 2001; Rubenstein & Merzenich, 2003), and (2) the individuals 
identified with mutations in NLGN-3 and -4 do not exhibit potentiated learning skills. 
The latter observations are consistent with a report of minimal aberrant behaviors in the 
NLGN-3 KI mice (Chadman et al., 2008). Nevertheless, the results suggesting that a 
disequilibrium between excitatory and inhibitory synapses can affect social behavior 
(Sudhof, 2008) and that decreasing inhibitory transmission may be an effective therapy in 
some autism patients are worth pursuing. In fact, administration of the NMDA receptor 
partial co-agonist D-cycloserine can rescue the excessive grooming behavior in adult 
NLGN-1 KO mice (Blundell et al., 2010).  
Unlike humans, the rodent Nlgn4 gene localizes to a still unknown autosome. 
Although there is only a 57% homology between the two species, the protein is found in 
synapses in both. Although NLGN-4 KO mice display abnormalities in two of the three 
core autistic symptoms, reciprocal social interaction, and impaired communication, as 
approximated by measuring USVs, they do not display repetitive behavior or 
impairments in some of the other autism symptoms such as sensory ability, sensorimotor 
gating, locomotion, exploratory activity, anxiety, or learning and memory (Jamain et al., 
2008). These observations are consistent with those seen in patients with the NLGN-4 
mutation, who do not show these comorbid features. MRI analysis of the brains of 
NLGN-4 KO mice show a slight reduction in size of the total brain, cerebellum, and brain 
stem, and some of these neuroanatomical changes are reminiscent of autism. 
To summarize, several NLGN models exhibit strong construct validity with the rare 
human mutations associated with human ASDs. Moreover, the face validity of the 
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NLGN-4 KO mice is fairly good at the behavioral level, but much remains to be done on 
its neuropathology.  
 
CNTNAP2  
One of the most validated susceptibility genes is contactin associated protein-like2 
(CNTNAP2). This gene encodes a member of the neuronal neurexin superfamily that is 
involved in neuron-glial interactions and is very likely to be important in brain 
development (Abrahams et al., 2008b). An intriguing feature of CNTNP2 is its enriched 
expression in circuits in the human cortex that are important for language development. 
Moreover, its expression is enriched in song nuclei important for vocal learning in the 
zebra finch, and feature is male-specific, as is the song behavior (Panaitof et al., 2010). In 
addition, CNTNP2 polymorphisms are associated with language disorders, and the 
expression of this gene can be regulated by FOXP2, a transcription factor that, when 
mutated, can cause language and speech disorders (Vernes et al., 2008). In light of these 
associations, it is important that recent study of the Cntnap2 KO mouse reveals a deficit 
in USVs. Moreover, these mice display the other core features of autism, repetitive 
behavior and a social interaction deficit. They also exhibit several other features of ASD: 
seizures, mild cortical laminar disorganization and hyperactivity (D. H. Geschwind, 
personal communication).  
 
En-2 
ENGRAILED-1 (En-1) and -2 encode transcription factors expressed during 
embryonic and postnatal stages that regulate the development of the cerebellum. En-2 
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localizes in proximity to an autism susceptibility locus on chromosome 7 (Liu et al., 
2001; Alarcon et al., 2002), and genetic variations in En-2 have also been reported to 
associate with ASDs (Petit et al., 1995; Gharani et al., 2004; Benayed et al., 2005; Wang 
et al., 2008; Yang et al., 2008), although one report could not replicate such association 
(Zhong et al., 2003). Although mice homozygous for a mutation in En-1 lack a 
cerebellum and die shortly after birth (Wurst, Auerbach, & Joyner, 1994), En-2 KO mice 
are viable and display some cerebellar pathologies resembling those reported in the brains 
of some autistic individuals, such as a decreased PC number, hypoplasia, and abnormal 
foliation (Kuemerle et al., 1997; Amaral, Schumann, & Nordahl, 2008). The juvenile KO 
mice display reduced social and play behaviors, and abnormal social behavior and 
repetitive self-grooming as adults (Cheh et al., 2006). In addition, although En2 KO mice 
display normal locomotor activity in the open field, motor deficits are observed in 
specific tasks such as mid-air righting, hanging-wire grip strength, and rotorod. Learning 
and memory impairments are also evident in the water maze and modified open field with 
objects. At the neurochemical level, mutant mice exhibit increased cerebellar serotonin 
compared to controls but no alteration in dopamine levels in hippocampus, striatum, and 
frontal cortex or cerebellum. Thus, En2 KO mice display face validity for autism, except 
for the motor deficits, which can interfere with some behavioral tests. It will be of interest 
to examine USVs in this model.  
 
Serotonin 
Several lines of evidence indicate that changes in serotonin signaling may 
contribute to autism pathogenesis. Serotonin levels in platelets are elevated in autistic 
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patients (Cook & Leventhal, 1996), and numerous polymorphisms in genes implicated in 
5-HT signaling or metabolism have been reported in autism, including the serotonin-
transporter gene SLC6A4 (SERT), monoamine oxidase A (MAOA), tryptophan 2,3 
dioxygenase gene, and two serotonin receptors, 5-HT2A (HTR2A) and 5-HT7 (HTR7). 
Pharmacological modulation of the serotonin system using the 5-HT receptor antagonist 
risperidone improves ritualistic behavior and irritability of autistic children and, similarly, 
selective 5-HT reuptake inhibitors ameliorate repetitive thoughts and behaviors as well as 
mood disturbances. Conversely, depletion of tryptophan, a serotonin precursor, 
aggravates autistic symptoms (Hollander et al., 2005). Abnormalities in brain serotonin 
synthesis at different ages, as well as cortical asymmetries in serotonin synthesis, have 
been reported in children with autism (Chugani et al., 1997; Chugani et al., 1999). These 
alterations could be linked to abnormalities in cortical minicolumn organization in autism 
(Casanova & Tillquist, 2008). Serotonin signaling modulates various aspects of preand 
postnatal brain development (Gaspar, Cases, & Maroteaux, 2003), and some mouse lines 
with disruption in the 5-HT system show neuropathology consistent with those observed 
in autism. Behavioral changes observed in these mutants relate to mood, aggression, 
anxiety, depression, seizure, and learning and memory, all of which are relevant to 
autism. 
A mouse line in which serotonin signaling is impaired is the Dhcr7 mutant. 
DHCR7 (7-dehydrocholesterol reductase) is an enzyme required for the biosynthesis of 
cholesterol, and mice lacking functional DHCR7 display an increase in the area and 
intensity of serotonin immunoreactivity in the embryonic hindbrain (Waage-Baudet et al., 
2003). Unfortunately, Dhcr7 KO mice die shortly after birth, precluding behavioral 
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studies. In humans, DHCR7 deficiency causes the Smith–Lemli–Opitz Syndrome 
(SLOS), a disease characterized by dysmorphic facial features, mental retardation, and 
limb defects (Yu & Patel, 2005). Approximately 50% of patients with SLOS are also 
diagnosed with autism (Tierney et al., 2001). Levels of cholesterol are decreased in some 
idiopathic autistic children (Tierney et al., 2006), and cholesterol dietary supplementation 
improves autistic-like behavior of patients with SLOS (Aneja & Tierney, 2008). 
Presently, the mechanisms by which cholesterol deficiency affects serotonin pathways 
are not fully elucidated, but it is known that cholesterol can modulate the functional 
activity of MAO (Caramona et al., 1996) and SERT (Scanlon, Williams, & Schloss, 
2001). Investigation of Dhcr7 heterozygous mice or development of conditional mutants 
could further the understanding of the role of cholesterol in autism. 
BDNF-deficient mice also display alterations in the serotonin system. Signaling 
mediated by BDNF and its receptor tyrosine kinase (TrkB) is crucial for serotonergic 
neuronal development, as well as a wide variety of other neuronal functions. Variants in 
the BDNF gene have been associated with autism (Nishimura et al., 2007), and post 
mortem analysis of brains from autistic adults show enhanced levels of BDNF (Perry et 
al., 2001), whereas blood and serum levels in autism are controversial (cf. Croen et al., 
2008). Various BDNF or TrkB mutant mouse lines are available, including heterozygous 
null mice (homozygous KOs are not viable), conditional, and inducible BDNF KO mice. 
Presence and severity of behavioral alterations in these mice depends on the stage at 
which BDNF is depleted, the brain regions targeted for BDNF deficiency, and the gender 
of the mutants (cf. Monteggia et al., 2004). Autistic-like behavioral impairments 
commonly reported are heightened aggression, hyperactivity, depression-like traits, and, 
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in some instances, altered locomotor activity. Hyperphagia is reported in some BDNF 
mutant lines, a finding inconsistent with autism per se but also observed in PWS. Despite 
behavioral deficits, surprisingly, dendritic morphology and GAD67 are not altered in 
brains from fetal and postnatal KOs (Hashimoto et al., 2005; Hill et al., 2005). In 
contrast, double BDNF +/x SERT -/mutants display exacerbated anxiety in the elevated 
plus maze, greater elevation in plasma ACTH after stressful stimulus, and reduction in 
the size of dendrites of hippocampal and hypothalamic neurons in comparison to WT, 
SERT+/+ x BDNF+/and SERT-/-x BDNF +/+ mice (Ren-Patterson et al., 2005). Because 
autism is often considered to be a multigenic disorder, investigation of gene/gene 
interaction is a logical approach. 
 
Urokinase Plasminogen Activator Receptor Knockout Mice 
Variations in the MET gene encoding a receptor tyrosine kinase are associated 
with autism (Campbell et al., 2006). Moreover, post mortem analysis of cortical tissue 
from autistic individuals reveals decreased levels of MET protein in comparison to 
matched controls (Campbell et al., 2007). Disruption in signaling mediated by MET and 
its ligand, hepatocyte growth factor/scatter factor (HGF/SF), may be particularly relevant 
to the etiology of the disorder because, in addition to playing a key role in the CNS 
during development and adulthood, it is also involved in gastrointestinal repair and 
regulation of the immune system, two other systems that are altered in autism (Vargas et 
al., 2005). The PI3K/Akt pathway is one of the prominent signaling cascades activated by 
MET, which thereby antagonizes PTEN function. In the CNS, HGF/SF-MET signaling 
promotes the migration of cortical interneurons during development (Powell, Mars, & 
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Levitt, 2001), contributes to cerebellar development and function (Leraci, Forni, & 
Ponzetto, 2002), stimulates dendritic growth in cortical neurons (Gutierrez et al., 2004), 
and induces protein clustering at excitatory synapses (Tyndall & Walikonis, 2006). 
Although genetic deletion of MET causes embryonic lethality, the KO of urokinase 
plasminogen activator receptor (uPAR), which exhibits reduced uPA activity (the 
protease required for the activation of HGF), is viable and displays a diminution in HGF 
levels and, as observed in autism, in MET levels. The uPAR KO mice display increased 
anxiety and are prone to seizures (Powell et al., 2003), features that are relevant to autism 
(Tuchman & Rapin, 2002). Whether these mice display deficits in any core symptoms of 
the disorder has not been reported. Gastrointestinal and immune pathology also needs to 
be assessed in these mutants. 
 
Disrupted in Schizophrenia-1Variants 
A balanced translocation between chromosome 1 and 11 t(1;11) (q42.2;q14.1) 
cosegregates with schizophrenia and related disorders in a large Scottish family (St Clair 
et al., 1990; Blackwood et al., 2001). Disrupted in Schizophrenia-1 (DISC1) is altered by 
this translocation (Muir et al., 1995; Millar et al., 2000; Millar et al., 2001), and there is 
an association between variations within the DISC locus and autism and Asperger 
Syndrome (Kilpinen et al., 2008). DISC1 is a scaffold protein, which, through 
interactions with various proteins (e.g., PDE4B, LIS1, NDEL1, NDE1, CIT, MAP1A), 
regulates cAMP signaling, cortical neuron migration, neurite outgrowth, glutamatergic 
neurotransmission, and synaptogenesis (Muir, Pickard, & Blackwood, 2008). There are a 
number of Disc1 mouse variants currently available: mice carrying a truncated version of 
 44 
the endogenous Disc1 ortholog, transgenic lines with inducible expression of mutant 
human DISC1 (hDISC1), and lines carrying N-ethyl-N-nitrosourea-induced mutations in 
Disc1 (Chubb et al., 2008). Hippocampal neurons in mice with mutations of endogenous 
Disc1 display dendritic misorientation and reduced number of spines, as observed in the 
Fmr1 KO mice. These mice display a working memory deficit but do not show deficits in 
PPI or latent inhibition (Koike et al., 2006; Kvajo et al., 2008). Transgenic mice 
expressing hDISC1 in forebrain regions show a mild enlargement of the lateral ventricles 
in comparison to WT animals, and neurite outgrowth is decreased in primary cortical 
neurons from these mutants. These neuropathologies are associated with altered social 
interaction and enhanced spontaneous locomotor activity in male hDISC1 mice and with 
mild impairment in spatial memory in females (Pletnikov et al., 2008). Tests assessing 
repetitive behavior and ultrasonic vocalizations remain to be reported. Further study of 
neuropathology in the various strains will also be important. 
 
Oxytocin and Vasopressin 
Neuropeptides and their associated receptors play a central role in the regulation 
of complex social behaviors. Several lines of evidence suggest that functional alterations 
in these systems may contribute not only to social deficits in autism but also to repetitive 
behaviors. (1) A reduction in oxytocin (OT) plasma levels, associated with an elevation 
in the prohormone form, is observed in autistic children (Modahl et al., 1998; Green et 
al., 2001). Mixed results have been reported for OT plasma levels in high-functioning 
adult autistic patients(Jansen et al., 2006; Andari et al., 2010). (2) Intranasal infusion of 
OT reduces stereotyped behavior and improves eye contact, social memory and use of 
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social information in high functioning autistic patients (Hollander et al., 2003, 2007; 
Guastella et al., 2009; Andari et al., 2010). (3) Genetic variations in OT receptor and 
vasopressin receptor V1aR can be associated with autism (Donaldson & Young, 2008; 
Israel et al., 2008; Gregory et al., 2009). (4) Oxytocin receptor mRNA is decreased in 
post-mortem autism temporal cortex (Gregeory et al., 2009). 
Current knowledge derived from studies in OT  and OT receptor (OTR) KO mice 
underscore the subtle role of this system in aggression and anxiety. Thus, OT KO adult 
male progeny from homozygous crosses display high levels of aggression, whereas levels 
of aggression in OT KO adult male progeny from heterozygous crosses are either less 
pronounced or similar to WT mice, suggesting that absence of OT during prenatal stages 
modulates the development of aggression in adulthood (Ferguson et al., 2000; Winslow et 
al., 2000; Takayanagi et al., 2005). OT KO female mice also display exaggerated 
aggression under controlled stress conditions designed to mimic the natural environment, 
indicating a possible interaction between the postnatal environment and the OT system 
(Ragnauth et al., 2005). Similarly, OTRr KO adult males display elevated aggressive 
behavior, as well as deficits in social discrimination (Takayanagi et al., 2005). OT KO 
adult mice nevertheless display reduced anxiety in the plus maze and acoustic startle 
reflex, a finding inconsistent with autism. In addition, as infants, both OT and OTR KO 
males emit fewer USVs in the isolation test than WT animals, which is also suggestive of 
decreased anxiety during maternal separation, but is also consistent with the lack of 
communication in ASD. The OT KO mice fail to recognize familiar conspecifics upon 
repeated social encounters, although olfactory and nonsocial memory are intact (Winslow 
& Insel, 2002). This has been interpreted as an autism-like social deficit, although social 
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amnesia has not been described in autism. Comprehensive neuropathology remains to be 
reported in these strains. Given the implications for ASD in the human findings, further 
study of OT mutant mice is warranted, although striking species differences are apparent 
for OT and vasopressin, and their receptors (Insel, 2010).  
Male V1aR KO mice exhibit deficits in olfactory social recognition and social 
interaction (Bielsky et al., 2004; Egashira et al., 2007). Similarly to OT and OTR KO 
mice, V1aR KO mice show reduced anxiety-like behavior in the elevated plus maze and 
the open field and the light/dark box, although high levels of anxiety are observed in the 
WT animals in comparison to other reports. No deficits in learning and memory in the 
Morris water maze or in PPI are detected, indicating that the face validity of this model is 
partial. V1bR KO adult females emit fewer USVs in a resident-intruder test. Although the 
number of USVs emitted by infant mutants is not affected during the conventional pup 
separation test, mutant pups fail to display maternal potentiation of USVs, which could 
suggest either a defect in a cognitive component or reduced anxiety (Scattoni et al., 
2008). Although reduced anxiety is inconsistent with autism, V1bR antagonists could be 
tested to lower anxiety.  
 
BTBR Mice 
The BTBR mouse strain exhibits low levels of sociability at juvenile and adult 
ages, as well as abnormal social learning in the transmission of food preference test. 
Moreover, BTBR mice show a high level of spontaneous repetitive grooming, poor shift 
performance in a hole-board task, and a deficit in the water maze reversal task, which can 
be interpreted as the resistance to change in routine that is observed in autism (Bolivar, 
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Walters, & Phoenix, 2007; Moy et al., 2007; Yang, Zhodzishsky, & Crawley, 2007; 
McFarlane et al., 2008; Moy et al., 2008). Finally, BTBR pups separated from their 
mother emit more and longer USVs in comparison to C57 pups (Scattoni et al., 2008). 
Their repertoire of vocalizations is also narrower in comparison to pups from standard 
mouse strains. The latter observation is significant, as human infants later diagnosed with 
autism make unusual vocalizations (Johnson, 2008). However, one might expect to see 
lower rates of USVs in pups if modeling the ASD communication deficit. Such a deficit 
is reported in adult BRBR mice (Wohr et al., 2010). Detailed study of the fine structure 
of USVs, as well as their behavioral functions in adult mice, is an important area for 
future studies of animal models of psychiatric disease.  
A recent study indicates that BTBR mice display an exaggerated response to 
stress that is associated with high blood levels of corticosterone in comparison to C57 
mice (Benno et al., 2009). Thus, it is not clear whether enhanced stress causes or 
aggravates the behavioral phenotype of these mice. Key anatomical features of BTBR 
mice are the absence of the corpus callosum and a reduced hippocampal commissure. 
These deficits correlate with impaired contextual fear memory, which could arise from an 
increased susceptibility to de-potentiation. Otherwise, electrophysiological properties of 
hippocampal slices from BTBR (LTP, paired pulse facilitation, and basal synaptic 
transmission) are similar to those of C57 (MacPherson et al., 2008). Thus, several BTBR 
behaviors are consistent with autism, and the most striking anatomical feature in this 
strain is consistent with many, but not all, studies of the corpus callosum in autism 
(Amaral, Schumann, & Nordahl, 2008). 
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A difficulty with this line is that comparisons are necessarily made to other, 
unrelated mouse lines, and it is not clear to which line(s) BTBR should be compared. For 
instance, similar to BTBR mice, but unlike C57 mice, BALB/c mice display low social 
behavior, reduced USVs and reduced empathy-like behavior (Silverman et al., 2010). 
Because it is likely that there is a wide variety of genetic differences between such 
strains, comparing their behaviors is not equivalent to comparing behaviors and 
neuropathology between mutant and WT mice of the same genetic background. 
Nonetheless, the search for the genes causing behavioral phenotypes is ongoing, and a 
single nucleotide polymorphism in Kmo, which encodes kynurenine 3-hydroxylase, has 
been found in BTBR mice when compared to unrelated strains (McFarlane et al., 2008). 
This enzyme regulates the synthesis of kynurenic acid, a neuroprotective compound for 
which levels are abnormal in other neuropsychiatric diseases, including schizophrenia. 
 
Myocyte Enhancer Factor 2 KO mice 
A recent homozygosity mapping study of autism loci identified several candidate 
genes that are regulated by myocyte enhancer factor 2 (MEF2) transcription factors 
(Morrow et al., 2008). MEF2 factors mediate synapse elimination. Conditional KO of 
Mef2c at the neural stem cell stage yields mice with fewer, smaller, and more compacted 
neurons that exhibit what is interpreted as immature electrophysiological network 
properties. It is of interest that these mice display marked paw-clasping stereotypy, 
possibly altered spatial memory, and complex changes in anxiety tests when tested as 
adults (Li et al., 2008). Indeed, such behaviors resemble those observed in Mecp2 
mutants. In addition, a recent study revealed that active FRMP is required for MEF2-
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dependant synapse elimination, thus further pinpointing the molecular factors at play in 
regulating synapse number (Pfeiffer et al. 2010).  
 
Copy Number Variations  
Copy number variations (CNVs) are DNA fragments whose number is altered by 
deletion or duplication between various individuals. They are thought to account for a 
significant proportion of normal phenotypic variation within the human population 
(Freeman et al., 2006). Several recent studies have indicated that de novo CNVs associate 
with autism. Interestingly, some of the genes identified within the loci subject to CNVs in 
autism are related to synaptic or neuronal activity (e.g., SHANK3, NLGN4, and NRXN1) 
(for reviews, see Abrahams & Geschwind, 2008a; Cook & Scherer, 2008). Thus, 
genome-wide investigation of CNVs might further implicate or reveal novel candidate 
genes in autism, for which rodent mutant lines can be developed. 
 
Lesions 
Autism is a common occurrence in children with brain lesions caused by 
hemorrhage or tumor (Asano et al., 2001; Limperopoulos et al., 2007). One of the 
examples is TSC, a genetic disorder that causes benign lesions or tumors to form in many 
different organs, including the brain. MRI and positron emission tomography (PET) 
demonstrate correlations between abnormalities in the cortex and communication deficits, 
whereas changes in subcortical circuits correlate with stereotypies and lack of social 
interaction (Asano et al., 2001). Therefore, the study of autism in children with TSC and 
the development of animal lesion models may provide clues about autistic behavior. 
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Although brain lesions have commonly been used in animal models to study the 
circuitry underlying behaviors (Lavond & Steinmetz, 2003), interpretation of such results 
can be complex. First, the loss of a behavior does not prove that the lesioned brain area is 
the originating source for brain activity associated with that behavior. Second, lesions 
often damage axons passing through the brain area of interest, giving rise to erroneous 
conclusions about that brain region’s importance in the behavior. Third, behavioral 
testing is necessarily performed on subjects responding to injury with various 
inflammatory and regenerative mechanisms whose influence on behavior is poorly 
understood. More recent advances in the ability to silence particular neuronal populations 
using genetic techniques promise much greater sophistication in unraveling the circuitry 
underlying behavior. 
 
Amygdala 
The amygdala has reciprocal connections with many areas, including the orbital 
and medial prefrontal cortex and the hippocampus, which are implicated in autism. 
Several post mortem studies have demonstrated amygdala abnormalities in autistic 
subjects, such as altered developmental trajectory and fewer neurons (Amaral et al., 
2008). In case reports, children with severe temporal lobe damage resulting from viral 
encephalitis, tumors, or other factors developed autistic symptoms (Sweeten at al., 2002). 
In children with TSC, symptoms of autism are strongly related to the presence of tubers 
in the temporal lobe (Gillberg et al., 1994). These findings, along with recent functional 
neuroimaging data, led Baron-Cohen to develop an “amygdala theory of autism” (2000), 
which suggests a crucial role for the amygdala in the impairment of social behavior. In 
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addition, patients with amygdala lesions (Adolphs, 2003) and individuals with autism 
(Adolphs et al., 2001) appear to have similar deficits in recognizing complex emotions in 
facial expressions. Neonatal ibotenic acid lesion of the amygdala in the rat has been 
proposed as an animal model of neurodevelopmental disorders such as autism (Daenen et 
al., 2001; 2002a; 2002b; Diergaarde et al., 2004). In this model, animals display 
increased latency to play with social partners decreases duration of contact and 
hyperactivity as well as decreases adaptation and habituation to the open field, which is 
interpreted as locomotor stereotypy and low anxiety (Daenen et al., 2001; 2002a). Thus, 
excitotoxic lesions of the amygdala in the neonatal rat produce multiple behavioral 
abnormalities relevant to autism. This conclusion differs from that found in similar 
nonhuman primate studies (Amaral et al., 2003). Moreover, humans with amygdala 
lesions do not display deficits in social interaction like those seen in autism (Amaral et 
al., 2003). 
 
Hippocampus 
Limbic system dysfunction is fundamental to autism (Amaral et al., 2008). 
Neonatal ibotenic acid lesion of the hippocampus in the rat causes locomotor stereotypy 
in the open field test, but there are mixed results concerning deficits in social behavior 
early in life or in adulthood (Daenen et al., 2002b; Silva-Gomez et al., 2003) In rodent 
models, hippocampal lesions grossly impair memory, and autistic subjects display a 
selective deficit in hippocampal-dependent memory (Lathe, 2006). Because there are 
only a few studies analyzing social behavior in hippocampus-lesioned rats, and the 
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damage in this area has no or only a temporary effect in monkeys (Amaral et al., 2003), 
more work is required in this area. 
 
Prefrontal Cortex 
Patients who suffer damage to the prefrontal cortex have problems in making 
decisions and in behaving appropriately in social situations where empathy and social and 
moral reasoning are appropriate (Anderson et al., 1999; Koenigs et al., 2007). There is 
also evidence that both the medial temporal lobe and dorsolateral prefrontal cortex are 
implicated in autism (Amaral et al., 2008). Moreover, lesions to the orbital and medial 
prefrontal cortex in nonhuman primates cause abnormal social personality expression, 
decision making, and loss of position within the social group (Butter & Snyder, 1972). 
Lesioning prefrontal cortex also provokes a decrease in positive social behaviors 
(grooming, huddling, and near-body contact) and socially communicative facial, vocal, 
and postural behaviors, as well as an increase in inappropriate social interactions (Myers 
et al., 1973). Consistent with these results are ibotenic acid lesion studies of the medial 
prefrontal cortex in rats (Schneider & Koch, 2005). In addition, the lesion-induced 
disturbances of juvenile play behavior in rodents may also contribute to the social deficits 
observed in adult animals, because play-fighting is important for the development of 
communicative skills and appropriate behavioral patterns. Further work on the rodent 
model  showed that neonatal lesion of the medial prefrontal cortex leads to reduced 
anxiety in the elevated plus maze, increased motor activity in open field, and, more 
interestingly, perseverative behavior in a reward-related test of operant behavior 
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(Schwabe et al., 2006). This is in line with the behavioral changes reported for 
cerebellum lesion models. 
 
Cerebellum 
The cerebellum is involved not only in the regulation of motor skills but also in 
higher functions, including cognition, language, and emotional expression (Turner et al., 
2007). Adults and children with cerebellar lesions have high social isolation, 
communicative disturbance, and deficits in cognitive processing (Eluvathingal et al., 
2006; Limperopoulos et al., 2007). A common finding in autism is a loss of PCs (72% of 
cases; Palmen et al., 2004; 79% of cases; Amaral et al., 2008). Therefore, surgical or 
toxin lesions of the cerebellum are of particular interest in studying animal models of 
autism. In addition to cognitive dysfunction reported in a rat model of cerebellum lesion 
(Gaytan-Tocaven & Olvera-Cortes, 2004), there are two rat models displaying 
perseverative behavior, which is common in autism and is expressed as insistence on 
sameness as well as inability to understand and cope with novel situations. This kind of 
behavior is found in a rat model of early (P10) midline cerebellar lesion (Bobee et al., 
2000). In addition, these animals display elevated spontaneous motor activity and exhibit 
lack of attention to environmental distractors. Unlike the autism phenotype, however, the 
lesioned animals are neophilic and less anxious than controls. Vermis-lesioned rats show 
a decreased coefficient of learning during extended training of an instrumental task, 
which is interpreted as perseverative behavior (Callu et al., 2007). 
In sum, the lesion models support dysfunction in autism in several areas: the 
prefrontal cortex, the temporal lobe and the cerebellum. This may be because an early 
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defect in the functioning of these areas of the brain alters the development of multiple 
other areas, however. Behavioral analysis has focused primarily on motor tasks and 
anxiety. These lesion models display hyperactivity and low anxiety in the open field, 
which is unlike the autism phenotype (Lathe, 2006). No changes, or decreased general 
social activity, are reported for rodent models with lesions in the amygdala, prefrontal 
cortex, or hippocampus. Early damage to the amygdala or the prefrontal cortex results in 
altered juvenile play behavior, the earliest form of non-mother-directed social behavior in 
rodents. Thus far, these lesion models display two types of behaviors impaired in 
autism—namely, a deficit in social behavior and stereotypy. It will be important to assay 
other types of social and communicative behavior (for example, ultrasonic vocalizations 
in different social contexts), as well as to compare the changes in brain pathology, 
biochemistry, and gene expression to those seen in autism. 
 
Conclusions 
Given that the background genotypes of the rat and mouse strains that are used for 
experiments are somewhat arbitrary, and that genotype is very important in autism, it is 
remarkable that both behaviors and neuropathology consistent with autism can be 
reproduced in rodents. This issue of background genotype could potentially become 
increasingly important as more sophisticated models incorporating human genetic 
variants are introduced. Although no single rodent model has yet been thoroughly studied 
at all levels of investigation, several models have already been explored in some depth. 
Among those that display face and construct validity are the maternal valproate and 
maternal infection models of environmental risk factors, as well as the NLGN-4, Frmr1, 
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CNTNAP2, and MeCP2 models of genetic risk factors. Nonetheless, no model has been 
thoroughly investigated with all available experimental tools, including behavior, 
histology, biochemistry, electrophysiology, and imaging. 
 
Challenges and future directions 
The fine structure of ultrasonic vocalizations, as well as their behavioral functions 
in adult mice, are intriguing areas for future study of potential communication 
abnormalities. Theory of mind, the ability to intuit another’s thinking, is an important 
deficit in autism. An analogous test of empathy can be done in mice, where observing 
cage mates experience stressful experiences can alter the witness’ responses to later tests 
(Langford et al., 2006; Chen, Panksepp & Lahvis, 2009). This assay should be widely 
tested in the available environmental and genetic models. To reach their full potential in 
mimicking the human situation, models of candidate genes should carry the variant 
identified in the human studies, not just a KO of the gene. 
It is now possible to test the hypothesis that the full autism phenotype may 
emerge from environmental risk factors acting on susceptibility genotypes. Multi-
electrode recording, functional imaging, and immediate early gene activation studies will 
be important for mapping patterns of functional activity in rodent models and comparing 
it to fMRI data from human subjects. Translational, preclinical studies in several mouse 
models have already stimulated small clinical trials in ASD-related disorders. Although 
this will likely accelerate in the near future, significant species differences will 
undoubtedly lead to failures along the way. 
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Figure 52–1. Timeline of Birth Defects Caused by Thalidomide, and the Critical 
Period of Vulnerability to Autism. The specific dysmorphologies in the offspring 
depend on the precise timing of drug ingestion. The fact that autistic features were only 
seen in offspring of a particular set of dysmorphologies indicates that the period of 
thalidomide-induced autistic features corresponds to days 20-23 of human gestation. 
Graphic after Rodier, PM. (2000) The Early Origins of Autism. Scientific American , 282 
(2), 56–63 
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Figure 52–2. Cytokines Produced by Activation of the Maternal Immune System 
Can Alter Fetal Brain Development. Various types of infection (bacterial, viral, 
parasitic) in pregnant rats or mice can be mimicked by injection of LPS or poly(I:C). 
These activate cells to produce cytokines, which travel in the blood to the placenta, where 
they can activate cells. The cytokines can also cross the placenta into the fetal circulatory 
system and activate cells in the fetal brain.  
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Figure 52-3. Maternal infection causes a spatially-restricted Purkinje cell deficit. 
Adult offspring of mice given a respiratory infection with influenza virus at midgestation 
display a deficit in Purkinje cells in lobules VII but not in other lobules. Left: Calbindin 
staining of adult cerebella from offspring of control (A,C) and infected mothers (B,D) 
reveals a deficit in lobule VII of the latter. Panels C and D (bar = 200 mm) are higher 
magnification views of panels A and B (bar – 800 mm). Right: (A) Quantification of the 
linear density of Purkinje cells reveals a 33% deficit in lobule VII of the adult offspring 
of infected mothers, while no difference from controls is found in lobule V. (B) A 
similar, localized deficit is observed in postnatal day 11 offspring of infected mothers. 
(Reprinted from Shi et al., 2009, with permission) 
 61 
 
 
Table 52-2. Amelioration or rescue of some features of the autism-like phenotype in 
double mouse mutants. Phenotypic improvements or reversals indicate functional 
(direct or indirect) interactions between the targeted genes, while persistence of one 
phenotype suggests that additional genes contribute to the full phenotype. Investigation of 
genetic interactions provides insight into the molecular pathways underlying particular 
facets of autism, and may suggest novel therapeutic targets. 
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Abstract 
 
Maternal infection can alter the intrauterine environment, placing the developing fetus at 
risk.  Serious infections of the mother or the fetus can cause severe problems or even 
miscarriage.  The more common and seemingly benign infections, such as influenza, are 
not associated with such severe outcomes.  However, recent work has shown that 
maternal inflammation associated with any infection has the potential to alter fetal brain 
development.  Epidemiological studies have demonstrated a strong association between 
maternal infection and subsequent development of mental illness in the offspring.  Mouse 
models of maternal infection have shown long-lasting changes in the brains of offspring 
following maternal immune activation, as well as behavioral abnormalities related to 
human mental illness.  Recent work has begun to elucidate the mechanisms through 
which the activated maternal immune system alters fetal brain development.  We review 
the evidence from human and rodent studies showing that maternal infection is a risk 
factor for mental illness, and describe the initial steps in the molecular mechanism 
mediating the effects of maternal immune activation on fetal brain development. 
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Introduction 
Surprisingly little is known about the subtle changes in the brain that  result in 
mental disorders such as schizophrenia and autism.  These disorders are defined by 
behavioral symptoms.  A child presenting before the age of three with abnormal language 
acquisition and reciprocal social interactions, as well as repetitive, stereotyped behaviors 
is diagnosed as autistic.  A young adult who reports positive (hallucinations or delusions) 
and negative (depression, apathy, social withdrawal) symptoms is diagnosed as 
schizophrenic.  Although these symptoms are dramatic, the brain looks grossly normal, 
and even upon microscopic examination the neuropathology is subtle.  However, studies 
of post-mortem protein and gene expression have identified many changes, including 
molecules involved in immune regulation, synaptic function and myelin.  Unfortunately, 
our understanding of the normal function of the brain is not sufficiently developed to 
form a coherent model of the malfunction in these disorders.   
Another approach to these disorders is to identify and study the risk factors that 
contribute to their development.  Despite the postnatal onset of the clinical symptoms, 
evidence suggests that schizophrenia and autism have their origins in early brain 
development. Retrospective examination of school records and home videos of children 
who subsequently display these disorders portray their early behaviors as “pre-
schizophrenic” or “pre-autistic” (Palomo, Belinchon, & Ozonoff, 2006). Moreover, 
postmortem examination of the brains of at least some affected individuals reveals subtle 
changes in the number, distribution or alignment of neurons, suggesting abnormalities in 
development in utero (Lewis & Levitt, 2002). Therefore, taking a bottom-up approach of 
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identifying risk factors and tracing their mechanism of action may be a productive path 
towards understanding these complex disorders with heterogeneous symptoms.   
 
Risk factors contributing to schizophrenia and autism 
While genetics clearly plays a major role in schizophrenia and autism, the 
complex nature of inheritance continues to puzzle researchers.  Autism is often cited as 
one of the most heritable mental diseases, with twin studies often cited as evidence: while 
~90% of identical twins are concordant for autism, that number falls to about 10% for 
fraternal twins.  Similar data exists for schizophrenia, with concordance rates of ~50% in 
monozygotic versus ~17% in dizygotic twins (Lewis & Lieberman, 2000). Despite the 
relatively high heritability, however, only about 5-10% of autism cases can be can be 
attributed to known chromosomal abnormalities or single gene mutations. Similarly, with 
notable exceptions (e.g., DISC1), very few cases of schizophrenia can be traced to a 
known genetic cause. Moreover, large, statistically powerful genetic association studies 
of patient populations have failed to identify more than a handful of implicated genetic 
variants, and these carry a small effect size (Grice & Buxbaum, 2006; Sykes & Lamb, 
2007).  
Several theories, reviewed elsewhere, attempt to reconcile the high apparent 
heritability of mental illness with the difficulty of identifying genetic risk factors.  An 
early explanation is the “multiple interacting genes” hypothesis, which states that the 
inheritance involves multiple genes, each of which displays incomplete penetrance (see, 
for example, (Grice & Buxbaum, 2006)). A more recent theory posits that de novo 
genetic mutations and chromosomal rearrangements contribute to risk.  Evidence 
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showing an elevated rate of microdeletions and microduplications in autistic and 
schizophrenic patient samples, as well as associations of autism with increasing parental 
age lends credence to this hypothesis (Cook & Scherer, 2008).  While de novo 
microdeletions and duplications would explain why so few candidate single gene 
mutations have been identified in studies of multiple populations, they do not explain the 
high heritability estimates of these disorders. Similarly, epigenetic regulation is 
postulated to be involved in autism and schizophrenia (for review see (Schanen, 2006)).   
Environmental factors may contribute to the difficulties in genetic analyses. Proof 
of principle for a role of environmental factors is provided by studies showing that 
exposure to thalidomide, valproic acid or prenatal infections strongly increase the risk for 
autism and schizophrenia in the offspring.  Therefore, it is possible that environmental 
risk factors contribute to genetic susceptibility or that environmental factors require a 
susceptibility genotype to increase risk. It will be important to understand all of the risk 
factors, genetic, epigenetic and environmental, in order to develop a complete 
understanding of, and more effective treatments for, these disorders.  
 
Maternal infection: an environmental risk factor 
 Maternal infection is among the most studied and best-established non-genetic risk 
factor for schizophrenia. The connection between schizophrenia and maternal influenza 
infection was first indicated by the work of Mednick et al. (Mednick, Machon, Huttunen, & 
Bonett, 1988). Since then, over 25 studies have examined the rate of schizophrenia in 
populations which were in utero during influenza epidemics, and the majority found an 
increased incidence among the exposed offspring (reviewed by (Bagalkote, Pang, & Jones, 
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2001)).  However, such ecological studies are population-based; they are unable to 
document a one-to-one relationship between respiratory infection in individual mothers and 
later development of schizophrenia in their children. To overcome this limitation, Brown, 
Susser and colleagues examined a large pool of archived maternal serum samples that were 
collected in the 1960s and linked to detailed medical records of both mothers and children. 
They found that in cases where they were able to confirm maternal influenza infection by 
assaying the serum, the offspring were 3-7 times more likely than controls to develop 
schizophrenia (Brown, Begg, et al., 2004). Due to the high prevalence of influenza, they 
estimate that up to 21% of all schizophrenia cases may be traced to maternal influenza 
infection.  A separate study examining Danish medical records found an 8-fold risk 
increase in schizophrenia risk with maternal influenza infection (Byrne, Agerbo, 
Bennedsen, Eaton, & Mortensen, 2007). Further studies have found links between elevated 
levels of cord blood cytokines and development of schizophrenia, strengthening the 
association of influenza infection with schizophrenia risk (Brown, 2006; Brown, Hooton, et 
al., 2004). In addition, serological studies have found links between schizophrenia and 
maternal toxoplasmosis (Brown et al., 2005; Mortensen et al., 2007), and rubella (Buka et 
al., 2001), genital/reproductive (Babulas, Factor-Litvak, Goetz, Schaefer, & Brown, 2006), 
and bacterial infections (Sorensen, Mortensen, Reinisch, & Mednick, 2009).  Thus, many 
different pathogens increase the risk of mental disease in the offspring. 
An important insight into the heterogeneity of the schizophrenia phenotype and its risk 
factors was revealed by further study of the population being monitored by Brown et al. 
Comparison of schizophrenics born to infected versus non-infected mothers showed both 
anatomical (enlarged cavum septum pellucidum) and cognitive differences between the two 
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groups (Brown, in press; Brown et al., 2009).  It will be interesting to see if these two 
groups also display divergent responses to anti-psychotic drugs, and what the distribution 
of candidate gene variants for schizophrenia may be.  
 Similar, but considerably less extensive, epidemiological data exist for autism.  
Rubella epidemics in the 1960s were associated with a striking elevation in the incidence of 
autism in children born to infected mothers (Chess, 1977; Desmond et al., 1967). Studies of 
other maternal infections, such as toxoplasmosis, syphilis, varicella and rubeola, also 
support the idea that maternal infection can be a risk factor for autism (for a review, see 
(Ciaranello & Ciaranello, 1995)), although the number of individuals in these studies is 
very small.   
 
Animal models of immune activation 
 
Maternal influenza infection  
 Both the epidemiologic data and the serologic studies show that infection during 
early-to-mid pregnancy results in the greatest schizophrenia risk in the offspring (Brown, 
Begg, et al., 2004; Brown & Susser, 2002).  In order to produce an animal model that most 
closely replicates the human data, Shi et al. (Shi, Fatemi, Sidwell, & Patterson, 2003) 
inoculated mice intra-nasally with a human H1N1 influenza virus on day 9.5 of pregnancy, 
which is the rough equivalent of human early second trimester.  The pregnant dams 
develop lung pathology, show noticeable sickness behavior, and have elevated serum levels 
of several immune markers for approximately seven days, covering the second half of the 
pregnancy.  The adult offspring of influenza-infected mice appear superficially normal, but 
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display several behavioral abnormalities that are highly relevant to schizophrenia and 
autism.  For example, they have lower pre-pulse inhibition (PPI) than controls, and this 
deficit is rescued by acute treatment with antipsychotic drugs.  PPI is abnormal in 
schizophrenia (Turetsky et al., 2007; Wynn et al., 2004) and autism (Perry, Minassian, 
Lopez, Maron, & Lincoln, 2006), as well as in other mental disorders such as depression. 
The offspring also display heightened anxiety in the open field, and they show a reduced 
number of social interactions when placed in an open field with an unfamiliar, same-sex 
conspecific (Shi, et al., 2003). These offspring also display several histological 
abnormalities that are reminiscent of those found in autism and/or schizophrenia, such as 
reduced reelin (Fatemi et al., 1999) and parvalbumin (Meyer, Nyffeler, Yee, Knuesel, & 
Feldon, 2008) immunoreactivity. They also display a spatially restricted deficit in Purkinje 
cells (PCs) in lobules VI and VII of the cerebellum (Shi, Smith, Malkova, Tse, & Patterson, 
2008), which is consistent with the most commonly reported histological abnormality in 
autism (reviewed by (Amaral, Schumann, & Nordahl, 2008)).  
 
Maternal Immune Activation (MIA) 
 The fact that a wide variety of pathogens are able to increase schizophrenia risk in 
the offspring suggests that these pathogens alter fetal development by a common 
mechanism.  Direct infection of the fetus seems an obvious hypothesis.  However, most of 
the implicated infections are confined to specific areas of the body, and do not involve the 
fetus.  For example, influenza infection is confined to the lungs, since the membrane 
proteins that allow viral entry into a cell are found only in the lungs (Taubenberger & 
Morens, 2008).  In the mouse model of maternal influenza infection, using a sensitive RT-
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PCR assay that can detect as little as one plaque-forming unit of virus, no virus is detected 
in the exposed fetuses (Shi, Tu, & Patterson, 2005).  Maternal immune activation is also a 
plausible mechanism; all of the implicated pathogens trigger a maternal immune response, 
which will alter the biochemical environment of the fetus.  In strong support of this 
hypothesis, two rodent models have been developed in which behavioral deficits are 
induced in adult offspring by directly activating the maternal immune system in the 
absence of infectious organisms. 
    
Maternal poly(I:C) administration 
Poly(I:C) is a synthetic, double-stranded RNA that is a potent agonist of the toll-
like receptor-3 (TLR-3).  Double-stranded RNA is regarded by the innate immune system 
as a signal of viral infection; thus the activation of TLR-3 induces a pro-inflammatory, 
NF-kB-dependent cascade that results in the production of anti-viral cytokines and 
chemokines.  Injection of poly(I:C) in the pregnant rodent at mid-gestation produces 
offspring that are remarkably similar to the offspring of mice given a flu infection.  These 
offspring display deficits in PPI, latent inhibition, open field exploration and social 
interaction that are almost identical to those exhibited by influenza offspring (Smith, Li, 
Garbett, Mirnics, & Patterson, 2007).  Moreover, investigators using the poly(I:C) model 
of MIA have shown that the PPI and latent inhibition deficits occur in post-pubertal but 
not in juvenile rats, mimicking the adult-onset nature of schizophrenia (Piontkewitz, 
Weiner, & Assaf, 2007; Zuckerman, Rehavi, Nachman, & Weiner, 2003). These deficits 
are reversed by acute anti-psychotic drug treatment.  Maternal poly(I:C) also causes other 
changes relevant to autism and/or schizophrenia: a PC deficit 31,  increased dopamine 
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release and turnover (Ozawa et al., 2006), reduced parvalbumin expression (Meyer, et al., 
2008), and increased GABAA receptor expression (Nyffeler, Meyer, Yee, Feldon, & 
Knuesel, 2006) in the adult offspring.   
 
Maternal LPS administration 
MIA can also be induced by the injection of bacterial lipopolysaccharide (LPS), a 
natural ligand for TLR-4.  Intrauterine bacterial infection is commonly associated with 
preterm birth, obstetrical complications and cerebral palsy (R. Romero, Gotsch, Pineles, 
& Kusanovic, 2007).  There is evidence linking maternal bacterial infection with 
schizophrenia in the offspring (O'Callaghan et al., 1994; Watson, Kucala, Tilleskjor, & 
Jacobs, 1984), and ligands binding TLR-4 activate many of the same signaling pathways 
as TLR-3. The specific combination of cytokine and chemokine activation for TLR-4 is 
different than for TLR-3, but like poly(I:C), LPS produces a very strong, transient 
immune activation. Thus, bacterial and viral infections can induce similar responses.  
Indeed, some of the behavioral abnormalities seen in the offspring of poly(I:C)-treated 
mothers are also observed in the offspring of LPS-treated mothers.  PPI deficits are often 
reported, as are increased anxiety, social interaction deficits, and abnormalities in 
dopamine-related behaviors (Borrell, Vela, Arevalo-Martin, Molina-Holgado, & Guaza, 
2002; Fortier et al., 2004; H. M. Golan, Lev, Hallak, Sorokin, & Huleihel, 2005; Hava, 
Vered, Yael, Mordechai, & Mahoud, 2006; R. Romero, et al., 2007).  Histological 
findings in the LPS model include fewer, more densely packed neurons in the 
hippocampus, increased microglial and GFAP staining, altered tyrosine hydroxylase 
staining, and decreased myelin basic protein staining (Borrell, et al., 2002; Cai, Pan, 
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Pang, Evans, & Rhodes, 2000; H. M. Golan, et al., 2005; Ling et al., 2004; Paintlia, 
Paintlia, Barbosa, Singh, & Singh, 2004). 
 
Other protocols for maternal immune activation 
Bacteria commonly associated with periodontal disease have been isolated from 
preterm placentas, and epidemiological evidence links schizophrenia risk to both 
periodontal disease and preterm birth (Bobetsis, Barros, & Offenbacher, 2006).  Mouse 
models involving injection of periodontal bacteria into a pregnant dam result in fetal 
growth restriction and mortality (Bobetsis, et al., 2006).  Injection of LPS directly into the 
fetus also results in low birth weight and fetal mortality (reviewed by (Wang, Rousset, 
Hagberg, & Mallard, 2006)).  
There is also a large body of research on maternal stress causing abnormal 
behavior in the adult offspring.  Epidemiological evidence links maternal stress caused by 
diverse stimuli such as war or death of a loved one to schizophrenia in the offspring 
(reviewed by (Beydoun & Saftlas, 2008)), and animal models document behavioral 
changes in the offspring of rats exposed to daily restraint stress.  Barbazanges et al. 
(Barbazanges, Piazza, Le Moal, & Maccari, 1996) showed that this effect of stress is 
mediated by glucocorticoid, which can also have strong modulatory effects on the innate 
immune system.   
 
Mechanisms underlying MIA-induced behavioral abnormalities  
Cytokines are small (8-30 kD) signaling proteins that are released into the serum 
in response to a wide range of stimuli including infection, immune activation and stress. 
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Thus, even though an influenza infection is confined to the lungs, cytokines produced 
there will have access to the placenta and fetus.  Cytokines signal through several key 
kinase pathways, including JAK/STAT, NF-kB, and MAPK.  During brain development, 
these same pathways control functions such as neuronal differentiation and migration, 
axon pathfinding and synapse formation.  Moreover, many cytokine receptors are 
expressed in both developing and mature neurons and can cause morphological and 
functional changes in those cells (Bauer, Kerr, & Patterson, 2007; Gilmore, Jarskog, 
Vadlamudi, & Lauder, 2004; Jankowsky & Patterson, 1999).  If cytokines are able to 
cross from maternal circulation into the fetal brain, the resultant disruption in neuronal 
homeostasis could account for the long-term effects in the offspring. 
Mounting evidence shows that the maternal inflammatory response does, in fact, 
cross the placenta and affect the fetus.  Radiolabeling studies have demonstrated that 
labeled IL-6 and IL-2 enter the fetus when injected into pregnant dams (Dahlgren, 
Samuelsson, Jansson, & Holmang, 2006; Ponzio, Servatius, Beck, Marzouk, & Kreider, 
2007).  Several groups have shown increased cytokine protein in the fetal brain following 
MIA induced by LPS or poly(I:C).  Increases in cytokine mRNA have been found in fetal 
brain as well, making it unclear if the cytokines found in the fetal brain are of maternal or 
fetal origin.  Both protein and mRNA of IL-1β, IL-6, tumor necrosis factor α (TNF-α) 
and IL-10 are upregulated at various time points ranging from 2-24 hours post-injection 
(see Table I).  This response seems to be dose-dependent, as groups that use more severe 
treatments (i.e., higher doses of poly(I:C) or LPS; intravenous versus intraperitoneal 
injection) tend to see more robust increases in fetal brain cytokines. Recent work from 
our group has found evidence of induction of several response genes downstream of IL-6, 
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confirming that cytokines in the fetal brain are having significant biological effects (E. 
Hsiao and P.H. Patterson, unpublished).    
Manipulation of cytokine expression during MIA has demonstrated that cytokine 
signaling plays a key role in the development of abnormal behavior.  Meyer et al. were 
able to prevent the development of behavioral abnormalities in the offspring of MIA 
dams by overexpression of IL-10, an anti-inflammatory cytokine (Meyer et al., 2007).  
IL-10 can also protect against white matter damage caused by maternal E. coli infection 
(Pang, Rodts-Palenik, Cai, Bennett, & Rhodes, 2005).  Similarly, anti-TNFα antibodies 
can reduce the growth restriction and fetal loss caused by LPS injection, and conversely, 
injection of TNFα can mimic the effects of LPS (Silver, Lohner, Daynes, Mitchell, & 
Branch, 1994; Xu et al., 2006).  
Work from our laboratory has demonstrated that IL-6 plays a critical role in the 
effect of poly(I:C)-induced MIA (Smith, et al., 2007).  We screened for cytokines that 
might mediate the effect of MIA by co-injecting poly(I:C) and various anti-cytokine 
antibodies into pregnant mice.  We found that co-injection of anti-IL-6 prevented the 
behavioral deficits caused by poly(I:C).  Antibodies to IL-1β, TNFα, and interferon-γ had 
no significant effect. Moreover, blocking IL-6 also prevented maternal poly(I:C)-induced 
gene expression changes in the adult offspring brain, as measured by RNA microarray.  
In addition, IL-6 knockout mice did not show behavioral deficits after MIA. Conversely, 
a single injection of recombinant IL-6 (but not the other cytokines tested) into pregnant 
mice caused behavioral deficits similar to MIA.  Samuelsson et al. have reported long 
term effects of multiple IL-6 injections in pregnant rats (Samuelsson, Jennische, Hansson, 
& Holmang, 2006); the offspring showed deficits in learning as well as elevated serum 
 119 
levels of IL-6 as adults, which may mimic the ongoing immune activation observed in 
mental illness (see below).   
These animal models demonstrate that MIA, particularly maternal IL-6 activation, 
causes long term changes in the behavior of the offspring that are reminiscent of 
symptoms seen in human mental illnesss.  But how could a transient increase in a single 
immune signaling molecule such as IL-6 (albeit at a critical time in development) 
precipitate such life-long changes?  It is possible that the development of a homeostatic 
regulatory mechanism is disrupted, leading to dysregulation of gene expression not only 
in the brain, but in the immune system as well.  
 
The immune system in mental disorders 
Contrary to the popular myth of the brain as an “immune privileged organ”, the 
nervous and immune systems are significantly interconnected.  In fact, cytokines that are 
traditionally thought of as immune signaling molecules play important roles in neuronal 
functions as well (for review see (Bauer, et al., 2007)).  For example, IL-6 modulates 
neuronal long term potentiation, a process thought to underlie learning and memory 
(Balschun et al., 2004; Jankowsky & Patterson, 1999).  Cytokines can alter the 
morphology of several cell types of the brain; neurons retract their processes in response 
to application of different cytokines; astroglia and microglia can activate and take on a 
different morphology and function after immune stimulation (Bauer, et al., 2007; 
Gilmore, et al., 2004).  On an organismal level, cytokines have been shown to mediate 
several behaviors. IL-6 and IL-1β are responsible for sickness behavior in mice, defined 
as the characteristic ruffling of fur, anhedonia, and suppression of appetite (Swiergiel, 
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Smagin, Johnson, & Dunn, 1997).  These same cytokines probably cause the feeling of 
malaise associated with sickness in humans as well.   Injection of LPS into human 
volunteers causes depression and anxiety-like symptoms (Reichenberg et al., 2001).  IFN-
α given to cancer patients to lessen the side effects of chemotherapy also causes 
depression (Raison, Capuron, & Miller, 2006).  Clearly, cytokines have the potential to 
alter behavior in both the developing and adult brain (for review see (Yirmiya, 2000)). 
It is possible that abnormal inflammation is a core feature of schizophrenia and autism, as 
there is evidence of ongoing immune activation in the brains of affected individuals.  
Immune dysregulation has been frequently reported in blood (Croonenberghs, Bosmans, 
Deboutte, Kenis, & Maes, 2002; Garver, Tamas, & Holcomb, 2003; Singh, Warren, 
Odell, & Cole, 1991; Zhang, Zhou, Cao, Wu, & Shen, 2005; Zimmerman et al., 2005), 
cerebrospinal fluid (Chez, Dowling, Patel, Khanna, & Kominsky, 2007; Zimmerman, et 
al., 2005) and brain (Vargas, Nascimbene, Krishnan, Zimmerman, & Pardo, 2005) from 
both schizophrenic (for review see (Drzyzga, Obuchowicz, Marcinowska, & Herman, 
2006)) and autistic individuals (Table II). Moreover, microarray and proteome studies 
consistently show dysregulation of immune-related transcripts and proteins in 
schizophrenic(Arion, Unger, Lewis, Levitt, & Mirnics, 2007; Martins-de-Souza et al., 
2009; Saetre et al., 2007) and autistic(Garbett et al., 2008) brains.  The most visually 
compelling data supporting immune dysregulation is the severe glial activation reported 
in the postmortem autistic brain (Vargas, et al., 2005).  Despite different ages, causes of 
death and co-morbid diseases (e.g., epilepsy) among subjects, a consistent histological 
pattern of dense, activated microglia (mainly in grey matter) and astroglia (mainly in 
white matter) was observed.  A replication of the microgliosis was reported in autistic 
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brains as young as four years (Morgan, Chana, Buckwalter, Courchesne, & Everall, 
2007).   
Given the biological activity of cytokines, it is likely that this immune 
dysregulation plays an acute as well as developmental role in the behavioral 
abnormalities of patients. Parents report transient improvement in symptoms when an 
autistic child is sick (Curran et al., 2007), and the psychotic symptoms of schizophrenics 
given malaria are also reported to improve transiently (Hinsie, 1929; Tempelton & Glas, 
1924).  These types of sicknesses would alter the cytokine balance peripherally, and 
could therefore affect the brain’s immune status as well (Dantzer & Kelley, 2007). In 
addition, there is a growing recognition that antipsychotic drugs can have anti-
inflammatory effects (for review see (Drzyzga, et al., 2006)).  For example, olanzapine, 
risperidone, perospirone, ziprasidone, quetiapine and aripprazole suppress LPS-induced 
NO production in microglial cells (Bian et al., 2008; Hou et al., 2006; Kato, Monji, 
Hashioka, & Kanba, 2007), and some of these drugs suppress pro-inflammatory 
cytokines in LPS-treated mice (H. Sugino et al., 2009).  Perhaps the antipsychotic effects 
of these drugs are due to their anti-inflammatory properties as well as their antagonism of 
D2 dopamine receptors. In fact, several anti-inflammatory drugs have shown promise in 
the treatment of mental disease. Celecoxib, a COX-2 inhibitor, and minocycline, a 
tetracycline derivative with anti-inflammatory effects on microglia, have been reported to 
improve symptoms in schizophrenic patients (Akhondzadeh et al., 2007; Miyaoka et al., 
2008).   While the minocycline trial was open-label, the Celecoxib trial was double-blind 
and placebo-controlled.  Pioglitazone (Actos©), also an anti-inflammatory drug that 
inhibits microglial activation, showed promise in an early trial in autistic patients (Boris 
 122 
et al., 2007).  Parents reported improvements in several core behaviors in 76% of 25 
children enrolled.  A double-blind, placebo controlled trial of minocycline for the 
treatment of autism is ongoing at the NIH.  However, trials testing drugs in children are 
time-consuming, expensive and ethically delicate.  Novel treatments based on anti-
inflammatory therapies can initially be tested in the rodent models described here that 
have face and construct validity. 
Mice born to dams that received immune-activating treatments during pregnancy 
do show increased levels of inflammation in both the periphery and the brain.  As with 
cytokine expression in the fetus immediately following MIA, more severe immune-
activating treatments tend to produce more severe ongoing inflammation in adult 
offspring.  Daily injection with LPS throughout pregnancy produces offspring with 
chronically elevated levels of peripheral inflammatory cytokines. Treatment with 
antipsychotic drugs normalizes not only their behavior, but their cytokine profiles as well 
(E. Romero et al., 2007).  Three injections of IL-6 into pregnant mice produced elevated 
levels of IL-6 in the serum of the adult offspring (Samuelsson, et al., 2006). These animal 
models demonstrate the power of antipsychotic drugs to dampen abnormal inflammation 
while altering behavior, and highlight MIA in rodents as a model for features of human 
psychiatric disease.  
How does immune activation early in development set up an ongoing 
inflammatory state that persists months or years after the original insult?  Does immune 
activation cause mental illness, or does a mis-wired brain cause inflammation? Ongoing 
research is just beginning to address these questions.  In the meantime, analogies to other, 
more thoroughly-characterized model systems may guide our thinking. 
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  One hypothesis is that the abnormal immune system precipitates abnormal 
behavior in the offspring.  Maternal stress causes persistent behavioral, physiological and 
biochemical changes in the adult offspring. Maternal stress is a risk factor for 
schizophrenia (Beydoun & Saftlas, 2008), and a rat model was developed in the mid-
1990s in which researchers stress pregnant rats by restraining them in a tube for several 
hours each day. The adult offspring displayed an elevated response to stress as adults (as 
well as other abnormal behaviors).  When stressed themselves, the offspring of stressed 
mothers show a prolonged elevation of corticosterone after the stressor is removed 
compared to offspring of unstressed rats (Barbazanges, et al., 1996).  A similar result was 
recently reported in people whose mothers were exposed to stress during pregnancy 
(Entringer, Kumsta, Hellhammer, Wadhwa, & Wust, 2009).  This effect is dependent on 
corticosteroids, as stress in adrenalectomized pregnant rats does not affect the offspring, 
while corticosteroid injection does (Barbazanges, et al., 1996).  Mechanistically, 
corticosteroid injections alter the level of glucocorticoid receptor (GR) in the 
hippocampus, an area important in terminating the stress response (Levitt, Lindsay, 
Holmes, & Seckl, 1996; Meaney et al., 1996).  A related model involves the stress 
response of young rats whose mothers show high or low levels of pup-directed licking 
and grooming behavior (LG).  High-LG offspring have a reduced stress response 
compared to low-LG offspring, with correspondingly different levels of GR.  Maternal 
behavior alters GR expression in the offspring by altering histone acetyltransferase 
activity and subsequent methylation of the GR gene (for review see (Weaver, 2009)).  By 
analogy, perhaps a similar developmental “homeostat” is set early in development based 
on normal, low-level cytokine exposure.  In the MIA model where cytokines are 
 124 
abnormally elevated during a critical period of development, levels of a receptor protein 
could be altered, perhaps via DNA methylation, leading to persistent changes to baseline 
cytokine levels.  
An alternative hypothesis is that the abnormal brain causes an abnormal immune 
system.  If, for example, inhibitory GABAergic interneurons fail to properly develop, the 
resulting brain circuitry would show an imbalance between levels of excitation and 
inhibition.  Clinically, this may manifest as seizures (as observed in 40-50% of autistic 
children), or the loss of GABAergic markers such as parvalbumin (PV) (as is seen in 
schizophrenic brains (Beasley & Reynolds, 1997; Hashimoto et al., 2003), and offspring 
of MIA mothers (Meyer, et al., 2008)). Psychomimetic drugs such as ketamine, an 
NMDA antagonist, produce schizophrenia-like symptoms by inhibiting GABAergic 
neurons and producing a dis-inhibition of excitatory circuits (Behrens, Ali, & Dugan, 
2008). In fact, loss of GABAergic signaling may be a core feature of schizophrenia 
(Lewis, Hashimoto, & Volk, 2005).  Hyperexcited neuronal circuits can also produce an 
inflammatory state.  Using a mouse model in which subchronic administration of 
ketamine induced a loss of PV-positive neurons, Behrens et al. (Behrens et al., 2007) 
demonstrated that ketamine caused long-term damage to PV neurons by activating the 
superoxide-producing enzyme NADPH oxidase (NOX). NOX production was, in turn, 
dependent on neuronal IL-6 produced in response to sustained hyperexcitability 
(Behrens, et al., 2008).  This activation could be a homeostatic response to reduced 
inhibition whereby IL-6-dependent free radical production reduces excitatory 
transmission (via sensitivity of glutamatergic synapses to free radicals) and restores the 
inhibitory/excitatory balance of the circuit (Behrens, et al., 2008).  However, prolonged 
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exposure to ketamine over-activates this feedback system, and the free radical production 
causes long-term damage to PV interneurons.  Similarly, if IL-6 elevation due to MIA 
were to reach the fetus at a critical period of development, it could cause a reduction in 
PV interneurons, as reported in the MIA model (Meyer, et al., 2008).  This loss of 
inhibition could create a hyper-excited circuit similar to a ketamine-exposed brain, 
leading to more IL-6 production by a mechanism similar to ketamine exposure.  This IL-
6 production would further suppress PV interneurons, creating more excitation and an 
ongoing positive feedback loop.  Perhaps this process is set into motion soon after birth, 
resulting in autism, or perhaps a marginally stable circuit needs some later stimulus, such 
as peri-pubertal synaptic pruning, to tip the balance and create an inflammatory, 
hyperexcited, hallucinatory state (schizophrenia). 
Recognizing the interrelatedness of the brain and the immune system allows us to 
look at mental illness differently.  Emerging evidence includes the anti-inflammatory 
action of anti-psychotic drugs (and the potential efficacy of anti-inflammatory drugs as 
anti-psychotics), the behavioral consequences of exposure to inflammatory stimuli, and 
the profound dysregulation of the brain’s immune status seen in mental illness.  Whether 
an affected brain causes inflammation, or inflammation causes a brain to malfunction is 
an important issue in current research.  Answers to these key questions could 
fundamentally alter how we diagnose, treat or even prevent mental illness. 
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Treatment Findings Reference 
0.05 mg/kg LPS I.P. 
E18 rat 
No change in TNFa, IL1b, IL6 (Ashdown et al., 
2006) 
0.12 mg/kg LPS I.P. 
E17 mouse 
IL-6 increased (H. Golan, 
Stilman, Lev, & 
Huleihel, 2006) 
1 mg/kg LPS I.P. 
E18 rat 
TNFa, IL-1b, iNOS increased * (Paintlia, et al., 
2004) 
50ug LPS I.P. 
E18 mouse 
IL-1b, IL-6, MCP-1, VEGF increased 
* 
(Liverman et al., 
2006) 
2.5 mg/kg LPS I.P. 
E16 rat 
TNFa increased (Urakubo, 
Jarskog, 
Lieberman, & 
Gilmore, 2001) 
4 mg/kg LPS I.P. 
E18 rat 
TNFa, IL-1b increased * (Cai, et al., 
2000) 
20 mg/kg poly(I:C) I.P. 
E16 rat 
No change in TNFa (Gilmore, 
Jarskog, & 
Vadlamudi, 
2005) 
2 mg/kg poly(I:C) I.V. 
E9 mouse 
TNFa, IL-1b, IL-6, IL-10 increased (Meyer, et al., 
2007) 
5 mg/kg poly(I:C) I.V. 
E9 mouse 
IL-1b, IL-6 increased (Meyer et al., 
2006) 
5 mg/kg poly(I:C) I.V. 
E17 mouse 
IL-1b, IL-6, IL-10 increased (Meyer, Feldon, 
Schedlowski, & 
Yee, 2006) 
 
Table I. Maternal immune activation elevates cytokines in fetal brain. While some 
authors report no changes in cytokine levels, the majority of studies show significant 
increases.  The studies that report no changes use less severe methods of immune 
activation (lower dose of LPS or I.P. administration of poly(I:C)). Assays are for cytokine 
protein, except where noted (*mRNA assayed). 
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Sample Analyzed Findings Reference 
Serum from 23 autistic children Increased IL-2 and T8 antigen 
(Singh, et al., 
1991) 
Serum from 35 autistics Increased TNFR II 
(Zimmerman, et 
al., 2005) 
Unstimulated whole blood culture 
supernatant from autistic children 
Increased IFNγ and IL-1RA, IL-6 
trended higher (p= 0.06) 
(Croonenberghs, 
et al., 2002) 
Unstimulated PBMCs culture 
supernatant  from 10 autistic 
children 
Increased TH2 cytokines, increased 
IL-13/IL-10 and IFNγ/IL-10 ratios 
(Molloy et al., 
2006) 
Whole blood from 31 autistic 
children 
Increased monocyte count, increased 
neopterin level 
(Sweeten, 
Posey, & 
McDougle, 
2003) 
CSF from 12 autistic children 
Increased biopterin, decreased 
quinolinic acid and neopterin 
(Zimmerman, et 
al., 2005) 
CSF from 10 autistic children  Increased TNFα 
(Chez, et al., 
2007) 
CSF from 6 autistic children 
Increases in many cytokines, including 
IFNγ, TGFβ2 MCP-1 IL-8 
(Vargas, et al., 
2005) 
Fresh-frozen tissue from 7 autistic 
brains 
Increases in many cytokines, including 
MCP-1, IL-6 and TGFβ1 
(Vargas, et al., 
2005) 
LPS-stimulated PBMCs from 71  
autistic children 
Increased TNFα, IL-1β and IL-6 
production 
(Jyonouchi, 
Sun, & Le, 
2001) 
 
Table II. Inflammatory biomarkers are increased in autism.  Studies of serum, blood 
cell cultures, cerebrospinal fluid (CSF), and brain tissue consistently find elevated levels 
of pro-inflammatory markers in autistic individuals.  For a thorough review of similar 
findings in schizophrenia, see (Drzyzga, et al., 2006).  PBMC, peripheral blood 
mononuclear cells.      
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Abstract 
 
The core symptoms of autism are deficits in social interaction and language, and the 
presence of repetitive/stereotyped behaviors. We demonstrate that behaviors related to 
these symptoms are present in a mouse model of an environmental risk factor for autism, 
maternal infection. We stimulate the maternal immune system by injecting the viral 
mimic poly(I:C) during pregnancy, and analyze the social and communicative behaviors 
of the offspring. In one test, young pups respond to a brief separation from the mother 
with ultrasonic vocalizations (USVs). We find that, compared to pups born to saline-
injected mothers, pups born to maternal immune activation (MIA) mothers produce a 
lower rate of USVs in the isolation test starting at day 8. The quality of the vocalizations 
is also different; analysis of sound spectrograms of 10 day-old pups shows that male pups 
from MIA mothers emit significantly fewer harmonic and more complex and short 
syllables. These communication differences are also apparent in adult offspring. 
Compared to controls, adult MIA males emit significantly fewer USVs in response to 
social encounters with females or males, and display reduced scent marking in response 
to female urine. Regarding a second autism symptom, MIA males display decreased 
sociability. In a third test of characteristic autism behaviors, MIA offspring exhibit 
increased repetitive/stereotyped behavior in both marble burying and self-grooming tests. 
In sum, these results indicate that MIA yields male offspring with deficient social and 
communicative behavior, as well as high levels of repetitive behaviors, all of which are 
hallmarks of autism. 
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Introduction 
Autism is a neurodevelopmental disorder characterized by social impairments, 
communication difficulties and repetitive/stereotyped behaviors. While there is a 
substantial genetic component in autism, there is also evidence that environmental factors 
can contribute to the complex pathogenesis of autism spectrum disorders (ASD). Recent, 
large twin studies show a substantial concordance for autism between dizygotic as well as 
monozygotic twins ( [Rosenberg et al., 2009] and [Hallmayer et al., 2011]). Moreover, 
the significantly higher risk for dizygotic twins compared to non-twin siblings suggests a 
role for the maternal environment. In fact, epidemiologic studies provide evidence that 
maternal exposure to stress, infection, anti-depressant medications, thalidomide or 
valproic acid (VPA) increases the risk for ASD in offspring (reviewed by [Hyman et al., 
2005], [Kinney et al., 2008],[Patterson, 2009] and [Patterson, 2011a]). In particular, a 
recent study of over 10,000 records in the Danish Medical Register found a strong 
association between autism and maternal viral infection in the first trimester and a less 
robust but significant association between autism and maternal bacterial infection in the 
second trimester (Atladottir et al., 2010). There is also evidence of elevated levels of the 
chemokine MCP-1 in the amniotic fluid in ASD cases (Abdallah et al., 2012), and 
elevated levels of IFNγ, IL-4 and IL-5 in maternal serum are associated with increased 
risk for ASD in the offspring (Goines et al., 2011). These new results greatly extend prior 
work on the connection between maternal infection and autism. 
Animal models displaying certain autistic features can be generated by maternal 
environmental challenges such as infection and exposure to VPA. Such models can be 
useful tools for testing epidemiologic findings and investigating the molecular 
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mechanisms underlying the neuropathology (reviewed by [Iwata et al., 2010], [Hsiao et 
al., 2011] and [Patterson, 2011b]). Deficits in communication are among the most 
prominent and functionally important symptoms in ASD, and acoustic and chemical 
signals are two primary modes of communication in rodents. The number and quality of 
USVs and the chemical composition of urine can convey information regarding health 
and fitness. Male responses to female urine can involve USVs and marking the 
surrounding territory (scent marking). A deficit in social interaction is also a critical 
symptom of ASD, and there are a number of paradigms used to assess this feature in 
rodents. One test that was originally introduced to assay social affiliation and pair 
bonding in voles utilizes a three chamber apparatus. In mice, this can include a test for 
preference for an unfamiliar mouse over an unfamiliar object (Silverman et al., 2010). 
The third cardinal symptom of autism involves repetitive/stereotyped behavior, which 
can be assayed in mice by quantifying self-grooming and compulsive burying of marbles 
placed in the nest (Thomas et al., 2009). 
In the present study, we used these various assays to determine how closely the 
core symptomatology of autism can be reproduced in a model of an environmental risk 
factor for ASD. This model involves activating the immune system of pregnant mice in 
order to mimic the effects of maternal infection. Young and adult offspring of these mice 
were assessed for relevant behaviors in several paradigms. 
 
Results 
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Pups born to MIA mothers display a deficit in the number of USVs and an altered 
syllable repertoire 
Neonatal rodents emit USVs when separated from their mothers or littermates in 
order to attract the mother for retrieval to the nest. In most mouse strains, the rate of pup 
USVs increases during the first 5–6 postnatal days, reaching a peak on days 8–10, and 
decreasing to zero by the end of the second postnatal week (Motomura et al., 2002). We 
evaluated male MIA and control offspring for USV production in the isolation test during 
second postnatal week. Compared to controls, male pups from MIA mothers emit fewer 
vocalizations (F(1, 56) = 17.74, p < 0.0001; Bonferroni posthoc test p < 0.05 for P8, P10 
and P12 pups) and the total vocalization duration is less starting from day 8 (F(1, 
56) = 15.74, p < 0.0005; Bonferroni posthoc test p < 0.05 for P8, P10 and P12 pups) (Fig. 
1A and B). 
In order to minimize the effect of repetitive handling and isolation on pup USVs, 
data for structural analysis of the USVs were collected from pups tested only on P10. The 
proportion of each syllable type is shown in Fig. 1C. Since there is no difference in the 
proportion of one, two and multiple frequency step syllables, we present them as one 
group termed frequency step syllables. Although a two-way ANOVA test does not 
indicate a difference in the distribution of USV syllables between treatment groups 
(treatment, F(1, 41) = 0.292, p = 0.58), significant effects of syllable type (F(8, 
180) = 79.97, p < 0.0001) and treatment × syllable type interaction (F(8, 180) = 3.67, 
p < 0.0006) are evident. However, the Bonferoni post-hoc test shows a treatment-
dependent effect on the proportion of syllables in three of the nine syllable types. 
Compared to controls, MIA offspring produce 60% fewer harmonic syllables (p < 0.05) 
 148 
and significantly more short (MIA 13% versus control 7%, p < 0.05) and complex 
syllables (MIA 13% versus control 9%, p < 0.05) (Fig. 1C). ANOVA analysis of the 
duration of each syllable type also shows a difference between MIA and control offspring 
(treatment, F(1, 41) = 4.32, p < 0.05). The Bonferoni post-hoc test reveals a difference 
between the treatment groups in complex, downward and upward syllables (p < 0.05) 
(Table 1). However, no difference is found in the dominant frequency of any of the USV 
syllables (treatment, F(1, 41) = 0.022, p = 0.88 (Table 2). 
Body weight was used as a parameter to evaluate animals’ health and it does not 
differ between these two groups (Fig. S3). Moreover, we find no changes in the 
development of reflexes (negative geotaxis, grasp reflex and righting reflex) (data not 
shown). In addition, we analyzed maternal behavior toward pups in response to either 
nest relocation or to pup retrieval and found no difference between two treatment groups 
(Fig. S4). Thus, the reduction in the USV production is not due to a delay in gross pup 
development or evident differences in maternal responsiveness toward the offspring. 
 
Adult male offspring from MIA mothers display reduced USV responses to various social 
stimuli 
Adult mice produce USVs in several social contexts (Portfors, 2007). Encounters 
with females induce male USV production, which is most prominent during initial 
investigatory behavior and correlates well with the level of male sexual arousal (White et 
al., 1998). This USV production conveys an important communicative function, 
predominantly to engage the female’s attention. Before studying male–female 
interactions, we used anesthetized animals to conduct a pilot experiment to evaluate the 
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contributions of male and female mice in USV production. We detect USVs in two 
settings – when both the male and female are awake and when a male is exposed to an 
anesthetized female. In contrast, few vocalizations (2–3 during 3 min testing period) are 
detected when the male is anesthetized, although the female mouse interacts physically 
with the male by sniffing and walking around him (data not shown). Thus, female mice 
do not contribute significantly in USV production, at least in our test setting. Similar 
results were reported by several research groups using devocalized or anesthetized males 
( [Maggio and Whitney, 1985], [White et al., 1998] and [Sugimoto et al., 2011]). To test 
vocalizations in adult MIA offspring, we introduced an unfamiliar female to the male and 
recorded USVs. We find that, compared to control males, MIA offspring produce 
significantly fewer vocalizations in the presence of a female (t(41) = 2.092, p < 0.05) 
(Fig. 2A). While analysis of USV syllables using the two-way ANOVA does not show a 
significant difference in the distribution of syllable types between MIA and control males 
(treatment, F(1, 41) = 1.68, p = 0.2; syllable type, F(10, 450) = 54.66, p = 0.0001; 
treatment × syllable type, F(10, 450) = 1.13, p = 0.3), the Bonferoni post-hoc test reveals 
a significant reduction in the MIA offspring in the number of two frequency step (MIA 
8% versus control 12%, p < 0.05) and chevron syllables (MIA 10% versus control 13%, 
p < 0.05) (Fig. 2B). The two-way ANOVA test shows a difference between MIA and 
control male offspring in duration and dominant frequency of USV syllables during 
interaction with females (treatment, F(1, 41) = 7.42, p < 0.05 for syllable duration and 
F(1, 41) = 9.4, p < 0.05 for dominant frequency of syllables). The Bonferoni post-hoc test 
of individual syllables reveals a significant difference in duration of three and more 
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frequency step syllables (p < 0.05) ( Table 1 and Table 2). As with the pups, no treatment 
difference is found in the dominant frequency of any USV syllables (Table 2). 
Before studying male–male interactions, we also conducted a pilot experiment to 
evaluate the contributions of resident and intruder mice in USV production using 
anesthetized animals. We detected USVs in only two settings, when both males were 
awake or when the intruder was anesthetized. In contrast, no vocalizations were recorded 
when the resident was anesthetized, although the intruder mouse interacted physically 
with the resident by sniffing and licking him (data not shown). The pilot experiment 
suggests that resident males respond to an encounter with a male intruder by producing 
USVs, which likely serve an important defensive function. We next analyzed the 
responses of adult male offspring of control and MIA mothers to the presence of an 
unfamiliar male intruder. Compared to controls, MIA offspring produce significantly 
fewer USVs during this social encounter (Mann–Whitney U = 99, p < 0.05 one-tailed) 
(Fig. 3A). Since not all tested males produced USVs in the presence of a male intruder, 
the number of samples used to analyze the sound spectrograms was 16 for control and 19 
for experimental groups. While the two-way ANOVA test does not an effect of treatment 
on the total distribution of all syllables for male-male interaction (treatment, F(1, 
33) = 3.31, p = 0.08; syllable type, F(10, 330) = 84.04, p = 0.0001; treatment × syllable 
type, F(10, 330) = 0.83, p = 0.8), the Bonferoni post-hoc test of individual syllable 
differences reveals a significant reduction in the number of two frequency step syllables 
emitted by the MIA offspring (MIA 5% versus control 8%, p < 0.05) (Fig. 3B). No 
difference is seen in the duration of any USV syllables (treatment, F(1, 41) = 2.4, 
p = 0.12) (Table 1). Two-way ANOVA test shows a difference between MIA and control 
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male offspring in the dominant frequency of all USV syllables during male–male 
interaction (treatment, F(1, 41) = 16.32, p < 0.001). However, the Bonferoni post-hoc test 
reveals a significant change in the dominant frequency for flat syllables only (p < 0.05) 
(Table 2). Thus, in all three social paradigms, there is a decrease in the number of USVs 
emitted by the MIA offspring. In both of the adult social paradigms, MIA offspring 
produce fewer two frequency step syllables. Our results indicate that MIA not only 
affects USV production by the offspring, but also changes the quality of their 
communication in several social settings that have important biological roles in survival 
and reproduction. 
 
MIA males display a communication deficit in female urine-induced scent marking 
In addition to communication using acoustic signals, mice gain information 
through olfaction. Scent marks (urinary traces) are used to determine mouse identity, 
mark territory, and to attract mates (Hurst, 2009). During the 60-min habituation to a new 
clean cage, the two groups of mice showed no difference in scent marking. The total 
density of urine deposits for control and experimental males were 3899 ± 378 and 
4224 ± 525 for control and experimental groups, respectively; (t(41) = 0.51, p = 0.615). 
Then we used fresh male or female urine to stimulate scent marking from adult male 
mice in order to assess olfactory communication. Males from both MIA and control 
groups spend equal time exploring a female urine spot (data not shown), suggesting that 
they are both processing the olfactory social stimulus. (A further test of olfactory 
sensitivity is described below). But male offspring from MIA mothers deposit half as 
many scent marks compared to control animals during the 3 min test period 
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(t(41) = 3.266, p < 0.005) (Fig. 4A and Fig. S5). Interestingly, no group difference is 
found when male urine is used as the stimulus (t(41) = 0.021, p = 0.98) (Fig. 4B). It 
should be noted, however, that in control males, male urine induces half as many scent 
marks as does female urine (t(40) = 4.434, p < 0.0001). In sum, MIA males display a 
communication deficit in female-induced scent marking, which plays a key role in 
mediating sexual behavior. 
 
MIA offspring display reduced sociability 
Social behavior is a form of communication between members of the same 
species, and this type of behavior in rodents is thought to constitute a reasonable model of 
human interpersonal interaction. The three chamber apparatus can be used to assess 
autism-related behaviors such as sociability (Silverman et al., 2010). Shortly after a 
period of habituation, sociability is evaluated as the time the subject mouse spends in the 
chamber containing a wire cage holding an unfamiliar mouse compared to the time spent 
in the opposite chamber containing an empty wire cage (novel object). We find that 
males from saline-injected mothers spend 65% of the time in the social chamber and 26% 
of the time in the chamber with the novel object. In contrast, offspring of MIA mothers 
display decreased preference for the social chamber, spending only 50% of the time 
exploring the social chamber and significantly more time (37%) than controls exploring a 
novel object (F(2, 48) = 12.73, p < 0.0001; Bonferroni posthoc test p < 0.001 for time in 
the social chamber and p < 0.01 for time in the chamber with novel object) (Fig. 5A). 
This results in significantly different ratios of time spent in the two compartments 
(preference index) compared with the offspring from saline-injected mothers 
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(t(41) = 3.283, p < 0.005; Fig. 5B). This result is similar to that obtained with offspring of 
mothers injected just once with poly(I:C), and where both sexes were tested (Smith et al., 
2007). 
 
MIA offspring display high levels of repetitive/compulsive behavior in the marble burying 
test 
The marble burying test presents a novel situation that can evoke a highly 
repetitive and stereotyped response. The marble burying test was previously used to 
evaluate anxiety but it was recently shown that this behavioral response does not 
correlate with results from other tests of anxiety. Thus, marble burying is now used to 
evaluate repetitive and perservative behavior in small rodents (Thomas et al., 2009). We 
find that the offspring of MIA mothers display extremely high repetitive behavior in this 
test (t(41) = 8.535, p < 0.0001) (Fig. 6A and Fig. S6). Compared to the control group, 
MIA offspring bury 2.8-fold more marbles during the testing period. 
 
MIA offspring display elevated levels of self-grooming 
Self-grooming can provide another index of repetitive/stereotypic behavior in 
rodents (Silverman et al., 2010). We tested individual mice in a small glass beaker for 
10 min, as it is known that a restricted environment induces repetitive behavior (Lewis et 
al., 2007). MIA male offspring spend 50% more time on self-grooming than controls 
(t(41) = 2.335, p < 0.05) (Fig. 6B). 
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MIA offspring do not display an obvious olfactory deficit 
Since MIA offspring display decreased sociability and communication, we 
evaluated their olfactory sensitivity. Time spent sniffing a novel, vanilla-scented paper 
versus a plain water-scented paper was recorded, and no group difference is evident 
(t(18) = 0.361, p = 0.72) (Fig. 7). Therefore, the social and communication deficits found 
in the MIA offspring are not likely to be caused by olfactory malfunction. 
 
Discussion 
We here show that the offspring of poly(I:C)-treated mothers exhibit the three 
core features of autism. While prior work from our laboratory had demonstrated deficits 
in social interaction in MIA offspring, those studies utilized a different poly(I:C) 
injection schedule, different methods, and did not analyze males specifically ( [Shi et al., 
2003], [Smith et al., 2007] and [Hsiao and Patterson, 2011]). The present study is also the 
first to analyze scent marking, USVs, and repetitive/stereotyped behaviors in the MIA 
model. Moreover, this is the only model of an environmental risk factor for autism in 
which all three of the core features have been analyzed thus far. 
In the model of a different environmental autism risk factor, maternal VPA, 
behavioral studies revealed two core autism symptoms, repetitive/stereotypic-like 
hyperactivity and impairment in social interaction ( [Schneider and Przewłocki, 
2005] and [Schneider et al., 2006]). In the rat model of maternal stress, there are also 
male-specific behavioral abnormalities: poor sociability (Lee et al., 2007) and sexual 
behavior (Ward and Reed, 1985), as well as deficits in pup USVs ( [Morgan et al., 
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1999] and [Zimmerberg and Blaskey, 1998]). Activation of the maternal immune system 
with lipopolysaccharide (LPS), which mimics bacterial infection, also yields offspring 
with decreased social interaction ( [Hava et al., 2006] and [Kirsten et al., 2010]). In 
addition, pups from LPS-injected mothers display impaired play behavior and USV 
communication ( [Hava et al., 2006], [Baharnoori et al., 2010] and [Kirsten et al., 2010]). 
A neuropathology characteristic of autism, a spatially localized deficit in Purkinje cells in 
the cerebellum, is also found in the VPA and MIA mouse models ( [Ingram et al., 
2000] and [Shi et al., 2009]). Since the cerebellum is known to contribute to learning, 
language, sociability and emotionality ( [Ito, 1998] and [Thach, 1998]), the deficits in 
communication and social interaction observed in MIA and VPA mice may be associated 
with abnormalities in the cerebellum as well as other brain regions. Together, these 
rodent models exhibit a spectrum of autistic-like behaviors. 
It should be noted that maternal infection models also display features of schizophrenia. 
These include enlarged ventricles, enhanced responses to amphetamine and 
hallucinogens, alterations in dopamine and serotonergic pathways, as well as a number of 
other behaviors in the offspring that are also found in subsets of autistic subjects such as 
enhanced anxiety and eye blink conditioning, as well as a PPI deficit ( [Iwata et al., 
2010], [Hsiao et al., 2011], [Meyer and Feldon, 2010], [Patterson, 2011b] and [Moreno et 
al., 2011]). This is not surprising, as maternal infection is a well-characterized risk factor 
for schizophrenia as well as autism (Brown and Derkits, 2010). Moreover, these disorders 
have symptoms in common, such as impaired social interaction, elevated anxiety and 
abnormal responsivity to stress (Tordjman et al., 2007). On the other hand, schizophrenia 
and autism obviously have symptoms that differentiate them. Autism occurs in early 
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childhood whereas the psychotic symptoms of schizophrenia appear much later. In 
addition, delusions and hallucinations are typical of schizophrenic patients while motor 
stereotypies and lack of language are cardinal symptoms of autism. Thus, the MIA model 
displays both symptoms in common between these two disorders, as well as symptoms 
that differentiate them. Presumably the different disease phenotypes associated with 
maternal infection in human autism and schizophrenia are due to differences in genetic 
background of the mother and/or fetus, the timing of the infection, the presence of 
allergies or autoimmune disease in the mother, and possibly the severity of the infection. 
The present study shows that MIA offspring display altered emotional behavior 
early in postnatal life. The male pups display a reduced number of vocalizations when 
they are isolated from their littermates and mother. Similar findings were reported for 
pups born to mothers exposed to stress or LPS during pregnancy ( [Morgan et al., 
1999] and [Baharnoori et al., 2010]), and in reelin, Mecp-2 and CNTNAP2 mutant mice ( 
[Ognibene et al., 2007], [De Filippis et al., 2010] and [Peñagarikano et al., 2011]). The 
reduction in USV production is not, however, due to a delay in gross pup development or 
a difference in maternal care. Altered USVs can reflect a reduced response to stress or 
poor bonding with the mother; the latter was characterized in mice lacking the µ-opioid 
receptor gene (Moles et al., 2004). The former explanation appears unlikely in the MIA 
model as we do not see any changes in the pup locomotor activity (circling and pivoting) 
during the isolation test (data not shown). Interestingly, BTBR pups, a mouse strain with 
several autism-like features, vocalize more in this test compared to several other strains 
of mice, which could be due to an elevated emotional response to the novel environment 
(Scattoni et al., 2008). In addition, the BTBR pups exhibit an altered vocal repertoire, 
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producing a high level of harmonics but minimal syllables with a simple structure 
(chevron-shaped, upward, downward and short). MIA pups also show some structural 
changes in their vocalization patterns, but these are opposite what was reported for BTBR 
pups: lower level of harmonic syllables but increased level of complex and short 
syllables. Harmonic syllables are known to be prominent in the mouse pup repertoire 
(Grimsley et al., 2011). They amount to 16% of the pup repertoire, whereas the 
proportion of this type of syllable is very low in adult male song during male–female and 
male-male encounters (Figs. 1C, 2B and 3B). It is also interesting that a short reunion 
with the mother affects pup emotional response to a second isolation as evidenced by 
increased USV production and augmented proportion of multi-component syllables 
including harmonics (data not shown; Young et al., 2010). Moreover, harmonic syllables 
have some similarity to human baby cries (Zeskind et al., 2011), which is known to 
reflect the emotional state of the baby. Thus, harmonic syllables can be used as an index 
of pup emotional status, and MIA offspring demonstrate a reduced emotional response to 
separation from the mother. 
Importantly, we find that adult MIA males demonstrate decreased USV responses 
in social encounters with females or other males. Several mouse strains suggested as 
being relevant for autism studies (BTBR, NL-3-knockout (KO), NL-4 KO and Shank1 
KO) show a similar deficiency ( [Jamain et al., 2008], [Radyushkin et al., 2009], 
[Scattoni et al., 2011] and [Wohr et al., 2011b]). Frequency step syllables are the most 
frequent in adult male repertoire in both social settings (37–39%), and they likely reflect 
affiliative/social communication. Sound spectrogram analysis of MIA male vocalizations 
reveals reduced use of two frequency step syllables in both social paradigms. BTBR 
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males also emit fewer frequency step calls during interaction with females or males, 
although no changes in USV repertoire were found for NL-3 KO and NL-4 KO mice. 
Given the differences in syllable preference displayed by MIA versus control males, it 
will be of interest to examine such preferences more closely over developmental time, 
and in other social paradigms such as juvenile play. It will also be worthwhile to examine 
the serial order and groupings of the syllables to determine if these parameters are 
correlated with social paradigm, age or maternal insult. Such analyses could provide 
important information as to the relevance of syllable use in mice to the language deficit in 
autism. The deficit in male USVs in the presence of a female in estrous and the deficit in 
scent marking in the presence of female urine could suggest a lack of sexual interest. We 
know of no data on actual mating behavior or successful copulation by adult male MIA 
offspring. Similarly, the deficit in USVs in the presence of a male intruder suggests a lack 
of aggressiveness in defense of territory. It will be of interest in the future to test MIA 
males for dominant/submissive behaviors as well as sexual behavior. 
In addition to deficits in auditory communication, MIA males exhibit a reduction 
in female urine-induced scent marking, which was also found in BTBR and Shank1 KO 
males ( [Wohr et al., 2011a] and [Wohr et al., 2011b]). The deficits in auditory and 
olfactory communication tested here would also seem relevant for social interaction. The 
sociability test we used seems more appropriate for the social deficit in human autism 
than the social preference or social habituation tests. The latter tests are based on memory 
of prior social encounters, which has not been shown to be a key feature in autism social 
pathology. In contrast, the sociability test assesses whether the mouse prefers to be in the 
presence of a novel mouse versus a novel object. While many factors may be involved in 
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this decision (e.g., fear, curiosity, aggression), it does seem analogous to many human 
situations that confront autistic individuals. In this light, prior work on interaction with 
novel objects is of interest. MIA offspring display a deficit in interaction with a novel 
object (Shi et al., 2003), which is suggestive of anxiety in a novel situation, as is seen in 
autism. Further work of this type revealed that, compared to controls, MIA offspring 
display a distinct c-Fos expression pattern in hippoocampal area CA1 following novel 
object, but not novel location, exposure. Thus, the offspring of MIA mothers may have an 
abnormality in modality-specific information processing. Indeed, MIA offspring display 
enhanced discrimination in a novel object recognition, but not in an object location task 
(Ito et al., 2010). Thus, analysis of object and spatial information processing at both 
synaptic and behavioral levels reveals a largely selective abnormality in object 
information processing in this mouse model. We find that MIA offspring exhibit highly 
repetitive behavior in marble burying and self-grooming tests. Self-grooming is also 
increased in several other mouse strains with relevance to autism (BTBR, and Fmr1, 
MeCP2 and CNTNAP2 KO mice) ( [McNaughton et al., 2008], [McFarlane et al., 2008], 
[Chao et al., 2010] and [Peñagarikano et al., 2011]). 
In sum, this study provides new evidence that environmental risk factors such 
maternal infection during pregnancy yield the offspring with autistic-like behaviors, 
including communication and social interaction impairments as well as high repetitive 
behavior. This reinforces prior results indicating the face and construct validity of the 
model for both autism and schizophrenia. 
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Methods 
Generation of animals 
Female C57BL/6J mice (Jackson Laboratory, Bar Harbor, ME) were obtained from the 
California Institute of Technology breeding facility and were housed in ventilated cages 
under standard laboratory conditions. Mice were mated overnight, and the presence of a 
vaginal plug marked that day as embryonic day 0.5 (E0.5). Pregnant females were not 
disturbed, except for weekly cage cleaning, until E10.5 when they were weighed and 
pseudo-randomly assigned to one of two groups, poly(I:C) or saline. Each group initially 
contained five or six pregnant females. The maternal poly(I:C) treatment did not alter 
litter size (8.67 ± 0.56 and 7.83 ± 0.54 for control and experimental groups, respectively; 
t(10) = 1.07, p = 0.309). All pups from a single litter remained with the mother until 
weaning at P21, at which time male mice were housed with same-sex littermates in 
groups of two to four. All experimental mice underwent the same sequence of behavioral 
tests at the same times during development (n = 21 (5 litters) and 22 (5 litters) for control 
and experimental groups, respectively). All behavioral tests were conducted in behavioral 
testing rooms between 09.00 and 17.00 h during the light phase of the circadian cycle. 
Mice were habituated to a testing room at least 1 h prior to the start of the behavioral test. 
Order of testing was: (1) Pup USVs during the isolation test at age 10 days; (2) PPI at age 
6 weeks (Supplemental materials); (3) open field at 7 weeks (Supplemental materials); 
(4) adult male USV responses to female and male stimuli at age 8–9 weeks; (5) three 
chamber social test at 10 weeks; (6) scent marking at 11 weeks; (7) marble burying at age 
12 weeks; (7) self-grooming at age 13 weeks; and (8) olfactory sensitivity at age 13–
14 weeks. A separate experiment was carried out with another cohort of mice (n = 29 (6 
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litters) and 29 (6 litters) to test the USV profile during the second postnatal week. This 
was done for two reasons: first, to minimize effect of handling and stress on the USV 
structure; second, to lessen the effect of repeated stress during isolation in early postnatal 
life on adult behavior. 
 
Maternal administration of poly(I:C) 
One group of mice was given intraperitoneal injections of 5 mg/kg poly(I:C) (potassium 
salt; P9582; Sigma, St. Louis, MO) or saline on E10.5, 12.5 and 14.5. The manufacturer 
supplies poly(I:C) at 10% of the total weight of the salt, and the dosage was based on the 
weight of poly(I:C) itself. The inflammatory cytokine response in pregnant mice induced 
by an acute systemic challenge of poly(I:C) is time-limited, and the time of maternal 
immune challenge influences the pattern of behavioral abnormalities in the offspring 
(Meyer et al., 2006). Therefore, we challenged the maternal immune system three times 
during pregnancy to determine if the offspring develop a broader range of behavioral 
deviances. However, where comparisons are possible, the behavioral results from the 
current offspring do not appear to be significantly different from our prior results using a 
single poly(I:C) injection on E12.5. Mice born to triple-injected mothers have the deficit 
in prepulse inhibition (PPI) and reduced locomotion in open field (Fig. S1) that we have 
seen in single-injected mothers and influenza-infected mothers ( [Shi et al., 2003], [Smith 
et al., 2007] and [Hsiao and Patterson, 2011]). 
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Pup USVs during the isolation test 
Pups from mothers injected with saline or poly(I:C) were tested for USVs every other day 
from day 6 to day 14 in the isolation test as described (Hofer et al., 2002). During the test, 
the dam was removed from the home cage and placed in a separate cage away from the 
litter. Fifteen minutes after removing the dam, male pups were individually removed 
from the nest in random order and gently placed into an empty 15 × 15 cm white 
Plexiglas box. Ambient temperature in the room was 23.5–23.6 °C. In the pilot 
experiment the pups’ axillary temperature was measured prior and after testing and found 
to be decreased after isolation from 34.43 ± 0.19 to 31.97 ± 0.29 °C in 6 day-old pups. In 
a pilot experiment we tested P6 pups from MIA and control mothers in the isolation test 
and found no difference in the temperature decrease between the groups (data not 
shown). As it is known that small decreases in pup core temperature in the home cage 
before testing have no significant effect on their USV isolation performance (Hofer et al., 
2002), we did not measure the body temperature in order to minimize the effect of 
handling on pup behavior. USVs were recorded for 3 min using an UltraSoundGate 
Condenser Microphone (CM 16; Avisoft Bioacoustics, Germany) suspended 7 cm from 
the testing surface. The microphone was sensitive to frequencies of 0–250 kHz with a flat 
frequency response (±6 dB) between 25 and 120 kHz. It was connected via an Avisoft 
UltraSoundGate 116 USB Audio device (Avisoft Bioacoustics) to a personal computer, 
and the recordings were carried out with a sampling rate of 250 kHz. The vast majority of 
USVs were detected within the 0–150 kHz range. The recordings were analyzed using 
Avisoft SASLab Pro software (see below). After recording, the pups were weighed and 
placed back into the nest. Body weight was included as an indicator of pups’ nutritional 
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status and maturational age. The mother was returned to the pups after they all had been 
tested. The testing box was cleaned with water after each pup recording. 
 
Adult male USV responses to female and male stimuli 
Eight-to-ten week-old males were separated and housed singly for a week before testing. 
To provide a standardized history of sexual experience that is known to facilitate USVs 
(McGinnis and Vakulenko, 2003), adult male subjects were exposed to unfamiliar adult 
females for 15–20 min every day for 5 days. On the day of testing, the male was placed in 
a clean cage (30 × 16 × 14 cm) for 10 min habituation. The male was then tested for 
USVs in the presence of an unfamiliar female in the estrous phase for 3 min. The female 
was scored as in estrous when the vaginal area appeared wide, open and red. USVs were 
recorded as described above. After 5 min rest following removal of the female, the male 
subject was tested for USVs in the presence of an unfamiliar male intruder for 3 min. 
During male–male encounters, host males show characteristic behaviors such as active 
approaching, sniffing and following the intruder. USVs were analyzed using Avisoft 
SASLab Pro software as described below. 
 
Analysis of USVs 
For acoustical analysis, recordings were transferred to Avisoft SASLab Pro (version 4.38; 
Avisoft Bioacoustics) and a fast Fourier transformation was conducted (512 FFT-length, 
100% frame, Hamming window and 75% time window overlap). Detection of USVs was 
provided by manually setting a threshold-based algorithm and a hold-time mechanism 
(hold time: 5 ms). Since no USVs were detected below 30 kHz, a lower cut-off frequency 
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of 30 kHz was used to reduce background noise outside the relevant frequencies. The 
accuracy of detection was verified by an experienced investigator. The total number of 
vocalizations emitted, total vocalization time as well as duration and dominant frequency 
for each syllable type were measured automatically. Spectrographic analysis was 
conducted as originally described by Scattoni et al. (2008) with some modifications that 
were also made by Grimsley et al. (2011). All USVs were assigned to one of 11 structural 
groups, primarily according to their pitch contour shape, which is determined by the 
frequency modulation and duration of the acoustic signal (Fig. S2). Syllables that were 
described as composite by Scattoni et al. (2008) were classified as harmonics because 
these syllables often had a third harmonic component at 150 kHz. If the syllable was 
compound and contained multiple components such as harmonic and frequency steps, it 
was classified as a frequency step syllable with a harmonic component. In a pilot 
experiment, we compared the distribution of USV syllables collected during the entire 
3 min testing period and from every other 30 s period during the same 3 min testing and 
found that both methods of analysis yield similar data (Fig. S3). Thus, for the further 
analysis, USVs were collected from every other 30 s period during the 3 min testing 
period (average number of vocalizations per mouse was 250–300) unless an animal 
produced fewer than 100 vocalizations, in which case USVs were collected from the total 
3 min of testing. The total number of USV syllables was normalized to 100%. 
 
Three chamber social test 
Ten week-old mice were tested in a 60 × 40 cm Plexiglass box divided into three 
chambers as described previously (Smith et al., 2007). Mice could freely move between 
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chambers through a small opening (6 × 6 cm) in each divider. Mice to be tested were 
placed in the center chamber, and an overhead camera recorded their movements. Mice 
were allowed 10 min to explore the empty box in order to evaluate bias for either of the 
side chambers. For each animal, we confirmed that there was no side bias. Then an 
unfamiliar, same-sex mouse was placed in a wire cage (11 cm height, 10.5 bottom 
diameter, bars spaced 1 cm apart; Galaxy Cup, Spectrum Diversified Designs, Inc., 
Streetsboro, OH) in one side chamber. Another empty wire cage was placed in the 
opposite side chamber as a non-social object. Mouse behavior was recorded for 10 min. 
The time spent in each of the three chambers was measured, and the preference index for 
social object was calculated as [timesocial/(timesocial + timenon-social)] × 100 − 50 (Jamain et 
al., 2008). All testing chambers were cleaned vigorously with 70% ethanol followed by 
Process NPD before and after testing each mouse. 
 
Scent marking test 
This test was done according to the protocol described by Wohr et al. (2011a). Subject 
mice were placed in a clean cage (30 × 16 × 14 cm) containing a sheet of absorbent paper 
that covered the entire base (Strathmore Drawing Paper Premium, 400 series; Strathmore 
Artist Papers, Neenah, WI, USA). Female urine was collected from adult C57/B6 females 
in estrous. Male urine was collected from sexually experienced adult C57/B6 males. The 
adult male subject was habituated for 60 min to the clean cage lined with fresh paper. 
After the habituation period, the mouse was placed back in the home cage. A new sheet 
of paper was then placed in the cage and 15 µL of female urine was aliquotted onto the 
center. The mouse was placed back in the testing cage for 3 min. Scent marks deposited 
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on the paper during habituation or exposure to female/male urine were visualized using 
0.5% ninhydrin in 95% ethanol. Developed papers were scanned and analyzed for total 
density using ImageJ (NIH, USA). The data are shown as the ratio of density of the 
experimental group to the control group. 
 
Marble burying test 
This test was done as described by Thomas et al. (2009) with small modifications. In a 
pilot experiment under these conditions, we found that naive C57 males bury 50% of the 
marbles in a 10 min period so this testing time was used in further experiments so as to be 
able to detect either increases or decreases in the number of buried marbles. Clean cages 
(27 × 16.5 × 12.5 cm) were filled with a 4-cm layer of chipped cedar wood bedding. 
Males were habituated to this cage for 10 min and then returned to the home cage. 
Twenty navy blue glass marbles (15 mm diameter) were gently laid on top of the 
bedding, equidistant from each other in a 4 × 5 arrangement. Animals were placed back 
into the testing cage and the number of marbles buried (>50% marble covered by bedding 
material) in 10 min was recorded. 
 
Self-grooming test 
Self-grooming was evaluated in a 6.5 cm diameter × 10 cm tall, clear glass beaker 
covered with a filter top. After 10 min habituation in the beaker, self-grooming was 
measured for a further 10 min. The investigator sat 1 m away from the apparatus and 
recorded cumulative time spent in grooming (scratching fur with any foot). All testing 
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beakers were cleaned vigorously with water followed by Process NPD before and after 
testing. 
 
Olfactory sensitivity test 
The method for measuring olfactory sensitivity was adapted from Witt et al. (2009). On 
day 1, the subject was habituated to a clean empty cage for 10 min, and then a 2 × 2 cm 
damp Stathmore paper was placed in the cage and the time spent exploring the paper 
during 3 min period was recorded. On day 2, the paper was dampened with 10% vanilla 
scent in water instead of plain water. The data are presented as the time spent exploring 
the scented paper minus the time spent exploring the plain water paper. 
 
Statistical analysis 
Statistical analyses were carried out with Prism 4.0b software. Normally distributed data 
were plotted in the figures as means ± SEM. The means of two groups were compared by 
Student’s t test. Where data were not normally distributed (assessed by the Kolmogorov–
Smirnov test), they were plotted as medians plus 25% and 75% quartiles, and range. Two 
groups of such data were compared with the Mann–Whitney test. All statistical tests were 
two-tailed, except the number of vocalizations in the male-male encounter, with α ⩽ 0.05. 
The differences among groups with two variables were assessed using two-way 
ANOVAs followed by Bonferroni posthoc tests. Significant differences emerging from 
the above tests are indicated in the figures by ∗p < 0.05, ∗∗p < 0.01 and ∗∗∗p < 0.005. 
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Fig. 1. Male pups from MIA mothers emit altered number and quality of USVs in 
the isolation test. Pups were isolated from the nest and tested individually for USVs 
every other day from day 6 to day 14. Compared to control pups, the MIA pups emit 
fewer vocalizations (A), call for a shorter duration of time (B). Ten day-old pups from 
MIA mothers also produce significantly more short and complex syllables and fewer 
harmonic syllables than controls. (C) Significant differences are indicated by *p < 0.05, 
**p < 0.01 and ***p < 0.005. USV classification: FS, frequency step; HM, harmonic; 
CV, chevron; CX, complex; FT, flat; UP, upward; DN, downward; ST, short; RC, 
reversed chevron. 
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Fig. 2. Adult male offspring from MIA mothers display reduced USV responses in a 
social encounter with a female. During interactions with a female in estrous phase, MIA 
males emit fewer vocalizations (A) and also produce significantly fewer two step 
frequency and chevron syllables (B) than controls. Significant differences are indicated 
by *p < 0.05, **p < 0.01 and ***p < 0.005. USV classification: 1F, one frequency step; 
2F, two frequency step; 3F, three and more frequency step; HM, harmonic; CV, chevron; 
CX, complex; FT, flat; UP, upward; DN, downward; ST, short. 
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Fig. 3. Adult male offspring from MIA mothers display reduced USV responses in a 
social encounter with a male. During interactions with an unfamiliar male intruder, 
MIA males emit fewer vocalizations (A) and also produce significantly fewer two step 
frequency syllables (B) than controls. Data for the number of calls are plotted as medians 
plus 25% and 75% quartiles, and range. Two groups of such data were compared with the 
Mann–Whitney test. Significant differences are indicated by ⁄p < 0.05. USV 
classification as in Fig. 2. 
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Fig. 4. MIA males display a deficit in female urine-induced scent marking. 
Compared to controls, MIA males deposit fewer scent marks in the presence of female 
urine (A). However, no group difference is observed in the scent marking induced by 
male urine (B). A significant difference is indicated by ***p < 0.005. 
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Fig. 5. Adult male offspring from MIA mothers exhibit decreased sociability in the 
three chamber social test. Compared to controls, MIA males spend significantly less 
time in the chamber with an unfamiliar mouse and more time in the chamber with an 
unfamiliar, non-social object (A). The preference index for social object was significantly 
lower in the MIA offspring (B). Significant differences are indicated by *p < 0.05 and 
***p < 0.005. 
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Fig. 6. Offspring of MIA mothers display high levels of repetitive/compulsive 
behavior. Compared to controls, MIA offspring display extremely high repetitive 
behavior in the marble burying test (A), and increased self-grooming (B). Significant 
differences are indicated by *p < 0.05 and ***p < 0.001. 
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Fig. 7. MIA offspring do not display an obvious olfactory deficit. The data are 
presented as the ratio of the time spent exploring a scented paper to the time spent 
exploring a plain water spotted paper. 
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Abstract 
 
A variety prenatal insults are associated with the incidence of neurodevelopmental 
disorders such as schizophrenia, autism and cerebral palsy. While the precise 
mechanisms underlying how transient gestational challenges can lead to later life 
dysfunctions are largely unknown, the placenta is likely to play a key role. The literal 
interface between maternal and fetal cells resides in the placenta, and disruptions to the 
maternal or intrauterine environment are necessarily conveyed to the developing embryo 
via the placenta. Placental cells bear the responsibility of promoting maternal tolerance of 
the semi-allogeneic fetus and regulating selective permeability of nutrients, gases and 
antibodies, while still providing physiological protection of the embryo from adversity. 
The placenta’s critical role in modulating immune protection and the availability of 
nutrients and endocrine factors to the offspring implicates its involvement in 
autoimmunity, growth restriction and hypoxia, all factors associated with the 
development of neurological complications. In this review, we summarize primary 
maternal-fetal interactions that occur in the placenta and describe pathways by which 
maternal insults can impair these processes and disrupt fetal brain development. We also 
review emerging evidence for placental dysfunction in the prenatal programming of 
neurodevelopmental disorders.  
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Introduction 
A key advance in modern neurobiology is the understanding that the nervous 
system exhibits lifelong reciprocal interactions with the immune and endocrine systems. 
These interactions and their high sensitivity to environmental cues means that alterations 
in one domain leads to changes in another. This is evident in systemic infection, where 
activation of an immune response in the periphery leads to activation of vagal afferents 
and their projection areas in the brain, causing changes known as sickness behavior 
(Dantzer et al., 2008). In the other direction, during the stress response, activation of 
hypothalamic neurons stimulates the hypothalamic-pituitary-adrenal (HPA) axis and 
corticosterone production (Dedovic et al., 2009). These effects of stress lead to altered 
peripheral immune function (Segerstrom and Miller, 2004).  
Such plasticity is particularly important during embryonic development, enabling 
an organism to adapt to the demands of the environment in which it develops and will 
eventually inhabit. While this ability to reorganize regulatory systems in response to 
immediate environmental pressures confers an obvious adaptive advantage, it also entails 
a risk for adverse, long-term effects on physiological functions, particularly if the 
prenatal environment is discordant with the postnatal environment. That is, priming of 
fetal development in utero may lead the offspring to respond inappropriately to a 
postnatal environment that is different from that for which it was prepared. This is 
exemplified in the effect of maternal undernutrition on offspring metabolism and 
subsequent susceptibility to obesity (Krechowec et al., 2006). Such findings support the 
concepts of “fetal programming” and the “developmental origins of health and disease,” 
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which describe how environmental influences on early development initiate molecular 
responses that impact long-term predisposition for disease. 
A variety of maternal and intrauterine insults are known to affect fetal 
neurodevelopment, but the mechanisms underlying how such transient prenatal 
challenges can lead to persistent postnatal dysregulation are largely unknown. It is likely 
that the placenta, as a key regulator of maternal-fetal interactions, plays an important role. 
Indeed, changes in placental shape and weight are associated with the development of 
diseases such as hypertension, coronary heart disease and stroke in later life (Barker et 
al., 1990; Warning et al., 2011). Moreover, the placenta’s central role in regulating 
nutrient transport, endocrine function and immune tolerance implicates its involvement in 
growth restriction, hypoxia and related neurological complications (Jansson and Powell, 
2007; Bale et al., 2010; Fernandez-Twinn and Ozanne, 2010). In this review, we briefly 
describe some of the complex, maternal-fetal interactions that occur in the placenta. We 
further discuss the pathways by which maternal perturbations known to alter 
neurodevelopment also disrupt placental physiology. We place particular focus on murine 
studies, from which several mechanistic insights into how placental disruptions influence 
offspring development have been drawn. In closing, we review emerging evidence for a 
placental role in prenatal programming of neurodevelopmental disorders.  
 
Maternal-fetal interactions in the placenta 
Far from being a passive organ, the placenta plays a critical role in orchestrating 
the sequence and intensity of a series of complex maternal-fetal interactions. In essence, 
the placenta is of dual origin, comprised of both fetallyand maternally-derived cells (Fig. 
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1). The decidua, often referred to as the maternal compartment, forms the most 
superficial layer surrounding the placenta and is densely packed with maternal immune 
cells. Beneath this, a layer of fetally-derived trophoblast cells secretes hormones and 
endocrine factors that support both maternal and fetal health. Finally, maternal blood, 
descending from decidual spiral arteries, and fetal blood, rising through the umbilical 
arteries, converge in the villous spaces of what is known as the labyrinth layer, in mice, 
or the chorionic villi, in humans. Here, maternal and fetal blood flow countercurrently 
and are separated by two layers of fetal trophoblast cells, the syncytiotrophoblasts and the 
so-called mononuclear trophoblasts, in mice, or villous cytotrophoblasts, in humans. 
These trophoblasts are critical for regulating the selective entrance of nutrients and 
oxygen into the fetal bloodstream.  
 
Immune tolerance 
 The literal maternal-fetal interface resides at the decidual-trophoblast junction of 
the placenta and across the syncytiotrophoblast cells that form the boundary between 
maternal and fetal blood spaces in the villous layer (Fig. 1). It was recognized early on 
that the close contact between maternal and fetal cells at this interface represents an 
immunological paradox (Medawar, 1953); that is, how can trophoblast cells, which 
express paternal alloantigens, live harmoniously with maternal leukocytes that are 
developmentally educated to react against non-self antigens? Of particular concern is the 
reactivity of a unique population of uterine natural killer (uNK) cells, which constitutes 
approximately 70% of all decidual leukocytes (Bulmer et al., 2010) and displays 
cytotoxicity in vitro. Maternal macrophages, which form about 20% of all decidual 
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leukocytes, along with maternal T cells and dendritic cells, retain their effector functions 
and reside closely with fetal trophoblasts (Scaife et al., 2003). Furthermore, that Rhesus 
disease involves maternal antibody production against the offspring’s paternally-inherited 
Rh factor demonstrates that the maternal adaptive immune system is capable of reacting 
against fetal antigens. 
On the other hand, anti-fetal immune responses are specifically suppressed during 
pregnancy (Aluvihare et al., 2004). Remarkably, pregnant mice will accept an allogeneic 
tumor graft if harboring offspring with matching alloantigens (Tafuri et al., 1995). 
Furthermore, acceptance of the allograft is limited to the gestational period; after birthing, 
allografts are rejected. This indicates that the maternal immune system is specifically 
tolerized to fetal alloantigens during pregnancy.  
There are several mechanisms underlying immune tolerance in the placenta, and 
many of these depend on crosstalk between maternal and fetal cells (Table 1). Paracrine 
signaling between fetal and maternal cells is critical for establishing a state of 
immunosuppression. Trophoblast cells secrete a variety of immunosuppressive factors 
and harbor surface ligands to control immune reactivity through cell-cell interactions. 
Shedding of trophoblast antigens and trafficking of fetal cells into the maternal 
circulation are believed to promote classical immune tolerance during major 
histocompatibility complex (MHC) restriction and maturation of maternal T cells. Of 
principal importance is that trophoblasts exhibit limited expression of surface MHC 
alloantigens as a strategic way to evade maternal immune surveillance. Similar 
mechanisms of host immune evasion are used by tumor cells and the human 
immunodeficiency virus (HIV) (Collins and Baltimore, 1999; Fruh et al., 1999).  
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Breaching immunological tolerance at the maternal-fetal interface can result in a 
number of obstetric complications (Trowsdale and Betz, 2006; Warning et al., 2011). 
Insufficient immunological tolerance is believed to underlie many cases of pre-eclampsia 
and miscarriage, which is consistent with epidemiological associations of these 
conditions with pre-existing autoimmune disease in the mother (Wolfberg et al., 2004; 
Tincani et al., 2008). A signature of altered immunological status in the placenta is 
infiltration of uterine and decidual leukocytes into fetal compartments. Lack of tolerance 
also entails maternal reactivity against paternal antigens on fetal cells, which can result in 
cytotoxicity, placental necrosis and maternal production of anti-fetal antibodies. Notably, 
maternal autoantibody production against fetal antigens is involved in a number of 
developmental disorders, including autism (Braunschweig et al., 2008). Thus, while 
numerous strategic mechanisms have evolved to accommodate the coexistence of 
maternal and fetal cells in the placenta, insults which impact placental signaling factors 
and immune status can lead to deficits in immunological tolerance at the maternal-fetal 
interface. 
 
Trophoblast invasion 
At the same time that maternal and fetal cells in the placenta must interact to 
maintain immunological tolerance, they also need to coordinate to deliver progressively 
more nutrients to the growing embryo. This is achieved specifically in hemachorial 
placentas (where chorionic cells come into direct contact with maternal blood) by 
specialized groups of trophoblast cells that travel into spiral arteries and initiate vascular 
remodeling (Moffett and Loke, 2006; Cartwright et al., 2010). Interstitial trophoblasts, 
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which derive from villous trophoblasts, invade the decidua and spiral arteries. There, they 
initiate programmed cell death of existing maternal endothelial and smooth muscle cells, 
opening up blood flow to accommodate the needs of the developing fetus. This process 
effectively increases the diameter of the spiral arteries, allowing maternal blood to fill the 
villous spaces at an elevated rate with decreased resistance. Thus, greater levels of 
nutrients, growth factors and oxygen are transferred to the fetal circulation to promote 
healthy embryonic development.  
Successful trophoblast invasion is mediated by crosstalk between the interstitial 
trophoblasts and the diverse cell types that they encounter on the journey toward the 
decidua (Table 2). These interactions result in an intricate sequence of temporallyand 
spatially-restricted changes in gene expression. For example, interactions with distinct 
placental cell types trigger invading trophoblast cells to change their display of surface 
adhesion molecules as they migrate up to the decidua, progressively acquiring 
characteristics of endothelial cells. Furthermore, invading trophoblasts upregulate 
expression of molecules that help to digest the extracellular matrix barrier. The extent of 
invasion is further governed by cytokine signaling between decidual cells and interstitial 
trophoblasts. Direct cell-cell interactions between trophoblasts and decidual leukocytes 
may also regulate invasion and spiral artery modification. 
 
Modification of spiral arteries/vascular remodeling 
The transformation of spiral arteries after trophoblast invasion reflects a 
culmination of several molecular events that effectively alter the vascular properties of 
the spiral arteries. The invasive trophoblasts themselves are important for inducing 
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apoptosis of endothelial cells and stromal cells in the vasculature. Even prior to 
trophoblast invasion, decidual immune cells localized near the vessel walls initiate early 
arterial vacuolization and dilation (Hazan et al., 2010). Moreover, it is believed that the 
phagocytic properties uNK cells aid in the clearance of apoptosed endothelial and stromal 
cells surrounding the spiral arteries, making way for new endothelial-like trophoblasts to 
reconstitute the vasculature. 
Both trophoblast invasion and vascular remodeling are intimately tied to fetal 
growth and development. Disruption of either process leads to altered maternal blood 
flow into the villous spaces and inappropriate exchange of nutrients and respiratory 
gases. This can be detected histologically by shallow extravillous trophoblast invasion or 
over-infiltration of the decidual matrix and suboptimal vascularization. Associated 
changes in blood circulation and flow resistance can be conveyed by altered experimental 
parameters during placental perfusion. These molecular disruptions can form the 
mechanistic bases for fetal malnutrition, intrauterine hypoxia and altered placental weight 
or birth weight (Roberts et al., 2001; Redmer et al., 2004; Sibley et al., 2005; Cartwright 
et al., 2007). A variety of medical conditions arise from such complications, including 
premature birth, pre-eclampsia and intrauterine growth restriction (IUGR) (Sibley et al., 
2005; Cudihy and Lee, 2009), and these conditions are further associated with a number 
of neurodevelopmental disorders, such as cerebral palsy and schizophrenia (Preti et al., 
2000; Jarvis et al., 2006; Redline, 2006; Clarke et al., 2011; O'Callaghan et al., 2011).  
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Prenatal effects on the placenta and neurodevelopment  
It is clear that the molecular mechanisms regulating normal placental functions 
are tightly intertwined, governed by both cells at the maternal-fetal interface and soluble 
factors in the local microenvironment. Signaling of cytokines, growth factors and 
hormones are central to the cross-talk between maternal and fetal cells in the placenta, 
dictating the gene expression changes that modulate their physiological functions. Also, 
the activation states of decidual immune cells can influence not only immunological 
tolerance at the maternal-fetal interface, but also the production of soluble factors and 
types of cell-cell interactions that influence trophoblast invasion and vascular 
remodeling. Overall, the cellular interactions underlying these processes are critical for 
establishing normal placental architecture, delivering sufficient oxygen and nutrients to 
the fetus and protecting the fetus from maternal reactivity. Thus, a proper intrauterine 
environment is fundamental to the success of the placenta and pregnancy in supporting 
healthy fetal development. 
Maternal insults that disrupt the fine interplay of signaling networks at the 
maternal-fetal interface can alter placental capacity and complicate fetal development and 
behavior. Given that maternal challenges are conveyed to the fetus via the placenta, many 
maternal insults lead to altered intrauterine environments and consequent placental 
pathology. Maternal anemia, for example, is associated with altered placental 
angiogenesis, intrauterine hypoxia and perinatal brain injury in the offspring (Kadyrov et 
al., 1998; Fowden et al., 2008). Here we discuss maternal immune activation (MIA) as a 
major factor known to disturb placental physiology and lead to alterations in offspring 
brain development with long-term consequences.   
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Maternal immune activation (MIA) 
While normal pregnancy involves several mechanisms to promote 
immunosuppression and immune evasion at the maternal-fetal interface, the placenta 
retains the ability to detect and respond to infection and inflammation. Placental cells 
express a variety of pattern recognition receptors (PRRs) that recognize unique microbe-
associated molecular patterns (MAMPs) expressed extracellularly or intracellularly on 
microorganisms. PRRs such as mannose receptors, NOD-like receptors and Toll-like 
receptors (TLRs) are expressed not only on placental immune cells, but also on 
trophoblasts themselves (Koga and Mor, 2010). In fact, all 10 TLRs, in addition to many 
related co-receptors and accessory proteins, are found in the human placenta, rendering 
the placenta responsive to MAMPs on bacteria, viruses, parasites and fungi. 
In animal models, respiratory infection or injection of MAMPs, such as the 
bacterial cell wall component lipopolysaccharide (LPS) or the synthetic double-stranded 
RNA poly(I:C) (to mimic viral infection), into pregnant dams triggers a maternal 
inflammatory response that can lead to placental pathology and subsequent harm to the 
fetus (Koga and Mor, 2010). The precise developmental effects of MIA depend on the 
specific antigen used, as well as the dosage, route and timing of administration. Early 
gestational injection of LPS or poly(I:C), for example, can lead to implantation failure or 
fetal resorption, while exposure during late gestation can induce pre-term birth (Ilievski 
et al., 2007). Relatively low-dose LPS or poly(I:C) injection into rodents during mid-to-
late-gestation yields offspring with schizophreniaand autism-related developmental 
abnormalities in the absence of overt obstetric complications (Patterson, 2011). Common 
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to these variations of MIA, however, is a consistent upregulation of pro-inflammatory 
cytokines, chemokines and reactive oxygen species in the maternal blood and placenta. 
MIA induces the production of soluble pro-inflammatory factors that have access 
to placental cells via maternal blood in the spiral arteries and intervillous spaces. 
Moreover, MIA can alter the immune status of decidual leukocytes, including 
upregulation of activation markers and increased production of pro-inflammatory 
cytokines by uNK cells, macrophages and granulocytes (Zhang et al., 2007; Renaud and 
Graham, 2008; Hsiao and Patterson, 2011). Not surprisingly, these effects on uterine 
immune cells can lead to further disruption of immunological tolerance, cytoarchitecture 
and blood circulation in the placenta. Maternal LPS injection, for instance, induces 
necrosis and edema of the labyrinth layer, infiltration of maternal immune cells into fetal 
placental tissues and decreased placental perfusion (Girard et al., 2010; Carpentier et al., 
2011). LPS-mediated activation of TLR4 signal transduction also inhibits the migration 
of trophoblast cells (Abrahams et al., 2005), which may form the basis of observed 
decreases in placental circulation.  
In response to maternal poly(I:C) injection, however, the placenta experiences a 
dramatic upregulation of pro-inflammatory cytokines and activation of decidual immune 
cells, in the absence of obvious pathophysiology (Zhang et al., 2007; Hsiao and 
Patterson, 2011). The maternal pro-inflammatory response is further relayed to fetal 
spongiotrophoblast and labyrinth cells, which activate JAK/STAT signaling pathways 
and alter expression of several genes, including those that encode important endocrine 
factors such as growth hormone and insulin-like growth factor 1 (IGF1) (Fatemi et al., 
2011). Importantly, these effects on the placenta, as well as MIA-induced behavioral 
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abnormalities in the offspring, are dependent on IL-6 signaling (Smith et al., 2007; Hsiao 
and Patterson, 2011). In addition to these changes in factors that influence fetal health, 
some pro-inflammatory cytokines, such as IL-6 and IL-1β, can cross the placenta and 
enter the fetal bloodstream (Dahlgren et al., 2006; Girard et al., 2010). Thus, soluble 
factors produced in response to maternal insults can activate cells at the maternal-fetal 
interface and potentially be passively transported directly into the fetal circulation. These 
findings highlight the key role of the placenta in amplifying the maternal inflammatory 
response and potentiating detrimental effects on embryonic health. They further 
contribute to a growing number of MIA studies that demonstrate a critical role of 
cytokine signaling in triggering molecular cascades that ultimately impair fetal 
development.  
The long-term effects of MIA on the offspring include a variety of behavioral, 
histological and immunological abnormalities that relate to symptoms of human autism 
and schizophrenia. Adult MIA offspring exhibit deficits in pre-pulse inhibition, latent 
inhibition, open field exploration, social interaction and vocal and olfactory 
communication, as well as increased anxiety and repetitive/stereotyped behavior 
(Malkova et al., 2012). They also exhibit enlarged ventricles, a hallmark neuropathology 
of schizophrenia and a spatially-restricted deficit in cerebellar Purkinje cells, a 
characteristic neuropathology of autism, among several other neuropatholgies (Patterson, 
2007). Young and adult MIA offspring also display autism-related immune 
dysregulation, including decreased T regulatory cells and hyper-responsive CD4+ T cells 
(Hsiao et al., 2011). Together, these effects of MIA in animal models support large 
epidemiological studies linking maternal viral, bacterial and parasitic infection to 
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increased risk of schizophrenia or autism in the offspring (Patterson, 2007). Also 
supporting this body of work are associations between these mental illnesses and elevated 
cytokines in amniotic fluid and maternal serum. 
 
The placenta in programming of neurodevelopmental disorders    
Altered placental function and the release of deleterious factors to the fetus, in 
response to such challenges as MIA, are important risk factors for the pathogenesis of 
neurodevelopmental disorders. Several maternal insults, including maternal infection and 
maternal malnutrition, increase susceptibility to IUGR, and all three factors are 
epidemiologically linked to schizophrenia, autism and cerebral palsy in the offspring 
(Brown and Susser, 2008; Atladottir et al., 2010; Brown and Patterson, 2011; 
O'Callaghan et al., 2011). Placental pathologies relating to vascular impairments, 
including chorionic vessel thrombi, villous edemas and vascular necrosis, are prevalent in 
cerebral palsy (Redline, 2006). In addition, obstetric complications are associated with 
increased risk for schizophrenia and can predict treatment responses in schizophrenic 
individuals (Alvir et al., 1999; Preti et al., 2000). Exposure to obstetric complications and 
immune dysregulation are similarly linked to autism susceptibility in the offspring 
(Limperopoulos et al., 2008; Gardener et al., 2009; Sacco et al., 2010). In one study, 
trophoblast inclusions were increased in placental tissue derived from births of 
individuals who developed autism spectrum disorder (Anderson et al., 2007). In addition, 
chorioamnionitis, or inflammation of the fetal placental membranes, is associated with 
impairments in social interaction and communication in autistic children (Limperopoulos 
et al., 2008).  
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That placental pathologies are associated with brain injury and altered behavior 
suggests that dysfunction at the maternal-fetal interface can contribute to the 
pathogenesis of neurodevelopmental disorders (Fig. 2). Whether placental impairments 
can directly cause the disorders in subsets of individuals seems likely but remains to be 
firmly established. Studies of animal models of intrauterine infection and IUGR, where 
gestational challenges are confined to the uteroplacental compartment, demonstrate that 
primary insults to the placenta can manifest in perinatal brain damage in the offspring. 
Rodents, ewes and rabbits subjected to such placental challenges exhibit a variety of 
neuropathologies, including altered astrocyte development, microglial activation, white-
matter damage and impaired blood brain barrier integrity (Hutton et al., 2008; Bassan et 
al., 2010). Notably, uteroplacental inflammation is sufficient to induce the expression of 
the apoptotic markers, caspase-3 and 4-hydroxynonenal, by Purkinje cells of the fetal 
ovine cerebellum (Hutton et al., 2007). This is reminiscent of the Purkinje cell loss 
characteristic of autistic brains and observed in other neurodevelopmental disorders such 
as schizophrenia. It will be interesting to further assess the downstream effects of  
primary insults to the placenta on offspring behavioral development.  
Furthermore, the placenta is known to regulate the synthesis of neuroactive 
factors throughout gestation that could influence fetal brain development (Petraglia et al., 
2010). Recent findings in mice demonstrate that the placenta serves as a major source of 
serotonin to the fetal forebrain (Bonnin et al., 2011). Delivery of the precursor tryptophan 
through the maternal uterine artery leads to accumulation of newly synthesized serotonin 
in the placenta and fetal circulation, demonstrating the ability of the placenta to 
synthesize serotonin and transport it to the fetus. In contrast, delivery of a tryptophan 
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hydroxylase antagonist to the placenta sufficiently inhibits placental serotonin synthesis 
and reduces levels of forebrain serotonin in corresponding embryos. These findings 
contribute to a growing number of studies that illuminate the key role of the placenta in 
de novo synthesis of neuroactive factors that are necessary for normal brain development 
(Hirst et al., 2009; Petraglia et al., 2010). Interestingly, placental infection and 
inflammation is associated with disruptions to the kynurenine/tryptophan pathway in the 
placenta, which may have corresponding effects on serotonin production and neural 
development.  
The placenta is also a primary hematopoietic stem cell (HSC) niche during 
pregnancy, harboring a large population of HSCs during midgestation that are believed to 
seed the fetal liver (Gekas et al., 2005). Importantly, HSC development occurs in the 
placental vasculature independently of blood flow, supporting the finding that the 
placenta itself produces definitive hematopoietic cells that encompass both 
myeloerythroid and lymphoid potential (Rhodes et al., 2008). Thus, prenatal insults that 
influence placental physiology may also impact placental HSC development and 
postnatal immunity. Indeed, development of the immune system and responses of effecter 
immune cells are influenced by early life environments and changes in 
microenvironmental cues such as cytokines (Sobrian et al., 1997; Coe and Lubach, 2000). 
In addition, altered immunity is frequently associated with neurodevelopmental disorders, 
such as schizophrenia and autism spectrum disorders (Patterson, 2009; Onore et al., 
2011). It will be important to assess whether levels or properties of placental HSCs are 
altered by such prenatal insults as intrauterine infection.  
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Additional multi-disciplinary studies are needed to elucidate the mechanisms by 
which the placenta guides normal fetal brain development and to gain insight into its role 
in the developmental programming of long-term health and disease. Specifically, 
additional models that involve primary insults to the placenta itself, rather than secondary 
effects on the placenta resulting from primary maternal challenge, will help focus 
research on placenta-specific effects on fetal development in the absence of confounding 
maternal factors. Lentivirus-mediated, placenta-specific transgenesis (Okada et al., 2007) 
and the utilization of transgenic mice harboring placenta-specific drivers such as 
trophoblast-specific protein alpha (Tpbpa) and placental lactogens (Pl1 and Pl2) will 
facilitate studies on the effects of targeted placental manipulations on offspring 
development. It will be particularly important to determine the effects on disease-relevant 
behaviors and neuropathology. Finally, the study of placental responses to maternal or 
intrauterine insults offers the potential to identify early targets for prevention of later-life 
disease. Such promise can be seen with the increasing use of prenatal magnesium sulfate 
for promoting fetal neuroprotection and preventing cerebral palsy and substantial motor 
dysfunction in at-risk infants (Doyle, 2012). While the precise basis for this protection is 
unclear, several studies demonstrate anti-inflammatory, anti-apoptotic and vasodilatory 
properties of magnesium sulfate in the placenta (Kovac et al., 2003; Holcberg et al., 
2004; Dowling et al., 2012). Further studies into the role of the placenta in regulating 
fetal development will shed light on how alterations in a variety of interactions at 
maternal-fetal interface may form the basis of early life programming of neurological, 
metabolic, as well as immunological disorders. 
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Figure 1. The maternal-fetal interface in the murine placenta. The direct interaction 
between maternal and fetal cells during gestation occurs in the placenta. The placenta is 
of dual origin, with the outer decidual layer composed almost entirely of maternal 
immune cells, while the underlying junctional zone and labyrinth layers (chorionic 
villous layer, in human) are comprised exclusively of fetally-derived trophoblasts and 
leukocytes. Maternal immune cells and endothelial cells of the spiral arteries are 
juxtaposed along trophoblasts at the boundary between the decidua and junctional zone 
(upper right). In the labyrinth layer, intervillous spaces are lined by fetal 
syncytiotrophoblast cells, mononuclear trophoblast cells and fetal endothelial cells that 
separate maternal from fetal blood (lower right).  
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Figure 2. A placental role in developmental programming. Maternal and intrauterine 
challenges are necessarily conveyed to the developing offspring via the placenta. 
Maternal insults such as immune activation, malnutrition and stress result in altered 
composition of the maternal blood, which descends through the spiral arteries to fill the 
placental blood spaces. Changes in placental cytokines and endocrine factors can alter 
placental gene expression at the maternal-fetal interface. In light of the critical role of 
signaling factors in regulating normal placental processes, these alterations can further 
disrupt the maintenance of immune tolerance, progression of trophoblast invasion and 
spiral artery modification, or the de novo production of neuroactive molecules in the 
placenta. Placental pathophysiology contributes to a variety of obstetric complications 
and impairments to fetal development, such as hypoxia, growth restriction or immune 
dysregulation. These challenges further elaborate detrimental effects on early brain 
development, increasing susceptibility to neurodevelopmental disorders.  
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Abstract 
 
Activation of the maternal immune system in rodent models sets in motion a cascade of 
molecular pathways that ultimately result in autismand schizophrenia-related behaviors in 
offspring. The finding that interleukin-6 (IL-6) is a crucial mediator of these effects led 
us to examine the mechanism by which this cytokine influences fetal development in 
vivo. Here we focus on the placenta as the site of direct interaction between mother and 
fetus and as a principal modulator of fetal development. We find that maternal immune 
activation (MIA) with a viral mimic, synthetic double-stranded RNA (poly(I:C)), 
increases IL-6 mRNA as well as maternally-derived IL-6 protein in the placenta. 
Placentas from MIA mothers exhibit increases in CD69+ decidual macrophages, 
granulocytes and uterine NK cells, indicating elevated early immune activation. 
Maternally-derived IL-6 mediates activation of the JAK/STAT3 pathway specifically in 
the spongiotrophoblast layer of the placenta, which results in expression of acute phase 
genes. Importantly, this parallels an IL-6-dependent disruption of the growth hormone-
insulin-like growth factor (GH-IGF) axis that is characterized by decreased GH, IGFI and 
IGFBP3 levels. In addition, we observe an IL-6-dependent induction in pro-lactin-like 
protein-K (PLP-K) expression as well as MIA-related alterations in other placental 
endocrine factors. Together, these IL-6-mediated effects of MIA on the placenta 
represent an indirect mechanism by which MIA can alter fetal development.  
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Introduction 
Both autism and schizophrenia are relatively common disorders with often tragic, 
lifelong consequences.  Several susceptibility genes and environmental agents have been 
identified as risk factors, but few cases of autism or schizophrenia can be traced to a 
known cause. Maternal infection is regarded as a principal, non-genetic cause of 
schizophrenia, and is also associated with increased risk for autism in the offspring 
(reviewed by Brown & Derkits, 2010; Patterson, 2009; Atladóttir et al., 2010). In a 
mouse model of this risk factor, the offspring of mice injected with poly(I:C) dsRNA as a 
viral mimic develop behaviors and brain pathology consistent with those seen in human 
autism and schizophrenia (Lee et al., 2007; Makinodan et al., 2008; Meyer et al., 2006, 
2008; Nyffeler et al., 2006; Shi et al., 2003, 2009; Smith et al., 2007; Ito et al., 2010; 
Ozawa et al., 2006; Piontkewitz et al., 2009; Li et al., 2009; Winter et al., 2009; 
Zuckerman et al., 2003; Zuckerman & Weiner, 2005). These effects require a key 
mediator, the cytokine interleukin-6 (IL-6). Maternal injection of IL-6 alone is sufficient 
to cause the behavioral abnormalities seen in the offspring following maternal poly(I:C) 
injection or respiratory infection (Samuelsson et al., 2006; Smith et al., 2007). 
Conversely, co-injection of an antibody that neutralizes endogenous IL-6 along with 
poly(I:C) completely prevents the prepulse inhibition (PPI), latent inhibition (LI), 
exploratory and social deficits in the offspring caused by MIA (Smith et al., 2007). 
Furthermore, poly(I:C) injection of pregnant IL-6 knockout (KO) mice results in no such 
behavioral deficits. IL-6 is also required for induction of transcriptional changes as co-
injection of anti-IL-6 and poly(I:C) normalizes 92% of the MIA-induced changes in gene 
expression in brains of adult offspring (Smith et al., 2007).  
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The importance of IL-6 in mediating the development of schizophrenic and 
autistic endophenotypes in rodents is further supported by post-mortem studies of human 
subjects. The significant increases in pro-inflammatory cytokines, including IL-6, in fetal 
brains shortly after MIA in rodents (Meyer et al., 2008) are also observed in the brains of 
adult schizophrenic and autistic patients (Vargas et al., 2005; Arion et al., 2007; Saetre et 
al., 2007; Garbett et al., 2008; Li et al., 2009). IL-6 is also elevated in sera from living 
schizophrenic individuals (Potvin et al., 2008; Maes et al., 2002), and many pro-
inflammatory cytokines are increased in the cerebrospinal fluid and sera from living 
autistic individuals (Pardo et al., 2006; Chez, 2007; Ashwood et al., 2010). Furthermore, 
an IL-6 receptor polymorphism is associated with schizophrenia (Sun et al., 2008), and 
increased IL-6 levels are associated with several other environmental risk factors for 
schizophrenia, including maternal stress, maternal malnutrition and obstetric 
complications.    
Despite demonstration of the critical role of IL-6 in mouse MIA models and in 
human schizophrenia and autism, the mechanism underlying how IL-6 acts to disrupt 
early brain development is unknown. IL-6 can act directly on progenitor cells to regulate 
fetal neurogenesis and gliogenesis (reviewed by Deverman & Patterson, 2009). IL-6 can 
also act at the maternal-fetal interface to alter many parameters that influence fetal 
growth, including nutrient transfer, anoxia and vascular permeability (Jones et al., 2009).  
Moreover, IL-6 can disrupt the immunological balance of the placenta, altering Th1/Th2 
homeostasis, activation of uterine immune cells, and maintenance of maternal tolerance 
(Paul et al., 2003; Zimmerman et al., 2007; Arad et al., 2005; reviewed by Jonakait, 
2007). 
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We have studied the pathway of IL-6 action in the placenta to gain insight into the 
molecular processes that can lead to the postnatal manifestation of behavioral 
abnormalities. We confirm that MIA elevates IL-6 protein and mRNA expression in the 
placenta (Smith et al., 2007; Meyer et al., 2008; Gilmore et al., 2005; Koga et al., 2009). 
We determine the relative contribution of maternally-derived versus fetally-derived IL-6 
to the observed increases in placenta IL-6 levels. We identify activated decidual 
leukocytes as a likely source of MIA-induced placental IL-6, and we localize the site of 
maternal, IL-6-dependent STAT3 activation to fetal cells in the placental 
spongiotrophoblast layer. Finally, we report alterations in maternal-placental hormones 
and endocrine factors that may have important consequences for fetal development.  
 
Results 
Maternal IL-6 exposure yields offspring with behavioral abnormalities similar to those 
seen in MIA offspring.  
In the mouse MIA model, it was previously shown that the cytokine IL-6 is 
necessary and that a single IL-6 injection is sufficient for the development of behavioral 
and transcriptional changes in the offspring (Smith et al., 2007). Here we confirm and 
extend those data. The offspring of pregnant mice injected with 5 mg of rIL-6 on E12.5 
display decreased PPI compared to control offspring (Fig. 1A). Schizophrenic (Wynn et 
al., 2004) and autistic (Perry et al., 2006) individuals also exhibit abnormal PPI. PPI is a 
measure of sensorimotor gating, attention and distractibility. It refers to the inhibition of a 
startle response when the startling stimulus (120 db pulse) is preceded by a smaller, non-
startling stimulus (5 or 15 db pre-pulse). 
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LI is a measure of the ability to disregard irrelevant stimuli and refers to the 
inhibited acquisition of a conditioned stimulus when a subject has been exposed to the 
stimulus repeatedly prior to pairing with an unconditioned response. The disruption of LI 
seen in MIA and rIL-6 offspring mimics that which is characteristic of cognitive deficits 
in schizophrenia (Weiner, 2003). Adult offspring of rIL-6-injected mothers display 
elevated freezing compared to saline controls in response to the conditioned acoustic cue. 
This is indicative of decreased LI compared to the non-pre-exposed (NPE) group (Fig. 
1B). A similar deficit is observed in poly(I:C) offspring compared to controls.  
Offspring of rIL-6-injected mice exhibit decreased exploration of the open field 
(Fig. 1C). Compared to controls, rIL-6 offspring display fewer center entries, decreased 
center duration and decreased total distance traveled. Reluctance to enter the center area 
of an open arena is indicative of heightened anxiety under mildly stressful conditions. 
The decreased exploration exhibited by MIA and rIL-6 offspring is relevant to 
schizophrenia and autism-related anxiety-like behavior.  
Together, these data indicate that a single exposure to rIL-6 at mid-gestation 
causes offspring to develop autism and schizophrenia-related behavioral abnormalities 
similar to those induced by maternal injection of poly(I:C). Previous studies involving the 
injection of poly(I:C) into IL-6 KO mice, or the co-injection of poly(I:C) with blocking 
antibody against IL-6, demonstrated that IL-6 is necessary for mediating the effect of 
MIA on the development of behavioral abnormalities in offspring (Smith et al., 2007). 
Therefore, in order to elucidate the mechanism by which the maternal immune response 
affects fetal brain development, we focus on the IL-6 signaling pathway.  
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The placenta is a site of IL-6 induction in response to MIA.  
To explore how an immune challenge that is administered to the mother can lead 
to changes in the development of offspring, we examined the placenta as the site of direct 
contact between the maternal and fetal systems. Shortly after poly(I:C) injection, pro-
inflammatory cytokines including IL-6 are up-regulated in the maternal circulation 
(Gilmore et al., 2005; Smith et al., 2007; Meyer et al., 2008; Koga et al., 2009).  This 
signal is transmitted to the placenta, where levels of IL-6 and other pro-inflammatory 
cytokines are elevated. A striking increase in IL-6 protein is seen in the placenta by 3 
hours post-poly(I:C) injection; poly(I:C) placentas exhibit an approximately 17-fold 
increase over saline injection controls (Fig. 2A). IL-6 levels remain elevated for over 24 
hours after MIA, at levels over 4 times greater than in placentas from saline-injected 
mothers. Moreover, maternal poly(I:C) injection leads to a 16-fold up-regulation of 
placental IL-6 mRNA expression by 3 hours post-poly(I:C) injection (Fig. 2B). Tumor 
necrosis factor α (TNFa) and IL-1β expression are up-regulated in poly(I:C) placentas as 
well, approximately 3-fold over the level in the saline control. A trend for increases is 
also observed for placental expression of IL-17 and IL-10 in MIA placentas. However, 
there is no significant difference in expression of leukemia inhibitory factor (LIF), and 
interferon γ (IFNγ) is not detected in poly(I:C) and saline placentas.  
 
Increased levels of placental IL-6 are maternally-derived. 
 Elevated IL-6 protein in MIA placentas can come from the mother (e.g. 
bloodstream, decidual cells, uterine immune cells) and/or the fetus (e.g. bloodstream, 
trophoblasts, endothelial cells). To explore the relative contribution of the maternal and 
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fetal pools of IL-6, we crossed IL-6 +/females with IL-6 -/males, and injected pregnant 
females with either poly(I:C) or saline on E12.5. This creates a system to assay the role of 
IL-6 production from the fetal compartment: pregnant mothers are able to produce IL-6, 
whereas approximately one-half of the offspring (and the cells that comprise the 
spongiotrophoblast and labyrinth) will be null for the IL-6 allele, and thus incapable of 
generating IL-6 transcript. The remaining heterozygous conceptuses serve as internal 
controls. We also mated IL-6 -/females with IL-6 +/males to test the necessity of 
maternal/decidual IL-6 production (and sufficiency of fetal IL-6 production) in mediating 
the effects of MIA on embryonic development. It is important to note that in this latter 
paradigm, the decidua (the superficial layer of the placenta) and cells that fill the 
maternal blood spaces within the spongiotrophoblast and labyrinth, will still be of 
maternal genotype.  
Injection of poly(I:C) into pregnant IL-6 +/females induces the expected MIA 
response that is characterized by elevated placental IL-6 levels by 3 hours post-injection 
(Fig. 2C). Note that, compared to WT, IL-6 heterozygous mice display a weaker and 
more transient MIA response at 3 hours post-injection; placental IL-6 levels are increased 
~5-fold over controls, while a ~17-fold induction is seen in WT mice. Also, the placental 
IL-6 induction lasts between 6 and 24 hours in heterozygous mice, but lasts over 24 hours 
in WT mice. This indicates that maternal IL-6 gene dosage affects the IL-6 response to 
MIA in the placenta. 
Fetal or trophoblast expression of IL-6 contributes little to the pool of IL-6 
protein, as there is no significant difference between IL-6 levels in IL-6 -/placentas from 
+/mothers compared to IL-6 +/placentas from +/mothers (Fig. 2C). Negligible levels of 
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IL-6 are detected in IL-6 +/and -/placentas derived from saline or poly(I:C)-injected IL-6 
-/mothers (Fig. S1). Thus, the IL-6 protein response to MIA in the placenta is maternally-
derived.  
 
MIA activates uterine NK cells, granulocytes and macrophages that may contribute 
maternal IL-6 in the placenta.  
The finding that the placenta exhibits elevated levels of both IL-6 protein and 
mRNA in response to MIA suggests that placental IL-6 is supplied by not only by the 
maternal bloodstream, but also by the maternal cells within the placenta. We examined 
decidual immune cells as candidate sources of maternal IL-6 production. The decidua is 
the lining of the placenta that contains maternal vasculature and leukocytes, including a 
distinctive lymphocyte population of uterine NK (uNK) cells. By flow cytometry we 
assessed immune subtypes in the placenta for expression of CD69, a surface glycoprotein 
acquired during early lymphoid activation and inducibly expressed by T cells, B cells, 
NK cells, monocytes, neutrophils and eosinophils. 
Compared to saline controls, decidual cell suspensions generated from poly(I:C) 
injected mothers exhibit elevated CD69 expression in DBA lectin+ uNK cells, CD11b+ 
macrophages and Gr-1+ granulocytes (Fig. 3A,B). Similarly activated cells are observed 
in decidual cell suspensions from IL-6 -/mothers injected with poly(I:C), indicating that 
initial activation of placental immune cells occurs independently of IL-6 action. The 
increase in CD69+ innate immune cells coincides with an overall increase in placental 
CD69 expression (Fig. 3C). There is no significant difference in the percentages of these 
immune subtypes in response to MIA (Fig. S2). Furthermore, there is no apparent 
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difference in localization of uNK or macrophage cells, as demonstrated by 
immunofluorescence staining with DBA lectin and F4/80 (data not shown). Because 
CD4+, CD8+ and B220+ cells represent minor lymphocyte populations in the E12.5 
placenta, low levels of these cells are detected in saline and poly(I:C) decidual cell 
suspensions (Fig. S2). The significant increase in activated maternal leukocytes and 
lymphocytes in MIA placentas suggests that decidual uNK cells, macrophages and 
granulocytes are a likely source of maternally-derived IL-6 in response to MIA.  
 
Maternal IL-6 activates the JAK/STAT pathway in the fetal compartment of the placenta. 
 In order to localize the site(s) of IL-6 action within the placenta, we searched for 
downstream markers of IL-6 signaling. IL-6 and other IL-6 family cytokines, such as 
LIF, IL-11 and ciliary neurotrophic factor, signal by binding cytokine-specific membrane 
receptors to trigger further signal transduction: intracellular JAK proteins dimerize and 
auto-phosphorylate to activate downstream kinase activity, which ultimately leads to the 
phosphorylation of STAT transcription factors and global changes in gene expression, 
including increased transcription of the acute phase genes SOCS3, Pim1, TIMP1 and 
NOS2. In particular, IL-6 is known to signal through STAT3 and STAT1. We performed 
histological staining for phosphorylated (p)STAT3 and pSTAT1 in WT mice injected 
with poly(I:C) or saline, and also assayed gene expression of downstream markers of IL-
6 activity. To evaluate whether changes were initiated specifically by IL-6, we assessed 
STAT activation and downstream gene expression in IL-6 +/or -/placentas from poly(I:C) 
or saline-injected IL-6 +/or -/mothers.  
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Unlike saline controls, STAT3 is phosphorylated in the poly(I:C) 
spongiotrophoblast layer (Fig. 4) at 3 and 6 hours post-injection. This region of the 
placenta is comprised of a layer of fetal trophoblast cells that provides both structural 
support and hormones to maternal and fetal tissues. Widespread pSTAT3 staining is seen 
in IL-6 +/and -/spongiotrophoblasts from IL-6 +/mothers injected with poly(I:C). This 
staining is, however, absent in IL-6 +/and -/spongiotrophoblasts from IL-6 -/mothers, 
further confirming a specific effect of maternally-derived IL-6 on STAT3 activation in 
the placenta. There is no significant difference in the number of pSTAT3-positive cells in 
IL-6 +/versus -/spongiotrophoblasts from +/mothers, indicating a negligible effect of 
fetally-derived IL-6 on STAT3 activation (Fig. S3-A). No pSTAT1 staining is detected in 
the spongiotrophoblast layer of poly(I:C) or saline placentas (Fig. S3-B). Together, these 
data indicate that maternal IL-6 plays a specific role in mediating gene expression 
changes through STAT3 activation in the spongiotrophoblast layer of MIA placentas.  
MIA-induced activation of the STAT3 pathway coincides with a strong increase 
in SOCS3 expression in placentas from poly(I:C)-injected mothers (Fig. 4B). Expression 
of Pim1, TIMP1 and NOS2 is also increased in MIA placentas. Increased SOCS3 
expression is similarly observed in IL-6 +/placentas from poly(I:C)-injected IL-6 
+/mothers (Fig. 4C). Note that the up-regulation of SOCS3 expression in IL-6 
heterozygous MIA placentas is significantly attenuated compared to that in IL-6 WT 
placentas. This effect is similarly observed with MIA-induced IL-6 expression, as 
described above, and provides further evidence that maternal IL-6 gene dosage regulates 
the intensity and duration of the placental pro-inflammatory response to poly(I:C). 
Moreover, eliminating the contribution of maternal IL-6 significantly decreases the level 
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of SOCS3 expression in MIA placentas, while eliminating the contribution of 
fetal/placental IL-6 has no significant effect. These data indicate that MIA leads to 
increases in maternally-derived IL-6 and subsequent downstream action in the placenta.   
To examine whether maternally-derived IL-6 may act directly on 
spongiotrophoblasts to activate the JAK/STAT3 pathway, we used laser capture 
microdissection of the spongiotrophoblast layer and qRT-PCR to test for expression of 
IL-6 receptor components. On its target cells, IL-6 binds to its membrane-bound receptor, 
IL-6Rα, which associates with the signaling subunit of the receptor, gp130, to initiate 
intracellular signal transduction. Spongiotrophoblast cells from placentas of both saline 
and poly(I:C)-injected mothers indeed express IL-6Rα as well as gp130 (Fig. 4D) and are 
therefore likely to be capable of responding to placental IL-6. This offers the potential for 
direct IL-6 signaling in spongiotrophoblast cells and subsequent activation of STAT3.  
In addition to IL-6, other factors also mediate STAT3 and STAT1 activation in 
the placenta after MIA. Both pSTAT3 and pSTAT1 staining are localized to parietal 
trophoblast giant cells (pTGCs) and mononuclear sinusoidal trophoblast giant cells 
(sTGCs) that reside in the junctional zone and labyrinth (Fig. S3-B,C). This staining is 
present with the same localization and abundance in placentas from WT and IL-6 KO 
mice injected with poly(I:C), suggesting that MIA-induced pro-inflammatory factors 
other than IL-6 mediate this effect. Furthermore, the staining is not blocked by co-
injection of anti-IL-6 antibody and poly(I:C) in pregnant mothers (data not shown). Thus, 
MIA promotes widespread STAT3 and STAT1 activation in the fetal compartments of 
the placenta. 
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IL-6 specific signaling in response to MIA alters placental expression of factors that can 
influence fetal development.  
The finding that IL-6 mediates STAT3 activation specifically in the 
spongiotrophoblasts inhabiting the fetal compartment of MIA placentas suggests that IL-
6 may affect offspring development by altering expression of critical placental hormones 
and growth factors. In order to explore the downstream effects of MIA-induced STAT3 
activation in the placenta, we conducted real time qRT-PCR for relevant placental factors 
using WT placentas from poly(I:C)or saline-injected mothers at 3 hours post-injection, a 
time at which pro-inflammatory cytokines are highly up-regulated. To assess the 
functional relevance of IL-6-mediated signaling in the placenta, we conducted similar 
real time qRT-PCR assays utilizing placentas from pregnant IL-6 KO mice injected with 
poly(I:C).   
Maternal poly(I:C) injection leads to disruption of the GH-IGF axis in the 
placenta. Levels of GH protein are significantly reduced in MIA placentas (Fig. 5A-D), 
and there is also a corresponding decrease in IGFI expression, suggesting that reduced 
levels of GH may lead to decreased stimulation of IGFI production in the placenta 
(Forbes & Westwood, 2008). Furthermore, compared to saline-injected controls, 
placentas from poly(I:C)-injected mothers exhibit decreased IGFBP3 expression. 
IGFBP3 is a primary carrier binding protein responsible for increasing the half-life of 
IGFI, and its reduction is often associated with lower IGFI levels (Donahue & Beamer, 
1993; De Benedetti, 2001; Liao et al., 2008). Reductions in both IGFI and IGFBP3 are 
absent in placentas from IL-6 -/mice injected with poly(I:C). In fact, placentas from MIA 
IL-6 KO mice exhibit increased expression of IGFI and IGFBP3, suggesting that basal 
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levels of IL-6 are also critical for regulation of IGFI and IGFBP3 expression. A similar 
effect is seen with levels of placental IGFI protein, where WT MIA placentas display a 
decreased concentration of IGFI compared to saline controls, while IL-6 KO MIA 
placentas display higher levels of IGFI. This provides further evidence that both basal IL-
6 and MIA-induced IL-6 in the placenta play a role in suppressing IGFI and IGFBP3 
production.   
There are no differences between placentas from salineor poly(I:C)-injected 
mothers in the levels of GHRH, IGFII, IGF1R and IGFBP2, an inhibitory IGFI binding 
protein (Fig. 5A). Thus, MIA selectively reduces levels of placental GH and IGFI, two 
important hormones responsible for promoting embryonic development.  
MIA also alters the expression of placental lactogen (PL) and pro-lactin-like proteins 
(PLPs) in the placenta. The PL and PLPs comprise families of prominent placenta-
specific factors that regulate pregnancy, placental physiology and fetal development 
(Soares, 2004). Maternal poly(I:C) injection up-regulates placental PLP-K expression at 3 
hours post-injection and this effect is abrogated in placentas from poly(I:C)-injected IL-6 
-/mice (Fig. 6A, B). PLP-K is a placenta-specific protein that is widely expressed in the 
sTGCs of the labyrinth and in the spongiotrophoblast layer (Wiemers et al., 2003), an 
expression pattern that correlates precisely with IL-6-induced STAT3 activation in the 
placenta. Taken together, these data suggest that the activation of STAT3 driven by 
maternal IL-6 in response to MIA is responsible for the observed elevation in PLP-K 
expression. In addition, there is a trend towards increased expression of placental growth 
factor (PGF), a key a protein in angiogenesis and vasculogenesis in the placenta; 
placental lactogen 2 (PLII), a lactogen regulated by the inhibitory control of GH; as well 
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as PLP-F (Fig. 6A), a pro-lactin-like protein known to regulate hematopoiesis (Wiemers 
et al., 2003). No significant difference is seen in expression of PLI or PLP-E between 
saline and poly(I:C) placentas. Thus, MIA-induced IL-6 regulates expression of placenta-
specific hormones that influence the maternal response to pregnancy and the regulation of 
fetal growth.  
 
Discussion 
The finding that IL-6 is critical for mediating the effects of MIA on the 
development of schizophreniaand autism-related endophenotypes in the mouse model 
offers the opportunity to trace the molecular and cellular pathways by which maternal 
infection increases risk for these neurodevelopmental disorders. We show that a single 
injection of rIL-6 into pregnant mice yields offspring with PPI, LI and open field deficits 
that are equal, if not more severe, than those seen in MIA offspring.  
We find that maternally-derived IL-6 accounts for the increased pool of IL-6 in 
placentas from poly(I:C)-injected mothers. Potential sources of maternally-derived IL-6 
in the placenta include circulating IL-6 in the maternal bloodstream and IL-6 that is 
secreted by maternal cells that reside in the placenta, such as decidual immune cells, 
stromal cells and endothelial cells. It is clear that maternal poly(I:C) injection increases 
the level of IL-6 and other pro-inflammatory cytokines in the maternal circulation 
(Gilmore et al., 2005; Meyer et al., 2008; Smith et al., 2007; Koga et al., 2009). However, 
our finding that IL-6 mRNA expression is dramatically increased in MIA placentas 
suggests that resident placental cells of maternal origin may also be a source of increased 
placental IL-6. Furthermore, we show that MIA increases the number of CD69-
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expressing decidual macrophages, granulocytes and uNK cells in poly(I:C) placentas. 
CD69 is a marker of an early activation response, and its expression is associated with 
production of pro-inflammatory cytokines including IL-6 (Saito, 2000). Thus, following 
MIA, activated decidual leukocytes may contribute to the induction of IL-6 in the 
placenta (Lockwood et al., 2008). Some studies report that maternal stromal cells and 
endothelial cells in the placenta can also generate cytokines in response to other types of 
immune activation (Semer et al., 1991; Montes et al., 1995). Interestingly, in the CBA x 
DBA/2 model of miscarriage, early maternal poly(I:C) injection leads to increased 
expression of CD69, IFNγ and TNFα by uNK cells (Zhang et al., 2007). Altogether, 
these findings demonstrate that the MIA response is relayed to the maternal cells in the 
placenta, leading to increased levels of maternally-derived IL-6 directly at the materno-
fetal interface.  
Interestingly, compared to saline-injected controls, IL-6 protein is increased in 
amniotic fluid (AF) from poly(I:C)-injected mothers (Mandel et al., 2010). While the 
importance of the fetal placental component was stressed as the source of AF IL-6, it 
appears that much of the AF IL-6 is dependent on maternal IL-6 production. Eliminating 
the contribution of maternal IL-6 in poly(I:C)-injected mice decreases the concentration 
of AF IL-6 by over 14-fold compared to that observed in WT poly(I:C)-injected mice, 
and brings the final AF IL-6 concentration to a level lower than that observed in saline 
controls (Mandel et al., 2010). This indicates that maternal IL-6 production is critical for 
MIA-induced increases in AF IL-6. It will be important to compare AF from IL-6 
+/offspring of IL-6 -/mothers with AF from IL-6 +/offspring of IL-6 +/mothers as a 
control. 
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We further demonstrate that maternally-derived IL-6 is responsible for activation 
of the JAK/STAT3 pathway specifically in the spongiotrophoblast layer, a fetal 
compartment of the placenta. It is likely that this STAT3 activation occurs by a direct 
effect of maternally-derived IL-6 on spongiotrophoblast cells, since we find that they 
express IL-6Rα and gp130. Moreover, paracrine signaling is a well-established 
mechanism of materno-fetal communication between distinct placental layers (Petraglia 
et al., 1996; Bischof et al., 2000; Lacey et al., 2002; Hess et al., 2006). The spatially-
localized activation of STAT3 at the junctional zone of the placenta suggests that MIA 
induces maternally-derived IL-6 in the decidual layer (Fig. 7), which then signals in a 
paracrine manner to fetal spongiotrophoblast cells. It is important to note that, while a 
direct effect of IL-6 on placental cells is likely, we have not excluded the possibility that 
IL-6 may act as an upstream, indirect mediator of MIA effects on the placenta, and that 
IL-6 may act by so-called trans-signaling, or binding soluble IL-6Rα before complexing 
with membrane-bound gp130. Nonetheless, the maternal IL-6-dependent activation of the 
STAT3 pathway in spongiotrophoblast cells demonstrates a direct transfer of the MIA 
response from maternal to fetal cells.  
Spongiotrophoblast cells arise just prior to mid-gestation and are a prominent 
source of endocrine factors throughout the latter half of gestation (Soares, 2004). We find 
an IL-6-dependent elevation in placental PLP-K expression after MIA, along with mild 
increases in several other pro-lactogen and pro-lactin-like-protein family members.  
As a recently discovered PLP, PLP-K is characterized as a placenta-specific protein 
produced primarily by spongiotrophoblast cells and also by sTGCs (Wiemers et al., 
2003). The correlation of maternal-IL-6-dependent STAT3 activation in the 
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spongiotrophoblast with maternal-IL-6-dependent up-regulation of PLP-K suggests that 
modulation of PLP-K expression lies downstream of STAT3 activity. While its function 
is unclear, PLP-K possesses structural similarity to proliferin (PLF), a protein that binds 
mannose-6/IGFII complexes to regulate vasculogenesis and trophoblast proliferation. 
Thus, we demonstrate that MIA-induced maternal IL-6 alters expression of PLP-K and 
potentially other genes that encode endocrine or paracrine modulators of maternal and 
fetal cells.  
Furthermore, we find an IL-6-dependent dysregulation of the GH-IGF axis in 
MIA placentas, characterized by decreased levels of GH and IGFI mRNA, with 
corresponding decreases in placental IGFI and IGFBP3 protein. The actions of GH are 
achieved through the stimulation of IGFI production in target tissues. In addition, GH 
regulates the activity of IGFI by altering the production of either facilitatory or inhibitory 
binding proteins, including the IGFI stabilizing protein, IGFBP3. This suggests that the 
decreased GH levels seen in MIA placentas leads to the observed downstream 
suppression of IGFBP3 and IGFI production. It is believed that IGFs in the maternal 
circulation do not enter the placenta, and therefore IGFs in the placenta are derived from 
the placental compartment itself (Kanai-Azuma et al., 1993).  
We demonstrate that the changes in IGFI and IGFBP3 expression are mediated by 
IL-6. However, it is unclear whether decreases in placental GH and subsequent effects on 
IGF production are downstream of IL-6-specific STAT3 activation. IL-6 does modulate 
IGFI and IGFBPs in several tissues, including placenta and cord blood (De Benedetti et 
al., 2001; Street et al., 2009). Pro-inflammatory cytokines, including IL-6, decrease 
circulating and tissue concentrations of GH and IGFI (Lang et al., 2005). We observe that 
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IL-6-mediated STAT3 activation is associated with the expected IL-6-mediated increase 
in SOCS3 expression, along with other acute phase genes. Factors like SOCS play an 
important role in the down-regulation of GH and GH signaling (Herrington et al., 2000; 
Lang et al., 2005). Importantly, it is reported that IL-6 inhibits hepatic GH signaling 
through up-regulation of SOCS3 (Denson et al., 2003). As such, it is possible that, in 
MIA placentas, maternal IL-6-induced STAT3 activation and downstream sequelae lead 
to suppression of placental GH levels, disruption of IGFI production and further 
consequences on maternal physiology, placental function and fetal development.   
Altered placental physiology and release of deleterious mediators to the fetus are 
important risk factors for the pathogenesis of neurodevelopmental disorders. Placental 
IGFI in particular regulates trophoblast function (Forbes & Westwood, 2008), nutrient 
partitioning and placental efficiency (Fowden et al., 2009). Moreover, altered IGFI levels 
are associated with intrauterine growth restriction (IUGR) and abnormal development 
(Laviola et al., 2008; Crossey et al., 2002). Animal models of IUGR and intrauterine 
infection, where the immune insult is confined to the uteroplacental compartment, 
highlight the key role of placental inflammation in perinatal brain damage, involving 
altered cortical astrocyte development (Bassan et al., 2010), white-matter damage 
(reviewed by Dammann & Leviton, 1997), microglial activation, cell death (Hutton et al., 
2008) and reduced effectiveness of the fetal blood-brain-barrier (Yan et al., 2004). In 
addition, adult pathophysiology is subject to feto-placental “programming”, wherein 
molecular changes that occur prenatally reflect permanent changes that persist throughout 
postnatal life (Zhang et al., 2005; Seckl & Holmes, 2007; Merlot et al., 2008; Bilbo & 
Schwarz, 2009; Barker et al., 2010a,b; Frost & Moore, 2010). Interestingly, placental 
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responses to maternal insults can potentiate sexually dimorphic effects on fetal 
development (Clifton, 2005; Mueller & Bale, 2008). 
Obstetric complications are linked to schizophrenia risk (reviewed by Preti et al., 
2000) and to the treatment responses of schizophrenic individuals (Alivir et al., 1999). 
Notably, a greater occurrence of placental trophoblast inclusions was observed in 
placental tissue from children who develop autism spectrum disorder (ASD) compared to 
non-ASD controls (Anderson et al., 2007). Chorioamnionitis and other obstetric 
complications are significantly associated with socialization and communication deficitis 
in autistic infants (Limperopoulos, 2008). The characterization of placental 
pathophysiology and obstetric outcome in ASD and schizophrenic individuals will be 
useful for the identification of molecular mechanisms that underlie these disorders and 
for potential biomarkers for early risk diagnosis.  
In addition to the observed effects of IL-6 on placental physiology and its 
downstream effects on fetal brain development and postnatal growth, direct effects of IL-
6 on the fetal brain are also likely. Maternal IL-6 can potentially cross the placenta and 
enter the fetus after MIA (Dahlgren et al., 2006). Furthermore, IL-6 mRNA and protein 
are elevated and STAT3 is phosphorylated in the fetal brain itself following MIA 
(Gilmore et al., 2005; Meyer et al., 2008; Hsiao & Patterson, 2009), raising the obvious 
possibility that IL-6 acts directly on the developing brain to influence astrogliosis, 
neurogenesis, microglial activation and/or synaptic pruning (Conroy et al., 2004; Gilmore 
et al., 2004; reviewed in Deverman & Patterson, 2010). However, recall that the 
identification of IL-6 as a critical mediator of MIA is based on maternal co-injection of 
poly(I:C) and anti-IL-6 blocking antibody, in addition to experiments inducing MIA in 
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IL-6 KO animals. As such, in considering which pool(s) of IL-6 (e.g. maternal, placental, 
fetal brain, fetal periphery) is the “critical mediator”, it will be important to understand 
the potential interaction between maternal IL-6 and fetal brain IL-6 expression. While we 
believe that the endocrine changes triggered by maternal-IL-6 signaling in the placenta 
reported here are important for fetal growth, it will be crucial to assess the potential 
impact of these placental changes on offspring behavior and neuropathology. We are 
currently exploring the effects of MIA in targeted IL-6Rα KOs in order to tie tissueand 
cell-specific IL-6 activity to the manifestation of schizophreniaand autism-related 
endophenotypes.  
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Methods 
Generation of animals.  
Female C57BL/6J mice (Charles River; Wilmington, MA) were obtained from the 
Caltech breeding facility and housed under standard laboratory conditions. Mice were 
mated overnight and the presence of a vaginal plug on the following morning was noted 
as day E0.5. 
 
IL-6 KO mice.  
IL-6 KO mice, strain B6.129S2-IL6tm1Kopf/J, were obtained from Jackson Laboratory 
(Bar Harbor, ME). IL-6 -/females were mated with IL-6 +/males, and IL-6 +/females 
were mated with IL-6 -/males. For assays involving placental samples, a small amount of 
tissue from the corresponding fetus was used for genotyping. 
 
MIA.  
Pregnant C57BL/6J or IL-6 KO mice were injected on E12.5 with saline, poly(I:C), or 
recombinant IL-6 (rIL-6). For poly(I:C) injections, poly(I:C) potassium salt (Sigma 
Aldrich; St. Louis, MO) was freshly dissolved in saline and administered i.p. at 20 mg/kg 
based on the weight of the poly(I:C) itself, not including the total weight of the potassium 
salts. Control mice were injected with saline alone at 5 ml per gram body weight. For rIL-
6 injections, 5 mg carrier-free, recombinant mouse IL-6 (eBioscience; San Diego, CA) 
was freshly dissolved in 150 ml saline and injected i.p.  
 
Behavioral testing.  
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After injection on E12.5, each pregnant mouse was single-housed. At 6 weeks of age, 
offspring were behaviorally tested for PPI; at 8 weeks, for LI, and at 10 weeks, for open 
field exploration, according to methods described by Smith et al., 2007.  
 
Measurement of placental IL-6, growth hormone and IGFI.  
After injection on E12.5, wild type (WT) and IL-6 KO mice were sacrificed at 3, 6 or 24 
hours by an overdose of sodium pentobarbital (Nembutal). Placentas were dissected from 
the uterine horn and washed in PBS prior to snap-freezing in liquid nitrogen and storage 
at -80°C. To generate cell lysates, each placenta was placed in 1 ml of cell lysis buffer 
(50 mM Tris-HCl (pH 7.4) with 0.6 M NaCl, 0.2% Triton X-100, 1% BSA, and 1 EDTA-
free protease inhibitor cocktail tablet/10 ml buffer) (Roche Applied Sciences; 
Indianapolis, IN). Each tissue was homogenized on ice using a syringe fitted with an 18G 
needle and then sonicated for 5 seconds at 10 mV. The homogenates were centrifuged at 
4°C at 13,000 rpm for 20 minutes, and the supernatants aliquotted and frozen at -80°C 
until assayed. ELISAs for IL-6 (eBioscience), GH (Millipore; Billerica, MA), and IGFI 
(R&D Systems; Minneapolis, MN) were performed according to the manufacturers’ 
instructions and analyzed against cell lysis buffer negative controls. Total protein was 
measured by BCA assay (Thermo Scientific; Rockford, IL) according to the 
manufacturer’s instructions.  
 
Measurement of placental gene expression by real-time PCR.  
Placentas were quickly dissected from the uterine horn and washed in PBS prior to 
preservation in 1 ml TRIzol solution (Invitrogen; Carlsbad, CA). Tissues were passed 
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through an 18G needle and sonicated for two rounds of 3 seconds at 10 mV separated by 
incubation on ice. Homogenates were processed by chloroform extraction and washing 
with 70% ethanol according to standard procedures. RNA was further purified by 
applying the cleared lysate to an RNeasy mini column (Qiagen; Valencia, CA), and an 
on-column DNA digestion was performed according to the manufacturer’s protocols. 
Samples were assayed using the 2100 Bioanalyzer (Agilent Technologies; Santa Clara, 
CA) and confirmed to contain high integrity RNA (RIN > 8). 5 mg RNA per sample was 
reverse-transcribed using the iScript cDNA synthesis kit (Biorad; Hercules, CA). 
Resultant cDNA was purified using a PCR purification kit (Qiagen) and eluted in 50 ml 
PCR-grade water (Roche). Gene expression was measured using SYBR Green master 
mix with Rox passive reference dye (Roche) on the ABI 7300 Real Time PCR system. 
Target gene expression was normalized against beta-actin transcript, and data are 
expressed as ratios of gene expression of poly(I:C) to saline samples. The primers used 
were adapted from the Primerbank database (Spandidos et al., 2010).  
 
Immunohistochemistry.  
Placentas were dissected and washed in PBS prior to fixation for 1.5 hours in 4% 
paraformaldehyde at 4°C and cryopreservation in 30% sucrose overnight at 4°C. After 
equilibration for 1 hr in Tissue-Tek OCT (Sakura Finetek; Torrance, CA), each placenta 
was hemi-sected laterally prior to freezing. Placentas were cut in 12 mm sagittal sections, 
with 8 medial sections spanning approximately 576 mm of tissue (every sixth section) 
taken from each placenta for each histological stain. Sections were stained for phospho-
STAT3 and phospho-STAT1 (Cell Signaling; Danvers, MA) according to standard 
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procedures. Briefly, antigen retrieval was conducted for 30 minutes in a 95°C water bath 
in 10 mM sodium citrate pH 6.0, for pSTAT3, and 1 mM EDTA pH 9.0, for pSTAT1. 
Slides were equilibrated to room temperature, washed and incubated for 10 minutes in 
3% H2O2 in methanol. After washing, tissues were processed using Vectastain Elite ABC 
peroxide kits (Vector Labs; Burlingame, CA) according to the manufacturer’s 
instructions, with overnight incubation of primary antibody at 4°C. Staining was 
developed using ImmPACT DAB substrate (Vector Labs) and mounted in Vectamount 
aqueous mounting medium (Vector Labs). 
 
Flow cytometry of placental leukocytes.  
The decidua was dissected carefully from the labyrinth layer and washed in PBS on ice. 
7-8 tissues from each litter were pooled in RPMI 1640 medium with 10% FBS and 1% 
penicillin/streptomycin and subjected to mechanical disruption by passage through a 
syringe fitted with a 16G needle followed by a syringe with an 18G needle. Tissue 
suspensions were then enzymatically disrupted with 0.1% collagenase for 30 minutes at 
37°C, followed by 0.25% trypsin for 10 minutes at 37°C. Cell suspensions were washed 
with 3 volumes of RPMI and passed through 22G and 25G needles and subjected to 2 
rounds of RBC lysis and filtration through 40 mm cell strainers. Cell counts were 
performed on a hemocytometer, and 1 million cells were aliquotted for each subsequent 
reaction. Single cell suspensions were treated with anti-mouse CD16/CD32 Fc block 
(eBioscience) for 10 minutes on ice prior to staining in CBSS with the following antibody 
conjugates: DBA-lectin-FITC (Sigma), CD69-PE (eBioscience), Ter119-PerCP-Cy5.5 
(BioLegend; San Diego, CA), CD4-FITC (BioLegend), CD8-FITC (Biolegend), Gr-1-
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APC (BioLegend), B220-FITC (BioLegend) and CD11b-APC (BioLegend). Flow 
cytometry was performed using the FACSCalibur cytometer (BD Biosciences; San Jose, 
CA), and data were analyzed using FlowJo software (TreeStar Inc.; Ashland, OR) and 
presented as percent frequency of the parent population (non-erythroid (Ter119-) cells).  
 
Laser capture microdissection (LMD).  
Placentas were dissected, washed in PBS and immediately snap-frozen in liquid nitrogen. 
Tissues were then embedded in Tissue-Tek OCT and cut into 12 mm sections on PALM 
Membrane Slides (PALM Microlaser Technologies; Germany). Cryostat blades and 
workstations were cleaned with RNaseZap (Applied Biosystems; Austin, TX) to prevent 
RNA degradation. 6 medial sagittal sections were stained with hematoxylin QS (Vector 
Labs) and used for laser microdissection. Duration was limited to < 30 minutes per slide 
to prevent RNA degradation. For each placental section, the spongiotrophoblast layer was 
localized by morphology under the Axio Observer.Z1 confocal microscope (Zeiss; 
Thornwood, NY). Conservative regions of interest encompassing approximately 100 cell 
nuclei were microdissected (energy: 40-48; focus: 71) using the PALM Microbeam 
system and PALMRobo software 4.3 (Zeiss) and immediately expelled into an 
AdhesiveCap 500 microfuge tube (Zeiss). RNA isolation was performed immediately as 
described above, with the RNeasy Micro Plus kit (Qiagen). Genomic DNA was removed 
using gDNA eliminator columns (Qiagen). Total RNA was amplified and reverse 
transcribed using the Quantitect Whole Transcriptome Amplification kit (Qiagen). 100 ng 
cDNA was used for qPCR, according to the methods described above. No differences in 
relative ß-actin, IL-6Rα and gp130 expression were observed between saline and 
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poly(I:C) samples, and treatment groups were therefore merged for greater statistical 
power. 
 
Statistical analysis.  
Statistical analysis was performed with Prism software (Graphpad Software; La Jolla, 
CA). The statistical significance of differences between two treatment groups was 
assessed using the Student’s t-test, and differences among multiple groups was assessed 
using one-way ANOVA followed by Bonferroni post-hoc tests.  
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Fig. 1. Maternal IL-6 exposure yields offspring with behavioral abnormalities 
analogous to those seen in MIA offspring. A. Compared to controls, offspring of mice 
treated with rIL-6 or poly(I:C) display a PPI deficit [F(2, 74)=4.40, *p < 0.05]. B. rIL-6 
and poly(I:C) offspring display increased freezing in response to the conditioned acoustic 
cue during LI testing, as well as decreased LI compared to saline controls when measured 
against the NPE group [% freezing = 64.49 ± 6.05 (mean ± SEM)] [F(2, 41)=3.261, *p < 
0.05]. NPE poly(I:C) and saline offspring display no significant difference in freezing 
response. C. Compared to controls, offspring of rIL-6 or poly(I:C)-injected mothers 
exhibit fewer entries into the center of the open field [F(2, 92)=8.596; p < 0.0005] and 
shorter duration spent in the center field [F(2, 92)=3.140; *p < 0.05]. rIL-6 offspring also 
present shorter total distance traveled in the open field [F(2, 92)=12.81; p < 0.0001]. 
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Fig. 2. MIA upregulates maternally-derived IL-6 in the placenta. A. Compared to 
controls, placentas from poly(I:C)-injected mothers exhibit increased IL-6 protein at 3, 6 
and 24 hours post-injection [n= 9 per treatment per time point (from 3 independent 
litters); * p < 0.05, ** p < 0.001]. B. At 3 hours post-injection, compared to saline 
controls, placentas from poly(I:C)-injected mothers also display increased mRNA 
expression of pro-inflammatory cytokines, including a markedly elevated level of IL-6 
[n=9 per treatment group (from 3 independent litters); ***p < 0.0001]. C. Eliminating the 
contribution of fetally-derived IL-6 has no effect on total placental IL-6 levels, whereas 
eliminating the contribution of maternally-derived IL-6 completely diminishes total 
placental IL-6 to levels below those seen in saline controls at both 3 hours and 6 hours 
post-injection. This indicates that basal and MIA-induced placental IL-6 is maternally-
derived. [F(3,80)=24.89; ***p < 0.0001].  
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Fig. 3. MIA activates decidual leukocytes to express CD69. A. Compared to controls, 
placentas from poly(I:C)-injected mothers harbor increased numbers of CD69-expressing 
CD11b+, Gr-1+ and DBA lectin+ cells [F(1,12)=24.76, ***p=0.0003]. These are 
similarly increased in poly(I:C)-injected IL-6-/mothers, suggesting that this effect occurs 
independently of IL-6 action [F(1,12)=21.87, **p=0.0005]. B. Representative flow 
cytometry spectra show increased total CD69+ cells in poly(I:C) decidual suspensions 
(left) and increased CD69+ CD11b+ cells from a non-erythroid parent population (right) 
C. Increased activation of decidual leukocytes corresponds with a trending increase in 
total CD69+ gene expression (# p = 0.08)  
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Fig. 4. Maternally-derived IL-6 activates the JAK/STAT3 pathway in the fetal 
placental compartment in response to MIA. A. Representative sections of the 
spongiotrophoblast layer of the placenta (with decidua along the top edge and labyrinth 
along the bottom edge of each image) show positive pSTAT3 staining when placentas are 
isolated from poly(I:C)-injected mothers. Eliminating the contribution of fetally-derived 
IL-6 has no effect on pSTAT3 staining, while eliminating the contribution of maternally-
derived IL-6 completely abrogates pSTAT3 staining in the spongiotrophoblast. [n=5-7 
placentas per treatment group per genotype pair (from 3-5 independent litters)]. Dotted 
lines = boundary between decidua and spongiotrophoblast layers (upper) and boundary 
between spongiotrophoblast and labyrinth (lower); D=decidua, Sp=spongiotrophoblast, 
L=labyrinth; B. MIA-induced JAK/STAT3 activation is accompanied by increased 
expression of the downstream acute phase genes, SOCS3, TIMP1, Pim1 and NOS2, in 
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poly(I:C) placentas [n=9 per treatment group (from 3 independent litters); ***p < 0.0001, 
*p < 0.05, # p = 0.07]. C. Eliminating the contribution of maternally-derived IL-6 reduces 
placental SOCS3 induction [n=9 per treatment group per genotype pair (from 3 
independent litters); ***p < 0.0001, *p < 0.05]. D. Murine spongiotrophoblast cells 
express IL-6Rα and gp130 mRNA, indicating that they may respond directly to placental 
IL-6 activation. [n=3 saline, 3 poly(I:C}; merged]. 
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Fig. 5. MIA-induced IL-6 action reduces placental IGFI and IGFBP3. A. Compared 
to saline controls, placentas from poly(I:C)-injected mothers have significantly reduced 
expression of IGFI and IGFBP3 mRNA and a trending decrease in GH expression [n=9 
per treatment group (from 3 independent litters); **p < 0.001, # p = 0.24]. B. The deficits 
in IGFI and IGFBP3 expression observed in MIA placentas require IL-6 production 
[IGFI: F(2,23)=15.95; *p < 0.05; IGFBP3: F(2,23)=37.77; **p < 0.001]. C. MIA 
placentas exhibit significantly decreased GH protein [n=7 placentas per treatment group 
(from 3 independent litters); **p < 0.001]. D. MIA placentas exhibit significantly 
decreased IGFI protein, and this deficiency is dependent on IL-6 production [F(2, 
17)=5.908; *p < 0.05]. 
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Fig. 6. MIA-induced IL-6 action increases PLP-K and related growth factor gene 
expression. A. Placentas from poly(I:C)-injected mothers have significantly elevated 
expression of PLP-K and trending increases in PGF and PLII [n=9 per treatment group 
(from 3 independent litters); *p < 0.05, # p = 0.10, ψ p = 0.11]. B. The upregulation of 
PLP-K expression observed in MIA placentas require IL-6 action [F(2,23)=5.033; *p < 
0.05]. 
 
 249 
Fig. 7. Model of MIA-induced IL-6 effects on the placenta. Maternal injection of 
poly(I:C) leads to the activation of the maternal immune system via a TLR3-mediated 
anti-viral response. Pro-inflammatory factors, including IL-6, are secreted by activated 
TLR3+ cells into the maternal bloodstream. As maternal blood circulates continuously 
through the placenta, IL-6 and soluble pro-inflammatory factors increase in the spiral 
arteries that descend through the decidua and spongiotrophoblast, as well as in the 
maternal blood spaces of the labyrinth, and circulate back up into the maternal 
compartment. Resident immune cells in the decidua are activated by maternal cytokines 
and other signaling factors to express CD69, and they propagate the inflammatory 
response by further cytokine release. IL-6 derived from decidual cells acts in a paracrine 
manner on target cells in the spongiotrophoblast layer. Ligation with the cognate receptor 
IL-6Ra and gp130 leads to signal transduction resulting in JAK/STAT3 activation and 
downstream changes in gene expression. Increases in acute phase proteins, such as 
SOCS3, down-regulate placental GH production and signaling. This leads to reduced 
IGFBP3 and IGFI. Global changes in STAT3 activation in the spongiotrophoblast layer 
 250 
alter the production of placenta-specific PLP and pro-lactin proteins. These changes in 
endocrine factors lead to acute placental pathophysiology and subsequent effects on fetal 
development.  
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Fig. S1. Fetally-derived IL-6 contributes negligible amounts of IL-6 protein to the 
placenta after MIA. Placentas were collected to assess levels of placental IL-6 by 
ELISA. A low-level absorbance signal is observed in IL-6 -/placentas from IL-6 -
/mothers, indicating a degree of non-specific protein binding during the experimental 
procedure. All placentas from salineor poly(I:C)-injected IL-6 -/mothers exhibit similarly 
negligible amounts of absorbance signal.  
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Fig. S2. MIA has no affect on percentages of decidual immune cell subtypes. 
Compared to controls, placentas from poly(I:C)-injected mothers have no significant 
difference in the percentages of macrophages, granulocytes, uNK cells, CD4+ T cells, 
CD8+ T cells or B cells.  
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Fig. S3. MIA induces phosphorylation of STAT1 and STAT3 in sTGCs and pTGCs 
in an IL-6-independent manner. A. IL-6 +/and IL-6 -/placentas from poly(I:C)-injected 
IL-6 +/mothers display no significant difference in the number of pSTAT3-positive 
spongiotrophoblast cells. Thus, fetally-derived IL-6 contributes little to MIA-induced 
STAT3 activation. B. Representative images taken at 20X magnification depict saline 
placenta (left) and MIA placenta (right). Compared to saline controls, MIA placentas 
(right) stain positively for pSTAT1 in sTGCs and pTGCs (arrows). Dotted lines = 
boundary between decidua and spongiotrophoblast layers (upper) and boundary between 
spongiotrophoblast and labyrinth (lower); D=decidua, Sp=spongiotrophoblast, 
L=labyrinth; C. Representative images taken at 40X magnification depict pSTAT3 
staining in saline labyrinth (left) and MIA labyrinth (right). Compared to saline controls, 
MIA placentas stain positively for pSTAT3 in sTGCs.  
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Abstract 
 
We are exploring the mechanisms underlying how maternal infection increases the risk 
for schizophrenia and autism in the offspring. Several mouse models of maternal immune 
activation (MIA) were used to examine the immediate effects of MIA induced by 
influenza virus, poly(I:C) and IL-6 on the fetal brain transcriptome. Our results indicate 
that all three MIA treatments lead to strong and common gene expression changes in the 
embryonic brain. Most notably, there is an acute and transient up-regulation of the alpha, 
beta and gamma crystallin gene family. Furthermore, levels of crystallin gene expression 
are correlated with the severity of MIA as assessed by placental weight. The overall gene 
expression changes suggest that the response to MIA is a neuroprotective attempt by the 
developing brain to counteract environmental stress, but at a cost of disrupting typical 
neuronal differentiation and axonal growth. We propose that this cascade of events might 
parallel the mechanisms by which environmental insults contribute to the risk of 
neurodevelopmental disorders such as schizophrenia and autism. 
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Introduction 
Maternal infection is a risk factor for schizophrenia and autism. In the case of 
schizophrenia, a wide variety of infections during pregnancy (viral, bacterial, parasitic) 
are associated with increased risk for this disorder in the offspring. Summing these risks, 
Brown and Derkits (2010) estimate that >30% of schizophrenia cases would be prevented 
if infection could be averted in pregnant women. The fact that such a diverse set of 
pathogens is associated with risk suggests that it is the mother’s response to the infection 
that is critical for altering fetal brain development. In fact, the maternal response during 
gestation (elevated cytokines and anti-pathogen antibodies) is associated with the 
increase in schizophrenic outcome in the offspring(A. S. Brown & Derkits, 2010). 
Similarly for autism, a study of >10,000 cases in the Danish Medical Registry revealed 
an association between viral or bacterial infection in the mother and increased risk for the 
offspring(Atladottir et al., 2010). Also similar to schizophrenia are findings of an 
increased risk for autism in the offspring if particular cytokines or a chemokine are 
elevated in maternal serum or amniotic fluid (Abdallah et al., 2011; Goines et al., 2011). 
The observation of a significantly higher concordance in dizygotic twins than in non-twin 
siblings also suggests the importance of the maternal-fetal environment in autism 
(Hallmayer et al., 2011; Rosenberg et al., 2009). 
To mimic the environmental risk for development of schizophrenia and autism, 
several animal models for maternal immune activation (MIA) have been used 
successfully (Patterson, 2009). First, intranasal instillation of human influenza virus in 
pregnant mice or non-human primates induces a moderate but sublethal infection, and the 
offspring display a series of histological and molecular abnormalities in the hippocampus 
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and cortex (Fatemi, Cuadra, El-Fakahany, Sidwell, & Thuras, 2000; Fatemi et al., 1999). 
Young and adult mouse MIA offspring (Shi, Fatemi, Sidwell, & Patterson, 2003) also 
exhibit a cerebellar neuropathology that is commonly found in autism (Amaral, 
Schumann, & Nordahl, 2008; Palmen, van Engeland, Hof, & Schmitz, 2004) 
Furthermore, adult mice born to infected mothers display behavioral abnormalities that 
are relevant to both schizophrenia and autism, including deficits in social interaction, 
prepulse inhibition (PPI), and open field and novel object exploration (Shi, et al., 2003), 
as well as heightened responsivity to a hallucinogen (Moreno et al., 2011). Second, MIA 
can also be induced in the absence of pathogens by injecting pregnant rats, mice or 
monkeys with the synthetic dsRNA, poly(I:C) to mimic a viral infection, or with 
lipopolysaccharide (LPS) to mimic a bacterial infection. Overall, the behavioral results 
from the maternal infection, poly(I:C) and LPS models is consistent, with many results 
being reproduced in both rats and mice (Meyer & Feldon, 2010; Patterson, 2009, 2011). 
Molecular and cellular studies of adult offspring of poly(I:C)-treated rodents reveal 
abnormalities that are clearly relevant to schizophrenia, such as increased levels of 
GABAA receptor α2 immunoreactivity, dopamine hyperfunction, delay in hippocampal 
myelination, reduced NMDA receptor expression in hippocampus, reduced numbers of 
reelin and parvalbumin-positive cells in prefrontal cortex, reduced dopamine D1 and D2 
receptors in prefrontal cortex and enhanced tyrosine hydroxylase in striatal structures 
(Meyer et al., 2008). Third, MIA can be induced more directly by a single injection of the 
cytokine IL-6 in pregnant mice (Smith, Li, Garbett, Mirnics, & Patterson, 2007). This 
approach is based on findings that this injection yields offspring displaying many of the 
same behavioral abnormalities found in offspring of influenza-infected or poly(I:C)-
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treated dams. Moreover, co-injection of an anti-IL-6 antibody blocks the effects of 
poly(I:C), yielding offspring with normal behavior. The critical importance of IL-6 in 
MIA is further shown by the finding that poly(I:C) injection in IL-6 knockout mice also 
yields offspring with normal behavior (Smith, et al., 2007). Flavonoids that block 
JAK/STAT signaling downstream of the IL-6 receptor also block the induction of 
abnormal behaviors by maternal IL-6 injection (Parker-Athill et al., 2009). Maternal IL-6 
is also critical for the endocrine changes in the placenta induced by MIA (Hsiao & 
Patterson, 2011) 
However, the immediate effects of MIA on the fetal brain are not well 
understood. It is critical to examine the very early effects because the rise in IL-6 caused 
by maternal IL-6 injection is transient, as is the effect of injecting the anti-IL-6 blocking 
antibody in the pregnant dam. These acute effects nonetheless lead to permanent changes 
in the behavior of the offspring. To gain a better understanding of the molecular events 
that take place in the MIA-exposed developing brain, we examined the transcriptome 
changes associated with three different MIA models, and identify the critical early 
mediators that may contribute to the emergence of behavioral symptoms in MIA 
offspring. 
 
Results 
 
Transcriptome changes in flu-, poly(I:C)-, and rIL-6-treated embryonic brains 
Five pregnant dams were treated with a single, nasal installation of flu virus at 
E9.5. The embryos were dissected on E12.5, the time of peak maternal IL-6 expression, 
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and brains were collected. A single treatment of poly(I:C), rIL-6 or saline was 
administered to four pregnant dams per group at E12.5. The embryonic brains from these 
treatments were collected 3h after injection. RNA was isolated from the entire brain of 
individual embryos. We obtained 31 to 36 embryos per treatment, which totaled 138 
embryonic brain samples. For microarray analysis, embryonic brains from each litter 
were pooled into a single sample. Using a 30% expression difference from saline-injected 
controls and a statistical significance of p<0.05, we identified 256 genes differentially 
expressed in the flu model, 294 in the poly(I:C) model, and 195 in the IL-6 model. 
Examining all of the differentially expressed genes in a two-way (samples and genes) 
unsupervised hierarchical clustering of the gene expression intensities, the four 
experimental groups separate into distinct clusters (Fig. 1A) that correspond to the 
different MIA treatments, with the main clusters separating the saline-treatment from all 
three MIA-treatments. Interestingly, the majority of the genes altered in the poly(I:C) and 
IL-6 treatments were up-regulated, while there were as many down-regulated genes in the 
flu treatment, which might reflect secondary expression changes that occurred during the 
3 day period following the influenza virus exposure.  
Next, we tested if the transcriptome changes showed a common expression 
pattern across the three different MIA treatments. We created three groups of the most 
differentiallyexpressed genes: 256 genes in the flu model, 294 in the poly(I:C) model and 
195 in the IL-6 model. The mRNA signature of the 256 differentially expressed 
transcripts in the flu model was assessed in the poly(I:C) and rIL-6 transcriptomes. We 
found that, as a group, the flu-model transcripts are also significantly changed in the 
poly(I:C)-model and IL-6-model for MIA (r=0.88, p=1.8E-84 and r=0.85, p=5.95E-72 
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respectively) (Fig. 1B,C). Likewise, the 195 differentially expressed genes in the IL-6-
MIA group show a significant expression difference in the Flu-model and poly(I:C)-
model brains (r=0.85, p=1.42E-55 and r=0.85, p=1.06E-54 respectively) (Fig. 1D,E), and 
the 294 transcript changes in the IL-6 group are also significantly present in the fluand 
poly(I:C)-treatments (r=0.59, p=8.78E-29 and r=0.59, p=3.9E-29 respectively) (Fig. 
1F,G). This is a strong indication that all three treatments affect similar molecular 
processes, although their effects might be somewhat different because of the timing 
difference in flu exposure and potential downstream signaling differences. A 
comprehensive list of the differentially expressed genes and their expression levels is 
provided in Supplemental Material 2. 
Of the transcripts with “most changed” expression (>30% expression change and 
p<0.05 in all three treatments), 41 genes were altered in both IL-6 and flu treatment, 31 in 
poly(I:C) and flu, 17 in poly(I:C) and IL-6, and 12 genes were similarly changed in all 
three MIA models. A hierarchical clustering of the expression intensities of these 12 
genes clearly separates the saline-treated controls from the flu, poly(I:C) and IL-6 
treatments (Fig. 2). 
 
Common gene expression changes among treatments point to involvement of the 
crystallin gene family  
Surprisingly, 5 of the 12 genes that are up-regulated in all 3 MIA treatments 
belong to the crystallin gene family: crystallin alpha A (cryaa), crystallin beta B3 
(crybb3), crystallin beta B1 (crybb1), crystallin beta A1 (cryba1) and crystallin gamma 
B/C (crygb/crygc). To validate this finding with an independent method, we generated 
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cDNA from pooled RNA from embryos in each dam. In order to inquire about a possible 
effect of location in the uterus, RNA was separately pooled from embryos residing in the 
left and the right uterine horns, so there were two samples for each dam. For more 
detailed view on the crystallin family of genes we also tested the expression of crystallin 
alpha B (cryab), crystallin beta A2 (cryba2), crystallin beta A4 (cryba4) and crystallin 
gamma C/A (crygc/a). The qPCR data are highly correlated with the microarray data (flu: 
r=0.82, p=0.007; poly(I:C): r=0.84, p<0.005; rIL-6: r=0.89, p=0.001) (Fig. 3). No 
obvious effect of position is apparent. 
Since the expression of these crystallin genes is highly coordinated, we selected 
only cryaa, cryba1 and crybb1 for further qPCR analysis using RNA from the individual 
flu-exposed embryonic brains. The up-regulation of crystallin transcripts observed by 
microarray is confirmed by the qPCR analysis of the 36 individual embryonic RNA 
samples. Flu treatment results in significantly increased cryaa, cryba1 and crybb1 
transcript levels (cryaa: ddCt = 1.97, p = 0.001; cryba1: ddCt = 1.39, p = 0.01; crybb1: 
ddCt = 2.00, p = 0.0002) (Fig. 4). However, these data also reveal a remarkable 
individual variability in flu-induced crystallin up-regulation, which does not correspond 
to the uterine position of the embryos (flu: SD=2.8; saline: SD=1.6). This indicates that 
flu exposure does not equally affect all exposed embryonic brains within each dam, 
which could potentially contribute to eventual behavioral variability. 
 
Crystallin family up-regulation is transient 
Since the crystallin family genes are significantly up-regulated at both 3h 
following IL-6 and poly(I:C) treatment and at 3 days following flu treatment, we asked if 
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these expression changes persist throughout the lifespan of the offspring. We examined 
the expression of cryaa, cryba1 and crybb1 in the frontal cortex and hippocampus of 15 
week-old pups (n=12) from poly(I:C)and saline-treated dams. We find no significant 
difference between these groups in the expression of these genes. Furthermore, no 
difference is found in the frontal cortex between 6 month-old (n=6) offspring of saline-, 
rIL-6and poly(I:C)-treated dams. Similarly, in a different cohort of mice, no difference in 
crystallin expression is seen in the frontal cortex and hippocampus of poly(I:C)and 
saline-treated dams (n=15) at 12 months of age. Thus, we conclude that the up-regulation 
of crystallin genes observed across the three MIA models is transient.  
 
Crystallin expression level correlates with placental weight 
Maternal immune activation has a strong effect on development, and at least part 
of this effect is mediated through the influence of maternal IL-6 on the placenta (Hsiao & 
Patterson, 2011; Mandal, et al., 2010). To test whether there is a relationship between the 
effects of MIA on the placenta and on the fetal brain, we measured the placental weight 
of individual embryos from the three MIA conditions (Fig. 5). The average placental 
weight is significantly decreased in all three MIA-treatments compared to saline-
treatment (flu: p=0.00016; poly(I:C): p=0.03439; IL-6: p=0.0041). Furthermore, brain 
expression levels of cryaa, cryba1 and crybb1 determined by qPCR are highly correlated 
with the decrease in the average placental weight obtained for the all conditions (cryaa: 
r=0.85, p= 0.072; cryba1: r=0.72, p=0.138; crybb1: r=0.92, p=0.041). Thus, the response 
of the crystallin genes corresponds closely with the degree of MIA.  
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Discussion 
This study of the acute effects of MIA on the embryonic brain transcriptome 
reveals that: 1) all three MIA treatments (flu, poly(I:C) and IL-6) evoke strong gene 
expression changes in the embryonic brain; 2) the three MIA treatments yield diverse as 
well as overlapping transcriptome signatures; 3) all MIA treatments strongly up-regulate 
the crystallin gene family, represented by alpha, beta and gamma members, in the 
embryonic brain; 4) the up-regulation of crystallin genes is an acute reaction that does not 
persist into adulthood; 5) the level of crystallin gene expression is correlated with the 
degree of MIA as measured by placental weight. In addition, our data also reveal a 
remarkable variability in crystallin induction among the individual brains in the flu MIA 
model, indicating that this form of MIA does not affect all of the embryos equally within 
each dam.  
While we find that the three MIA models induce a number of genes in common, 
there are also significant differences among the groups. This can be attributed in part to 
differences in the molecular action of the three perturbation agents, but also to the 
differences in the time point of the flu, poly(I:C) and IL-6 exposure. The efficiency of flu 
exposure and disease time-course are challenging to control, and the flu-triggered 
cytokine response is gradual and takes days to develop. The time point chosen for IL-6 
and poly(I:C) injection (E12.5) approximately mimics the peak of IL-6 induction 
following flu infection (E9.5) (Shi, et al., 2003; Smith, et al., 2007). However, cytokine 
induction is longer lasting following infection than it is for the other two treatments. 
Likewise, the molecular effects of poly(I:C) versus IL-6 at 3 hours after exposure may 
not be fully equivalent, resulting in both common and divergent gene expression changes 
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at the same time point. Thus, we believe that the overall data argue that the transcriptome 
differences we observe are part of the same process, providing molecular “snapshots” of 
canonical, transient expression changes that are rapidly changing. Nonetheless, the 
common gene expression patterns across the three MIA models likely give rise to the 
behavioral deficits that are common in the offspring of all three treatments such as PPI, 
social interaction, and open field exploration (Shi, et al., 2003; Smith, et al., 2007). This 
possibility provides strong motivation to further pursue the potential effects of 
dysregulation of these particular genes on brain development, with a primary focus on the 
role of the crystallin gene family. 
That elevated brain crystallin expression is common among three MIA mouse 
models aligns well with studies implicating crystallins in human autism and 
schizophrenia. Altered aB-crystallin protein levels are detected in the frontal cortex of 
autistic brains (Pickett, 2001). In addition, anti-aB crystallin antibodies are reported to be 
elevated in sera of autistic subjects compared to controls (Vojdani et al., 2002). 
Moreover, increased expression of aB-crystallin is detected in Rett syndrome brains 
(Colantuoni et al., 2001), and aB-crystallin is found in inclusions in brains from patients 
with Fragile X–associated tremor/ataxia syndrome (Iwahashi et al., 2006). In 
schizophrenia, altered expression of both a-crystallin and µ-crystallin are reported in the 
anterior cingulate cortex (Martins-de-Souza et al., 2010) and prefrontal cortex (Arion, 
Unger, Lewis, Levitt, & Mirnics, 2007; Middleton, Mirnics, Pierri, Lewis, & Levitt, 
2002). Furthermore, dysregulated brain crystallin levels are implicated in the 
manifestation of a variety of neurodegenerative disorders, including Parkinson’s disease, 
Alzheimer’s disease (AD), multiple sclerosis, Creutzfeldt-Jakob disease and Alexander 
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disease (Bajramovic, Lassmann, & van Noort, 1997; Braak, Del Tredici, Sandmann-Kiel, 
Rub, & Schultz, 2001; Dabir, Trojanowski, Richter-Landsberg, Lee, & Forman, 2004; 
Lowe et al., 1992; Renkawek, Voorter, Bosman, van Workum, & de Jong, 1994; 
Shinohara, Inaguma, Goto, Inagaki, & Kato, 1993; Stoevring, Vang, & Christiansen, 
2005).  
While the exact role of crystallins in these disorders is unclear, studies in animal 
models suggest that up-regulated crystallin levels serve a neuroprotective function. 
Knocking out aB-crystallin in AD or experimental autoimmune encephalitis (EAE) mice 
causes worsened symptoms (Ojha, Karmegam, Masilamoni, Terry, & Cashikar, 2011; 
Ousman et al., 2007). These effects in EAE mice are in turn ameliorated by systemic 
delivery of recombinant aB-crystallin (Ousman, et al., 2007), as are the effects of 
experimental stroke in mice (Arac et al., 2011). Similarly, transgenic over-expression of 
aB-crystallin ameliorates symptoms in a mouse model of Alexander disease, a fatal 
developmental neurodegenerative disorder originating in astrocytes (Hagemann, Boelens, 
Wawrousek, & Messing, 2009). In addition, aA-crystallin exhibits anti-apoptotic 
protective effects in experimentally-induced inflammation of the uvea (Rao et al., 2008), 
and pretreatment with a-crystallin blocks systemically induced inflammation in the brain 
(Masilamoni et al., 2006).  
Recent studies have shown that, in addition to their canonical roles as molecular 
chaperones, crystallins serve a wide variety of other functions that may underlie their 
protective roles in vivo. For example, aA-crystallin-mediated inhibition of caspase-3 
rescues Pax6-deficient dopaminergic neurons from apoptosis (Ninkovic et al., 2010). 
Likewise, aB-crystallin protects against Fas/APO-1-induced cell death in vitro. 
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Crystallins can also confer neuroprotection by modulating cytoplasmic calcium levels. 
Retinal bB2-crystallin, for example, colocalizes with synaptotagmin 1, a primary calcium 
sensor, as well as calmodulin, a major calcium-binding protein (Liedtke, Schwamborn, 
Schroer, & Thanos, 2007a), and several crystallins harbor Greek key motifs that 
sequester calcium ions (Jobby & Sharma, 2007; Rajini et al., 2001; Sharma et al., 1989). 
These properties in aand bB2-crystallins are thought to confer their ability to promote 
neurite-outgrowth during retinal repair (Liedtke, Schwamborn, Schroer, & Thanos, 
2007b; Wang, Wang, Wu, Wang, & Yin, 2010). Another pathway of crystallin activity is 
through regulation of oxidative stress and acute phase immune responses. For instance, 
aB-crystallin modulates NFκB activity based on its phosphorylation status (Adhikari, 
Singh, Rao, & Rao Ch, 2011), and pre-treatment with aB-crystallin prevents NFκB-
induced neurotoxic effects (Steinman, 2009). Moreover, aB-crystallin adminstration in 
vitro and in vivo down-regulates TNFa and nitric oxide synthase in activated microglia 
(Wu et al., 2009).  
Given this literature, the induction of crystallins in response to MIA can be seen 
as an attempt of the developing brain to counteract the immune system challenge. 
Importantly, the crystallin up-regulation we observe in embryos in response to MIA 
cannot be detected in the hippocampus and the frontal cortex of MIA-treated adolescent 
mice, indicating that crystallin induction is transient and characteristic of the acute phase 
of the MIA exposure. Furthermore, comparing our data to previous transcriptome studies 
of MIA offspring suggests that the fetal and adolescent/adult brain transcriptome changes 
do not share significant commonalities (Asp et al., 2005; Fatemi, Pearce, Brooks, & 
Sidwell, 2005; Smith, et al., 2007). 
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In addition to crystallin up-regulation, several other genes are altered in all three 
models of MIA tested here. For some of them (mip, si, tnnc2), there is insufficient 
knowledge about the function of the proteins they encode, which makes it difficult to 
envision their particular roles in the brain, while other transcripts are likely to play an 
important role in brain development. Aldh1a1 is an important player in environmentally-
induced oxidative damage (Lassen et al., 2007), and this might explain its strong up-
regulation in these MIA models. As an enzyme, ALDH1A1 exerts a cellular protective 
role by metabolizing highly reactive aldehydes, including ethanol metabolite 
acetaldehyde and major products of lipid peroxidation. ALDH1A1 is best known for 
converting retinaldehyde to retinoic acid, and altered retinoic acid levels in the brain 
might disrupt normal anteroposterior neural development (Duester, 2008). Similarly, 
sterol-C4-methyl oxidase-like protein (SC4MOL) is localized to the endoplasmic 
reticulum membrane and is believed to be involved in cholesterol biosynthesis, which 
when dysregulated, has clinical manifestations in neurologic development (He et al., 
2011). In addition, atonal homolog 7 (atoh7) is involved in the development of the optic 
nerve (N. L. Brown, Dagenais, Chen, & Glaser, 2002). Therefore, the up-regulation of 
these three genes, aldh1a1, sc4mol and atoh7, may represent an important change in the 
molecular environment of the embryonic brain that could result in aberrant neural 
development. Finally, we find that the expression levels of many genes with known roles 
in cell cycle regulation, neuronal development and differentiation (e.g. cyclin-dependent 
kinase 12, cyclin-dependent kinase 17, insulin-like growth factor binding protein 3, 
neural cell adhesion molecule 1 and 2, transforming growth factor beta 2, transducer of 
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ERBB2, 2, etc.) are highly correlated with the expression of the crystallins (Supplemental 
Material 2). 
The common gene expression pattern across the various MIA treatments, in 
conjunction with previous findings, argues that IL-6 is a critical mediator of MIA, and 
that crystallins are important molecular mediators of this process. This raises several 
important questions. First, is the IL-6/crystallin cascade a promising target for molecular 
intervention in the context of schizophrenia and autism treatment or prevention? Second, 
are the currently used anti-inflammatory therapies (which show promise as adjuvant 
therapy in schizophrenia) modulating the IL-6/crystallin pathway, and acting through this 
mechanism? Third, how is crystallin overexpression in the embryonic brain disrupting 
normal development, and does it alter the typical connectivity between the developing 
brain regions? Finally, what is the critical time window for modulating the IL-6/crystallin 
pathway during which we can reverse the detrimental behavioral effects of MIA? The 
answers to these critical questions remain mostly unknown to date, and will have to be 
answered by comprehensive follow-up experiments. 
Overall, based on our findings and the known molecular effects of crystallins we 
propose that the induction of the crystallin genes in response to MIA is a neuroprotective 
attempt of the developing brain to counteract environmental stress. However, this 
response is likely to have detrimental consequences. Due to their additional roles in 
neuronal differentiation and axonal growth 42, (Liedtke, et al., 2007b), 47, over-expression 
of crystallins (and other genes such as aldh1a1, sc4mol and atoh7) might tip the delicate 
balance between neurogenesis and differentiation in the embryonic brain. This view is 
strongly supported by the observation that poly(I:C) MIA leads to decreased hippocampal 
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and cortical neurogenesis (De Miranda et al., 2010; Wolf, Melnik, & Kempermann, 
2011). We also propose that once the immune activation disappears, the normal brain 
developmental program resumes, but with a time-lag. As a result, layer formation in the 
cortex (Soumiya, Fukumitsu, & Furukawa, 2011) and communication between the 
various brain regions is altered, leading to permanent changes in connectivity and 
neurochemistry (Deng et al., 2011). This ultimately results in the various behavioral 
abnormalities that are found in the offspring of all three MIA models. Finally, we also 
argue that this cascade of events might parallel the mechanisms by which environmental 
insults contribute to the risk of neurodevelopmental disorders such as schizophrenia and 
autism. 
 
Methods 
Animals and MIA treatments 
All procedures involving animals were approved by the Caltech Animal Care and 
Use Committee. Female C57BL/6J mice (The Jackson Laboratory, Bar Harbor, ME) 
were obtained from our in-house breeding facility and were housed in ventilated cages 
under standard laboratory conditions. Mice were mated overnight, and the presence of a 
vaginal plug marked that day as embryonic day 0 (E0). Pregnant females were not 
disturbed, except for weekly cage cleaning, until E9.5 when they were weighed and 
pseudo-randomly assigned to one of four groups. Each group contained four to five 
pregnant females. 
Treatments with human influenza virus, poly(I:C), and recombinant IL-6 (rIL-6) 
were used to induce maternal immune activation (MIA) at conditions that previously 
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resulted in offspring altered behavior (Shi, et al., 2003; Smith, et al., 2007). To allow for 
time to develop a flu infection, pregnant mice on E9.5 were anesthetized intra-
peritoneally (i.p.) with 10 mg/kg xylazine and 100 mg/kg ketamine and inoculated intra-
nasally with 6000 plaque-forming units of human influenza virus in 90 µl phosphate-
buffered saline (PBS). Pregnant mice on E12.5 were injected with saline, poly(I:C) or 
rIL-6. For poly(I:C) injections, poly(I:C) potassium salt (Sigma Aldrich; St. Louis, MO) 
was freshly dissolved in saline and administered i.p. at 20 mg/kg based on the weight of 
the poly(I:C) itself, not including the total weight of the potassium salts. Control mice 
were injected with saline alone at 5 µl per gram body weight. For rIL-6 injections, 5 µg 
carrier-free, mouse rIL-6 (eBioscience; San Diego, CA) was freshly dissolved in 150 µl 
saline and injected i.p. Pregnant mice were sacrificed on E12.5 (3h after poly(I:C) or rIL-
6 injection and 3 days after influenza inoculation), and the embryonic brains were 
removed quickly and frozen in 1.5 ml tubes. 
 
Transcriptome analysis 
RNA was isolated from individual embryonic brains using PureLink RNA mini 
kit (Ambion). RNA quality was assessed using the Agilent (Palo Alto, CA) Bioanalyzer. 
To reduce gene expression variability that was not related to MIA-exposure, RNA from 
each embryonic brain within a litter was pooled into a single sample, and used for 
generation of biotin-labeled sample for microarray hybridization (Supplemental 
Material 1). This allowed us to identify MIA-induced gene expression changes that were 
commonly found in the embryonic brains of each litter, resulting in 4-5 replicates for 
each of the 4 conditions. Thus, from a total of 138 embryos, 17 pooled RNA samples 
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(each originating from all the embryonic brains within an individual pregnant dam) were 
generated and hybridized on a GeneChip HT MG-430 PM 24-Array Plate. Based on the 
variability in our previous mouse experiments, we estimated that we had an 80% 
probability to identify significant gene expression changes that were >30%. The data 
were log2 transformed using the RMA algorithm, and differential expression was 
established. A gene was considered differentially expressed if 1) the average log2 ratio 
(ALR) between the experimental treatment and control exceeded 30% (|ALR| > 0.3785) 
and 2) the statistical significance of differences was p < 0.05 using the Student's t test. 
GenePattern software (Broad Institute) was used for hierarchical clustering of the gene 
expression intensities. 
 
qPCR 
RNA isolated from embryos residing in the left or the right uterine horn was 
pooled proportionately, so there were two samples per each pregnant dam. Individual 
embryonic brain RNA or pooled RNA samples were used to generate cDNA with High-
capacity cDNA reverse transcription kit (Applied Biosystems). SYBR Green intercalation 
qPCR was run in a 7300 real time PCR system (Applied Biosystems) with the following 
primers: 
cryaa (F: TCTTCTTGGACGTGAAGCAC, R: GAAATGTAGCCATGGTCATCC), 
cryab (F: TGTGAATCTGGACGTGAAGC, R: TGACAGGGATGAAGTGATGG), 
cryba1 (F: CCTGGAAAGAGGAGAATACCC, R: 
TTATGATTAGCGGAACAGATGG), cryba2 (F: ACCAGCAAAGATGTGGGTTC, R: 
GCCTAATGCTGGACTCTTCG), 
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cryba4 (F: CACCACTCAGGTGACTACAAGC, R: CCAGAGGACACAAGGGTAGC), 
crybb1 (F: TCCCAGGAACATAAGATCTGC, R: ACGGTCACAGAAGCCATAAAC), 
crybb3 (F: CAGCCGACGTAGTGACATTC, R: TCATCTACGATCTCCATCTTGC), 
crygb/a/c (F: AGCGAGATGGGAAAGATCAC, R: AGTACTGGTGGCCCTGGTAG), 
crygc/a (F: TGCGGCTGTATGAGAAAGAA, R: CCTCGGTAGTTAGGCATCTCA).  
All these custom-designed primers reported amplification efficiency >90%. qPCR data 
was analyzed using the ddCt method with the housekeeping gene phosphoglycerate 
kinase 1 (http://www.genenames.org/data/hgnc_data.php?hgnc_id=8896PGK1) as a 
normalizer.  
In addition, qPCR for the crystallin genes cryaa, cryba1 and crybb1 was performed with 
34 RNA samples pooled from the embryos identified as residing in the left or right 
uterine horns. Furthermore, the expression of cryaa, cryba1, and crybb1 was also 
examined by qPCR in all 36 individual embryonic brains originating from the influenza-
treated dams.  
 
Correlation of placental weight with gene expression measurements 
At the time of the dissection, the weight of the individual placentas was measured 
for each embryo. Placental weight was assessed across the treatments with a groupwise, 
two-tailed t-test. In addition, qPCR-reported crystallin expression was correlated with 
average placental weight across the treatments and control groups using Pearson-
correlation. 
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Figure 1. The transcriptome of the embryonic brain is altered in three maternal 
immune activation (MIA) models. A. All differentially expressed transcripts in the MIA 
treatments were subjected to a two-way (horizontal:genes; vertical:samples) unsupervised 
clustering using GenePattern. Gene expression differences are color-coded (red-increased 
expression; blue-decreased expression), and the intensity of the color corresponds to the 
magnitude of gene expression change. Note that the experimental groups separate into 
distinct clusters that correspond to the different MIA treatments, with the main clusters 
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separating the saline-treatment from all three MIA-treatments. B-G. Three dataset-driven 
gene groups were created, each containing genes that were differentially expressed in one 
of the three MIA models (256 genes in the flu model, 294 in the poly(I:C) model and 195 
in the rIL-6 model). We then examined the expression of each of these gene groups in the 
other two MIA cohorts. Thus, the pattern of differentially expressed genes in the flu 
treatment was tested in the poly(I:C) and rIL-6 cohorts (B and C, respectively), the 
pattern of differentially expressed genes in the rIL-6 treatment was tested in the flu and 
poly(I:C) cohorts (D and E, respectively), and the pattern of differentially expressed 
genes in the poly(I:C) treatment was assessed in the flu and rIL-6 cohorts (F and G, 
respectively). Note that the gene expression patterns uncovered in any of the three MIA 
treatments show a very strong, highly significant correlation to the other two MIA-
treatments. 
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Figure 2. The most significantly changed transcripts in all three MIA treatments 
include multiple members of the crystallin gene family. Clustering was performed as 
described in Fig 1A. Note that, of the 12 gene expression changes observed in all three 
MIA conditions, 5 are mRNA species belonging to the crystallin gene family.   
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Figure 3. qPCR validates crystallin gene expression changes across the MIA models.  
The expression of nine genes was tested (Cryaa, Crygb/c/a, Crygc/b/, Crybb1, Cryba2, 
Crybb3, Cryba1, Cryba4, Cryab) on pools of RNA derived from the three MIA-
treatments. The X axis denotes average log2 ratios reported by microarrays, while the 
ddCt qPCR values are plotted on the Y axis. Note that the qPCR and microarray-reported 
expression changes are highly correlated across the three MIA models.  
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Figure 4. Crystallin expression is variable in individual brains from flu-exposed 
embryos. Expression of cryaa, cryba1 and crybb1 was assessed by qPCR across the 
individual brains of 36 flu and 36 saline embryos. Each symbol represents a PGK1-
normalized gene expression level in a single embryonic brain. The dashed gray line 
denotes the reliable transcript detection threshold by qPCR. Note the up-regulation of the 
three crystallin genes in the flu group compared to controls, and the considerable 
variability of crystallin expression levels between the flu-exposed embryonic brains. 
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Figure 5. Crystallin expression is correlated with placental weight. qPCR expression 
levels of cryaa (red), cryba1 (green) and crybb1 (blue) are correlated with mean placental 
weights across the MIA groups and controls. The X axis denotes the magnitude of 
expression change measured in ddCT (1Ct =2 fold change), and the Y axis depicts 
average placental weight. Squares denote saline treatment, diamonds denote poly(I:C) 
treatment, triangles denote IL-6 treatment, and circles denote flu treatment. Note that the 
average placental weight is significantly different between the controls and all three MIA 
treatments, and that the magnitude of all the crystallin expression changes is highly 
correlated with placental weight.  
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Supplemental Material 1. Experimental animals and pooling strategy.  
The experiment used 17 timed-pregnant mice: 4 controls, 4 poly(I:C)-exposed, 4 IL-6-
exposed and 5 flu-exposed. RNA from all embryonic brains within a litter was pooled 
into a single sample, and used for generation of biotin-labeled samples for microarray 
hybridization. Thus, from a total of 138 embryos, 17 pooled RNA samples (each 
originating from all the embryonic brains within a pregnant dam) were generated and 
hybridized on a GeneChip HT MG-430 PM 24-Array Plate. This allowed us to identify 
MIA-induced gene expression changes that were commonly found in the embryonic 
brains of each liter, resulting in 4-5 biological replicates for each of the 4 conditions.  
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Supplemental Material 2 (Dataset online). Many significant microarray-reported 
gene expression changes are found in the flu, poly(I:C) and IL-6 MIA models. 
Column A:  DNA microarray Probe set ID provided by Affymetrix; Columns B-E: RMA-
normalized average log2 expression level for the four experimental groups (three 
MIAand one saline-treated group); Columns F, H, J: Average log2 ratios between the 
three MIA-treatments and control group. Positive values represent overexpression in 
experimental groups. Columns G, I, K: Group-wise two-tailed Student t-test values for 
the three MIA-control comparisons. Column L: Pearson correlation of each gene with 
cryaa expression levels. Column M: NCBI accession ID; Column N: NCBI gene symbol.  
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Maternal infection is a risk factor for autism spectrum disorder (ASD) and schizophrenia 
(SZ). Indeed, modeling this risk factor in mice through maternal immune activation 
(MIA) causes ASD and SZ-like neuropathologies and behaviors in the offspring. 
Although MIA upregulates pro-inflammatory cytokines in the fetal brain, whether MIA 
leads to long-lasting changes in brain cytokines during postnatal development remains 
unknown. Here, we tested this possibility by measuring protein levels of 23 cytokines in 
the blood and three brain regions from offspring of poly(I:C)and saline-injected mice at 
five postnatal ages using multiplex arrays. Most cytokines examined are present in sera 
and brains throughout development. MIA induces changes in the levels of many 
cytokines in the brains and sera of offspring in a region and age-specific manner. These 
MIA-induced changes follow a few, unexpected and distinct patterns. In frontal and 
cingulate cortices, several, mostly pro-inflammatory, cytokines are elevated at birth, 
followed by decreases during periods of synaptogenesis and plasticity, and increases 
again in the adult. Cytokines are also altered in postnatal hippocampus, but in a pattern 
distinct from the other regions. The MIA-induced changes in brain cytokines do not 
correlate with changes in serum cytokines from the same animals. Finally, these MIA-
induced cytokine changes are not accompanied by breaches in the blood-brain barrier, 
immune cell infiltration or increases in microglial density. Together, these data indicate 
that MIA leads to long-lasting, region-specific changes in brain cytokines in offspring—
similar to those reported for ASD and SZ—that may alter CNS development and 
behavior.  
Introduction 
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Autism spectrum disorder (ASD) and schizophrenia (SZ) are devastating disorders 
that each affect cognitive and social functions of approximately 1% of the population 
(Kogan et al., 2009). Although the etiology of these disorders is unclear, genetics and 
environmental factors appear to interact to increase risk (Nawa et al., 2000; Patterson, 
2009). Indeed, many of the environmental insults linked to SZ and ASD involve the 
maternal-fetal environment. Large SZ and ASD twin studies highlight the fact that 
concordance for dizygotic twins is much greater than that for siblings (Brown and 
Patterson, 2011; Hallmayer et al., 2011; Patterson, 2007; Rosenberg et al., 2009; 
Szatmari, 2011) and concordance for SZ is also higher for monochorionic twins, who 
share a placenta, than for dichorionic twins, who do not (Davis et al., 1995). Together, 
these studies indicate a significant role for the fetal environment in these disorders. In 
addition, maternal infection greatly increases the risk for SZ and ASD in offspring 
(Brown and Derkits, 2010; Brown and Patterson, 2011; Patterson, 2011a), and maternal 
viral infection is associated with increased risk of ASD as well as a 3-7-fold increased 
risk of SZ in the offspring (Atladottir et al., 2010; Brown et al., 2004; Brown and 
Patterson, 2011). Since different types of viral, bacterial, and parasitic infections are 
associated with ASD and SZ, the critical link between prenatal maternal infection and 
postnatal brain and behavioral pathology appears to be the maternal immune response 
and factors that mediate that response, such as cytokines (Deverman and Patterson, 2009; 
Garay and McAllister, 2010).  
These correlations from epidemiological studies are supported by work in rodent 
models of maternal infection. Adult offspring of pregnant mice given intranasal influenza 
virus exhibit behavioral abnormalities and changes in gene expression, neuroanatomy, 
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and neurochemistry consistent with both SZ and ASD (Fatemi et al., 2002; Fatemi et al., 
1998). Because these outcomes are also elicited in the absence of infection by maternal 
injection of synthetic dsRNA (poly(I:C)), which mimics the acute phase response to viral 
infection (Traynor et al., 2004), it is maternal immune activation (MIA) that drives the 
changes in fetal brain development (Shi et al., 2005). Offspring born to pregnant mice 
injected with poly(I:C) at embryonic day 12.5 (E12.5) display the three core behavioral 
symptoms of ASD: stereotyped and repetitive behaviors, deficits in social interaction, and 
deficits in communication (Malkova et al., 2012; Smith et al., 2007). These offspring also 
display behaviors that are consistent with both SZ and ASD, including elevated anxiety 
and deficits in prepulse inhibition (PPI), latent inhibition (LI), and working memory 
(Patterson, 2011b), some of which can be alleviated by treatment with anti-psychotic 
drugs (Meyer and Feldon, 2010; Meyer et al., 2010; Piontkewitz et al., 2009; Shi et al., 
2003). Adult MIA offspring also exhibit abnormalities in gene expression and 
neurochemistry similar to those noted in SZ and ASD (Meyer et al., 2011). Finally, 
neuropathology is also seen in this model, including enlarged ventricles and a spatially-
localized deficit in Purkinje cells, characteristic of SZ and ASD, respectively (Meyer et 
al., 2009; Piontkewitz et al., 2009; Shi et al., 2009). Related findings have also been 
reported in non-human primate models of maternal infection and poly(I:C) MIA 
(Bauman, 2011; Short et al., 2010). 
Despite recent progress in developing and characterizing rodent MIA models, much 
remains to be studied about how MIA alters fetal brain development. Current evidence 
indicates that the maternal cytokine response is crucial (Patterson, 2009), which leads to 
immune activation and endocrine changes in the placenta (Hsiao and Patterson, 2011; 
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Mandal et al., 2011). Interleukin (IL)-6 is necessary and sufficient to mediate these 
effects since the effects of MIA on neuropathology and behavior in the offspring are 
prevented by injection of pregnant dams with poly(I:C) combined with an anti-IL-6 
antibody and are mimicked by a single maternal injection of IL-6 (Smith et al., 2007). 
Induction of maternal cytokines then alters cytokine expression in the fetal brain, 
including IL-1β, IL-6, IL-17, IL-13, MCP-1, and MIP1α, hours after MIA (Fatemi et al., 
2008; Meyer et al., 2006b; Meyer et al., 2008), with only IL-1β remaining elevated in the 
fetal brain 24 hours following poly(I:C) injection (Arrode-Bruses and Bruses, 2012). 
However, it is unknown if MIA causes chronic changes in brain cytokines and/or immune 
cell infiltration in offspring during postnatal development and/or in adult offspring.  
Here, we test this possibility using proteomic analysis of cytokine levels in the 
postnatal brain. The levels of 23 cytokines were measured in the blood and three brain 
regions from offspring of poly(I:C)and saline-injected mice at five ages (postnatal day 0 
(P0), P7, P14, P30, and P60) using multiplex technology. Perhaps surprisingly, in control 
brains, most of the 23 cytokines examined are detectable in serum and in all three brain 
regions (frontal cortex (FC), cingulate cortex (CC), and hippocampus (HC)) from birth 
through adulthood. The levels of individual cytokines are modulated in age and region-
specific patterns that have not been previously described. Most important, MIA induces 
striking, long-lasting changes in cytokine levels in the brains of offspring, many of which 
are region and age-specific and include widespread decreases as well as increases, 
compared to controls. Our results indicate that MIA leads to chronic changes in brain 
cytokine levels in offspring that may mediate MIA-induced changes in CNS development 
and behavior.  
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Results 
Several cytokines, including IL-1β, IL-6, IL-10, IFNγ, and TNFα, have been 
reported to be present in the healthy brain where they perform a wide range of functions 
(Deverman and Patterson, 2009; Garay and McAllister, 2010). However, it was unknown 
if other cytokines and chemokines are present in early postnatal development in the 
healthy brain, and if so, whether their levels change with age and following MIA. Here, 
we utilized the approach previously published for 3-plex BioRad luminex kits (Datta and 
Opp, 2008) for use with BioRad luminex mouse 23-plex bioplex kits. The high sensitivity 
of this approach allowed us to measure levels of 23 cytokines and chemokines from small 
regions of the developing mouse brain. The cytokines measured were IL-1α, IL-1β, IL-2, 
IL-3, IL-4, IL-5, IL-6, IL-9, IL-10, IL-12 (p40), IL-12 (p70), IL-13, IL-17, interferon 
gamma (IFNγ), tumor necrosis factor alpha (TNFα), granulocyte colony-stimulating 
factor (G-CSF), and granulocyte-macrophage colony-stimulating factor (GM-CSF). The 
chemokines measured included Eotaxin, keratinocyte chemoattractant (KC/CXCL1), 
monocyte chemoattractant protein-1 (MCP-1/CCL2), macrophage inflammatory protein-
1α (MIP-1α/CCL3), MIP1β/CCL4, and regulated upon activation, normal T-cell 
expressed, and secreted (RANTES/CCL5).  
Levels of these factors were measured in FC, CC, and HC at P0, P7, P14, P30, 
and P60. These brain regions were selected based on their involvement in ASD and SZ. 
The five ages represent periods before most synapses have formed (P0), the start of 
synaptogenesis (P7), the peak of synaptogenesis (P14), peak activity-dependent plasticity 
(P30), and early adulthood (P60). An average of six animals from at least two litters were 
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used for each data point. Samples were run in duplicate and replicated on at least two 
arrays. Litters were obtained from pregnant mice injected at mid-gestation either with 
saline (typically-developing or control offspring) or with 20 mg/kg poly(I:C). We use 
maternal polyI:C injection at E12.5, since this stage of gestation correlates with the late 
first trimester in humans (Clancy et al 2007)—the time that infections are most closely 
linked to increased incidence of SZ and ASD (Atladottir et al. 2010, Brown et al. 2004).   
 
Most cytokines are expressed in an age and region-specific manner in the brain and 
blood of typically-developing offspring from birth to adulthood 
Surprisingly, most of the cytokines and chemokines examined are detectable in 
both brain and serum from control offspring, even at birth (Fig. 1). Although a few of the 
cytokines are undetectable in specific brain regions or serum during the first postnatal 
week, including IL-1α, IL-3, IL-4, IL-5, Eotaxin, G-CSF, and RANTES, all are 
detectable in brain and serum after the first postnatal week (Suppl. Tables 1-2). Most of 
the cytokine concentrations range from 1-100 pg/mg brain tissue. Cytokines with the 
lowest concentrations in multiple brain regions include IL-1α, TNFα, IL-3, IL-4, IL-5, 
G-CSF, and RANTES. Conversely, cytokines with the highest concentrations in multiple 
brain regions include IL-9, IL-13, and Eotaxin. Almost all cytokines are found at higher 
concentrations in serum (Fig. 1 M-P) compared to brain (Fig. 1 A-L; note that the scale is 
10-fold greater for serum compared to brain regions). 
Cytokine concentrations in the typically-developing brain change with age and 
some changes are region-specific. To illustrate changes in cytokine concentrations with 
age, the average values for each cytokine concentration (pg/mg from brain and pg/ml 
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from serum) are plotted at the five ages examined (Fig. 1). Error bars are not included in 
these graphs to enhance visibility of the trends in expression of each cytokine with age, 
however all values of mean ± SEM concentration are included in Suppl. Tables 1-2. For 
presentation, we separated the 23 cytokines into four groups: (1) commonly-studied 
cytokines, (2) a first set of additional cytokines with a similar step-like increase in serum 
concentration with age, (3) a second set of additional cytokines with stable levels in 
serum, and (4) chemokines.  
Although the developmental profiles of these cytokines are diverse, some 
generalizations can be made. First, most cytokine profiles are similar across the three 
brain areas. This is most clearly seen for the chemokines, where the profiles for each 
chemokine in the three brain areas are nearly identical (Fig. 1D, H, L). There are, 
however, clear exceptions to this generalization, particularly in FC. For instance, IL-1β 
levels in HC and CC are similar with age, but quite different in FC where they are highest 
at P0 and P7 and then dramatically decrease at P14 (Fig. 1A, E, I). Levels of IL-9 are 
steadily high with age in CC and HC and are also relatively high in FC during the period 
of rapid synaptogenesis (P0-P14), but decrease in FC with maturity (Fig. 1C, G, K). 
Conversely, IL-6 decreases at P60 in HC and CC, but not in FC where it remains high in 
adulthood (Fig. 1A, E, I). A second point of interest is that some cytokines, including IL-
4, IL-2, IL-17, are higher in mid-postnatal life, but lower at birth and in the adult (Fig. 
1B-C, F-G, J-K). Third, several cytokines dip in concentration specifically at P14, a 
period of intense synaptogenesis; these include IL-3, IL-13, IL-12 (p40), Eotaxin, 
MIP1α, and KC in addition to IL-2 and IL-5 specifically in CC and HC (Fig. 1A-L). 
Fourth, another set of cytokines increase in concentration with age, including IL-6, IL-10, 
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IFNγ, GM-CSF, IL-12 (p70), IL-17, and MIP1β  (Fig. 1A-L). Finally, the concentration 
of a subgroup of cytokines does not change with age, including TNFα, G-CSF, MCP-1, 
and RANTES, in addition to IL-1α in FC and IL-10, IL-5, and GM-CSF in HC (Fig.1A-
L). Together, these results indicate that cytokines are expressed in the typically 
developing brain in an ageand region-specific manner.  
Cytokine concentrations also change with age in serum (Fig. 1M-P), but the 
patterns are simpler than in brain and fall into just two distinct groups. Regardless of their 
starting concentration, 17 of the 23 cytokine levels are steady from P0 to P7 and then 
increase abruptly to a higher level at P14, where they remain through P60 (Fig. 1M-N,P). 
Importantly, this trajectory is not found in any area of the brain, indicating that the brain 
measurements are not significantly contaminated by blood cytokines and that changes in 
peripheral cytokines do not reflect the direction of cytokine changes in the CNS. The six 
other cytokines in the serum (TNFa, IL-2, -5, -9, -12, -17) remain at a constant level 
throughout development, a pattern that is also rare in the brain (Fig. 1O).  
 
MIA alters brain cytokine profiles in an age-and region-specific manner 
In order to determine if brain cytokines are altered in newborn MIA offspring and 
if these changes are developmentally regulated, pregnant mice were injected with 
poly(I:C) (MIA) or saline (control) in mid-gestation (E12.5) and FC, CC, and HC were 
collected from the offspring at P0, P7, P14, P30, and P60. The protein levels of 23 
cytokines were measured as above on the same plates as the age-matched control 
samples. Average values were compared between saline and poly(I:C) offspring for each 
cytokine at each age in each brain region.  Previous reports using ELISAs to measure 
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cytokines in fetal brain of MIA offspring showed that some pro-inflammatory cytokines 
(IL-1β, IL-6, TNFα, and IFNγ) are increased in the brains of offspring during gestation 
within hours following MIA (Fatemi et al., 2008; Meyer et al., 2006b; Meyer et al., 
2008). However, those studies did not determine if brain cytokines are chronically altered 
in postnatal MIA offspring and if so, what the trajectory of those changes is with age.  
 
Frontal Cortex (FC) 
In FC, cytokine levels are altered at every age examined in MIA offspring (Figure 
2A-F, Suppl. Table 1) and follow a clear pattern of elevations at birth, decreases 
throughout postnatal brain development (P7-P30), and elevations again in the adult. 
Compared to controls, many cytokines in MIA FC are higher at birth and in adulthood. 
At birth (Fig. 2A, F), four cytokines are significantly higher than controls: IL-1β (1.9-
fold), IL-10 (2.8-fold), IL-12 (p70; 2.2-fold), and GM-CSF (3.1-fold). Although not 
statistically significant, IL-6 is dramatically higher (3.3-fold, p=0.09), and IL-1α (1.4-
fold; p=0.07) and IL-4 (1.3-fold; p=0.09) trend toward higher levels. A somewhat 
different subset of cytokines is also higher in the adult FC (Fig. 2E-F), including IL-1α 
(2.5-fold), IL-6 (1.7-fold), IL-9 (1.4-fold), and IL-10 (1.3-fold).  
In contrast to the increased levels in MIA FC cytokines at birth and in the adult, many 
cytokines are lower than controls during the period of synaptogenesis and remodeling 
(P7, P14, and P30). Most of the cytokines that are elevated at P0 are not altered at P7 
except for IL-10, which changes from being elevated 2.8-fold at P0 to being decreased 
(0.8-fold) at P7 (Fig. 2B,F). Including IL-10, six cytokines are significantly altered at P7. 
IL-2 (0.7-fold), IL-4 (0.3-fold), IL-5 (0.4-fold), and IL-12 (p40; 0.5-fold) are lower, while 
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G-CSF is the lone cytokine that is higher at P7 (1.5-fold). Several additional cytokines 
trend toward significantly lower levels than controls, including IL-3 (0.2-fold, p=0.08) 
and IFNγ (0.4-fold, p=0.09). At P14 (Fig. 2C,F), several of these cytokines remain lower, 
including IL-2 (0.6-fold), IL-5 (0.5-fold), and IL-10 (0.7-fold) and an additional eight 
cytokines are lower at this age, including IL-1α (0.4-fold), IL-1β (0.6-fold), IL-9 (0.8-
fold), IL-13 (0.8-fold), Eotaxin (0.7-fold), GM-CSF (0.8-fold), IFNγ (0.8-fold), and 
MCP-1 (0.7-fold). At P14, there are also trends toward significantly lower levels than 
controls (MIP-1β (0.8-fold, p=0.07) and IL-3 (0.7-fold, p=0.06)). Many cytokines remain 
lower than controls at P30 (Fig. 2D,F) including IL-1β (0.8-fold), IL-5 (0.6-fold), IL-10 
(0.8-fold), GM-CSF (0.6-fold), and MCP-1 (0.7-fold), and an additional six cytokines are 
also lower at this age, including IL-3 (0.7-fold), IL-6 (0.6-fold), IL-12 (p40; 0.8-fold), IL-
12 (p70; 0.8-fold), G-CSF (0.5-fold), and MIP-1β (0.7-fold).  
Together, these results indicate that cytokines are indeed chronically altered in the 
FC of postnatal MIA offspring in a distinct developmental pattern. Both the subsets of 
cytokines that are altered and the direction of change are age-dependent. Perhaps most 
surprising, many cytokines are altered in the MIA FC and the majority of these cytokines 
are significantly decreased during the periods of circuit formation and plasticity within 
the FC (Fig. 2F).  
 
Cingulate Cortex (CC) 
In CC, cytokine levels are also changed at every age examined in MIA offspring 
compared to controls (Figure 3A-F, Suppl. Table 1) in a pattern similar to that found in 
FC. As in FC, cytokines are generally higher at birth and in adulthood and lower during 
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the periods of synaptogenesis and plasticity (P7, P14, and P30). At birth (Fig. 3A,F), 
three cytokines are significantly higher than controls: IFNγ (1.4-fold), IL-12 (p70; 1.6-
fold), and MCP-1 (1.4-fold). Although not statistically significant, IL-1α (1.9-fold, 
p=0.07) and IL-10 (1.7-fold, p=0.06) are also higher in the CC at birth. A somewhat 
different subset of cytokines is higher in the adult CC (Fig. 3E,F), including IL-10 (1.4-
fold) and IFNγ (1.5-fold). MIP1α (1.45-fold) and RANTES (1.6-fold) are also close to 
significance and TNFα and IL-2 are dramatically higher (3.4 and 2.9-fold, respectively) 
but not statistically significant in the adult MIA CC. 
Similar to the pattern in FC, many cytokines are lower than controls during the 
periods of synaptogenesis and remodeling. By P7 (Fig. 3B,F), all of the cytokines that are 
higher at P0 return to control levels, but a new set of six cytokines is significantly altered: 
five are lower, including IL-2 (0.4-fold), IL-5 (0.6-fold), IL-6 (0.3-fold), IL-10 (0.7-fold), 
and Eotaxin (0.6-fold), while IL-17 is dramatically higher (2.2-fold). Although not 
statistically significant, IFNγ (0.3-fold, p=0.08), IL-12 (p70; 0.7-fold, p=0.07), and KC 
(1.5-fold, p=0.06) also trend away from controls in MIA CC. Of the cytokines altered at 
P7, IL-10 remains lower at P14 (0.7-fold) as does IL-17, but the direction of change in 
IL-17 is reversed (0.8-fold; Fig. 3C,F). In addition, five different cytokines are 
significantly lower in the P14 MIA CC, including IL-1β (0.6-fold), GM-CSF (0.63-fold), 
IFNγ (0.7-fold), KC (0.7-fold), MCP-1 (0.6-fold), and MIP-1β (0.7-fold). Although 
Eotaxin and MIP-1α are also lower in P14 MIA CC (Fig. 3C), they are not statistically 
different from controls. At P30, even more cytokines are lower in MIA CC compared to 
controls (Fig. 3D,F). Four cytokines that are lower at P14 remain lower than control 
levels at P30, including IL-1β  (0.8-fold), IL-10 (0.7-fold), IL-17 (0.7-fold), and MCP-1 
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(0.8-fold) and seven additional cytokines are also lower at P30: IL-3 (0.7-fold), IL-4 (0.7-
fold), IL-5 (0.7-fold), IL-6 (0.2-fold), IL-12 (p40; 0.8-fold), IL-12 (p70; 0.8-fold), and G-
CSF (0.6-fold). IL-13 (0.7-fold, p=0.08), IFNγ (0.7-fold, p=0.08), and MIP1α (0.8-fold, 
p=0.08) are also close to significantly decreased at P30.  
 
Hippocampus (HC) 
In HC, MIA induces changes in the levels of cytokine at every age examined 
except for P60 (Fig. 4A-F, Suppl. Table 2) in a pattern distinct from that found in FC and 
CC. However, unlike the clear directional switch in MIA-induced changes in FC and CC 
in the first postnatal week, the direction of change in cytokine levels is mixed at most 
ages in HC. At birth (Fig. 4A,F), seven cytokines are altered in MIA HC. IL-6 (1.6-fold) 
is significantly elevated over controls, while IL-1β (0.7-fold), IL-2 (0.6-fold), IL-4 (0.8-
fold), KC (0.7-fold), MCP-1 (0.7-fold), and MIP-1α (0.3-fold) are lower. Although not 
statistically significant, IL-13 is also lower at birth (0.7-fold, p=0.06). Of the cytokines 
altered at P0, only IL-4, KC, and MIP-1α remain changed at P7 (Fig. 4B,F): IL-4 remains 
lower (0.6-fold) and KC and MIP1α reverse direction towards a large elevation at P7 
(1.6-fold; 1.6-fold). Four different cytokines are altered at P7 including IL-3 (0.4-fold), 
IL-5 (0.7-fold), IL-9 (1.6-fold), and IL-10 (0.8-fold). At P14, eight cytokines are 
significantly different in MIA HC compared to controls (Fig. 4C,F). Compared to the 
cytokines altered at P7, only IL-5 (0.4-fold) remains lower, and IL-9 is reversed in 
direction from being higher at P7 to being lower at P14 (0.7-fold). At P14, six different 
cytokines are altered in MIA HC: IL-1α (1.4-fold), IL-2 (0.4-fold), IL-6 (1.5-fold), 
Eotaxin (0.7-fold), MCP-1 (0.8-fold), and RANTES (0.6-fold). At this age, IL-10, IL-12 
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(p40), and MIP-1β are also lower than controls, although not significantly. Far fewer 
cytokines are altered in MIA HC at P30 (Fig. 4D,F). Only two cytokines are significantly 
lower than controls—IL-6 (0.6-fold) and MIP-1α (0.8-fold)—although several other 
cytokine changes approach significance including IL-1β (0.8-fold; p=0.09), IL-12 (p70; 
0.7-fold; p=0.06), IL-13 (0.7-fold, p=0.08), G-CSF (0.6-fold, p=0.08), and RANTES 
(0.8-fold, p=0.09). Compared to controls, no cytokines are significantly altered in HC in 
adult MIA offspring (Fig. 4E, F). 
 
MIA alters cytokine profiles in serum in an age-specific manner 
MIA also causes chronic changes in cytokine levels in the serum of offspring 
throughout postnatal development (Figure 5A-F, Suppl. Table 2). At birth, five cytokines 
are altered in MIA serum compared to controls. IL-12 (p40; 1.8-fold) and RANTES (2.4-
fold) are higher, while IL-3 (0.7-fold), GM-CSF (0.8-fold), and MIPα (0.5-fold) are 
lower than controls (Fig. 5A,F). However, the most dramatic changes are one week after 
birth (P7), when twelve cytokines are altered in MIA serum (Fig. 5B,F). IL-1β (1.9-fold), 
IL-3 (1.4-fold), IL-6 (1.5-fold), IL-12 (p40; 3.0-fold), G-CSF (2.6-fold), IFNγ (1.3-fold), 
KC (2.2-fold), RANTES (1.9-fold), and TNFα (1.5-fold) are all higher, while IL-1α (0.6-
fold), IL-2 (0.7-fold), and IL-12 (p70; 0.6-fold) are lower relative to controls at P7. By 
P14 (Fig. 5C,F), most of these widespread changes in MIA sera are back to control levels 
except for TNFα, which remains slightly higher (1.2-fold) and MIP-1β, which is 
significantly higher (1.1-fold). Although not statistically significant, IL-10 is also higher 
at P14 (1.5-fold, p=0.07). At P30, the cytokine profile is changed again, and four 
different cytokines are altered: IL-1β (1.7-fold), IL-6 (1.4-fold), and IL-9 (1.2-fold) are 
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higher than controls, while IL-3 (0.6-fold) is lower (Fig, 5D,F). In adults, no significant 
differences in cytokine levels relative to controls are found in sera of MIA offspring 
(P60; Fig. 5E-F).  
 
MIA-induced changes in serum cytokines do not correlate with changes in brain 
cytokines 
As illustrated in the summary Fig. 6, MIA causes changes in cytokine levels in 
brain and serum in offspring throughout postnatal development. In this figure, only 
statistically significant changes in cytokine levels are indicated by colored boxes; the 
direction and magnitude of change is indicated by red for higher, and blue for lower, 
levels than controls. These MIA-induced changes are complex, being both age and 
region-specific, and involve significant changes at some point during development in 
levels of 22 of the 23 cytokines assayed in brain (the exception being TNFα). In striking 
contrast to the generally consistent cytokine profiles between brain regions in the control 
brain, at a given age, the nature and direction of MIA-induced changes in cytokines are 
different between brain regions. Moreover, within each brain region, the MIA-induced 
changes are different between ages. Although the changes are complex, they are not 
random; instead, they fall into a few, distinct patterns. In general, compared to controls, 
many cytokines in FC and CC are higher at P0, lower from P7-P30, and then higher again 
in the adult, although the specific cytokines that are altered at each age differ between 
these two regions. This general pattern of cytokine change is distinct from that in the HC, 
where fewer cytokines are altered and their direction of change is mixed at each age. 
Finally, the changes in cytokine levels observed in serum are also different at each age, 
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but as in the control brains, these changes do not correlate with changes in cytokine levels 
in any brain region from the same animals. This supports the conclusion that our brain 
cytokine measurements are unlikely to be contaminated by serum cytokines. Finally, 
although cytokine levels are altered in all three brain regions and serum throughout 
postnatal development, they remain altered in the adult only in FC and CC, but not in HC 
or serum. 
 
MIA-induced changes in brain cytokines are not due to immune cell infiltration through a 
leaky blood-brain barrier 
Changes in brain cytokines in MIA offspring could be due to cytokines produced 
by infiltrating immune cells, which might gain access to the brain through MIA-induced 
breaches in the blood-brain barrier (BBB). To test this possibility, first BBB integrity was 
qualitatively assessed using Evans Blue (Suppl. Fig. 1); breaches in BBB integrity are 
typically indicated by dark blue staining of the brain.  There is little to no BBB 
permeability detected at any postnatal age examined and no change in staining of MIA 
brains compared to controls at any age tested. Second, immune cell infiltration into the 
three brain regions was examined using immunohistochemistry with cell-type-specific 
antibodies to label B and T lymphocytes and neutrophils (Suppl. Fig. 2A). In general, 
there is virtually no staining for any of these immune cell types in any region of the brain 
at any age examined. This lack of staining is not due to an inability of our protocol to 
detect these cells, since we obtain clear labeling of these cells in spleens of control mice 
and spinal cord from EAE mice (Suppl. Fig. 2B). Taken together, these results support 
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the interpretation that the MIA-induced changes in brain cytokines are most likely 
produced by brain-resident cells.  
 
Microglial number is not altered by MIA 
Microglia are present in the brain during all stages of development and are well-
documented to increase in number and state of activation during neural inflammation 
(David and Kroner, 2011; Ransohoff and Perry, 2009).  Because of the subjectivity 
inherent in classifying microglial activation morphologically, we chose to quantify only 
microglial density in sections from MIA and control brains. Microglia were labeled with 
the standard marker, Iba1, using immunohistochemistry and counted using Stereologer 
(Fig. 7). There are no qualitative changes in microglial morphology in any brain region 
from MIA offspring compared to controls (Fig. 7A). In general, the density of microglia 
in each brain region increases from low levels at birth to a peak at P14 and then decreases 
to intermediate levels in the adult brain (Fig. 7B). MIA does not cause any significant 
change in microglial density within any of the three brain regions at any of the five ages 
examined (Fig. 7B).  
 
Behavioral abnormalities in MIA offspring 
Previous studies have documented ASD and SZ-relevant abnormal behaviors in 
adult poly(I:C)-induced MIA offspring (Meyer and Feldon, 2010). To confirm that the 
MIA mice used in this study were likely to exhibit the expected behavioral changes, we 
tested two of these behaviors in a parallel cohort of animals that was raised alongside the 
cohort used for cytokine measurements. The two behavioral tests performed were LI and 
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PPI. LI is a measure of the ability to ignore irrelevant stimuli and its disruption is 
considered to be pertinent for the cognitive deficits in SZ (Weiner, 2003). LI is disrupted 
in SZ subjects and in amphetamine-treated humans and rats, restored to normal levels in 
SZ by neuroleptic drugs, and enhanced in normal humans and rats by antipsychotic drugs 
(Weiner, 2003). PPI measures sensorimotor gating, and deficits are present in ASD, SZ 
and several other mental disorders. As in prior work (Meyer et al., 2009; Patterson, 2009) 
we find deficits in LI and PPI in the parallel cohort of mice used here (data not shown). 
MIA offspring exhibit increased freezing in response to a conditioned acoustic cue (LI) 
compared to controls when measured against the non-pre-exposed group [F(1, 23)=1.029, 
p=0.0149; n=28 saline, 24 poly(I:C)]. Compared to control offspring, MIA offspring also 
display decreased PPI when presented with either a 5 dB pre-pulse or 15 dB pre-pulse 
preceding a 120 dB pulse (PPI5 and PPI15, respectively) [F(1, 104)=4.830, p=0.0302; 
n=29 saline, 25 poly(I:C)]. 
 
Discussion  
In order to determine if poly(I:C)-induced MIA leads to chronic changes in brain and 
blood cytokines in offspring throughout postnatal development, proteomic analysis of the 
cytokine response in the developing brains of offspring was performed. In typically-
developing, control offspring, we find that most of the cytokines examined are present in 
serum as well as in the three brain regions examined from birth through adulthood. This 
data adds new evidence to the case that cytokines play a role in normal brain 
development and function (Deverman and Patterson, 2009; Garay and McAllister, 2010; 
Gilmore et al., 2004; Juttler et al., 2002; McAfoose and Baune, 2009; Stellwagen, 2011). 
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Another striking observation from the control data is that the levels of 17 of the 23 
cytokines assayed in serum increase abruptly on P14, and they remain at that level 
through P60. Although many aspects of immune system development occur during the 
second postnatal week in mice, the precise events that lead to this abrupt increase in 
serum cytokines are unknown. Importantly, this jump in cytokine levels is not found for 
any of the 23 cytokines in any of the brain areas, indicating that the measurements in the 
brain are not significantly contaminated by serum cytokines.  
Remarkably, most of the 23 cytokines examined are altered in the brains of MIA 
offspring and these changes occur in a regionand age-specific manner. While several of 
the commonly studied, pro-inflammatory cytokines are altered by MIA, significant and 
widespread changes in anti-inflammatory cytokines and chemokines are also detected in 
brain and serum at every age examined. Although complex, MIA-induced changes in 
brain cytokines fall into a few, distinct patterns. In FC and CC, many proand anti-
inflammatory cytokines are elevated in early postnatal MIA offspring, lower than 
controls in early adolescence, and a few cytokines are again elevated in the adult brain. 
The developmental pattern in HC is distinct from the other brain areas, with both 
increases and decreases in cytokines occurring at every age examined, except in the adult. 
Finally, these striking and complex changes in brain and serum cytokines are not 
accompanied by obvious changes in BBB permeability, immune cell infiltration, or 
increases in microglial density. Together, these data indicate that MIA leads to significant 
changes in brain cytokines in the postnatal offspring, which may alter CNS development 
and behavior in the absence of overt signs of neural inflammation.  
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The poly(I:C) MIA mouse model employed in this study has both face and construct 
validity for ASD and SZ, and predictive validity for at least SZ (Meyer and Feldon, 
2010). Despite recent progress in developing and characterizing rodent MIA models, 
little is known about how MIA alters fetal brain development. Current evidence indicates 
that the maternal cytokine response is crucial (Patterson, 2009). Poly(I:C) injection at 
either midor late gestation leads to marked increases in levels of IL-1β, IL-6, IL-10, and 
TNF-α in the pregnant dam’s serum (Gilmore et al., 2005; Koga et al., 2009; Meyer et 
al., 2006b), which is reminiscent of similar increases in serum cytokines in mothers of 
children with ASD (Goines et al., 2011). Perturbation experiments indicate that IL-6 is 
necessary and sufficient to mediate the effects of the maternal immune response in the 
fetus (Smith et al., 2007). Induction of maternal cytokines then alters cytokine expression 
in the fetal brain, including IL-1β, -6, -10, -13, and -17, and MCP-1 and MIP1α, hours 
after MIA (Arrode-Bruses and Bruses, 2012; Meyer et al., 2006b), but it has been unclear 
if MIA causes changes in brain cytokines in postnatal offspring. 
It has been suggested that brain cytokines would be altered in MIA offspring based 
on observations of neural inflammation and cytokine changes in blood, CSF, and 
postmortem brain tissue from individuals with ASD and SZ (Ashwood et al., 2011; 
Ashwood et al., 2011; Ashwood et al., 2010; Chez et al., 2007; Molloy et al., 2006; Pardo 
et al., 2005; Vargas et al., 2005). These human data predict that pro-inflammatory 
cytokines may be chronically increased in MIA brains and indeed, most of the few 
cytokines previously detected in the brains of MIA offspring were acute phase cytokines 
including IL-6, IL-1β, IFNγ, and TNFα (Gilmore et al., 2005; et al., 2006b; Meyer et al., 
2008). Here, we took an unbiased approach to test this hypothesis and measured cytokine 
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levels throughout postnatal development. Our results clearly demonstrate that MIA leads 
to dynamic changes in cytokine levels in the brains of offspring. Our results are also 
somewhat consistent with the expected pro-inflammatory changes in brain cytokines 
resulting from MIA in that there are increases in some of the acute phase cytokines at 
birth and in the adult MIA FC, CC, and HC, as well as in serum throughout development.   
Although it is theoretically possible that these MIA-induced changes in brain 
cytokines in offspring could be influenced by changes in the dam’s behavior following 
MIA, there is little evidence supporting this possibility.  The dosage of poly(I:C) 
administered results in an approximately three hour period of sickness behavior (lethargy, 
lack of grooming, etc.), after which the mother recovers fully. Consistent with this, levels 
of maternal and placental pro-inflammatory cytokines peak by 3 hours post injection and 
decline considerably by 24 hours post injection (Meyer et al. 2006). The dam loses 
weight (~1.0-1.5 g) by 24 hours post-injection, but recovers to levels comparable to 
controls by 48 hours post injection. We have found no difference between poly (I:C) and 
saline-injected mothers in maternal care, as measured by equivalent time spent 
licking/nursing pups and comparable latency to retrieve individual pups removed from 
the nest (Malkova and Patterson, personal communication). Although cross-fostering 
control offspring with immune-challenged mothers can alter behavior in control offspring 
(Meyer et al. 2006c), there is extensive evidence that cross-fostering MIA offspring with 
control mothers does not protect against the emergence of neuropathology and behaviors 
in the offspring (Meyer et al. 2008). Together, current data in the field is most consistent 
with the hypothesis that MIA causes changes in brain development that lead to ASDand 
SZ-like behaviors in offspring. 
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Despite evidence for a pro-inflammatory brain cytokine profile at birth and in the 
adult MIA offspring, our results also reveal that MIA induces long-lasting changes in a 
surprisingly wide range of cytokines. These cytokines include both pro-inflammatory, 
anti-inflammatory, and regulatory cytokines, as well as several chemokines. In fact, most 
of the cytokines examined are significantly altered at some point in the MIA brain 
compared to controls. Perhaps most important, our results also reveal an unexpected and 
widespread decrease relative to controls in many brain cytokines during peak periods of 
synaptogenesis and plasticity (P7-P30). These decreases are in contrast to the expected 
pro-inflammatory phenotype and suggest that dramatically decreased cytokine signaling 
may be a critical variable causing altered brain connectivity and ASD and SZ-like 
behaviors in the offspring. Consistent with this idea, decreases in a few cytokines have 
been reported in postmortem brain tissue from individuals with ASD (Vargas et al., 2005) 
and SZ (Toyooka et al., 2003). The impact of widespread decreases in brain cytokines on 
the development and plasticity of cortical connections and synaptic transmission and 
plasticity will be the focus of future studies. 
There is a rich complexity in the regionand age-specific changes in MIA brain 
cytokines. There are only a few reports of brain region-specific changes in cytokine 
levels following any manipulation, but our data and the few reports in non-MIA mouse 
models (Johnson and Kan, 2010; Kasten-Jolly et al., 2011) are consistent with the single 
report of region-specific changes in postmortem brain tissue from individuals with ASD 
(Vargas et al., 2005). Region-specific changes in overall gene expression have also been 
reported for SZ and ASD (Focking et al., 2011; Ji et al., 2011; Suda et al., 2011), 
suggesting that regional-specificity may contribute to both disorders. Detection of region-
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specificity of MIA-induced cytokine changes during development was made possible 
only recently due to the increased sensitivity of multiplex analysis from small amounts of 
tissue (Datta and Opp, 2008). The advantage of the Luminex x-map technology over 
traditional ELISAs is that the former requires only a small sample volume (50µl) to 
simultaneously measure multiple analytes. Luminex technology is being utilized to 
measure adult brain cytokines in an increasing number of reports (Abazyan et al., 2010; 
Dalgard et al., 2012; Datta and Opp, 2008; Erickson and Banks, 2011; Gandhi et al., 
2007; Li et al., 2009; Mukherjee et al., 2011), and the greater sensitivity of the Bioplex 
system we used has been validated against both ELISA and other multi-plex systems (Fu 
et al., 2010; Mukherjee et al., 2011). Our results clearly demonstrate that a single, 
common maternal immune response (MIA during mid-gestation) can cause long-lasting 
changes in cytokines that are specific to particular brain regions. How this occurs is 
unknown, but may involve differential responses to MIA-induced cytokines elevated in 
fetal development mediated by well-documented region-specific differences in the 
distribution of cytokine receptors in the normal fetal brain (Bauer et al., 2007; Garay and 
McAllister, 2010). In the future, additional research is needed to determine if these 
region-specific patterns of changes in brain cytokines contribute to specific ASDand SZ-
like behaviors in offspring. 
In addition to region-specific changes in brain cytokines, we also observe age-
specific changes. Within a given brain region, the profile of cytokines that is altered in 
MIA offspring is distinct at each age. This dynamic response is not unexpected since 
cytokines are part of both positive and negative feedback loops that regulate each other’s 
expression and function to keep immune responses within a homeostatic range. 
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Individual cytokines do not work in isolation, but rather in complex networks (Careaga et 
al., 2010). Interestingly, we find no obvious pattern in the age-specific changes in terms 
of alternating pro-or anti-inflammatory cytokines. However, classifying cytokines in this 
way is only partially useful as most cytokines can be either pro-or anti-inflammatory 
depending on the cellular context and the levels of other cytokines. Moreover, the 
biological effects of individual cytokine levels can vary widely—a small change in levels 
of some cytokines can cause dramatic physiological effects, while large changes in others 
may have minimal outcomes. Taken together, these properties caution against general 
conclusions about the effects of MIA-induced changes in cytokines on inflammation in 
the brain.  
Another indication that cytokines may not have traditional pro-or anti-
inflammatory roles in MIA brains is that there is no overt evidence of inflammation in 
any brain region at any age examined, even at times when traditionally pro-inflammatory 
cytokines are elevated. The lack of immune cell infiltration into the brain, combined with 
little evidence of changes in gross BBB permeability, suggests that poly(I:C) MIA does 
not cause inflammation in the postnatal brain in the classic sense. Consistent with this 
interpretation, there is also no change in microglial density in any of the three brain 
regions examined and there is no qualitative change in microglial morphology in MIA 
brains (Fig. 7). These results are also consistent with a lack of immune cell infiltration, 
but inconsistent with reports of microglial activation in postmortem brain tissue from 
ASD individuals (Vargas et al., 2005). Since increased brain cytokines cannot be 
attributed to infiltrating immune cells, it is possible that any of the cell types endogenous 
to the brain could be responsible. Prior work has shown that neurons, microglia, and 
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astrocytes can produce cytokines during normal development in vivo (Deverman and 
Patterson, 2009). Although cytokines could in principle also come from the periphery by 
crossing the BBB, the postnatal BBB is relatively impermeable to most cytokines 
(Erickson and Banks, 2011) and MIA-induced changes in brain cytokines are region-
specific and do not correlate with serum cytokines at any age (Fig. 6). Identifying the 
source and targets of the MIA-induced cytokines will be important for understanding the 
consequences of these changes on neuronal connectivity and potentially glial function. 
Both epidemiological and experimental results indicate that the effect of MIA on 
neuropathology and behavior in offspring is determined by the timing of the infection. 
Maternal viral infection during the late first and early second trimesters, in particular, is 
associated with increased risk of ASD (Atladottir et al., 2010; Brown 2012; Hagberg et 
al., 2012; Patterson, 2011a). Similarly, infection during early to mid-pregnancy is related 
to an increase in risk for SZ in offspring (Brown et al., 2004; Brown 2012). Moreover, 
differential effects of Poly(I:C) injection during early and late gestation on 
neuropathology and behaviors in offspring have been found in the MIA mouse model 
(Meyer et al 2006b). Our experiments used poly(I:C) injection at E12.5, since this stage 
of gestation correlates with the late first trimester in humans (Clancy et al 2007)—the 
time that infections are most closely linked to increased incidence of ASD and SZ 
(Atladottir et al. 2010, Brown et al. 2004).   
Remarkably, many of the cytokines altered in the MIA brains and serum are similar 
to those found to be altered in ASD and SZ (Bauer et al., 2007; Brown and Patterson, 
2011; Careaga et al., 2010; Nawa et al., 2000). Significant increases in plasma cytokine 
levels (IL-1β, IL-6, TNFα, IFNγ, IL-8, IL-12p40) have been reported in children 
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diagnosed with ASD when compared with children without a family history of ASD 
(Ashwood et al., 2011; Molloy et al., 2006; Vargas et al., 2005). Most of these cytokines 
are also increased at P7 in MIA offspring serum (Figs. 5,6). Chemokines, including 
Eotaxin, RANTES, and MCP-1, are also elevated in the serum of autistic children 
(Ashwood et al., 2011) and all of these are elevated in MIA serum at P7 (Fig. 6). Neural 
inflammation, marked by increased pro-inflammatory cytokines and chemokines, 
including IFN-γ, IL-1β, IL-6, IL-12p40, TNF-α, and MCP-1, is also found in postmortem 
brain tissue from individuals with ASD over a wide range of ages (Vargas et al., 2005). 
Although we found changes in many of these cytokines in the MIA mouse brain, it is 
difficult to directly compare these results because of the wide range of ages examined in 
the human study (4–45 years of age). Similar findings in SZ also indicate elevated levels 
of cytokines in the blood of patients, including elevations in IL-1β, IL-6, IL-12, IFNγ, 
TNFα, and RANTES (Kunz et al., 2011; Yao et al., 2003), although many of these 
studies did not control for secondary variables and often report conflicting results. The 
fact that the poly(I:C) model displays several cytokine changes in common with both SZ 
and ASD reinforces the construct validity of the model, given that these disorders share 
the risk factor of maternal infection and that their psychiatric and anatomical pathologies 
significantly overlap (Lord et al., 2000; Meyer et al., 2011; Rapoport et al., 2009). How 
the risk of these distinct disorders is increased in humans via a single environmental risk 
factor is currently unknown but is likely to involve genetic susceptibility and/or the 
timing and intensity of the infection (Fatemi et al., 2008; Meyer et al., 2006a,b). 
Identifying how this large family of signaling molecules, the cytokines, are altered over 
time in brain development by infection and other environmental risk factors may 
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highlight targets for novel diagnostic tests and new immune-based therapies for ASD and 
SZ in the future. 
 
Methods 
MIA for cytokine measurements 
Female C57BL/6J mice (Charles River; Wilmington, MA) were obtained from the 
Caltech breeding facility and housed on a 12:12 h light:dark cycle at 29 ± 1 °C with food 
and water available ad libitum. Mice were mated overnight, and the presence of a vaginal 
plug on the following morning was noted as E0.5. Pregnant mice were injected 
intraperitoneally (i.p.) on E12.5 with saline or poly(I:C) potassium salt (Sigma Aldrich; 
St. Louis, MO). E12.5 was chosen since this stage of gestation correlates with the late 
first trimester in humans (Clancy et al 2007)—the time that infections are most closely 
linked to increased incidence of SZ and ASD (Atladottir et al. 2010, Brown et al. 2004).  
Poly(I:C) was freshly dissolved in saline and administered i.p. at 20 mg/kg based on the 
weight of the poly(I:C) itself, not including the total weight of the potassium salts. 
Control mice were injected with saline alone at 5 µl per gram body weight. This 
concentration of Poly(I:C) is higher than that used for intravenous injections (Meyer et al. 
2006) and was selected because it is the optimal i.p. dose that causes MIA, while 
preserving viability of offspring (Ito et al. 2010).  
 
Blood collection and brain dissections  
Control and poly(I:C) offspring were sacrificed at 5 ages: P0, P7, P14, P30, and P60. 
Both male and female offspring were used in this study. Mice were deeply anesthetized 
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with Nembutal (10 µl/g). At least 150 µl of blood/animal was first collected by cardiac 
puncture and transcardial perfusion was then performed using 10-30 ml of sterile PBS 
(by weight). P0 offspring were processed without perfusion. Whole brains were quickly 
removed and placed in ice-cold Earle’s balanced salt solution for microdissection of the 
FC, CC, and HC. All tissues were snap-frozen in liquid nitrogen and stored at −80°C. 
Both blood and brains were sent overnight on dry ice to U.C. Davis for processing. 
 
Sample processing  
Blood was centrifuged (12,000 x g, 4°C, 20 min) to obtain serum, which was then stored 
at −80°C. Frozen tissues were thawed and disrupted in Bioplex cell lysis buffer (BioRad) 
containing factors 1 and 2 (protease and phosphatase inhibitors, respectively; BioRad) 
and the protease inhibitor phenyl-methylsulfonyl fluoride (500 mM; Sigma–Aldrich). A 
small plastic pestle was used to homogenize the samples. Tissue was further 
homogenized by trituration using 200 µl pipette tips. The homogenate was then agitated 
for 30-40 min on ice and centrifuged at 4°C and 6000 x g (Eppendorf centrifuge 5417R) 
for 20 min. The supernatant was removed and aliquots stored at −80 °C. The protein 
content of each sample was determined using the BioRad Protein Assay (BioRad), with 
bovine serum albumin as a standard, according to the manufacturer's protocol. Sample 
absorbances were read at 560 nm using a spectrophotometer (Perkin Elmer HTS7000). 
 
Cytokine measurements 
BioRad (Hercules, CA) 23-plex mouse kits were used for all assays. Assays were 
performed according to the manufacturer’s instructions. Reagents were kept on ice until 
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use, minimizing exposure of the beads to light. All samples were run in duplicate and 
were assayed with the BioRad cytokine reagent kit and either the diluent kit for serum 
samples or the cell lysis kit for tissue samples. All buffers and diluents were warmed to 
room temperature prior to use. Lyophilized cytokine standards (containing IL-1α, IL-1β, 
IL-2, IL-3, IL-4, IL-5, IL-6, IL-9, IL-10, IL-12 (p40), IL-12 (p70), IL-13, Eotaxin, G-
CSF, GM-CSF, IFNγ, KC, MCP-1, MIP 1α, MIP1β, RANTES, and TNF-α) were 
reconstituted first to a master standard stock using 500 µl of diluent. Nine concentrations 
of the standards were made by eight, three-fold serial dilutions of the master standard 
stock in either cell lysis buffer (for brain tissue) or serum diluent. Samples were run at 
200 µg protein/well for the mouse brain homogenates. Serum samples were diluted 1:3 
prior to assay. All samples were held at 4°C for 10 min before the start of the assay. 
Corresponding buffer blanks were run to determine the level of background. All the wash 
steps were performed on a Bio-Plex Pro Wash Station at room temperature. The plates 
were then read in the Bio-Plex 200 System and the data analyzed using BioPlex Manager 
4.1 software with 5-parameter logistic regression (5PL) curve fitting to determine the 
standard curve from the 8 standards in duplicate and extrapolate the sample 
concentrations from the standard curve. The goodness-of-fit for each point on the 
standard curve was determined by the BioPlex Manager software. The standard recovery, 
calculated by taking the ratio of the calculated concentration value divided by the 
expected amount of standard, was within an acceptable range of recovery of between 70-
130% for all of the standards used. Only standards and samples with coefficients of 
variance under 5% were used. Readings were excluded if they were at or below the 
background value.  
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MIA for immunohistochemistry 
Female C57BL/6J mice (Charles River) were housed at U.C. Davis in accordance with 
the protocol approved by the Institutional Animal Care and Use Committee. Mice were 
mated overnight and the presence of a vaginal plug on the following morning was noted 
as day E0.5. Pregnant mice were injected (in the same fashion as for MIA for cytokine 
measurements described above) on E12.5 with saline or poly(I:C). Brains of offspring at 
the five ages were dissected into the three regions and post-fixed for 3 hrs in 4% 
paraformaldehyde in PBS. The paraformaldehyde was then replaced with 30% sucrose 
and left overnight at 4o C. The sucrose solution was changed twice until the brains sank. 
The brains were then frozen in OCT on dry ice and cut into 30 µm sections using a 
freezing microtome (Leica). The sections were blocked with 5% horse serum + 0.025% 
Triton in PBS for 2 hrs at room temperature, and then stained with primary antibodies, all 
at 1:1000: rabbit anti-IBA1 (WAKO, Japan), anti-CD45R (Abcam), rat anti-CD3 (R&D 
Systems), rat anti-GR1 (R&D Systems) at 4°C for 48 hrs. Sections were washed three 
times for 10 min each in PBS while shaking. Sections were incubated in secondary 
antibody for 90 min (1:200; Cy2 anti-rabbit, Cy3 anti-rabbit, and Cy2 anti-rat, Vector 
Laboratories) and mounted with Vectashield mounting media containing DAPI (Vector 
Laboratories) on 1% gelatin-coated slides.  
 
Imaging 
For assessing immune cell-infiltration, immunostaining was imaged with a 40x 1.2 NA 
objective on an epifluorescent microscope (Nikon E600, Nikon, Tokyo) under a mercury 
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arc lamp using computer software to run the camera (a Spot View Advanced 2.0 
(Diagnostic Imaging Inc.) For microglia, immunostaining was imaged using a 1.2 NA 
40x oil objective on an Olympus Fluoview 2.1 laser-scanning confocal system.  
 
Stereology  
The density of Iba-1-positive microglia was quantified using stereological methods (Feng 
et al., 2011). Every third section (of nine sections) were used for a total of three sample 
sections per brain region. The Iba-1 cell counts were made on an epifluorescent 
microscope (Nikon E600, Nikon, Tokyo) and analyzed using Stereologer computer 
software (version 1.3, Systems Planning & Analysis, Inc., Alexandria, VA). Microglia 
cell counts were taken from FC layer 2-3, CC layer 2-3, and HC area CA1 of the stratum 
radiatum at five ages (P0, P7, P14, P30, P60). Microglia were identified by Iba-1-positive 
cell body staining. The brain region of interest was outlined using a 4x (0.67 NA) 
objective. Microglia identification and counting were performed with a 100x oil (1.2 NA) 
objective. 
 
Blood-brain barrier integrity  
25 mg/kg Evan’s blue dye was injected i.p. in offspring at the five ages examined. Four 
hours later, the brain was removed, rinsed in PBS, examined using a dissecting 
microscope (Olympus CK30-F100), and imaged using a digital camera (Olympus FE-
370). Changes in the amount of Evans Blue signal were compared qualitatively. 
 
Statistics  
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Unpaired t-tests were used to determine statistical significance (* = p< 0.05) using 
GraphPad Prism software.  
 
Behavioral Testing  
Behavioral tests were conducted on mice starting at six weeks of age according to 
previously published methods (Smith et al., 2007). Mice were tested for PPI of acoustic 
startle using SR-LAB startle chambers (San Diego Instruments). Mice were acclimated to 
the chambers for 5 minutes before exposure to 6, 120 db tones (startle stimulus). They 
were then subjected to 14 randomized blocks of either no startle, startle only, startle 
preceded by a 5 db pre-pulse, or startle preceded by a 15 db pre-pulse. PPI is defined as 
the percentage of (startle only – 5 or 15 db pre-pulse)/startle only. For LI testing, mice 
were placed in chambers with parallel-grid shock floors (Coulbourn Instruments). On the 
first day of testing, mice were presented with a pre-exposure to 40, 30 sec tones followed 
by three pairings of the tone with a mild foot shock. Non-pre-exposed mice are presented 
with the three pairings only. On the second day, mice were placed in the same chambers 
for 8 min to record freezing in response to the context. On the third day, mice were 
placed back in the same chambers and presented with an 8 min tone. LI is defined as the 
difference in freezing in response to the tone in pre-exposed mice compared to non-pre-
exposed mice.  
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Figure 1. Many cytokines are expressed in serum and brain throughout normal 
development. Cytokine concentrations in the typically-developing brain change with age 
and some are region-specific. To illustrate changes in cytokine concentrations with age, 
the average values for each cytokine concentration are plotted at the five ages examined. 
Cytokine concentrations are plotted in pg/mg brain tissue (A-L) and pg/ml serum (M-P) 
for FC (A-D), CC (E-H), HC (I-L), and serum (M-P). The 23 cytokines are separated into 
4 groups: (1) commonly-studied brain cytokines (A,E,I,M) including IL-1α, IL-1β, IL-6, 
IL-10, IFNγ, and TNFα, (2) a first set of additional cytokines with similar step-like 
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changes in serum concentration with age (B,F,J,N) including IL-3, IL-4, IL-12(p40), IL-
13, G-CSF, and GM-CSF, (3) a second set of additional cytokines with stable levels in 
serum (C,G,K,O) including IL-2, IL-5, IL-9, IL-12(p70), and IL-17, and (4) chemokines 
(D,H,L,P) including Eotaxin, KC, MCP-1, MIP1α, MIP1β, and RANTES. Error bars are 
not included in these graphs to enhance visibility of the trends in expression, however all 
values of mean ± SEM concentration are included in Suppl. Tables 1 and 2. 
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Figure 2.  MIA induces long-lasting changes in cytokines in frontal cortex 
throughout development. The fold-change ± SEM in cytokine concentration in MIA 
brain regions compared to control values is plotted. Values from MIA brains are either 
black or red, and the control values are superimposed in clear bars outlined in grey. Red 
bars indicate statistically significant changes compared to controls (p < 0.05). Increases 
are shown above 1 and decreases, below 1. (A) At P0, MIA-induced increases are found 
for four cytokines. IL-3 and RANTES are below the level of detection at this age. (B, C, 
D) At P7, P14 and P30, many cytokines in MIA FC are lower compared to controls. (E) 
At P60, fewer cytokines in MIA FC are altered and all of these are elevated. (F) A heat 
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map is used to summarize the results for MIA-induced changes in cytokines at all ages 
examined. Statistically significant changes are indicated in color: red indicates increases, 
and blue decreases, in cytokine levels compared to controls. The degree of change is 
indicated by the depth of color as indicated in the lower panel. ND = below the level of 
detection. n = 5–6 brains per treatment group (pooled from at least two independent 
litters). 
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Figure 3. MIA induces long-lasting changes in cytokines in cingulate cortex 
throughout development. Data is plotted as in Fig. 2. (A) At P0, MIA induces increases 
in three cytokines. (B) At P7, five cytokines are lower than controls, while IL-17 is the 
only elevated cytokine at this age. IL-1α, IL-3, and IL-4 are below the level of detection. 
(C) At P14, eight cytokines are also lower. (D) At P30, eleven cytokines remain lower 
than controls. (E) At P60, fewer cytokines are altered and both are higher than controls. 
(F) A heat map is used to summarize the results for MIA-induced changes in cytokines at 
all ages examined. Statistically significant changes are indicated in color: red indicates 
increases and blue decreases in cytokine levels compared to controls. The degree of 
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change is indicated by the depth of color as indicated in the lower panel. ND = below the 
level of detection. n = 5–6 brains per treatment group (pooled from at least two 
independent litters). 
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Figure 4. MIA induces long-lasting changes in cytokines in hippocampus throughout 
development. Data is plotted as in Fig. 2. (A) At P0, MIA induces higher levels of IL-6 
and lower levels of six other cytokines, while MIP1α, IL-3, and RANTES are below the 
level of detection. (B) At P7, three cytokines are elevated, while four are lower than 
controls. IL-1α and G-CSF are below the level of detection. (C) At P14, IL-1α and IL-6 
are higher and six other cytokines are lower than controls. (D) At P30, IL-6 and MIP1α 
are lower than controls. (E) At P60, no cytokines levels are changed relative to controls. 
(F) A heat map summarizes the results for MIA-induced changes in cytokines at all ages 
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examined. Statistically significant changes are indicated in color: red indicates increases 
and blue, decreases in cytokine levels compared to controls. The degree of change is 
indicated by the depth of color as indicated in the lower panel. ND = below the level of 
detection. n = 5–6 brains per treatment group (pooled from at least two independent 
litters). 
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Figure 5. MIA induces long-lasting changes in cytokines in serum throughout 
development. Data is plotted as in Fig. 2. (A) At P0, MIA increases two cytokines and 
decreases three. (B) At P7, MIA increases levels of nine cytokines and decreases three. 
IL-5 is below the level of detection at this age. (C) At P14, two cytokines are higher than 
controls. (D) At P30, three cytokines are increased and one is decreased. (E) At P60, no 
cytokines levels are changed relative to controls. (F) A heat map to summarize the results 
for MIA-induced changes in cytokines at all ages examined. Statistically significant 
changes are indicated in color: red indicates increases, and blue decreases, in cytokine 
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levels compared to controls. The degree of change is indicated by the depth of color as 
indicated in the lower panel. ND = below the level of detection. n = 5–6 brains per 
treatment group (pooled from at least two independent litters). 
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Figure 6. Summary of cytokine changes in brain and serum across development. 
A heat map is used to summarize the results for MIA-induced changes in cytokines at all 
ages examined. Statistically significant changes are indicated in color: red indicates 
increases and blue indicates decreases in cytokine levels compared to controls. The 
degree of change is indicated by the depth of color as indicated in the lower panel. This 
figure clearly shows the similar overall pattern in MIA-induced cytokine changes in FC 
and CC during development, characterized by increases in cytokines at birth (P0) and in 
the adult (P60), and dramatic decreases in many cytokines during periods of 
synaptogenesis and activity-dependent plasticity (P7-P30). This pattern is distinct from 
that in HC, where there are both increases and decreases in cytokine in MIA offspring at 
all ages examined. Finally, MIA-induced changes in serum cytokines do not correlate 
with changes in brain cytokines. ND = below the level of detection.  
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Figure 7. MIA does not alter microglial number or morphology. 
The density of Iba1 + microglia (white) was quantified using Stereologer in each brain 
region at each age examined. (A) Representative images of coronal sections taken at 40X 
through FC, CC, and HC at five ages during postnatal development. (B) Quantification of 
the density of Iba1+ microglia for each brain region over age. The density generally 
increases from birth to P14 and then decreases to intermediate levels in the adult. There is 
no difference in microglial density between MIA and control brains. Open bars indicate 
control values and gray bars, MIA values. 
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Supplemental Fig. 1. MIA does not cause major breaches in the BBB. 
Representative brains from control and MIA offspring are shown for each of the four 
ages examined, following Evans Blue staining to detect BBB permeability. There is no 
qualitative difference in BBB permeability in MIA brains compared to controls at any 
age examined.  
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Supplemental Fig. 2. MIA does not induce immune cell infiltration in the CNS of 
offspring. 
(A) Representative images of coronal sections taken at 10X through the three brain 
regions are shown at five different ages. Sections were stained with antibodies specific 
for B cells, T cells, and neutrophils. No immunoreactivity is seen over that detected in the 
no-primary antibody control. Adult spleen is included as a positive control and, as 
expected, all three cell types are visible in spleen. (B) Spinal cord sections from mice 
subjected to experimental autoimmune encephalitis (EAE) are included as a second 
positive control for our ability to detect immune cell infiltration. All immune cell types 
are stained, at the expected low levels, in EAE spinal cord. 
 
 
 
 
 
 
 
 
 
 
 
 
 353 
Supplemental Table 1 (Dataset online). Cytokine concentrations in FC and CC. 
Average concentrations (pg/ml for brain regions and pg/ml for serum) ± SEM for 23 
cytokines are shown for saline (control) and poly(I:C) (MIA) conditions for each brain 
region at each age. The fold-change in cytokines resulting from MIA was calculated as 
the ratio of the average values for poly(I:C)/saline (P/S). P-values for t-tests between 
MIA and controls for each comparison are also indicated. Grey fills indicate cytokines 
that are significantly different between MIA and control values (p<0.05). ND = not 
detected. 
 
Supplemental Table 2 (Dataset online). Cytokine concentrations in HC and Serum. 
Average concentrations (pg/ml for brain regions and pg/ml for serum) ± SEM for 23 
cytokines are shown for saline (control) and poly(I:C) (MIA) conditions for HC and 
serum at each age. The fold-change in cytokines resulting from MIA was calculated as 
the ratio of the average values for poly(I:C)/saline (P/S). P-values for t-tests between 
MIA and controls for each comparison are also indicated. Grey fills indicate cytokines 
that are significantly different between MIA and control values (p<0.05). ND = not 
detected. 
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Abstract 
The observation that maternal infection increases the risk for schizophrenia in the 
offspring suggests that the maternal immune system plays a key role in the etiology of 
schizophrenia. In a mouse model, maternal immune activation (MIA) by injection of 
poly(I:C) yields adult offspring that display abnormalities in a variety of behaviors 
relevant to schizophrenia. As abnormalities in the hippocampus are a consistent 
observation in schizophrenia patients, we examined synaptic properties in hippocampal 
slices prepared from the offspring of poly(I:C)and saline-treated mothers. Compared to 
controls, CA1 pyramidal neurons from adult offspring of MIA mothers display reduced 
frequency and increased amplitude of miniature excitatory postsynaptic currents. In 
addition, the specific component of the temporoammonic pathway that mediates object-
related information displays increased sensitivity to dopamine. To assess hippocampal 
network function in vivo, we used expression of the immediate-early gene, c-Fos, as a 
surrogate measure of neuronal activity. Compared to controls, the offspring of poly(I:C)-
treated mothers display a distinct c-Fos expression pattern in area CA1 following novel 
object, but not novel location, exposure. Thus, the offspring of MIA mothers may have an 
abnormality in modality-specific information processing. Indeed, the MIA offspring 
display enhanced discrimination in a novel object recognition, but not in an object 
location, task. Thus, analysis of object and spatial information processing at both synaptic 
and behavioral levels reveals a largely selective abnormality in object information 
processing in this mouse model. Our results suggest that altered processing of object-
related information may be part of the pathogenesis of schizophrenia-like cognitive 
behaviors. 
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Introduction 
Schizophrenia is a major psychiatric disorder with a strong genetic contribution 
(Burmeister et al., 2008; Bertolino and Blasi, 2009). Nonetheless, epidemiologic 
evidence indicates that genetic factors alone cannot explain the pathogenesis. For 
example, the concordance for schizophrenia in monozygotic twins is approximately 48% 
(Gottesman, 1991). Furthermore, while the concordance between monozygotic twins who 
share a placenta is 60%, the concordance rate between such twins who do not share a 
placenta is only 10% (Davis et al., 1995; Patterson, 2007). These studies suggest the 
importance of the fetal environment. Supporting this idea, Mednick et al. (1988) reported 
that fetuses gestating during a viral epidemic are at elevated risk for developing 
schizophrenia. Subsequent prospective studies have shown that maternalinfections of 
various types increase the risk for schizophrenia in the offspring 3to 7-fold (reviewed by 
Patterson, 2009; Brown and Derkits, 2010). 
Based on this evidence, several animal models of MIA have been established 
(reviewed by Meyer et al., 2009; Patterson, 2009). Among these, administration of the 
synthetic dsRNA, poly(I:C) can effectively induce MIA, resulting in offspring that 
display a variety of behaviors and neuropathologies that are consistent with those seen in 
schizophrenia patients (Meyer and Feldon, 2009; Patterson, 2009). Thus, this animal 
model is useful for investigating the pathophysiology of schizophrenia. 
Clinical studies reveal an important role for dopamine (DA)mediated signaling in 
the pathophysiology of schizophrenia. For example, drugs that increase DA release 
induce several aspects of schizophrenic psychosis in normal adults, and exacerbate 
psychotic symptoms in patients with schizophrenia (Angrist and Vankammen, 1984; 
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Lieberman et al., 1987). Moreover, all drugs currently in widespread use for the treatment 
of schizophrenia block DA D2 receptors (Creese et al., 1976). Other studies suggest that 
there is a deficit in DA D1 receptor-mediated transmission in prefrontal areas of 
schizophrenic patients (Davis et al., 1991; Toda and Abi-Dargham, 2007). Indeed, 
imaging studies of patients reveal an increased D2 receptor density in the striatum 
(Weinberger and Laruelle, 2001) and a decreased D1 receptor density in the prefrontal 
cortex (Okubo et al., 1997). 
Deficits in other cortical regions may also play a key role in the pathophysiology 
of schizophrenia. Among them, hippocampal abnormalities are commonly found 
(Heckers and Konradi, 2002). Lipska et al. (1993) suggested that the important variable is 
the developmental period during which the hippocampal damage takes place, because 
lesion of the adult rat hippocampus fails to produce schizophrenia-like behaviors, while 
hippocampal disruption in neonatal stages causes these behavioral alterations to emerge 
in adulthood. Most importantly in the present context, DA D1and D2-like receptors are 
highly expressed in the hippocampus (Wamsley et al., 1989; Meador-Woodruff et al., 
1994; Khan et al., 1998) and a reciprocal functional interaction between the DA system 
and the hippocampus has been suggested (Lisman and Grace, 2005). Together, these 
studies indicate that hippocampal dysfunction participates in the pathogenesis of 
schizophrenia. 
Considering these findings, we used the poly(I:C) MIA mouse model to 
investigate the pathogenesis of schizophrenia-like behaviors. We focus on the 
hippocampal network and the influence of DA, conducting experiments at the synaptic as 
well as the behavioral level. The data suggest a link between synaptic dysfunction, DA 
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and altered behavior. 
 
Results 
CA1 pyramidal neurons in the offspring of poly(I:C)-treated mothers display a reduced 
frequency and increased amplitude of mEPSCs 
A number of studies indicate that the brains of schizophrenia patients exhibit a 
reduction in the volume of the hippocampus (Nelson et al., 1998; Heckers and Konradi, 
2002). Although most studies on schizophrenia patients report no significant change in 
neuronal density in the hippocampus (Dwork, 1997; Harrison, 1999), many post-mortem 
studies have reported an abnormal expression of synaptic proteins, including 
synaptophysin (Eastwood and Harrison, 1995; Davidsson et al., 1999), synapsin I 
(Browning et al., 1993), SNAP-25 (Young et al., 1998) and spinophilin (Law et al., 
2004). 
Therefore, we asked whether the MIA offspring display abnormalities in synaptic 
number or efficacy in CA1 pyramidal neurons. We observe an increased amplitude, but 
decreased frequency in miniature excitatory postsynaptic currents (mEPSCs) (amplitude: 
saline 8.5 ± 0.3 pA, poly(I:C) 9.9 ± 0.5 pA; frequency: saline 0.95 ± 0.15 Hz, poly(I:C) 
0.60 ± 0.05 Hz) (Fig. 1A). There is no significant difference in the kinetics of mEPSC 
waveforms (Fig. 1B) or membrane properties (membrane capacitance: saline 220 ± 36 
pF, poly(I:C) 210 ± 33 pF, membrane resistance: saline 194 ± 62 MX, poly(I:C) 149 ± 55 
MX, in mean ± SD), suggesting that the observed differences in mEPSC amplitude and 
frequency are primarily due to altered synaptic properties. The decrease in mEPSC 
frequency suggests either presynaptic dysfunction or a reduction in excitatory synapse 
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number per neuron. To assess presynaptic function, we analyzed paired-pulse facilitation 
but do not find a significant difference between the groups (saline: 2.1 ± 0.2, poly(I:C): 
2.0 ± 0.2; ratio of 2nd to 1st EPSC amplitude) (Fig. 1C), suggesting that presynaptic 
function in the experimental group is normal and that the reduced mEPSC frequency is 
likely due to a reduction in excitatory synapse number. The increase in mEPSC amplitude 
in the offspring of poly(I:C)-treated mothers may be a compensatory response for the 
reduction of mEPSC frequency (Turrigiano et al., 1998; Sutton et al., 2006). We also 
tested synaptic plasticity at Schaffer-collateral-CA1 synapses. When LTP was induced by 
a single train of 100 stimuli at 100 Hz, the magnitude of LTP in slices prepared from the 
offspring of poly(I:C)-treated mothers is similar to controls (saline: 1.45 ± 0.05, 
poly(I:C): 1.36 ± 0.07; mean fEPSP slope at 55– 60 min after LTP induction relative to 
the baseline) (Fig. 1D). Taken together, these results indicate that the adult offspring of 
poly(I:C)treated mothers display a reduced number of normally functioning excitatory 
synapses on CA1 pyramidal neurons. 
We next performed immunohistochemistry of the synaptic proteins synaptophysin 
and GluR1 in area CA1. Dendritic distribution of these proteins is similar between 
control and MIA offspring. In contrast, we found that a cytoskeletal protein, MAP2, 
shows a distinct distribution along the dendritic axis of CA1 pyramidal neurons in MIA 
offspring (Supplemental Fig. 1), which is consistent with a study on schizophrenia 
patients showing an elevated expression of MAP2 in the hippocampus (Cotter et al., 
2000). 
To examine inhibitory synaptic transmission, we recorded mIPSCs from CA1 
pyramidal neurons. We do not find a significant difference in either amplitude or 
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frequency of mIPSCs between groups (amplitude: saline 13.9 ± 1.1 pA, poly(I:C) 13.6 ± 
1.0 pA, frequency: saline 4.9 ± 0.3 Hz, poly(I:C) 4.3 ± 0.5 Hz) (Fig. 1E), suggesting that 
the function of inhibitory synapses is normal in area CA1. 
 
Temporoammonic-CA1 synapses in MIA offspring display increased sensitivity to 
dopamine 
Many lines of evidence indicate that DA signaling plays an important role in 
hippocampal function, as well as in the pathophysiology of schizophrenia. For example, 
DA neurons in the substantia nigra compacta and ventral tegmental area innervate the 
hippocampus (Swanson, 1987; Gasbarri et al., 1997) and release DA when animals are 
exposed to novel environments (Ihalainen et al., 1999). This neurotransmitter influences 
hippocampal synaptic plasticity (Huang and Kandel, 1995; Otmakhova and Lisman, 
1996; Li et al., 2003) and frequency-dependent synaptic transmission (Ito and Schuman, 
2007). Furthermore, disruption of DA-mediated signaling impairs hippocampal-
dependent learning (Gasbarri et al., 1996; El-Ghundi et al., 1999; Rossato et al., 2009). 
Therefore, we investigated DA-mediated synaptic control in hippocampal area CA1. As 
previous studies showed a selective influence of DA on the temporoammonic (TA)-CA1 
synapses compared to Schaffer-collateral-CA1 synapses (Otmakhova and Lisman, 1999; 
Ito and Schuman, 2007; Supplemental Fig. 2), we examined DA modulation of TA-CA1 
synapses. The TA pathway includes axonal populations from both the medial (MEC) and 
lateral (LEC) entorhinal cortexes (Steward, 1976; Witter and Amaral, 2004). These 
projections are topographically organized along the transverse-axis of area CA1, such 
that the projections from MEC make synapses at proximal CA1 (close to CA3), while 
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those from the LEC project to distal CA1 (close to subiculum) (Fig. 2A; Steward, 1976; 
Witter and Amaral, 2004). Previous anatomical studies in the mouse brain showed a 
topographic projection of the TA pathway similar to that observed in the rat brain (van 
Groen et al., 2003). Our immunohistochemical analysis of the presynaptic proteins 
synapsin I and bassoon in the stratum lacunosum-moleculare indeed indicates expression 
differences between distal and proximal regions of area CA1 (Supplemental Fig. 3). 
Thus, the presynaptic properties of the proximal and distal TA-CA1 synapses in the 
topographic projection of entorhinal-cortical fibers may be distinct. This organization of 
presynaptic proteins is observed in both MIA and control offspring (Supplemental Fig. 
3). 
We recorded fEPSPs simultaneously from proximal and distal TA-CA1 synapses. 
The application of DA (20 lM; Otmakhova and Lisman, 1999) to slices prepared from 
control mice induces a significantly larger depression at proximal TA-CA1 synapses 
compared to distal TA-CA1 synapses (proximal TA: 57.6 ± 2.2%; distal TA: 65.3 ± 
2.3%, relative to baseline; Fig. 2B and 4C). Furthermore, we found that another 
neuromodulator, norepinephrine (NE), also differentially controls TA synapses made by 
MEC and LEC inputs (Supplemental Fig. 4). These data indicate that the 
neuromodulators, DA and NE, can differentially control MEC and LEC inputs to area 
CA1 of the mouse hippocampus. 
In slices prepared from MIA offspring, DA induces a depression comparable to 
that observed in control slices at proximal TA-CA1 synapses (proximal TA: 55.4 ± 3.1%, 
relative to baseline; Fig. 2C). At distal TA-CA1 synapses, however, the slices prepared 
from MIA offspring show a significantly larger depression compared to controls (distal 
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TA: 56.3 ± 1.4%, relative to baseline; Fig. 2C). To further examine DA sensitivity at 
distal TA-CA1 synapses, the neurotransmitter was applied sequentially from low to high 
concentration to acute slices (Fig. 2D) and DA-mediated depression was quantified. We 
find that, compared to controls, the amount of depression is significantly larger at each 
DA concentration in the slices prepared from the MIA group (Fig. 2E). These results 
indicate that the adult offspring of poly(I:C)-treated mothers display an enhanced 
sensitivity to DA selectively at LEC inputs. 
 
The offspring of poly (I:C)-treated mothers display a distinct c-Fos expression pattern in 
hippocampal area CA1 following novel object exposure 
While the major afferent inputs to the hippocampus are provided by the entorhinal 
cortex (Cajal, 1911), recent studies demonstrated that two subdivisions of the entorhinal 
cortex, MEC and LEC, provide distinct information modalities to the hippocampus. 
Spatial information is carried by axons from the MEC, whereas nonspatial, or object 
information is carried by axons from the LEC (Hargreaves et al., 2005; Knierim et al., 
2006; Manns and Eichenbaum, 2006). Because MIA offspring display higher sensitivity 
to DA in the LEC projection to area CA1, these animals may exhibit abnormal object 
information processing. 
One of the major features shared by hippocampal and DAreleasing neurons in vivo is the 
modulation of neuronal activity by stimulus novelty (Knight, 1996; Schultz, 1998; 
Horvitz, 2000; Rutishauser et al., 2006). Therefore, we examined how hippocampal 
neurons are activated in vivo during novel object exposure using immunostaining for an 
immediate-early gene product, cFos (Morgan and Curran, 1991). Immediate-early gene 
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expression in resting animals is very low (e.g. Supplemental Fig. 5C), but rapidly 
increases following patterned neuronal activity that induces synaptic plasticity (Cole et 
al., 1989), suggesting that c-Fos expression can be used as a surrogate marker for 
synaptic modification (Guzowski et al., 2005). Following accommodation to the home 
cage for several days, control and experimental mice were exposed to novel objects in the 
home cage (Fig. 3A). After 2 h of exposure, animals were sacrificed and 
immunohistochemistry was performed. Control mice show differential c-Fos expression 
between proximal and distal CA1 pyramidal neurons (Figs. 3B and C and Supplemental 
Fig. 5A). In contrast, MIA offspring do not show clear differential c-Fos activation 
between proximal and distal CA1 pyramidal neurons (Figs. 3B and C and Supplemental 
Fig. 5A). These results suggest that MIA offspring display abnormal object information 
processing in the hippocampus. 
We also examined c-Fos expression after animals were exposed to a novel cage 
environment. Following accommodation to the home cage for several days, animals were 
placed in a new cage, which lacked a food box and contained new bedding with a 
different texture and scent than the prior bedding. After 2 h of such novel location 
exposure, animals were sacrificed and immunohistochemistry was performed (Fig. 4A). 
In contrast to the results after novel object exposure (Fig. 3), we observe a similar c-Fos 
expression pattern in the transverse-axis of area CA1 between the offspring of salineand 
poly(I:C)-treated mothers (Figs. 4B and C and Supplemental Fig. 5B). Thus, MIA 
offspring appear to have a selective abnormality in object, but not spatial, information 
processing, which could be due to hyper-DA sensitivity in LEC inputs at TA-CA1 
synapses. 
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The offspring of poly(I:C)-treated mothers display behavioral inflexibility and abnormal 
novel object recognition 
Our slice recording and c-Fos expression analyses indicate that MIA offspring 
have a selective abnormality in nonspatial information processing in the hippocampus. To 
examine if these animals display a corresponding behavioral abnormality, we tested the 
performance of hippocampus-dependent behavior using the Morris water maze task 
(Morris, 1984). 
We do not find a significant difference in the learning of the initial platform 
location between experimental and control groups (Fig. 5A and B), suggesting that the 
MIA offspring have normal ability to acquire spatial navigation memory. After animals 
learned the initial platform location, we moved the platform to a different location. Two-
way ANOVA with session number and prenatal treatment as variables reveals a 
significant effect of prenatal treatment (T1,222 = 5.693, p < 0.05), as well as a significant 
effect of session number (T3,222 = 5.875, p < 0.01) with no interaction between the two 
variables, indicating that while both groups improve their performance over time, the 
MIA offspring display a significantly slower learning of the new platform location (Fig. 
5C). Thus, although the MIA offspring have normal ability to 
learn a spatial context per se, they have difficulty in adapting to a change introduced in a 
previously-learned context. 
To further test this idea, we examined how these animals perform in novel object 
recognition and object location tasks. We placed two different objects in a test cage and 
allowed animals become familiar with them. One object was subsequently moved to a 
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new location (object location test) (Fig. 5D). Both groups of animals display a higher 
preference for the moved object, and we do not find a significant difference in the 
magnitude of preference between groups (Fig. 5E). In another set of experiments, after 
familiarization with the two objects, a novel object replaced one of the familiar ones at 
the same location (novel object recognition test) (Fig. 5D). Although both groups of 
animals display preference for the new object, the MIA offspring display a significantly 
stronger preference than control animals (Fig. 5F). Thus, the MIA offspring display 
abnormally high sensitivity to a novel object, but not to a novel location, which may be 
due to altered processing of nonspatial information in the hippocampus of these animals. 
This is consistent with the slice recording and c-Fos findings. 
 
Discussion 
 
Reduced excitatory input on CA1 pyramidal neurons 
Our electrophysiological studies demonstrate that the offspring of poly(I:C)-
treated mothers display a decreased number, but enhanced efficacy, of excitatory 
synapses on CA1 pyramidal neurons. Synaptic abnormalities have also been observed in 
area CA3 in schizophrenia patients, including abnormal mRNA expression of presynaptic 
proteins (Harrison and Eastwood, 2001). 
We do not observe a significant abnormality in the mIPSC amplitude or frequency 
in the offspring of poly(I:C)-treated animals. Although several studies have reported a 
decreased number of GABAergic neurons in the hippocampus, most of these differences 
were observed in area CA2/3, not in area CA1 (Benes et al., 1996, 1997; Heckers and 
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Konradi, 2002). Thus, GABAergic input to area CA1 pyramidal neurons appears normal 
in both our model and in patients. 
 
Increased dopamine sensitivity in the temporoammonic pathway 
Compared to the Schaffer-collateral pathway in area CA1, the TA pathway has 
been a relatively unexplored circuit in the hippocampus. Many recent findings highlight 
its unique role in hippocampal function, however (Brun et al., 2002; Remondes and 
Schuman, 2004; Nakashiba et al., 2008). Some interesting features of this pathway 
include its topographic projection pattern and its sensitivity to neuromodulators. 
A topographic projection in which LECor MEC-derived axons terminate in different 
regions allows the EC to send nonspatial and spatial information to distinct neuronal 
populations in area CA1 (Steward, 1976; Witter and Amaral, 2004). The efferents from 
area CA1 are also topographically organized such that neurons in proximal CA1 send 
projections back to the MEC, while neurons in distal CA1 project back to the LEC 
(Tamamaki and Nojyo, 1995). Thus, two independent circuit loops for nonspatial and 
spatial information exist between the EC and CA1. This architecture, based on the TA 
pathway, may allow the hippocampus to independently process nonspatial and spatial 
information, providing an unique role for the TA pathway in the hippocampus. 
Sensitivity to neuromodulators is another feature of the TA pathway. In recordings from 
control mouse hippocampal slices, DA induces a larger depression at proximal compared 
to distal TA-CA1 synapses. However, hippocampal slices prepared from 
offspring of poly(I:C)-treated mothers exhibit a significantly larger DA-induced 
depression, selectively at distal TA-CA1 synapses compared to controls, which may 
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abolish the differential control of LEC and MEC inputs by DA. Our present observations, 
based on both electrophysiology and c-Fos expression, suggest that the offspring of 
poly(I:C)-treated mothers have altered DA-mediated control of the TA pathway and may 
have an abnormality in object information processing. This altered DA signaling may be 
due to the abnormal development of the DA system recently observed in MIA offspring 
(Vuillermot et al., 2010), although the hippocampus and EC in this animal model have 
not yet been examined for expression of DA receptor or transporter with regard to the TA 
pathway. It is worth noting that the antipsychotic drug, clozapine, effectively blocks DA-
induced depression at TA-CA1 synapses (Otmakhova and Lisman, 1999), indicating that 
the TA pathway may be a locus for clozapine action in schizophrenia. 
The proper integration between Schaffer-collateraland TA-CA1 synapses is 
critical for controlling spike initiation and synaptic plasticity in CA1 pyramidal neurons 
(Dvorak-Carbone and Schuman, 1999; Remondes and Schuman, 2002; Jarsky et al., 
2005; Ang et al., 2005; Dudman et al., 2007). Thus, abnormal DA-mediated control of 
TA-CA1 synapses, together with reduced number of excitatory inputs on CA1 pyramidal 
neurons, will likely lead to altered synaptic plasticity or information integration in CA1 
pyramidal neurons in the MIA offspring. 
 
Perseveration behavior and hypersensitivity to a novel object 
Our behavioral analyses indicate that the offspring of poly(I:C)treated mothers 
show behavioral inflexibility in the Morris water maze task and increased sensitivity in 
the novel object recognition task. The normal acquisition of an initial platform location in 
the water maze task indicates that MIA offspring have normal spatial navigation, such as 
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in self-localization, route learning and motor function for swimming (Redish and 
Touretzky, 1998). A selective deficit in learning a moved platform location suggests that 
these animals have difficulty in adapting to a modification introduced in previously 
acquired information, which may correspond to perseveration behavior. Such behavior is 
defined as contextually inappropriate and unintentional repetition, and is often observed 
in schizophrenia patients (Crider, 1997). These patients have difficulty in switching 
behavioral-strategy, or reversal learning, and tend to repeat the same response or strategy 
(Fey, 1951; Nolan, 1974; Floresco et al., 2008). Interestingly, a recent human study 
indicates that maternal infection is correlated in the offspring with impaired performance 
in the Wisconsin card sorting test, which provides a good measure of perseveration 
behavior (Brown et al., 2009). That is, the subset of schizophrenia subjects born to 
infected mothers display a more severe behavioral deficit in this test than schizophrenia 
subjects born to non-infected mothers. In experimental animals, the offspring of 
poly(I:C)-treated mothers display deficits in reversal learning in a left–right 
discrimination task (Meyer et al., 2006). Perseveration behavior is also observed in 
hippocampus-lesioned animals in the Morris water maze task (Whishaw and Tomie, 
1997). Both hippocampus-lesioned animals (Kim and Frank, 2009) and rodents injected 
with a DA receptor agonist (Boulougouris et al., 2009) exhibit impaired reversal learning. 
Thus, abnormalities in the hippocampus and the DA system may play a key role in 
perseveration behavior. 
In light of perseveration behavior in the water maze, the increased sensitivity to a 
novel object that we observe in the MIA offspring may be due to an enhanced 
expectation for the original object, which will increase novelty for a switched object. 
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Importantly, the abnormal preference in the MIA offspring was observed selectively in 
the novel object recognition (nonspatial information), but not in the object location 
(spatial information), task. 
These altered behaviors in the MIA offspring may be due to abnormal processing 
of nonspatial information in the hippocampus, as observed in our slice physiology and c-
Fos expression analyses. Contrary to our results, Ozawa et al. (2006) and Ibi et al. (2009) 
reported a deficit in a novel object recognition test. However, they used a more severe 
regimen of poly(I:C) treatment for 5–6 consecutive days at a different time during 
development, and they employed a longer time away from the object, making the test 
more of a memory test than a novelty preference test. Moreover, Golan et al. (2005) 
obtained a result similar to ours in a novel object recognition test using maternal injection 
of lipopolysaccharide to mimic maternal bacterial infection. It should also be noted that, 
in the water maze test, Zuckerman and Weiner (2005) reported some similarities and 
some differences in results compared to ours. However, they used rats and administered 
poly(I:C) at a much later time in gestation. 
 
Integration of information processed in parallel 
A major feature of brain function is parallel information processing. For example, 
visual information is processed in two distinct information streams: a ventral stream that 
subserves object recognition, or ‘‘what” perception, and a dorsal stream that primarily 
subserves spatial information, or ‘‘where” perception (Ungerleider and Haxby, 1994). 
The distributed information, processed in different brain areas, must be integrated for 
coherent perception. 
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Recent imaging and physiology studies report abnormal visual object recognition 
in schizophrenia patients (Doniger et al., 2002; Wynn et al., 2008). Wynn et al. (2008) 
measured activity in early retinotopically organized areas (V1–V4), motion-sensitive 
areas (human area MT) and object-recognition areas (lateral occipital complex), and 
found that schizophrenia patients display more widely-distributed activation in areas 
involved in object recognition than controls. Thus, the abnormal distribution of activity in 
object-selective cortex in schizophrenia patients may indicate a problem in the integration 
of spatial and nonspatial information. 
In the hippocampus, the integration of spatial and nonspatial information is 
critical for constructing a neural representation of environmental context. As such, the 
hippocampus plays an essential role in contextual memory formation. Interestingly, 
several studies indicate that schizophrenia patients have a severe problem in contextual 
memory formation (Boyer et al., 2007; Rizzo et al., 1996; Danion et al., 1999), although 
other types of memory, which do not require contextual information, are relatively intact. 
Our findings raise the question of whether this memory deficit could be due to abnormal 
DA-mediated control of the TA pathway in the hippocampus. Interestingly, a recent study 
using model simulation predicts a dominance of object over spatial information 
processing in the medial temporal lobe of schizophrenia patients (Talamini and Meeter, 
2009). Thus, the altered hippocampal information processing we observe in MIA 
offspring may underlie some schizophrenia-like behaviors of these animals, such as in 
pre-pulse inhibition, latent inhibition and perseverative behavior. Further investigation 
based on this perspective may shed new light on the pathophysiology of schizophrenia. 
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Methods 
Animals 
Pregnant C57BL/6J mice were injected either i.v. with 5 mg/kg or i.p. with 20 mg/kg 
poly(I:C) potassium salt freshly dissolved in 0.9% sterile saline on E12.5. Both doses and 
routes of administration have been used to induce MIA and behaviors relevant to 
schizophrenia in adult offspring (Meyer et al., 2006; Smith et al., 2007). Control females 
were injected with the same volume of saline. The offspring were undisturbed until 
weaning on P21. Offspring were behaviorally tested from 6 to 11 weeks for pre-pulse 
inhibition (PPI), latent inhibition and open field exploration, to confirm behavioral 
deficits observed in previous studies (Shi et al., 2003; Smith et al., 2007; data not shown), 
and for Morris water maze, object location and novel object recognition. Five litters each 
from salineand poly(I:C)-treated mothers were generated (3 by i.p. injection and 2 by i.v. 
injection), and four litters each were used for analysis in the present study. One pair of 
litters generated by i.p injection was not included because control and MIA offspring did 
not show significant differences in PPI and latent inhibition. The litters generated by i.p. 
injection (24 offspring pairs in total) were used for the analysis in Figs. 1A and B, 2D and 
E and for all of the behavioral analysis in Fig. 5. The rest of experiments, including those 
in supplemental figures, were conducted using the litters generated by i.v. injection (28 
offspring pairs in total). No striking differences in PPI, latent inhibition or open field 
behavior was observed between the offspring of i.p. and i.v. injected mothers. To avoid 
influences of prior behavioral testing, animals used for electrophysiology, 
immunohistochemisty and c-Fos expression analysis were sacrificed at least 3 days after 
the last behavioral test. 
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Hippocampal slice preparation 
For each experiment, hippocampal slices were made from paired adult offspring (same 
sex and age, between 7to 15week-old, randomly selected from each litter for each set of 
experiments without regard to the results of behavioral tests) from salineand poly(I:C)-
treated mothers. In brief, a vibrating microtome (Leica VT1000S) was used to cut 
transverse hippocampal sections from the intermediate part of a dorsoventral axis of the 
hippocampus (400 lm thickness) in ice-cold, oxygenated artificial cerebrospinal fluid 
(ACSF) containing (in mM) 119 NaCl, 2.5 KCl, 1.3 MgSO4, 2.5 CaCl, 1.0 NaH2PO4, 
26.2 NaHCO3, 11.0 glucose. Slices were recovered at room temperature for at least 2 h in 
an interface chamber, and then transferred to a submerged recording chamber perfused 
with ACSF. Concentric bipolar tungsten electrodes (FHC) and stimulus isolators (Axon 
Instruments) were used for the stimulation. 
 
Electrophysiology 
Extracellular field potential recordings were made with 1–3 MX resistance 
microelectrodes filled with 3 M NaCl using a bridge amplifier (Axoclamp 2B, Molecular 
Devices). The recordings were made at 25 °C. Whole-cell voltage-clamp recordings from 
CA1 pyramidal neurons were obtained without visualization with an Axopatch 200B 
(Molecular Devices). The internal solution of whole-cell patch pipettes contained (in 
mM) 115 cesium gluconate, 20 cesium chloride, 10 sodium phosphocreatine, 10 HEPES, 
0.2 EGTA, 2 MgATP, 0.3 NaGTP (pH 7.3). The membrane capacitance was canceled 
and series resistance was compensated (60– 70%) for paired-pulse facilitation 
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experiments, but uncompensated for miniature recordings. Recordings were discarded 
when the series resistance was over 20 MX or either series or membrane resistance 
changed more than 20% (30% for mIPSC recordings) during data acquisition. The 
amplitude of test pulses was 20–40 lA for recordings from SC-CA1 synapses and 50–150 
lA for recordings from TA-CA1 synapses, and the duration of pulse was 100 ls. The test 
pulses were applied once every 30 s. Dopamine was obtained from Sigma. All other 
drugs were obtained from Tocris. For mEPSC recordings, whole-cell patch clamp 
recordings were obtained from CA1 pyramidal neurons in extracellular solution 
containing TTX (1 lM) and bicuculline (10 lM) at 25 °C. For mIPSC recordings, the 
internal solution of patch pipettes was a cesium chloride-based solution (in mM): 115 
cesium chloride, 20 KCl, 10 sodium phosphocreatine, 10 HEPES, 0.2 EGTA, 2 MgATP, 
0.3 NaGTP (pH 7.3). The recordings were made at 28°C, using TTX (1lM), NBQX (20 
lM) and APV (50 lM) to block excitatory synaptic transmission, and the extracellular 
potassium concentration was increased from 2.5 mM to 5 mM to enhance the frequency 
of miniature synaptic events. Membrane voltage was clamped at "70 mV. For the 
analysis of paired-pulse facilitation, whole-cell patch clamp recordings were obtained 
from CA1 pyramidal neurons. The membrane potential was clamped at "60 mV, and 
recordings were made at 25 °C under bicuculline (10 lM) and CGP55845 (1 lM) to block 
inhibitory synaptic transmission. The interstimulus interval was 50 ms. The LTP 
induction protocol was a single train of 100 pulse stimuli at 100 Hz. All stimulus pulses 
were of the same length and amplitude as test pulses. The baseline fEPSP slope prior to 
LTP induction was adjusted within the range of 0.2– 0.3 mV/ms. 
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Behavioral manipulations for c-Fos expression analysis 
All the behavioral manipulations were carried out at night (12– 4 Am) to maximize active 
exploration of the environment. The objects used for novel object exposure were two 
small children’s toys, made of either plastic or wood. The new cage for novel place 
exposure was in the same color and dimensions as the original cage, but had new 
woodchip bedding of a different scent and texture than the prior bedding, and the new 
cage did not have a food box on the ceiling. Such sensory cue changes in the 
environmental 
context, without geometric changes in the cage configuration, are sufficient for 
remapping of hippocampal place cell activities (Anderson and Jeffery, 2003), implying 
that animals should recognize the new cage as a different context. More radical changes 
in the new cage configuration were not made in an effort not to introduce fear or anxiety 
in the mice. 
 
Behavioral tests 
Water maze task 
Water maze testing followed previously published procedures (Zuckerman and Weiner, 
2005). Briefly, mice were introduced to the maze (water made opaque with non-toxic 
latex paint) in a random spot and allowed 60 s to find a platform submerged 1 cm under 
the water. The walls of the room contained visual cues (four 0.5 m diameter pieces of 
different color paper cut into different shapes). Mice were given four trials per session, 
two sessions per day separated by approx 4 h. In between trials mice were allowed to 
recover for approx 5 min in a cage lined with paper towels and warmed with an electric 
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heating pad. If the mice found the platform within 60 s, the time to find the platform was 
recorded and the mouse was removed after 10 s on the platform; if it did not find the 
platform it was placed on the platform for 10 s and the time was recoded as 60 s. On the 
afternoon of the 4th day, the platform was removed and swim pattern was recorded for 60 
s (probe trial). On the day following the probe trial, the platform was placed in the 
opposite quadrant of the pool, and three more sessions were conducted with the platform 
in the novel location. Finally, the water level was dropped and four visible platform trials 
were conducted. 
 
Novel object recognition and object location recognition tasks 
Mice were first allowed to explore the environment (a 50 cmsquare white plastic 
box) for 10 min. They were then removed for 5 min, during which time two different 
objects were placed in opposite corners of the box, and the mice were allowed to explore 
the objects for 5 min. The mice were again removed from the box for 5 min, and for the 
novel object recognition test, one of the objects was replaced with a novel object (the 
target object), and the mice were allowed to explore for another 5 min. On the following 
day, the object location test was administered. The procedure was identical to the 
previous one except that new objects were used, and rather than replacing the target 
object during the second phase of the test, it was moved 90 degrees to a different corner 
of the box (see Fig. 5D). To eliminate experimental bias due to innate preference for an 
object, the five objects used (a plastic pickle, a ‘‘minikoosh” ball, a plastic top, a small 
metal knife, and a small candle) were pseudo-randomized such that different mice saw 
different combinations of objects at each stage of the test; however no innate preferences 
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for an object were observed. 
 
Data analysis 
Electrophysiology 
Data were collected using a custom-written program (LabView data acquisition 
system; National Instruments) for extracellular recordings, or DigiData 1200 and pClamp 
9 (Molecular Devices) for whole-cell recordings. For the analysis of miniature synaptic 
transmission, current traces were acquired for 3 min, and mEPSCs or mIPSCs were 
detected using a template-matching algorithm of Clampfit 9 (Molecular Devices). All 
numerical values listed represent mean ± SEM. Student’s t-test was performed to analyze 
the significance of the data. 
 
Immunohistochemistry 
Slices (400lm thickness) were prepared from randomly selected pairs of animals 
using the same procedures as for electrophysiology recordings. After cutting, slices were 
quickly fixed in 4% paraformaldehyde in phosphate-buffered saline (PBS) for at least 2 
days. Thin (50 lm) sections were cut with a vibrating microtome (Leica VT1000S). 
The sections were incubated overnight with either of 1:250 concentration of anti-c-Fos 
(sc-52) (Santa Cruz), 1:1000 of anti-synaptophysin (Millipore), 1:1000 of anti-synapsin I 
(Millipore), 1:1000 of anti-Bassoon (Stressgen), 1:1000 of NeuN (Millipore), 1:1000 of 
GluR1 (Millipore), or 1:1000 of anti-MAP2 (Sigma) antibodies. The incubation was 
carried out at room temperature in Tris-buffered saline containing 0.2% Triton X-100, 
BSA 2%, NGS 4%, followed by 4 h of secondary-antibody incubation with 1:1000 of 
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Alexa 488-conjugated anti-rabbit and 1:1000 of Alexa 543-conjugated anti-mouse 
antibodies (Invitrogen). For the analysis of immunohistochemistry experiments, images 
were obtained with Zeiss LSM 510 laser scanning confocal microscopes using a Plan-
Neofluor 10#/0.3 air objective. Alexa 488 and 546 were visualized by excitation with the 
488 line of an argon ion laser and the 543 nm line of a HeNe laser, respectively. The 
optical section was 20 lm and fluorescent signals were acquired throughout the section 
thickness. Each 50 lm section was obtained from a different 400 lm slice and two sections 
were analyzed from each animal. Slices were obtained from the same septo-temporal 
position in all experiments. To count the number of c-Fos positive neurons, fluorescent 
signals of less than the mean + two times the standard deviation were excluded. Then 
automated particle analysis was carried out using ImageJ (NIH) based on the following 
criteria: the particle size was larger than 39 lm2 and the circularity was larger than 0.5. 
Statistical differences between animals groups were assessed by ANOVA. 
 
Behavioral analysis 
Water maze task 
All trials were recorded by a camera suspended over the pool, and data was 
analyzed with Ethovision (Noldus). Swim speed, mean distance swam and performance 
in the visible platform task was not significantly different between groups (data not 
shown). 
 
Novel object recognition and object location tasks 
The trials were recorded by an overhead camera, and object investigation was 
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measured as the number of times a mouse brought its nose within 2 cm of the object, by 
an observer blind to the identification of each mouse. Data was expressed as percent nose 
pokes to the target object [nose-pokes to target]/[nose-pokes to target + nose-pokes to 
non-target object] # 100), where the target object is represented by the novel object 
during the novel object recognition task and by the re-located object during the object 
location task. 
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Fig. 1. CA1 pyramidal neurons in MIA offspring display a reduced frequency and 
an increased amplitude of mEPSCs, but no significant difference in mIPSCs. (A) 
Typical recordings and quantification of mEPSCs from CA1 pyramidal neurons are 
shown (saline: n = 11 neurons, poly(I:C): n = 12 neurons, 4 pairs of animals) (scale bar = 
500 ms, 10 pA) (*p < 0.05 relative to control). (B) Averaged mEPSC waveforms from 
animals used for the analysis in A are shown on the left. The mEPSC waveform in MIA 
offspring shows larger amplitude compared to that in control animals. To examine the 
kinetics of the waveforms, the amplitudes of mEPSC waveforms are normalized on the 
context, without geometric changes in the cage configuration, are
sufficient for remapping of hippocampal place cell activities
(Anderson and Jeffery, 2003), implying that animals should recog-
nize the new cage as a different context. More radical changes in
the new cage configuration were not made in an effort not to intro-
duce fear or anxiety in the mice.
2.5. Behavioral tests
2.5.1. Water maze task
Water maze testing followed previously published procedures
(Zuckerman and Weiner, 2005). Briefly, mice were introduced to
the maze (water made opaque with non-toxic latex paint) in a
Fig. 1. CA1 pyramidal neurons in MIA offspring display a reduced frequency and an increased amplitude of mEPSCs, but no significant difference in mIPSCs. (A) Typical
recordings and quantification of mEPSCs from CA1 pyramidal neurons are shown (saline: n = 11 neurons, poly(I:C): n = 12 neurons, 4 pairs of animals) (scale bar = 500 ms, 10
pA) (*p < 0.05 relative to control). (B) Averaged mEPSC waveforms from animals used for the analysis in A are shown on the left. The mEPSC waveform in MIA offspring shows
larger amplitude compared to that in control animals. To examine the kinetics of the waveforms, the amplitudes of mEPSC waveforms are normalized on the right. There is no
significant difference in kinetics of mEPSCs between the groups. (C)Whole-cell voltage-clamp recordings were performed in CA1 pyramidal neurons under inhibitory blockade
with the GABA receptor antagonists bicuculline (10 lM) and CGP55845 (1 lM). Membrane potential was clamped at !60 mV. Paired-pulse facilitation (PPF) was analyzed at
Schaffer-collateral-CA1 synapses. The top panel shows representative waveforms (interstimulus interval is 50 ms; scale bar = 50 ms), and the bottom panel shows the PPF ratio
(2nd/1st EPSC amplitude) of individual recordings (gray triangles), and the mean values (black diamonds) (n = 5 neurons for each group, 3 pairs of animals). (D) Extracellular
field recordings were performed at Schaffer-collateral-CA1 synapses under fast inhibitory transmission block with the GABAA receptor antagonist bicuculline. The left panel
shows the normalized fEPSP slope from control animals (black diamonds) and MIA offspring (gray triangles) and LTP was induced at 20 min by a single train of 100 stimuli at
100 Hz. The right panel shows representative waveforms before (black) and after (gray) LTP induction (scale bar = 0.2 mV, 5 ms). No significant difference is observed in LTP
magnitude between animal groups (n = 8 slices for each group, 3 pairs of animals). (E) Typical recordings and quantification of mIPSCs from CA1 pyramidal neurons are shown
(n = 12 neurons for each group, 3 pairs of animals). A cesium chloride-based solution was used as the internal solution of patch pipettes and recordings were made at 28 !C in
the presence of TTX (1 lM), NBQX (20 lM) and APV (50 lM) to bl ck excitatory sy aptic transmission. The extracellul r potassium concentr tion was increased from 2.5 to
5 mM to enhance the frequency of miniature synaptic events. No significant difference is observed in mIPSC amplitude or frequency between the groups.
932 H.T. Ito et al. / Brain, Behavior, and Immunity 24 (2010) 930–941
 392 
right. There is no significant difference in kinetics of mEPSCs between the groups. (C) 
Whole-cell voltage-clamp recordings were performed in CA1 pyramidal neurons under 
inhibitory blockade with the GABA receptor antagonists bicuculline (10 lM) and 
CGP55845 (1 lM). Membrane potential was clamped at "60 mV. Paired-pulse facilitation 
(PPF) was analyzed at Schaffer-collateral-CA1 synapses. The top panel shows 
representative waveforms (interstimulus interval is 50 ms; scale bar = 50 ms), and the 
bottom panel shows the PPF ratio (2nd/1st EPSC amplitude) of individual recordings 
(gray triangles), and the mean values (black diamonds) (n = 5 neurons for each group, 3 
pairs of animals). (D) Extracellular field recordings were performed at Schaffer-
collateral-CA1 synapses under fast inhibitory transmission block with the GABAA 
receptor antagonist bicuculline. The left panel shows the normalized fEPSP slope from 
control animals (black diamonds) and MIA offspring (gray triangles) and LTP was 
induced at 20 min by a single train of 100 stimuli at 100 Hz. The right panel shows 
representative waveforms before (black) and after (gray) LTP induction (scale bar = 0.2 
mV, 5 ms). No significant difference is observed in LTP magnitude between animal 
groups (n = 8 slices for each group, 3 pairs of animals). (E) Typical recordings and 
quantification of mIPSCs from CA1 pyramidal neurons are shown (n = 12 neurons for 
each group, 3 pairs of animals). A cesium chloride-based solution was used as the 
internal solution of patch pipettes and recordings were made at 28 °C in the presence of 
TTX (1 lM), NBQX (20 lM) and APV (50 lM) to block excitatory synaptic transmission. 
The extracellular potassium concentration was increased from 2.5 to 5 mM to enhance 
the frequency of miniature synaptic events. No significant difference is observed in 
mIPSC amplitude or frequency between the groups. 
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Fig. 2. The offspring of poly(I:C)-treated mothers display increased DA-induced 
depression at distal temporoammonic-CA1 synapses. (A) A schematic diagram is 
shown depicting the two distinct axonal projections in the TA pathway from MEC and 
LEC. (B) Extracellular field recordings are obtained simultaneously from proximal and 
distal TA-CA1 synapses. For each recording from proximal or distal TA-CA1 synapses, 
the left panels show the normalized fEPSP slopes from control (black diamonds) and 
MIA offspring (gray triangles), and the right panels show representative traces of fEPSP 
random spot and allowed 60 s to find a platform submerged 1 cm
under the water. The walls of the room contained visual cues (four
0.5 m diameter pieces of different color paper cut into different
shapes). Mice were given four trials per s ssi n, two s ssions per
day separated by approx 4 h. In between trials mice were allowed
to recover for approx 5 min in a cage lined with paper towels and
warmed with an electric heating pad. If the mice found the plat-
form within 60 s, the time to find the platform was recorded and
the mouse was removed after 10 s on the platform; if it did not find
the platform it was placed on the platform for 10 s and the time
was recoded as 60 s. On the afternoon of the 4th day, the platform
was removed and swim pattern was recorded for 60 s (probe trial).
On the day following the probe trial, the platformwas placed in the
opposite quadrant of the pool, and three more sessions were
conducted with the platform in the novel location. Finally, the
water level was dropped and four visible platform trials were
conducted.
2.5.2. Novel object ecognition and object locatio recognition tasks
Mice were first allowed to explore the environment (a 50 cm-
square white plastic box) for 10 min. They were then removed
for 5 min, during which time two different objects were placed in
opposite corners of the box, and the mice were allowed to explore
the objects for 5 min. The mice were again removed from the box
for 5 min, and for the novel object recognition test, one of the ob-
jects was replaced with a novel object (the target object), and the
mice were allowed to explore for another 5 min. On the following
day, the object location test was administered. The procedure was
identical to the previous one except that new objects were used,
and rather than replacing the target object during the second phase
Fig. 2. The offspring of poly(I:C)-treated mothers display increased DA-induced depression at distal temporoammonic-CA1 synapses. (A) A schematic diagram is shown
depicting the two distinct axonal projections in the TA pathway from MEC and LEC. (B) Extracellular field recordings are obtained simultaneously from proximal and distal
TA-CA1 synapses. For each recording from proximal or distal TA-CA1 synapses, the left panels show the normalized fEPSP slopes from control (black diamonds) and MIA
offspring (gray triangles), and the right panels show representative traces of fEPSP waveforms before (black) and after (gray) DA application (scale bar = 0.05 mV, 5 ms). The
test pulse was applied every 30 s and DA (20 lM) was bath applied during the time indicated by the thick line (*p < 0.05 relative to control) (saline: n = 7 slices, poly(I:C): n = 6
slices, 4 pairs of animals). (C) In hippocampal slices prepared fro control animals, DA induces a significantly larger depression at proxim l compared to distal TA-CA1
synapses. While the slices prepared from MIA offspring show a normal DA-induced depression at proximal synapses, they exhibit a significantly larger depression at distal
TA-CA1 synapses, compared to controls (*p < 0.05). (D) Hippocampal slices prepared from MIA offspring show increased DA-induced depression at distal TA-CA1 synapses.
The DA concentration as increased every 10 min, from 1 to 20 lM (*p < 0.05 relative to ontrol). (E) Analysis of the data in D is shown. The mean fEPSP slopes at 5–10 min
after the application of each designated concentration of DA were analyzed. Slices prepared from MIA offspring show a significantly larger depression at each DA
concentration examined (n = 12 slices for each group, 8 pairs of animals) (*p < 0.05 relative to control).
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waveforms before (black) and after (gray) DA application (scale bar = 0.05 mV, 5 ms). 
The test pulse was applied every 30 s and DA (20 lM) was bath applied during the time 
indicated by the thick line (*p < 0.05 relative to control) (saline: n = 7 slices, poly(I:C): n 
= 6 slices, 4 pairs of animals). (C) In hippocampal slices prepared from control animals, 
DA induces a significantly larger depression at proximal compared to distal TA-CA1 
synapses. While the slices prepared from MIA offspring show a normal DA-induced 
depression at proximal synapses, they exhibit a significantly larger depression at distal 
TA-CA1 synapses, compared to controls (*p < 0.05). (D) Hippocampal slices prepared 
from MIA offspring show increased DA-induced depression at distal TA-CA1 synapses. 
The DA concentration was increased every 10 min, from 1 to 20 lM (*p < 0.05 relative to 
control). (E) Analysis of the data in D is shown. The mean fEPSP slopes at 5–10 min 
after the application of each designated concentration of DA were analyzed. Slices 
prepared from MIA offspring show a significantly larger depression at each DA 
concentration examined (n = 12 slices for each group, 8 pairs of animals) (*p < 0.05 
relative to control). 
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Fig. 3. The offspring of poly(I:C)-treated mothers display abnormal c-Fos 
expression in area CA1 pyramidal neurons following novel object exposure. (A) A 
schematic diagram of the behavioral procedure is shown. After mice were accommodated 
to their new home cages for a few days, two novel objects were placed in the cage. After 
a 2 h exposure to allow c-Fos gene activation to be expressed as protein, the hippocampus 
was processed for immunohistochemistry. (B) Examples of c-Fos expression in the 
of the test, it was moved 90 degrees to a different corner of the box
(see Fig. 5D). To eliminate experimental bias due to innate prefer-
ence for an object, the five objects used (a plastic pickle, a ‘‘mini-
koosh” ball, a plastic top, a small metal knife, and a small candle)
were pseudo-randomized such that different mice saw different
combinations of objects at each stage of the test; however no in-
nate preferences for an object were observed.
2.6. Data analysis
2.6.1. Electrophysiology
Data were collected using a custom-written program (LabView
data acquisition system; National Instruments) for extracellular
recordings, or DigiData 1200 and pClamp 9 (Molecular Devices)
for whole-cell recordings. For the analysis of miniature synaptic
transmission, current traces were acquired for 3 min, and mEPSCs
or mIPSCs were detected using a template-matching algorithm of
Clampfit 9 (Molecular Devices). All numerical values listed repre-
sent mean ± SEM. Student’s t-test was performed to analyze the
significance of the data.
2.6.2. Immunohistochemistry
Slices (400 lm thickness) were prepared from randomly
selected pairs of animals using the same procedures as for
electrophysiology recordings. After cutting, slices were quickly
fixed in 4% paraformaldehyde in phosphate-buffered saline (PBS)
for at least 2 days. Thin (50 lm) sections were cut with a vibrating
microtome (Leica VT1000S).
Fig. 3. The offspring of poly(I:C)-treated mothers display abnormal c-Fos expression in area CA1 pyramidal neurons following novel object exposure. (A) A schematic diagram
of the behavioral procedure is shown. After mice were accommodated to their new home cages for a few days, two novel objects were placed in the cage. After a 2 h exposure
to allow c-Fos gene activation to be expressed as protein, the hippocampus was processed for immunohistochemistry. (B) Examples of c-Fos expression in the pyramidal layer
of area CA1 are shown. The pyramidal layer was divided into equal proximal and distal regions. The c-Fos signals that are larger than the mean + two times the standard
deviation, were quantified using ImageJ (see Section 2 for details) (scale bar = 100 lm). (C) The number of c-Fos signals was quantified in proximal and distal regions of the
CA1 pyramidal layer. A two-way ANOVA was performed with 2 variables: animal group (saline vs. poly(I:C)) and CA1 subregion (distal vs. proximal), and revealed a
significant interaction (*p < 0.05) (n = 6 pairs of animals, 2 sections analyzed and averaged from each).
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pyramidal layer of area CA1 are shown. The pyramidal layer was divided into equal 
proximal and distal regions. The c-Fos signals that are larger than the mean + two times 
the standard deviation, were quantified using ImageJ (see Section 2 for details) (scale bar 
= 100 lm). (C) The number of c-Fos signals was quantified in proximal and distal regions 
of the CA1 pyramidal layer. A two-way ANOVA was performed with 2 variables: animal 
group (saline vs. poly(I:C)) and CA1 subregion (distal vs. proximal), and revealed a 
significant interaction (*p < 0.05) (n = 6 pairs of animals, 2 sections analyzed and 
averaged from each). 
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Fig. 4. The offspring of poly(I:C)-treated mothers display comparable c-Fos 
expression in area CA1 pyramidal neurons following novel place exposure. (A) A 
schematic diagram of the behavioral procedure is shown. After mice were accommodated 
to the new home cage for a few days, they were moved to a novel cage. After a 2 h 
The sections were incubated overnight with either of 1:250 con-
centration of anti-c-Fos (sc-52) (Santa Cruz), 1:1000 of anti-synap-
tophysin (Millipore), 1:1000 of anti-synapsin I (Millipore), 1:1000
of anti-Bassoon (Stressgen), 1:1000 of NeuN (Millipore), 1:1000
of GluR1 (Millipore), or 1:1000 of anti-MAP2 (Sigma) antibodies.
The incubation was carried out at room temperature in Tris-buf-
fered saline containing 0.2% Triton X-100, BSA 2%, NGS 4%, fol-
lowed by 4 h of secondary-antibody incubation with 1:1000 of
Alexa 488-conjugated anti-rabbit and 1:1000 of Alexa 543-conju-
gated anti-mouse antibodies (Invitrogen).
For the analysis of immunohistochemistry experiments, images
were obtained with Zeiss LSM 510 laser scanning confocal micro-
scopes using a Plan-Neofluor 10!/0.3 air objective. Alexa 488
and 546 were visualized by excitation with the 488 line of an argon
ion laser and the 543 nm line of a HeNe laser, respectively. The
optical section was 20 lm and fluorescent signals were acquired
throughout the section thickness. Each 50 lm section was ob-
tained from a different 400 lm slice and two sections were ana-
lyzed from each animal. Slices were obtained from the same
septo-temporal position in all experiments. To count the number
of c-Fos positive neurons, fluorescent signals of less than the
mean + two times the standard deviation were excluded. Then
automated particle analysis was carried out using ImageJ (NIH)
based on the following criteria: the particle size was larger than
Fig. 4. The offspring of poly(I:C)-treated mothers display comparable c-Fos expression in area CA1 pyramidal neurons following novel place exposure. (A) A schematic
diagram of the behavioral procedure is shown. After mice were accommodated to the new home cage for a few days, they were moved to a novel cage. After a 2 h exposure,
immunohistochemistry on the hippocampus was carried out. (B) Examples of c-Fos expression in the pyramidal layer of area CA1 are shown. The pyramidal layer was divided
into equal proximal and distal regions. The c-Fos signals that are larger than the mean + two times the standard deviation, were quantified using ImageJ (see Section 2 for
details) (scale bar = 100 lm). (C) The number of c-Fos signals was quantified in proximal and distal regions of CA1 pyramidal layer (n = 5 pairs of animals, 2 sections analyzed
from each).
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exposure, immunohistochemistry on the hippocampus was carried out. (B) Examples of 
c-Fos expression in the pyramidal layer of area CA1 are shown. The pyramidal layer was 
divided into equal proximal and distal regions. The c-Fos signals that are larger than the 
mean + two times the standard deviation, were quantified using ImageJ (see Section 2 for 
details) (scale bar = 100 lm). (C) The number of c-Fos signals was quantified in proximal 
and distal regions of CA1 pyramidal layer (n = 5 pairs of animals, 2 sections analyzed 
from each). 
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Fig. 5. The offspring of poly(I:C)-treated mothers display behavioral inflexibility in 
platform relocation in the Morris water maze task, and abnormal preference in the 
novel object recognition task. (A) In the Morris water maze, the latency to find the 
platform is similar in the MIA offspring compared to controls (saline: n = 16, poly(I:C): n 
= 17). (B) Both control and MIA offspring show a significant learned preference for the 
target quadrant in the session 7 probe trial, which was not present before training (*p < 
0.05 vs. all other quadrants). (C) When the location of the platform was moved after 
39 lm2 and the circularity was larger than 0.5. Statistical differ-
ences between animals groups were assessed by ANOVA.
2.7. Behavioral analysis
2.7.1. Water maze task
All trials were recorded by a came su pended over the pool,
and data was analyzed with Ethovision (Noldus). Swim speed,
mean distance swam and performance in the visible platform task
was not significantly different between groups (data not shown).
2.7.2. Novel object recognition and object location tasks
The trials were recorded by an overhead camera, and object
investigation was measured as the number of times a mouse
brought its nose within 2 cm of the object, by an observer blind
to the identification of each mouse. Data was expressed as percent
nose pokes to the target object [nose-pokes to target]/[nose-pokes
to target + nose-pokes to non-target object] ! 100), where the
target object is represented by the novel object during the novel
object recognition task and by the re-located object during the
object location task.
Fig. 5. The offspring of poly(I:C)-treated mothers dis lay behavioral inflexibility in platform relocation in the Morris water maze task, and abnormal preference in the novel
object recognition task. (A) In the Morris water maze, the latency to find the platform is similar in the MIA offspring compared to controls (saline: n = 16, poly(I:C): n = 17). (B)
Both control and MIA offspring show a significant learned preference for the target quadrant in the session 7 probe trial, which was not present before training (*p < 0.05 vs.
all other quadrants). (C) When the location of the platform was moved after training (indicated by arrow), the MIA offspring do not learn the new location as quickly as
controls (*p < 0.05). The experimental groups diverge significantly after the platform is moved, at the point indicated by the arrow. (D) A graphical representation of the object
location and novel object recognition tests illustrates how the location of the target object, or the type of target object itself, is changed in the 5 min interval between trial 1
and 2. Asterisks indicate the target objects. (E) In the novel location test, both control and MIA offspring show a significant preference for the target object in trial 2, compared
to trial 1 (p < 0.05), but there is no difference between control and MIA offspring. (F) In the novel object recognition test, both groups also display a significant preference for
the target object in trial 2 compared to trial 1 (p < 0.05). Moreover, compared to control animals, the MIA offspring show a significantly greater preference for the target object
in trial 2 (n = 16 animals per group) (*p < 0.05).
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training (indicated by arrow), the MIA offspring do not learn the new location as quickly 
as controls (*p < 0.05). The experimental groups diverge significantly after the platform 
is moved, at the point indicated by the arrow. (D) A graphical representation of the object 
location and novel object recognition tests illustrates how the location of the target object, 
or the type of target object itself, is changed in the 5 min interval between trial 1 and 2. 
Asterisks indicate the target objects. (E) In the novel location test, both control and MIA 
offspring show a significant preference for the target object in trial 2, compared to trial 1 
(p < 0.05), but there is no difference between control and MIA offspring. (F) In the novel 
object recognition test, both groups also display a significant preference for the target 
object in trial 2 compared to trial 1 (p < 0.05). Moreover, compared to control animals, 
the MIA offspring show a significantly greater preference for the target object in trial 2 (n 
= 16 animals per group) (*p < 0.05). 
 
Appendix A. Supplementary data 
Supplementary data associated with this article can be found, in the online version, at 
doi:10.1016/j.bbi.2010.03.004. 
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Abstract 
 
Several of the environmental stimuli suggested to play a role in the pathogenesis of ASD 
involve altered immune responses during gestation. In this review, we discuss maternal 
immune activation as a primary risk factor for ASD, with an emphasis on recent findings 
from animal models of prenatal immune challenges. We further address the presence of 
autoantibodies as an additional immune-related autism risk factor, drawing upon work 
done in rodent and monkey models. We then explore the intersection between genetic and 
environmental susceptibility, with a focus on gene-environment interactions and immune 
involvement in genetic risk factors for autism. Finally, we provide emerging evidence for 
the role of immune dysregulation in the pathogenesis of ASD. 
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Introduction 
Autism spectrum disorder (ASD) consists of a heterogeneous group of syndromes 
defined by the presence and severity of repetitive/stereotypic behaviors, abnormal social 
interaction and impaired communication. ASD is highly heritable, as indicated by 
increased concordance in monozygotic versus dizygotic twins and by elevated risk 
observed in the siblings of an affected child (Rosenberg et al., 2009). Accordingly, 
genome-wide association and linkage studies have uncovered a number of genetic copy 
number variants, short nucleotide polymorphisms and common risk variants that increase 
the susceptibility for ASD (Betancur, 2011). Despite continued advances in next 
generation sequencing, very few ASD cases can be attributed to a defined genetic 
etiology, and it is estimated that identified genetic risk factors collectively account for 
only 10-20% of ASD cases (Abrahams & Geschwind, 2008; Anney et al., 2012). 
Moreover, findings from two very large autism twin studies demonstrate a significant 
difference in concordance between dizygotic twins and non-twin siblings, indicating a 
substantial contribution of the maternal-fetal environment to ASD risk (Hallmayer et al., 
2011; Rosenberg et al., 2009). This, combined with profound increases in autism 
prevalence over the past two decades ("Prevalence of autism spectrum disorders--Autism 
and Developmental Disabilities Monitoring Network, 14 sites, United States, 2008," 
2012), highlights the importance of environmental factors in the etiology of ASD.  
 
Immune-related risk factors for ASD 
Maternal immune activation 
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Several environmental factors increase susceptibility to ASD, with early immune 
activation being one of the most strongly supported by epidemiological, clinical and 
animal studies (Brown, 2012). Large epidemiological studies assessing over 10,000 ASD 
cases from Danish national birth records and over 4,000 ASD cases identified from 
Swedish residence registries demonstrate that maternal infection during pregnancy 
increases the risk for ASD (Atladottir et al., 2010; Lee et al., 2012). In addition, early 
infection with any of a variety of pathogens, including rubella, cytomegalovirus or 
varicella, is linked to elevated autism risk (Brown, 2012). The impact of maternal 
immune activation (MIA) on ASD is further supported by associations between maternal 
fever during pregnancy and ASD (Zerbo et al., 2012). Moreover, elevation of the 
cytokines IFN-γ, IL-4 or IL-5 in maternal blood and TNFa and MCP-1 in amniotic fluid 
is linked to risk for ASD (Abdallah et al., 2011a, 2011b, 2012; Goines et al., 2011).  
In animals, MIA is induced by perinatal infection with specific pathogens, 
exposure to microbe-associated molecular patterns (MAMPs) or direct administration of 
recombinant cytokines. MIA by any of these inflammatory stimuli leads to autismand 
schizophrenia-related behavioral abnormalities in the offspring (reviewed in (Harvey & 
Boksa, 2012a; Macedo et al., 2012; Meyer, Feldon, & Fatemi, 2009; Oskvig, Elkahloun, 
Johnson, Phillips, & Herkenham, 2012)). Intranasal inoculation of pregnant mice with 
influenza virus, for example, yields offspring with heightened anxiety, deficient 
sensorimotor gating and reduced social interaction, and a localized reduction in Purkinje 
cell number (Shi et al., 2009), all features of autism. Moreover, offspring of mothers 
injected with the viral mimic poly(I:C) during midgestation exhibit the three cardinal 
behavioral symptoms of autism: impaired sociability and social preference, defective 
 417 
communication as assessed by pup and adult ultrasonic vocalizations and odorant 
communication by scent marking, and elevated repetitive behaviors as measured by self-
grooming and stereotyped marble burying (Malkova, Yu, Hsiao, Moore, & Patterson, 
2012; Yee, Schwarting, Fuchs, & Wohr, 2012). Similar changes in core ASD-related 
behaviors are observed after first trimester injection of LPS in pregnant rats (Baharnoori, 
Bhardwaj, & Srivastava, 2012). Midgestational injection of recombinant IL-6 in pregnant 
mice is sufficient to induce behavioral deficits in the offspring that are comparable to 
those induced by maternal influenza or poly(I:C) injection (Hsiao & Patterson, 2011; 
Smith, Li, Garbett, Mirnics, & Patterson, 2007). Similarly, maternal IL-2 injection leads 
to anxiety-like and repetitive behaviors in mouse offspring (Ponzio, Servatius, Beck, 
Marzouk, & Kreider, 2007). In contrast, over-expression of the anti-inflammatory 
cytokine IL-10 in pregnant mice sufficiently prevents MIA-induced behavioral and 
biochemical abnormalities in the offspring (Meyer et al., 2008). In addition, several 
studies utilizing early postnatal immune activation in rodents, to better mimic second 
trimester human brain development, also report long-term changes in neuropathology and 
behavior (Bland et al., 2010; Harvey & Boksa, 2012b).  
The impact of MIA on brain and behavior is further supported by non-human 
primate studies. Pregnant rhesus monkeys infected with influenza virus during the third 
trimester yield offspring with significant decreases in cortical gray matter and reduced 
white matter in the parietal lobe, in addition to decreased social contact with the mother 
(Short et al., 2010). Notably, these abnormalities occur in the absence of primary viral 
infection of the fetal compartment. Low-dose maternal LPS injection in monkeys, 
however, leads to the opposite neural phenotype in which infant offspring display 
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increased cortical white matter compared to controls, analogous to changes observed in 
autistic children, and decreased vocalizations during an intruder paradigm, among several 
other behavioral abnormalities (Willette et al., 2011). First or second trimester maternal 
poly(I:C) injection of rhesus macaques also leads to autism-related endophenotypes in the 
offspring, including motor stereotypies, elevated distress and self-soothing behaviors, and 
a deficit in verbalizations (Bauman et al., 2011). Overall, that MIA can be translated to 
non-human primate models to induce ASD-related neuropathology and behavioral 
symptoms further supports the study of MIA in animals as models with face and 
construct validity for autism. 
The symptomatic overlap between different modes of MIA indicates that the 
production of pro-inflammatory cytokines in response to immune activation is likely a 
key pathophysiological step in the development of autism-related impairments. It is well 
established that MIA induces a maternal pro-inflammatory response that is quickly 
relayed to the maternal-fetal interface. Several pro-inflammatory cytokines, including IL-
6, IL-1b and TNFa, are elevated in the placenta and amniotic fluid by one-hour post MIA 
challenge (Hsiao, McBride, Chow, Mazmanian, & Patterson, 2012; Mandal, Marzouk, 
Donnelly, & Ponzio, 2011; Meyer et al., 2006). Maternal LPS injection can lead to 
dramatic changes in placental physiology, including necrosis, infiltration of immune cells 
and altered perfusion (Carpentier, Dingman, & Palmer, 2011; Girard, Tremblay, Lepage, 
& Sebire, 2010). Similar changes are observed in placentas from influenza-infected 
mothers, in addition to widespread effects on the placental transcriptome (Fatemi et al., 
2012). Furthermore, placentas from poly(I:C)-injected mothers exhibit increased 
activation of decidual immune cells and altered endocrine function (Hsiao & Patterson, 
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2011). Interestingly, placental trophoblast cells are activated in response to MIA, 
reflecting a direct transfer of the maternal MIA response to fetally-derived placental cells. 
It is very likely, however, that the extent of placental damage seen in these various 
models depends on the dose of the agent administered. Altogether, the downstream 
effects in the placenta raise the intriguing question of how changes at the maternal-fetal 
interface impact fetal brain development. Notably, subclassification of ASD cases by 
behavioral symptoms, patient and family history and biological endophenotypes reveals 
that immune dysregulation in autism and obstetric complications in the mother cluster 
together as central characteristics of a subgroup of ASD individuals (Sacco et al., 2012). 
Moreover, trophoblast inclusion histopathology is found in placentas from births that 
yield an ASD outcome (Anderson, Jacobs-Stannard, Chawarska, Volkmar, & Kliman, 
2007). Given that MIA can induce striking placental pathology, it seems likely that the 
maternal infection risk factor contributes to pre-term birth, low birth weight and obstetric 
complications, which are associated with increased risk for ASD (Kuban et al., 2009; 
Lyall, Pauls, Spiegelman, Ascherio, & Santangelo, 2012; Movsas & Paneth, 2012; Pinto-
Martin et al., 2011).  
In addition to altering placental status, MIA quickly leads to altered gene 
expression and cytokine profiles in the fetal brain. Shortly after MIA, the fetal brain 
exhibits elevated levels of pro-inflammatory cytokines (Arrode-Bruses & Bruses, 2012), 
suggesting a possible feed-forward propagation of pro-inflammatory MIA responses from 
the maternal circulation to the placenta, and to the fetus itself. The initial induction of 
fetal brain cytokines typically diminishes after 24 hours post MIA, but may trigger 
molecular events that lead to lasting neuroimmune changes. Consistent with this notion, 
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poly(I:C) offspring exhibit dynamic ageand region-specific changes in brain cytokines 
throughout postnatal development (Garay, Hsiao, Patterson, & McAllister, 2012; 
Pacheco-Lopez, Giovanoli, Langhans, & Meyer, 2011). In response to maternal LPS, 
fetal brains exhibit altered gene expression profiles, with upregulation of genes related to 
oxidative stress and downregulation of genes related to GABAergic interneuron 
migration (Oskvig et al., 2012). After maternal influenza infection, embryos exhibit 
altered brain expression of many genes relevant to autism and schizophrenia, including 
Sema3a, Foxp2 and Vldlr (Fatemi et al., 2008). Furthermore, MIA induction by 
influenza, poly(I:C) or recombinant IL-6 injection results in distinct as well as shared 
changes in gene expression in the embryonic brain. Of particular note is the upregulation 
of genes of the crystallin small heat shock protein family (Garbett, Hsiao, Kalman, 
Patterson, & Mirnics, 2012). Interestingly, the severity of these gene expression changes 
correlates with reductions in placental weight, suggesting that placental status can serve 
as a marker of disrupted neurodevelopment. This is consistent with findings that placental 
size correlates with the risk for several adult-onset diseases (Barker, Gelow, et al., 2010; 
Barker, Thornburg, Osmond, Kajantie, & Eriksson, 2010a, 2010b; Eriksson et al., 2012). 
Acute transcriptional changes and cytokine effects in the fetal brain may serve as an 
underlying basis for several of the neurodevelopmental impairments observed in MIA 
offspring (reviewed in (Harvey & Boksa, 2012a; Macedo et al., 2012; Meyer et al., 2009; 
Oskvig et al., 2012)), including altered cortical neurogenesis (Smith, Elliott, & Anderson, 
2012; Soumiya, Fukumitsu, & Furukawa, 2011), hippocampal synaptic transmission 
(Escobar et al., 2011; Ito, Smith, Hsiao, & Patterson, 2010) and serotonergic and 
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dopaminergic signaling (Vuillermot, Weber, Feldon, & Meyer, 2010; Wang, Yan, Lo, 
Carvey, & Ling, 2009; Winter et al., 2009).  
Research conducted in MIA animal models collectively demonstrates that 
transient immune activation is sufficient to cause long-term changes in neurodevelopment 
and behavior. However, the particular phenotypes induced by MIA differ depending on 
the type, timing, frequency and route of administration, as well as the genetic and 
immunological background of the host (Bronson, Ahlbrand, Horn, Kern, & Richtand, 
2011; Harvey & Boksa, 2012b; Meyer et al., 2006; Rana, Aavani, & Pittman, 2012). 
Such variations across MIA studies impedes cross-comparison between findings (Harvey 
& Boksa, 2012a). At the same time, the information garnered from diverse MIA studies 
raises the intriguing question of whether differences in the severity, timing and type of 
MIA can produce distinct forms of neurodevelopmental disorders. The distinction 
between ASD and schizophrenia is particularly interesting in this regard, as the 
association between maternal infection and increased schizophrenia risk in the offspring 
is supported by numerous epidemiological and clinical studies (Brown, 2011, 2012). 
Moreover, schizophrenia and autism have several, shared clinical features, including 
social withdrawal, impaired communication and deficient sensorimotor gating, as well as 
shared genetic susceptibility factors (Talkowski et al., 2012). Offspring of immune 
activated dams exhibit features of both schizophrenia and autism, including decreased 
pre-pulse inhibition and social interactions and elevated anxiety leading to the use of 
MIA in animals to model both disorders (Harvey & Boksa, 2012a; Macedo et al., 2012). 
It will be interesting to assess how particular autismversus schizophrenia-related 
symptoms are modulated by changes in timing, intensity and type of MIA (Meyer, 
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Feldon, & Dammann, 2011). It will also be important to test for endophenotypes that are 
not shared between these disorders such as repetitive/stereotyped behaviors (Malkova et 
al., 2012), which are characteristic of autism, and enlarged ventricles (Q. Li et al., 2009) 
and enhanced sensitivity to hallucinogenic drugs (Moreno et al., 2011), which are 
characteristic of schizophrenia. 
The role of maternal immune activation has been explored in several recent gene 
x environment studies, supporting the interaction of both environmental influence and 
genetic susceptibility in the pathogenesis of neurodevelopmental disorders, such as 
autism and schizophrenia. In transgenic mice expressing mutant human DISC1, 
poly(I:C)-induced MIA interacts with genetic risk to alter social behavior and produce 
depression and enhance anxiety-like symptoms, along with several neurochemical and 
neuropathological changes such as decreased number of hippocamal granule cell 
dendrites and reduced serotonergic neurotransmission (Abazyan et al., 2010). MIA also 
synergizes with genetic Nurr1 deficiency to exacerbate sensorimotor and attentional 
behavior, and to alter expression of dopaminergic markers in the prefrontal cortex and 
ventral striatum (Vuillermot et al., 2012). In a mouse model of tuberous sclerosis, 
maternal poly(I:C) injection and Tsc2 haploinsufficiency together lead to increased 
gestational miscarriage and abnormal social approach behavior (Ehninger et al., 2012). 
Together, these studies support the importance of environmental risk factors in 
predisposing for neurodevelopmental disease in individuals displaying genetic 
susceptibility.  
 
Autoantibodies in ASD mothers or individuals 
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Another immune-mediated risk factor for ASD involves serum immunoglobulins 
that react against self-antigens. Such “autoantibodies” have been identified in plasma 
from mothers of ASD children and from ASD individuals themselves, and some have 
been shown to react against neural components, including myelin basic protein and 
GAD65 in cerebellar Purkinje cells (Braunschweig & Van de Water, 2012; Mostafa & 
Al-Ayadhi, 2011; Rout, Mungan, & Dhossche, 2012). Although the majority of these 
autoantibodies are also detected at some frequency in non-ASD, typical controls, 
particular maternal autoantibodies that react against fetal brain proteins at approximately 
37 kDa and 73 kDa display high specificity to autism cases, with striking reproducibility 
across large experimental cohorts (Braunschweig & Van de Water, 2012). Importantly, 
autoantibodies with the same reactivity have also been identified in plasma collected 
during the gestational period from ASD mothers, in contrast to typical studies that isolate 
the autoantibodies from samples collected up to 18 years post-partum (Croen et al., 
2008). Moreover, the autoantibodies are reported to correlate with impaired expressive 
language in ASD children (Braunschweig et al., 2012). Identifying the specific target 
antigens to which these autoantibodies react will be critical in uncovering a mechanistic 
link between maternal autoantibodies and ASD. Furthermore, whether maternal 
autoantibodies can be detected in corresponding ASD children is still unclear.  
Studies that translate this autoantibody risk factor to animal models for ASD are 
intriguing, but few. An early case study identified anti-Purkinje cell antibodies in a 
mother of an ASD child (Dalton et al., 2003). Daily injection of this serum into pregnant 
mice from E10 to E17 yields offspring with decreased exploration and impaired motor 
coordination. In another study, injection of purified IgG pooled from over 60 ASD 
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mothers into pregnant mice resulted in heightened anxiety, hyperactivity and an age-
specific deficit in sociability (Singer et al., 2009). Lastly, an additional study in rhesus 
macaques revealed that first-trimester injection of pregnant monkeys with IgG pooled 
from 21 ASD mothers yields offspring that display whole body stereotypies, 
hyperactivity and increased nonsocial behavior (Martin et al., 2008).  
Much remains to be explored in animal models of the autoantibody risk factor for 
ASD, including the question of whether maternal autoantibodies can cross the placenta 
and enter the fetal brain at significant levels. And importantly, what are the antigenic 
targets of particular autoantibody subclasses, and are these antigens specific to the fetal 
brain? Interestingly, a study examining reactivity of different ASD-associated maternal 
autoantibodies to various tissues reveals that some react against proteins from adult brain 
and fetal small intestine. In such cases, it will be important to assess effects of ASD-
related IgG on maternal behavior and physiology and to determine whether reactivity of 
autoantibodies against non-CNS antigens represents an indirect effect of autoantibodies 
on brain and behavior. Notably, the impact of autoantibodies derived from ASD 
individuals, rather than their mothers, has not yet been evaluated in animal models. In 
addition, the cause of ASD-related autoantibody production has been largely unexplored. 
It will be fascinating to evaluate whether autoantibody production occurs as a result of 
other ASD-related genetic and environmental risk factors. Two models of particular 
interest are MIA, which displays evidence of disrupted immunological tolerance at the 
maternal-fetal interface (Carpentier et al., 2011; Girard et al., 2010), and MET-deficient 
mice, in light of findings linking the MET common risk variant to ASD-related 
autoantibodies in clinical cohorts (Heuer, Braunschweig, Ashwood, Van de Water, & 
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Campbell, 2011). Finally, autoantibody animal models will serve as a useful tool to 
explore potential therapeutics for treatment of autism in well-defined subsets of ASD 
individuals. 
 
Immune dysregulation in ASD 
 
MIA and maternal autoantibody production represent two immune-mediated risk 
factors whose influences during early life may contribute to ASD onset. In addition to 
these prenatal immune insults, increasing evidence highlights a role for postnatal immune 
alterations in the pathogenesis of ASD (Michel, Schmidt, & Mirnics, 2012; Onore, 
Careaga, & Ashwood, 2012). Several studies report striking immune dysregulation in the 
neural, peripheral and enteric immune systems of autistic individuals (Fig. 1). 
Postmortem brains from ASD patients exhibit elevated activation of microglia and 
astrocytes, in addition to increased levels of pro-inflammatory cytokines (Morgan et al., 
2010; Vargas, Nascimbene, Krishnan, Zimmerman, & Pardo, 2005). Notably, 
transcriptome analysis of ASD brains reveals altered expression of neuronal-related 
genes, including ASD susceptibility genes, alongside dysregulated expression of 
immune-related genes related to inflammation and glial activation (Michel et al., 2012; 
Voineagu et al., 2011). Altered cytokine profiles are also observed in cerebrospinal fluid 
and sera collected from living autistic individuals (X. Li et al., 2009; Morgan et al., 2010; 
Vargas et al., 2005). In the periphery, several subsets of leukocytes isolated from ASD 
blood display altered function, reflecting altered innate and adaptive immune responses 
(Onore et al., 2012). Interestingly, significant subsets of autistic children experience 
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gastrointestinal complications, including increased intestinal permeability, lymphoid 
hyperplasia, lymphocyte infiltration and altered microbial composition (Adams, 
Johansen, Powell, Quig, & Rubin, 2011; Buie et al., 2010; Finegold, Downes, & 
Summanen, 2012). Importantly, a number of these autism-associated immune changes 
are associated with elevated severity of ASD symptoms (Onore et al., 2012).  
 
Immune effects on behavioral symptoms of ASD 
Whether immune abnormalities in the brain, periphery and/or gastrointestinal tract 
are involved in the development or persistence of ASD symptoms is unclear. However, it 
is well established that immune status across all of these domains is important for normal 
brain function and behavior. Cytokines in the brain play a fundamental role in synaptic 
development, and traditional components of the immune system, such as complement 
proteins and major histocompatibility complexes, are critical for synaptic pruning, 
neuronal plasticity and the patterning of neural circuits in the normal brain (Deverman & 
Patterson, 2009; Garay & McAllister, 2010; Needleman & McAllister, 2012; Shatz, 
2009; Stephan, Barres, & Stevens, 2012). In the periphery, cytokine responses to 
infection are known to stimulate vagal nerve afferents, ultimately leading to altered 
behavior (Dantzer, 2009). Furthermore, knockout of canonical immune components, such 
as RAG1 and T cell receptor, leads to impaired cognitive behavior and learning and 
memory (Brynskikh, Warren, Zhu, & Kipnis, 2008; Cushman, Lo, Huang, Wasserfall, & 
Petitto, 2003; Kipnis, Cohen, Cardon, Ziv, & Schwartz, 2004). In the gastrointestinal 
tract, the commensal microbiota plays a critical role in the development and status of the 
immune system (Hooper, Littman, & Macpherson, 2012). Interestingly, germ-free 
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animals reared in the absence of any microbial exposure, exhibit abnormalities in 
nociceptive, motor and anxiety-like behaviors (Amaral et al., 2008; Heijtz et al., 2011). 
Overall, several lines of evidence suggest that immune alterations could directly 
contribute to the pathogenesis or maintenance of ASD symptoms.  
Recent studies in animal models have explored the influence of systemic immune 
dysfunction on ASD symptoms. In addition to core ASD symptoms and neuropathology, 
poly(I:C) MIA offspring exhibit lasting peripheral immune dysregulation, including 
hyper-responsive CD4+ T cells and deficits in splenic regulatory T cells (Hsiao, 
McBride, Chow, et al., 2012; Mandal et al., 2011). Poly(I:C) offspring also exhibit 
altered immune function in the mesenteric lymph nodes, as well as deficient intestinal 
barrier integrity, which is reminiscent of GI abnormalities seen in subsets of ASD 
individuals (Hsiao, McBride, Chow, et al., 2012; Hsiao, McBride, Hsien, et al., 2012). 
There is also evidence of microglial activation in some MIA models (Juckel et al., 2011; 
Roumier et al., 2008). Recent experiments support the notion that systemic immune 
abnormalities can contribute to the persistence of ASD-related symptoms. Following 
irradiation and bone marrow transplantation, poly(I:C) offspring exhibit decreased 
stereotypic and anxiety-like behaviors (Hsiao, McBride, Chow, et al., 2012). Similar 
findings are observed in a mouse model of Rett syndrome, where irradiation and bone 
marrow transplantation in MeCP2 knockout mice arrests disease development as 
measured by lifespan, respiration, body weight and locomotion (Derecki et al., 2012). 
Importantly, however, the improvement observed in the Rett model is attributed to 
engraftment of new microglial cells, whereas the improvement observed in the MIA 
model is primarily an effect on peripheral immunity. In addition, the BTBR strain, which 
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displays reduced sociability and verbal communication compared to several other mouse 
strains, also exhibits increased peripheral CD4+ T cells, peripheral B cells and serum and 
brain immunoglobulin levels, among other immune abnormalities (Heo, Zhang, Gao, 
Miller, & Lawrence, 2011). The role of immune abnormalities in ASD symptoms in the 
BTBR mice, however, is unknown. Extending these types of studies to additional animal 
models for autism will be important for better defining the immune-ASD connection. The 
notion that immune abnormalities may arise as a result of genetic alterations is also 
interesting in this regard, in light of the several ASD genes that are relevant to both brain 
and immune function, including those encoding various HLA haplotypes, receptor 
tyrosine kinase and complement C4B (Chien et al., 2011; Mostafa & Shehab, 2010; 
Thanseem et al., 2010; Torres et al., 2006). Unfortunately, few of these immune-related 
genetic risk factors for autism have been translated to animal models or evaluated for 
ASD-related immune and behavioral symptoms. Future studies in these areas will be 
important for identifying converging pathways for several related environmental and 
genetic risk factors for ASD.    
   
Immune therapies for ASD 
Despite numerous findings of immune abnormalities in autism and the known 
effects of immune modulation on brain and behavior, there are very few published, 
controlled studies evaluating the efficacy of immunomodulatory therapeutics in treating 
ASD symptoms (Chez & Guido-Estrada, 2010). Intravenous immunoglobulin treatment 
has been evaluated in ASD case studies, where up to 10-20% of children undergoing 
treatment exhibit symptomatic improvement (Gupta, Samra, & Agrawal, 2010). Oral 
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immunoglobulin treatment, however, has no significant effect on GI symptoms in ASD 
children (Handen et al., 2009). Also interesting is that fever is associated with improved 
behavioral symptoms in ASD children (Curran et al., 2007). The anti-inflammatory 
antibiotic minocycline can rescue synaptic abnormalities and deficits in ultrasonic 
vocalizations in mouse models of fragile X syndrome, and recent studies report efficacy 
in treating symptoms in fragile X patients (Bilousova et al., 2009; Hagerman, Lauterborn, 
Au, & Berry-Kravis, 2012; Rotschafer, Trujillo, Dansie, Ethell, & Razak, 2012). Whether 
it is also effective in autism is still unclear, although a small pilot study reported no 
significant clinical improvement after treatment in ASD children (Swedo et al., 2010). 
The antibiotic D-cycloserine is effective in treating social impairments and stereotypic 
behavior in animal models relevant to autism (Deutsch et al., 2012; Won et al., 2012) and 
has also reduced social withdrawal in a small clinical cohort of ASD children (Posey et 
al., 2004). These effects are commonly attributed to the activity of D-cycloserine as a 
partial NMDA-receptor agonist, but whether its antibiotic properties are also important in 
this regard are unknown. 
Several other classes of drugs that are used to treat ASD, including 
antidepressants and antipsychotics, are known to display immunomodulatory properties. 
The antipsychotic drug risperidone is FDA-approved for treatment of ASD symptoms 
and also known to modulate immune function, T cell differentiation and serum cytokine 
profiles via suppression of the AKT/NFkB pathway (Chen et al., 2011; Chen et al., 2012; 
Kim et al., 2001; Zhang et al., 2004). The antidepressant aripiprazole has effectively 
treated irritability, hyperactivity and stereotypy in two large randomized controlled trials 
of ASD children (Ching & Pringsheim, 2012) and is reported to prevent microglial 
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activation, reduce reactive oxygen species and suppress pro-inflammatory cytokines 
(Cecchelli, Grassi, & Pallanti, 2010). Fluoxetine, another antidepressent, exhibits several 
effects on immune function (Basterzi et al., 2010; Frick, Rapanelli, Cremaschi, & 
Genaro, 2009; Nunez et al., 2006; Rogoz, Kubera, Rogoz, Basta-Kaim, & Budziszewska, 
2009) and has reduced repetitive behaviors in a double-blind placebo-controlled trial of 
adults with ASD (Hollander et al., 2012). The beneficial effects of the 
acetylcholinesterase inhibitors galantamine and donepezil on reducing social withdrawal, 
irritability and inattention in children with autism (Hardan & Handen, 2002; Nicolson, 
Craven-Thuss, & Smith, 2006) are believed to be due in part to activation of the 
cholinergic anti-inflammatory pathway (Pavlov et al., 2009). Finally, the PPARy agonist 
piaglitozone is known to display immunosuppressive properties and, in a small clinical 
cohort, significantly improves ASD symptoms, including irritability, lethargy, stereotypy 
and hyperactivity. (Boris et al., 2007). Additional studies are needed to determine 
whether the immunomodulatory properties of these drugs are necessary to confer 
ameliorative effects on ASD symptoms. 
 
Concluding remarks 
Increasing evidence points to an immune involvement in the development and/or 
persistence of ASD symptoms. Maternal immune activation is a principal environmental 
risk factor for ASD that is sufficient to cause autism-related behavioral abnormalities and 
neuropathologies in rodent and primate models. Gene x environment studies demonstrate 
that immune activation in the background of various genetic susceptibility factors can 
exacerbate pre-existing abnormalities or perpetuate new ASD-associated 
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endophenotypes. ASD-related autoantibodies represent another immune-mediated 
pathway affecting neurodevelopment and behavior, but additional studies in animal 
models are needed to identify the mechanisms underlying autoantibody production and 
action. ASD individuals also exhibit various aspects of immune dysregulation in the 
brain, periphery and GI tract. Still unknown are the etiologies and functional 
consequences of these immune abnormalities on ASD symptoms. Animal models will be 
useful for determining whether these endophenotypes impact core ASD behaviors and 
neuropathologies and whether they converge with identified genetic and environmental 
risk factors for autism. Studies in these areas will sharpen our understanding of 
immunomodulatory approaches towards treating particular autism-associated 
endophenotypes in defined subclasses of ASD individuals.     
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Figure 1. Widespread immune dysregulation may play a role in ASD. Autistic 
individuals display a variety of immune abnormalities in the brain, periphery and 
gastrointestinal tract that may contribute to the pathogenesis or maintenance of ASD 
symptoms. 
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Abstract 
 
Increasing evidence highlights a role for the immune system in the pathogenesis of 
autism spectrum disorders (ASD), as immune dysregulation is observed in the brain, 
periphery and gastrointestinal tract of ASD individuals. Furthermore, maternal infection 
(maternal immune activation, MIA) is a risk factor for ASD. Modeling this risk factor in 
mice yields offspring with the cardinal behavioral and neuropathological symptoms of 
human ASD. In this study, we find that offspring of immune-activated mothers display 
altered immune profiles and function, characterized by a systemic deficit in CD4+ 
TCRβ+ Foxp3+ CD25+ T regulatory cells, increased interleukin-6 (IL-6) and IL-17 
production by CD4+ T cells and elevated levels of peripheral Gr-1+ cells. In addition, 
hematopoietic stem cells (HSCs) from MIA offspring exhibit altered myeloid lineage 
potential and differentiation. Interestingly, repopulating irradiated control mice with bone 
marrow (BM) derived from MIA offspring does not confer MIA-related immunological 
deficits, implicating the peripheral environmental context in long-term programming of 
immune dysfunction. Furthermore, behaviorally-abnormal MIA offspring that have been 
irradiated and transplanted with immunologically normal BM from either MIA or control 
offspring no longer exhibit deficits in stereotyped/repetitive and anxiety-like behaviors, 
suggesting that immune abnormalities in MIA offspring can contribute to ASD-related 
behaviors. These studies support a link between cellular immune dysregulation and ASD-
related behavioral deficits in a mouse model of an autism risk factor. 
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Introduction  
Autism is a complex neurodevelopmental disorder and a pressing medical concern, 
affecting over 1% of children in the United States (CDC, 2012). While autism spectrum 
disorders (ASD) are characterized by stereotypic behaviors and language and social 
deficits, increasing evidence suggests a role for the immune system in ASD pathogenesis. 
Altered cytokine profiles in postmortem brain, cerebrospinal fluid and plasma are found 
in ASD, and several studies have demonstrated elevated number and activation of 
microglia and astrocytes in postmortem brain (Patterson, 2011). There are also many 
reports of peripheral immune abnormalities in autistic individuals, including increased 
NK cell activity, differential monocyte responses to in vitro stimulation and altered serum 
immunoglobulin (Ig) levels (P. Goines & Van de Water, 2010; Onore, Careaga, & 
Ashwood, 2011). 
Abnormal activation of the immune system may also be involved in the etiology 
of autism. Several studies have associated ASD risk with immune-related susceptibility 
genes, such as MET receptor tyrosine kinase, PRKCB1, complement C4B and specific 
HLA haplotypes (P. Goines & Van de Water, 2010; Onore et al., 2011). In addition, anti-
brain antibodies are elevated in ASD sera and in mothers of autistic children (Croen et 
al., 2008; Singer et al., 2008; Zimmerman et al., 2007). Family members of autistic 
children, particularly the mother, show a higher incidence of allergy or autoimmune 
diseases (Atladottir et al., 2009; Comi, Zimmerman, Frye, Law, & Peeden, 1999). 
Consistent with immune involvement are findings that maternal infection is a risk factor 
for autism (Patterson, 2011). After the 1964 rubella pandemic, 8-13% of children born to 
infected mothers developed features of autism (Chess, 1977). In a recent study surveying 
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all children born in Denmark from 1980-2005, a very significant association was found 
between autism and maternal viral infection during the first trimester of pregnancy 
(Atladottir et al., 2010). Moreover, elevation of IFNγ, IL-4 or IL-5 in maternal serum is 
associated with increased risk for ASD in the offspring (P. E. Goines et al., 2011), as is 
elevation of MCP-1 in the amniotic fluid (Abdallah et al., 2011).  
Whether the immune abnormalities in ASD actually contribute to its behavioral 
symptoms or whether they are an epiphenomenon of primary neural dysfunction is an 
outstanding question. The immune system exhibits lifelong reciprocal interactions with 
the central nervous system and that immune status can influence behavioral responses is 
exemplified by early studies demonstrating that responses to infection and inflammation 
are relayed to the brain, resulting in the induction of fever and sickness behavior 
(Dantzer, O'Connor, Freund, Johnson, & Kelley, 2008). Moreover, administration of 
certain cytokines to human subjects frequently causes striking changes in mental state 
(Capuron & Miller, 2011). Conversely, emotional and psychological state can influence 
immune function. Perhaps the strongest evidence to date is the finding that both shortand 
long-term stress lead to disruption of immune function (Segerstrom & Miller, 2004). 
Immune dysregulation has also been implicated in the etiology of a variety of 
neurodegenerative, psychiatric and neurodevelopmental disorders, including Parkinson’s, 
Huntington’s and Alzheimer’s diseases, multiple sclerosis, major depression, 
schizophrenia and addiction (Amor, Puentes, Baker, & van der Valk, 2010; Dantzer, 
O'Connor, Lawson, & Kelley, 2011; Patterson, 2007; Shie, Chen, Chen, & Ho, 2011). 
Here we ask whether a mouse model exhibiting many features of autism also 
displays altered immune function. We utilize the maternal immune activation (MIA) 
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model, which is based on maternal infection as a key environmental risk factor for 
autism. Pregnant mice are injected with the synthetic, double-stranded RNA, poly(I:C), to 
initiate a pro-inflammatory, anti-viral response. This type of MIA yields offspring with 
the core behavioral and neuropathological symptoms of autism, including reduced social 
interaction, abnormal communication, stereotyped/repetitive behavior and a spatially-
restricted deficit in Purkinje cells (Malkova, Yu, Hsiao, Moore, & Patterson, 2012; L. Shi 
et al., 2009). 
In this study, we profile peripheral immune subtypes, assess the functional activities of 
major leukocyte lineages and evaluate the lineage potential of fetal and adult 
hematopoietic stem cells (HSCs) and progenitors. To explore the potential for prenatal 
programming of long-term immune dysfunction, we examine whether transferring HSCs 
from MIA offspring into non-MIA offspring can induce cell-autonomous immune 
abnormalities. To gain insight into whether immune abnormalities in MIA offspring 
contribute to the pathogenesis of ASD-related behaviors, we behaviorally assess 
poly(I:C) offspring repopulated with bone marrow from saline offspring. Our findings 
demonstrate that immune challenge during prenatal life leads to persistent immune 
alterations in the postnatal offspring, which can further impact the development or 
maintenance of abnormal behavior. 
 
Results 
MIA offspring exhibit deficits in T regulatory cells and elevated CD4+ T cell responses.  
Many studies of immune dysregulation in human ASD report a bias toward a pro-
inflammatory phenotype (P. Goines & Van de Water, 2010; Onore et al., 2011). We 
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therefore investigated regulatory T cells (Tregs) as known suppressors of the innate and 
adaptive immune responses. Compared with controls, adult offspring of poly(I:C)-
injected mothers display a ∼50% decrease in splenic CD4+ Foxp3+ CD25+ Tregs (Fig. 
1A). This deficit is also reflected in significantly decreased levels of total CD4+ Foxp3+ 
cells and possible decreases (P = 0.0846) in CD4+ Foxp3+ CD25− T cells. Similar 
deficits in total CD4+ Foxp3+, Foxp3+ CD25−, and Foxp3+ CD25+ cells are also 
observed in mesenteric lymph nodes (MLNs) from adult poly(I:C) offspring (Fig. S1A). 
Despite these differences in Treg levels, there is no difference in the suppression of 
CD4+CD25− T-cell proliferation between Tregs from saline versus poly(I:C) offspring 
(Fig. S2). Taken together, these findings indicate a systemic deficit in the abundance of 
Tregs. 
We further tested MIA offspring for levels of IL-17–producing CD4+ T (Th17) 
cells, given their proinflammatory nature and reported reciprocal relationship with Tregs. 
In assays done in parallel with those for Tregs, we find no significant difference from 
controls in levels of CD4+ TCRβ+ IL-17+ (Th17) cells, with or without IFN-γ expression 
(Fig. 1B). There is also no difference in the level of CD4+ TCRβ+ IL-17− IFN-γ+ (Th1) 
cells. To further examine CD4+ T cells, we measured their secretion of IL-6 and IL-17 in 
response to in vitro stimulation. Compared with controls, CD4+ cells from spleens of 15-
wk-old poly(I:C) offspring release significantly more IL-6 and IL-17 after in vitro 
stimulation, with no difference in TNF-α secretion (Fig. 1C). This result is similarly 
observed with splenic CD4+ T cells derived from 3-wk-old offspring (Fig. S3A) and 1-y-
old offspring (Fig. S3B), suggesting an early onset of persistent immune dysfunction. 
Interestingly, splenic CD4+ T cells from 3-wkold mice produce much lower levels of IL-
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17 than do such cells from adult offspring (0–10 pg/mL compared with 50–400 pg/ mL), 
reflecting the immunological immaturity reported in young versus adult mice and humans 
(Adkins, Leclerc, & Marshall-Clarke, 2004). CD4+ T cells from MLNs of poly(I:C) 
offspring are also hyper-responsive to in vitro stimulation, suggesting that this 
abnormality is common to secondary lymphoid organs (Fig. S1C, D). Overall, MIA leads 
to lower Treg levels and elevated CD4+ T cell responsiveness in spleens and MLNs from 
MIA offspring. This can be characterized as a persistent, pro-inflammatory T helper cell 
phenotype.  
 
MIA offspring display increased levels of Gr-1+ cells and skewed HSC differentiation 
To determine whether MIA during fetal development alters the profile of other 
immune subtypes in the offspring, we assessed major leukocyte classes in spleens from 
poly(I:C) and saline offspring. Compared with controls, adult poly(I:C) offspring exhibit 
a 1.5-fold higher level of Gr-1+ cells and trending increase in CD11b+ cells (P = 0.1256) 
(Fig. 2A). In contrast, there is no difference from controls in the percentages of total 
B220+ B cells, NK1.1+ NK cells, CD4+ T cells, or CD8+ T cells. Moreover, no 
significant differences are detected for any of the primary leukocyte subtypes in the 
MLNs (Fig. S1B). 
Gr-1+ cells reflect a heterogeneous group of immune subtypes that includes 
neutrophils and monocytes, inflammatory cells, and suppressor cells, alike. To determine 
whether the elevated levels of Gr-1+ cells observed in poly(I:C) spleens could be 
attributed to particular Gr-1+ subtypes, we further characterized the splenic Gr-1+ 
population using CD11b, Ly6C, and Ly6G markers. Interestingly, poly(I:C) offspring 
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exhibit mild increases in all three populations of Gr-1+ cells resolved: (i) Gr-1hi CD11b+ 
Ly6Cmid Ly6Ghi SSCmid, (ii) Gr-1mid CD11b+ Ly6Cmid Ly6Gmid SSCmid, and (iii) 
Gr-1mid CD11b+ Ly6Chi Ly6GSSClo (Fig. S4). Gr-1+ subtypes i and ii are referred to 
as neutrophils, by histology and in line with their high granularity, and subtype iii is 
identified as a monocyte population (C. Shi et al., 2011). Overall, that poly(I:C) offspring 
display increases in all identified Gr-1+ populations suggests that skewing at the HSC or 
progenitor level may underlie the elevated Gr-1 phenotype observed in adult poly(I:C) 
offspring compared with controls. + 
To evaluate the origin of the increase in splenic Gr-1 we assessed the lineage 
potential and differentiation of BM cells from adult poly(I:C) versus saline offspring. 
Using a colonyforming assay to morphologically assess lineage differentiation, we find 
that HSCs and progenitors from poly(I:C) offspring BM exhibit increased differentiation 
into CFU-G (granulocyte) precursors and decreased differentiation into early CFU-GM 
(granulocyte-macrophage) precursors (Fig. 2B). Turning to the fetus, we find that similar 
differentiation is observed with fetal liver HSCs and progenitors from poly(I:C) offspring 
(Fig. 2C). Thus, MIA induces preferential differentiation of fetal as well as adult HSCs 
and progenitors into granulocyte precursors, which may account for the increased levels 
of mature Gr-1+ cells in spleens of poly(I:C) offspring compared with controls. 
 
Immune abnormalities observed in MIA offspring are not transferred via bone marrow 
transplant.  
Our data demonstrate that MIA leads to an altered profile of peripheral immune 
cells in the offspring, characterized by decreased levels of Tregs, hyperresponsive CD4+ 
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T cells, and elevated levels of Gr-1+ cells. To explore whether these immune 
abnormalities (and the Gr-1 phenotype, in particular) can be attributed to cell-intrinsic 
developmental programming of HSCs, we transferred BM from the immunologically 
aberrant poly(I:C) offspring into irradiated saline and poly(I:C) offspring and assessed 
whether any MIA-associated immune abnormalities were reestablished. 
We find that saline and poly(I:C) offspring that were irradiated and reconstituted 
with poly(I:C) BM do not develop or retain any of the immune abnormalities exhibited 
by unmanipulated MIA offspring. All BM-transplanted groups exhibit levels of splenic 
CD4+ TCRβ+ CD25+ Foxp3+ Tregs and Gr-1+ cells that are comparable to those 
observed in untransplanted saline offspring (Fig. 3 A and B). There is also no difference 
between saline and BM-transplanted mice in distributions of progenitor subtypes after in 
vitro differentiation of BM HSCs (Fig. S5). Furthermore, CD4+ T cells isolated from 
spleens of any of the types of BM-transplanted mice secrete levels of IL-6 and IL-17 in 
response to phorbol 12-myristate 13-acetate (PMA)/ionomycin stimulation that are 
similar to those produced by CD4+ T cells isolated from spleens of untransplanted saline 
offspring (Fig. 3C). Importantly, the fact that saline mice transplanted with saline BM 
display equivalent levels of Tregs and Gr-1+ cells and similar CD4+ T-cell 
responsiveness to those observed in unmanipulated saline offspring suggests that the 
irradiation and BM-transplant procedure itself does not skew immune system profiles 
under these conditions. Overall, these experiments indicate that MIA-associated immune 
abnormalities are not transferred via transplant of poly(I:C) BM into irradiated saline or 
poly(I:C) offspring. This finding suggests either that the HSC microenvironment is 
important for maintaining altered HSC potential in MIA offspring, or that the particular 
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MIAassociated immune abnormality is not programmed at the stem cell level. 
 
Bone marrow transplant in MIA offspring normalizes repetitive and anxiety-like 
behavioral abnormalities  
To investigate whether the immune abnormalities found in MIA offspring are an 
independent parallel pathology or if they actually contribute to the development or 
maintenance of ASD-like behaviors, we assessed behavioral performance in poly(I:C) 
offspring transplanted with saline BM. Poly(I:C) offspring were first confirmed to exhibit 
their expected behavioral phenotypes before the procedure. Compared with controls, 
poly(I:C) offspring display a deficit in prepulse inhibition (PPI) (Fig. S6A). PPI is used to 
measure sensorimotor gating of the startle reflex, and decreased PPI is frequently 
observed in autistic individuals (Perry, Minassian, Lopez, Maron, & Lincoln, 2007). 
Poly(I:C) offspring also exhibit core behavioral symptoms of autism, including increased 
repetitive behavior as measured by higher levels of stereotypic marble burying and 
decreased social preference, as assessed by reduced duration spent and entries into a 
chamber housing a novel mouse versus a familiar mouse (Fig. S6 B and C). In addition, 
MIA offspring exhibit increased anxiety, as reflected byeduced duration spent, and 
entries into, the center arena of an open field, despite no significant difference in total 
distance traveled (Fig. S6D). 
After this initial behavioral testing, the mice were irradiated and transplanted with 
donor BM harvested from either adult saline or poly(I:C) offspring. Notably, mouse 
heads were shielded during the procedure to limit known effects of irradiation on 
neurogenesis and glial activation, and to preclude any associated downstream influences 
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on behavioral performance. Furthermore, MIA offspring do not exhibit global changes in 
levels of activated or total brain macrophages/microglia (Fig. S7), suggesting that 
microglial abnormalities do not contribute the persistence of ASD-related behaviors in 
these mice. 
After irradiation and transplantation with saline BM, MIA offspring no longer exhibit 
behavioral abnormalities in several of these tests. Irradiation and saline BM transplant in 
poly(I:C) offspring restores repetitive marble burying to levels observed in saline controls 
(Fig. 4A). In addition, irradiated and BM-transplanted MIA offspring exhibit 
significantly decreased anxiety-like behavior, as measured by elevated duration of time 
spent and entries into the center arena of the open field (Fig. 4B). Interestingly, both 
saline and poly(I:C) BM-transplanted mice exhibit significantly increased number of 
center entries compared with untransplanted offspring. This finding is similarly reflected 
by a statistically significant increase in total distance traveled by transplanted offspring 
versus untransplanted controls. This finding may be a result of effects of the irradiation 
and transplant procedure on behavior rather than habituation of the mice to repeated 
testing, because we are able to replicate open field deficits of equivalent intensity in 
poly(I:C) offspring after retesting at different adult ages (Fig. S8). On the other hand, 
treatment of poly(I:C) offspring with saline BM has no significant effect on the deficit in 
social preference, as measured by duration and number of entries into the social chamber 
(Fig. 4C). 
Although treatment of MIA offspring with irradiation and saline BM 
transplantation significantly restores normal behavior in several tests, we find that 
treatment of MIA offspring with irradiation and poly(I:C) BM transplantation also 
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improves those behaviors. Notably, irradiated MIA offspring transplanted with poly(I:C) 
BM exhibit improved open field and marbleburying performance (Fig. S9). This result is 
consistent with our finding that transplant of poly(I:C) BM does not give rise to 
cellautonomous immune abnormalities (Fig. 3). As such, both poly (I:C) BM and saline 
BM can be considered immunologically normal in these experiments. Taken together, 
these data demonstrate that MIA offspring that had previously exhibited abnormal 
behaviors fail to exhibit repetitive and anxiety-like behavior after exposure to irradiation 
and BM transplant. 
 
Discussion 
In the present study, we identify differences in dynamic cellular immune 
responses in a mouse model of an autism risk factor. Offspring of immune-activated 
mothers develop altered immune profiles and function in the spleen and MLN, which are 
consistent with a pro-inflammatory phenotype. In addition, we demonstrate preferential 
myeloid differentiation of fetal HSCs and progenitors, which is also found in adult HSCs. 
This could form the basis for the altered immune distributions in secondary lymphoid 
organs from MIA offspring. However, BM transplant of HSCs derived from MIA 
offspring is not sufficient to recapitulate the elevated levels of Gr-1+ cells exhibited by 
untransplanted MIA offspring. This result highlights the importance of appropriate 
environmental cues for preserving this phenotype, as discussed below. We also used the 
irradiation-BM transplant approach to explore the role of peripheral immune dysfunction 
on behavioral performance. Interestingly, this procedure corrects some of the ASD-like 
behavioral symptoms in the MIA offspring.  
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MIA leads to permanently hyper-responsive CD4+ T cells as well as decreased Tregs in 
the offspring, suggesting a chronic, pro-inflammatory phenotype. This finding is 
consistent with decreased numbers CD4+ CD25+ and CD3+GITR+ T cells observed in 
children with ASD (Ashwood et al., 2011b; Mostafa, Al Shehab, & Fouad, 2010). 
Diminished Treg levels and associated decreases in immune regulation may reflect the 
finding that autistic individuals exhibit decreased levels of regulatory cytokines, such as 
TGFβ1, and increased levels of pro-inflammatory cytokines in serum, cerebrospinal fluid 
and postmortem brain (Patterson, 2011). Furthermore, given that Tregs are critical for 
limiting immune activation and preventing self-reactivity, their deficiency may underlie 
the reports of a link between ASD and autoimmune disease (Atladottir et al., 2009; 
Enstrom, Van de Water, & Ashwood, 2009).  
Our finding that CD4+ T cells from MIA offspring are hyper-responsive to in vitro 
stimulation further reflects diminished immune homeostasis. Increases in activated DR+ 
T cells are observed in human autism (Plioplys, Greaves, Kazemi, & Silverman, 1994; 
Warren, Yonk, Burger, Odell, & Warren, 1995). In addition, elevated levels of TNFαand 
IFNγ-producing T cells are found in peripheral blood and gastrointestinal mucosa from 
autistic individuals (Ashwood & Wakefield, 2006). A number of other altered immune 
responses have been reported in ASD (P. Goines & Van de Water, 2010; Onore et al., 
2011), and we find that MIA offspring also exhibit some of these changes, including 
altered leukocyte subsets and CD4+ T cell responses to stimulation. This overlap between 
findings of immune dysregulation in ASD and our current results lends support to MIA as 
a mouse model with construct and face validity for this disorder.  
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We further demonstrate that MIA during fetal development leads to significantly 
increased levels of peripheral Gr-1+ CD11b+ neutrophilic and monocytic cells in adult 
offspring. Granulocytosis is typically observed after acute inflammation (Hansen, Karle, 
Andersen, Malmquist, & Hoff, 1976; Ricevuti, Mazzone, Pasotti, de Servi, & Specchia, 
1991) and is also a feature of a number of chronic diseases (Cascao, Rosario, Souto-
Carneiro, & Fonseca, 2010; Courtney et al., 1999; Passegue, Jochum, Schorpp-Kistner, 
Mohle-Steinlein, & Wagner, 2001). There have been no reports of altered neutrophil 
levels in ASD, however. In one study, children with ASD exhibited increased plasma 
monocyte counts, but no significant abnormalities in major granulocyte subtypes 
(Sweeten, Posey, & McDougle, 2003). In light of the present results, it will be of interest 
to extend these immunophenotypic studies to behavioral or symptomatic subpopulations 
of ASD individuals.  
It is intriguing to consider that MIA effects on developing HSCs may underlie 
some of the persistent peripheral immune changes found in the offspring. We find that 
both adult and fetal HSCs and progenitor cells display preferential differentiation into 
CFU-G colonies, which provides an explanation for how increases in such short-lived 
cells are maintained over the lifespan of MIA offspring. Maternal poly(I:C) injection is 
known to induce dramatic increases in pro-inflammatory cytokines in the placenta, a 
principal HSC niche during midgestation (Hsiao & Patterson, 2011). Since HSCs and 
progenitors respond to inflammatory signals such as cytokines and TLR ligands, it will be 
interesting to explore whether MIA-induced changes in the HSC environment can skew 
hematopoietic lineage decisions and fate.  
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Despite the fact that HSCs and progenitors isolated from poly(I:C) offspring are 
developmentally skewed toward granulocyte precursors, transplantation of BM from 
poly(I:C) offspring into irradiated saline offspring or back into irradiated poly(I:C) 
offspring does not transfer the Gr-1 phenotype. This suggests that developmental 
programming of HSCs to skew lineage differentiation in MIA offspring is not governed 
solely by stably-encoded cell-intrinsic factors, such as epigenetic modification. Rather, it 
is likely that an MIA-induced peripheral environment is necessary to supply the cues that 
guide preferential myeloid development. Changes in G-CSF, IL-5 and IL-3 levels, for 
example, are implicated in fine-tuning the transcription factor activity that governs 
lineage choice for granulocyte/macrophage progenitors (Robb, 2007). Indeed, we have 
found that MIA offspring exhibit dynamic and chronically altered peripheral blood and 
splenic cytokine profiles (Hsiao, Garay, Patterson, & McAllister, 2011). It will be of 
interest to assess whether the BM microenvironment differs in poly(I:C) and saline 
offspring. Overall, it is intriguing that the Gr-1 phenotype observed in MIA offspring is 
not transferred via BM transplant, suggesting a lack of sufficient cell-intrinsic epigenetic 
programming and/or a key role for environmental factors in promoting this lineage 
choice.  
We demonstrate that subjecting MIA offspring that have validated behavioral 
deficits to irradiation and reconstitution with immunologically normal BM alters their 
behavioral phenotype. Namely, these MIA offspring no longer exhibit their previous 
abnormalities in repetitive marble burying and open field exploration. These findings 
imply that correcting immune function can correct some autism-related behavioral 
abnormalities. However, this experiment has a significant limitation. In the absence of a 
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positive control (MIA offspring that retain behavioral deficits after irradiation and BM 
transplantation), we are unable to distinguish between the potential restorative effects of 
the BM itself (that is, the effects of restoring immune phenotype) versus the effect of 
confounding factors associated with the transplant procedure. The most obvious of these 
is the effect of irradiation on various aspects of recipient homeostasis, including 
metabolic function, GI microbial composition and oxidative stress, all of which may 
indirectly influence behavioral outcome. We are, however, inspired by recent work 
demonstrating that stereotyped grooming behavior in hoxb8 mutant mice is, in fact, 
transferrable via BM transplant (Chen et al., 2010). This shows, at least in that 
experimental model, that mice can reconstitute an expected behavioral impairment via 
BM transplant despite prior irradiation. It will be important to explore other experimental 
approaches to treat immune dysfunction in MIA offspring and to further assess whether 
these can alleviate behavioral outcomes.  
Nonetheless, our finding that behavioral abnormalities in the MIA offspring can 
be corrected by the irradiation-BM transplant procedure contributes to a growing number 
of studies reporting the efficacy of BM transplant in ameliorating symptoms of 
neurological and psychiatric disorders (Chen et al., 2010; Derecki et al., 2012; Kwan et 
al., 2012). Furthermore, several experiments utilizing RAG1 KO, SCID and athymic 
mice demonstrate that primary immune dysfunction can lead to behavioral impairment 
(Brynskikh, Warren, Zhu, & Kipnis, 2008; Cushman, Lo, Huang, Wasserfall, & Petitto, 
2003; Kipnis, Cohen, Cardon, Ziv, & Schwartz, 2004; Mombaerts et al., 1994). 
Interestingly, work with germ-free mice links the absence of microbiota and associated 
alterations in the immune system to abnormal behavioral performance (Heijtz et al., 
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2011). Some immune alterations have been described in the maternal valproic acid model 
and the BTBR mouse strain that display behavioral features of autism (Heo, Zhang, Gao, 
Miller, & Lawrence, 2011; Schneider et al., 2008). In contrast, much remains to be 
learned about potential immune changes in mouse models of ASD candidate genes. One 
such gene is particularly attractive in this regardMET, which encodes a tyrosine kinase 
receptor and is known to play a role in immune regulation (Campbell, Li, Sutcliffe, 
Persico, & Levitt, 2008).   
Altered peripheral immune profiles and cellular activity are also associated with 
core behavioral impairments in human ASD. Increased plasma IL-4 levels correlate with 
greater deficits in communication, while increased plasma IL-8, IL-12p40, IL-6 and IL-
1β are linked to stereotypy, hyperactivity and lethargy scores from ASD children 
(Ashwood et al., 2011a). Altered levels of other immune factors, including TGF, MIF and 
CD31, have also been associated with the severity of ASD-related behaviors or 
pathophysiology (Onore et al., 2011). In addition, reduced levels of plasma IgG and IgM 
are associated with behavioral severity in ASD children (Heuer et al., 2008).  
It is striking that in a mouse model of an autism environmental risk factor that 
exhibits the cardinal behavioral and neuropathological symptoms of autism, there is also 
permanent peripheral immune dysregulation. This provides the opportunity to explore 
molecular mechanisms underlying the relationship between brain dysfunction and altered 
immunity in the manifestation of abnormal behavior. Furthermore, it provides a platform 
for investigating how prenatal challenges can program long-term postnatal immunity, 
health and disease. Maternal insult-mediated epigenetic modification in HSC and 
progenitor cells is one possible mechanism for how effects may be established by 
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transient environmental changes yet persist permanently into adulthood. However, the 
BM transplant results suggest that the peripheral environment of the MIA offspring is 
also critical for maintaining a permanently modified immune state. 
 
Methods 
MIA 
Pregnant C57BL/6J mice were injected on E12.5 with saline or poly(I:C). For poly(I:C) 
injections, poly(I:C) potassium salt (Sigma Aldrich; St. Louis, MO) was dissolved in 
saline at 4 mg/ml and administered i.p. at 20 mg/kg (based on the weight of the poly(I:C) 
itself, not including the total weight of the potassium salt). Control mice were injected 
with saline alone at 5 µl/g body weight.  
 
CD4+ T cell in vitro stimulation 
106 CD4+ T cells were cultured in complete RPMI with PMA (50 ng/mL) and ionomycin 
(750 ng/mL) for 3 days at 37°C with 5% CO2. Each day, 0.5 ml supernatant was 
collected. ELISA assays to detect IL-6, IL-17 and TNFα were performed according to the 
manufacturer’s instructions (eBioscience).  
 
Flow cytometry 
For subtyping of Gr-1+ splenocytes, cells were stained with Gr-1-APC, CD11b-PE, 
Ly6G-APC, Ly6C-FITC and Ter119-PerCP-Cy5.5 (Biolegend; San Diego, CA). For 
detection of Th17 cells and Tregs, splenocytes were stimulated for 4 hours with 
PMA/ionomycin in the presence of GolgiPLUG (BD Biosciences). Suspensions were 
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blocked for Fc receptors and labeled with CD4-FITC, TCRb-PerCP-Cy5.5 and CD25-PE 
before labeling with IFNγ-PE and Foxp3-APC (eBioscience). Samples were processed 
using the FACSCalibur cytometer (BD Biosciences). Data were analyzed using FlowJo 
software (TreeStar). 
 
Treg suppression assay 
105 CD4+CD25T responder cells were cultured in complete RPMI with 2 x 104 irradiated 
antigen-presenting cells and 2.5 µg/ml anti-CD3, with CD4+CD25+ Tregs at a ratio to T 
responder cells of 1:1, 1:2 and 1:4, according to methods from (Collison & Vignali, 
2011).  After 3 days of culture, suspensions were stained with CD4-APC antibody and 
assessed by flow cytometry.  
 
Methylcellulose colony forming assay 
2 x 105 fetal liver or BM cells were added to 3 ml of thawed methylcellulose 
supplemented with SCF, IL-3, IL-6 and Epo (StemCell). Total colony number was 
counted on day 5 and confirmed to be equivalent across groups. CFU-G, -M, -E, -GM 
and -GEMM colonies were blindly scored on day 12 according to standard protocols.   
 
BM transplantation 
Behaviorally tested, 9-week-old mice were injected i.p. with high dose ketamine/xylazine 
(5.6 µl/1 g mouse) and lethally irradiated (1000 rads) with heads shielded by 4mm lead. 
The effectiveness of the head shields was confirmed by selective graying of black coat 
color in the irradiated area. Recovered mice were anesthetized with isofluorane and 
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injected retro-orbitally with 5 x 106 donor BM cells. Mice were re-tested in behavioral 
paradigms at 17-19 weeks of age and sacrificed for immunological assays at 19-20 weeks 
of age.  
 
Behavioral testing 
At 6-8 weeks of age, mice were behaviorally tested for pre-pulse inhibition (PPI), open 
field exploration, repetitive marble burying and social preference (Hsiao & Patterson, 
2011; Malkova et al., 2012; Smith, Li, Garbett, Mirnics, & Patterson, 2007; Walf & Frye, 
2007). 8 weeks after transplant, mice were similarly tested in all paradigms but PPI since 
PPI performance is highly sensitive to handling and prior testing experience (Plappert, 
Kuhn, Schnitzler, & Pilz, 2006).  
 
Statistical analysis 
Statistical analysis was performed with Prism software (Graphpad). Differences between 
two treatment groups were assessed using Student’s t-test, and differences among 
multiple groups were assessed using one-way ANOVA + Bonferroni post-hoc test. Two-
way ANOVA + Bonferroni post-hoc test was used for PPI, CD4+ T cell stimulation and 
methylcellulose assay data. 
 
Mice 
C57BL/6J mice (Charles River) were housed under specific pathogen-free conditions in 
the California Institute of Technology’s Broad animal facility. Mice were mated 
overnight and the presence of a vaginal plug on the following morning was noted as 
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embryonic day (E) 0.5. All experiments were performed under the approval of the 
California Institute of Technology Institutional Animal Care and Use Committee. 
 
Spleen and Mesenteric Lymph Node Suspensions 
Spleens and mesenteric lymph nodes (MLNs) were harvested, washed in complete RPMI 
media on ice, and forced through 40-µm cell strainers (BD Biosciences). In some trials, 
spleens from the same treatment group were pooled in groups of three to facilitate 
accommodating a large number of samples, while preserving cell viability. Singlecell 
suspensions were subjected to RBC lysis (Sigma Aldrich). CD4+ T cells were isolated by 
negative selection using a CD4+ Isolation kit (Miltenyi Biotec). Cell counts were 
performed on a hemocytometer, and 106 cells were aliquoted for each CD4+ stimulation 
reaction. 
 
Flow Cytometry 
For extracellular staining, cells were treated with anti-mouse CD16/CD32 Fc block 
(eBioscience) before staining with subsets of these antibody conjugates: Ter119-PerCP-
Cy5.5, CD4-FITC, CD8-FITC, Gr-1-APC, B220-FITC, CD11b-APC (eBioscience), 
NK1.1-PE (Biolegend). 
 
Regulatory T-Cell Suppression Assay 
For regulatory T-cell (Treg) suspression assay, 105 CD4+CD25− T-responder cells were 
cultured in complete RPMI with 2 × 104 irradiated antigen-presenting cells and 2.5 
µg/mL anti-CD3, with CD4+CD25+ Tregs at a ratio to T-responder cells of 1:1, 1:2, and 
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1:4, according to methods from (1). After 2 d of culture, suspensions were stained with 
CD4-APC antibody and assessed by flow cytometry. 
 
Fetal Liver Suspensions 
Fetal livers were harvested from E13.5 and E15.5 embryos and washed in PBS. Six to 
seven fetal livers from a single litter were pooled, forced through a 40-µm cell strainer, 
and washed with Iscove’s modified Dulbecco’s medium (IMDM) + 2% (vol/vol) FBS 
(StemCell Technologies). Cells were counted using a hemocytometer, and 2 × 105 cells 
used per methylcellulose solution. 
 
Donor Cell Harvest for Bone Marrow Transplantation 
Four adult saline offspring (two male, two female) and four adult poly(I:C) offspring 
(two male, two female) were selected from an independent cohort of behaviorally tested 
maternal immune activation (MIA) and control mice, and designated as bone marrow 
(BM) donors. Donor adult saline and poly(I:C) mice were killed by CO2 gas, and BM 
was harvested by flushing femurs and tibias with DMEM (Thermo Scientific). BM 
suspensions from each treatment group were pooled, subjected to RBC lysis (Sigma 
Aldrich), filtered through a 40-µm cell strainer, and stored on ice. 
 
Behavioral Testing 
For prepulse inhibition (PPI), mice were acclimated to an SR-LAB testing chamber (SD 
Instruments) for 5 min, presented with six, 120-dB pulses of white noise (startle 
stimulus), and then subjected to 14 randomized blocks of either no startle, startle stimulus 
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only, 5-dB prepulse + startle, or 15-dB prepulse + startle. The startle response was 
recorded by a piezoelectric sensor, and PPI defined as: (startle stimulus only – 5 or 15 dB 
prepulse + startle)/startle stimulus only × 100. 
For open-field testing, mice were allowed to explore a 50 × 50-cm white Plexiglas 
box for 10 min. An overhead video camera was used to record the session, and 
Ethovision software (Noldus Information Technology) used to analyze the distance 
traveled, and the number of entries and duration of time spent in the center arena (central 
square, 17 × 17 cm). 
For marble-burying testing, mice were acclimated for 10 min to a new testing 
cage containing Aspen pine bedding (NEPCO), 3-cm deep. The mice were briefly placed 
in a fresh holding cage while 18 navy blue marbles (15-mm diameter, washed with 70% 
ethanol and mixed in Aspen pine bedding) were laid in a 6 × 3 pattern in the testing cage. 
Mice were placed back to the testing cage, and the number of buried marbles (>50% 
covered with bedding) was scored after a 10-min trial. 
For social interaction testing, mice were first habituated for 10 min to a 60 × 40-
cm Plexiglas box with three equally-sized chambers, with each of the two side chambers 
containing an empty Plexiglas cylinder. During a second 10-min trial, the mouse was 
placed in the center chamber and given the choice to interact with an unfamiliar, same-
sex mouse that was placed in one of the side chamber cylinders, or with a nonsocial 
object (novel green, sticky ball toy), placed in the other side chamber cylinder. In the 
third and final 10-min trial, social preference was measured by replacing the nonsocial 
object with a new, unfamiliar, same-sex mouse. In this trial, the mouse was given the 
choice to interact with the now familiar mouse (from trial 2) or the new unfamiliar 
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mouse. The cylinders holding the stimulus mice or the toy have small holes (∼10 mm 
diameter) over the entire surface area to permit direct interaction. Mice to be tested were 
prehabituated to the Plexiglas cylinders and three-chambered box for 20 min each day for 
3 d before testing. All equipment was cleaned with 70% ethanol and Process NPD 
(STERIS Life Sciences) before and after testing. The side chamber used for placement of 
the social object or the nonsocial object, and the familiar mouse or the unfamiliar mouse 
was alternated in each trial to prevent bias. The duration of time spent and number of 
entries into each chamber were recorded using an overhead video camera and analyzed 
with Ethovision software. Equivalent levels of chamber duration and chamber entries 
during the habituation phase were used to ensure that the mice did not exhibit chamber 
bias. “Social preference, chamber duration” is measured by: (duration in the novel mouse 
chamber – duration in the familiar mouse chamber). “Social preference, chamber 
frequency” is measured by: number of entries into the novel mouse chamber – number of 
entries into the familiar mouse chamber. For post-BM transplant behavior testing, 
different stimulus (familiar and unfamiliar) mice were used to prevent potential 
confounding effects of social memory. 
 
 
Footnotes 
EYH, PHP & SKM designed research; EYH, SM & JC performed research; EYH & JC 
analyzed data; EYH, SM, JC, PHP & SKM wrote the paper.  
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Fig. 1. MIA leads to decreased levels of Tregs and hyperresponsiveness in CD4+ T 
cells from spleens of adult offspring. (A) Compared with controls, adult poly(I:C) 
offspring exhibit decreased levels of CD4+ Foxp3+ splenocytes and CD4+ Foxp3+ 
CD25+ Tregs (n = 5, where each sample represents a pool of three spleens). (B) Adult 
poly(I:C) offspring exhibit decreased levels of splenic CD4+ TCRβ+ Foxp3+ CD25+ 
Tregs, but no significant difference in splenic CD4+ TCRβ+ IFN-γ+ IL-17+ Th17+ Th1 
cells or CD4+ TCRβ+ IFN-γ− IL-17+ Th17 cells (n = 4, where each sample represents a 
pool of three spleens). (C) CD4+ T cells from the spleens of adult offspring secrete 
elevated levels of IL-6 and IL-17 in response to PMA/ionomycin stimulation. In contrast, 
CD4+ T cells from spleens of adult poly(I:C) and saline offspring do not differ the level 
of TNF-α secreted (n = 11–16). *P < 0.05, **P < 0.01, ***P < 0.001; n.s., not significant. 
All panels show one representative experiment of at least two separate trials. 
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Fig. 2. MIA leads to increased levels of splenic Gr-1+ cells in adult offspring and 
preferential differentiation of HSCs into granulocyte precursors in fetal and adult 
offspring. (A) Spleens from adult poly(I:C) offspring exhibit increased levels of Gr-1+ 
cells and no significant differences in other major lineages compared with controls (n = 4, 
where each sample represents a pool of three spleens). (B) Compared with BM HSCs 
from control offspring, BM HSCs from adult poly(I:C) offspring display increased 
differentiation into CFU-G precursors and decreased differentiation into early CFU-GM 
precursors (n = 4). Compared with controls, fetal liver HSCs from embryonic day (E) 
13.5 (C, Left) and E15.5 (C, Right) poly(I:C) offspring also display increased 
differentiation into CFU-G and decreased differentiation into CFU-GM, in addition to 
decreased percentages of CFU-GEMM with E13.5 HSCs and increased percentages of 
CFU-E with E15.5 HSCs (n = 4, where each sample represents a pool of cells from six 
fetal livers from a single litter). *P < 0.05, **P < 0.01, ***P < 0.001; n.s., not significant. 
All panels represent one representative experiment of at least two separate trials. 
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Fig. 3. Immune abnormalities observed in MIA offspring are not transferred by BM 
transplant into irradiated mice. (A) There is no difference in levels of splenic CD4+ 
TCRβ+ CD25+ Foxp3+ Tregs between saline or poly(I:C) offspring transplanted with 
BM from saline or poly(I:C) offspring. Levels of splenic Tregs between BM transplant 
groups are comparable to those observed in untransplanted saline offspring; 
untransplanted poly(I:C) offspring display a significant deficit in Treg percentages (n = 
4–5). (B) BMtransplanted mice do not display MIA-associated increases in splenic Gr-1+ 
cells. Percentages of Gr-1+ cells are comparable between BM transplanted groups and 
untransplanted saline offspring (n = 4–5), but untransplanted poly (I:C) offspring exhibit 
significantly elevated levels of splenic Gr-1+ cells. (C) CD4+ T cells from BM-
transplanted mice exhibit statistically equivalent levels of IL-6 (Left) and IL-17 (Right) in 
response to PMA/ionomycin stimulation in vitro. There are no differences between 
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concentrations of IL-6 and IL-17 secreted by CD4+ cells from BM-transplanted groups 
and from untransplanted saline offspring, despite significant hyperresponsiveness of 
CD4+ T cells from poly(I: C) offspring [n = 11–16 for saline and poly(I:C) groups, 4–5 
for BM transplant groups]. *P < 0.05, **P < 0.01. BM transplant data were acquired from 
one large experiment. 
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Fig. 4. MIA offspring irradiated and transplanted with saline BM exhibit decreased 
repetitive and anxiety-like behavior. (A) Irradiation and transplantation of saline BM 
into MIA offspring restores repetitive marble-burying behavior to a level at or below that 
observed in controls. (B) Irradiation and transplantation of saline BM into MIA offspring 
decreases anxiety-like behavior as measured by significant increases in the number of 
center entries (Center) and duration in the center arena (Left), compared with those 
observed in untransplanted MIA mice. Both saline and poly(I:C) BM-transplant mice also 
exhibit increased overall activity in the open field, as measured by significantly increased 
total distance traveled compared with untransplanted mice (Right). (C) Transplanting 
saline offspring BM into poly(I:C) offspring has no significant effect on their social 
preference behavior, as measured by chamber duration (Left). There is, however, a 
trending improvement in social preference behavior as measured by chamber frequency 
in BM-transplanted MIA offspring (Right). *P < 0.05, **P < 0.01; n.s., not significant. 
BMtransplant data were acquired from one large experiment. 
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Fig. S1. Some of the immune changes observed in spleens of MIA offspring are 
recapitulated in the MLN. (A) Consistent with what is observed in the spleen, MLNs 
from poly(I:C) offspring exhibit decreased levels of total CD4+ Foxp3+, CD4+ Foxp3+ 
CD25−, and CD4+ Foxp3+ CD25+ T cells, but no significant difference in levels of 
CD4+ TCRβ+ IL-17+ IFN-γ+ Th17+ Th1 cells or CD4+ TCRβ+ IL-17+ IFN-γ− Th17 
cells (n = 5, where each sample represents a pool of three spleens). (B) There are no 
significant differences between MLNs from adult poly(I:C) versus saline offspring in the 
distribution of major leukocyte classes [n = 8 saline, 9 poly(I:C)]. (C) Consistent with 
what is observed in the spleen, CD4+ T cells from the MLNs from 15-wk-old poly(I:C) 
offspring produce increased levels of IL-6 and IL-17 at 1, 2, and 3 d after phorbol 12-
myristate 13-acetate (PMA)/ionomycin stimulation (n = 4, where each represents a pool 
MLNs from three animals). (D) This hyperresponsive phenotype of MLN CD4+ T cells 
is maintained in 1-y-old poly(I:C) versus saline mice (n = 11–16). *P < 0.05, **P < 0.01, 
***P < 0.001. All panels represent one representative experiment of at least two separate 
trials. 
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Fig. S2. There is no significant difference in the suppression of CD4+CD25− T-cell 
(effector T cells, Teff) proliferation by splenic Tregs from adult saline versus 
poly(I:C) offspring. Similar levels of Teff proliferation are observed after 48 h of 
coculture of Tregs with Teffs at ratios of 1:1, 1:2, and 1:4 (n = 4). 
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Fig. S3. Hyperresponsiveness of CD4+ T cells from MIA offspring is established 
early in development and maintained through adulthood. CD4+ T cells from the 
spleens of 3-wk-old MIA offspring (A) and 1-y-old MIA offspring (B) secrete elevated 
levels of IL-6 (Left) and IL-17 (Right) in response to PMA/ionomycin stimulation (n = 
5–7). *P < 0.05, **P < 0.01, ***P < 0.001. All panels represent one representative 
experiment of at least two separate trials. 
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Fig. S4. Increases in both neutrophilic and monocytic Gr-1+ CD11b+ cells constitute 
the MIA-associated increase in total Gr-1+ cells. (A) Three populations of Gr-1+ cells 
are resolved based on Gr-1 intensity and granularity (side scatter, SSC). (B) Further 
stratification by CD11b and Ly6C intensity demonstrates that all three populations are 
CD11b+ and Ly6C+ (high or mid). (C) Assessment for Ly6G intensity reveals monocytic 
Gr-1+ cells [Ly6G−, population (iii)] and neutrophilic Gr-1+ cells [Ly6G high or mid, 
populations (i) and (ii)]. (D) Adult poly(I:C) offspring exhibit mild increases in all three 
populations of Gr-1+ cells identified: (i) Gr1hi CD11b+ Ly6Cmid Ly6Ghi SSCmid, (ii) 
Gr-1mid CD11b+ Ly6Cmid Ly6Gmid SSCmid, and (iii) Gr-1mid CD11b+ Ly6Chi 
Ly6G− SSClo, which result in a statistically significant difference based on treatment 
group (n = 5). **P < 0.01. 
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Fig. S5. There is no significant difference between unmanipulated saline mice and 
BM-transplanted mice in the lineage potential of BM HSCs and progenitors 
differentiated in vitro. Transplant of poly(I:C) or saline BM into irradiated 
poly(I:C) offspring corrects the abnormal lineage differentiation phenotype 
associated with unmanipulated poly(I:C) offspring. Similarly, transplant of poly(I:C) 
BM into irradiated saline offspring does not transfer the preferential skewing toward 
CFU-G (granulocyte) colonies that is observed in unmanipulated poly(I:C) offspring (n = 
3). *P < 0.05. 
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Fig. S6. BM transplant recipients are validated to be behaviorally abnormal in PPI, 
social preference, repetitive marble burying, and open-field exploration. (A) MIA 
offspring display significantly decreased PPI when prepulses are administered at 5 dB 
and 15 dB above background (PPI5 and PPI15, respectively). (B) Offspring of poly(I:C)-
injected mothers exhibit decreased social preference for a novel mouse over a familiar 
mouse, as measured by differences in chamber duration (Left) and chamber frequency 
(Right). (C) MIA offspring bury significantly greater numbers of marbles compared with 
saline controls, pre-BM transplant. (D) Poly(I:C) offspring exhibit increased anxiety in 
the open field compared with saline controls, as measured by decreased entries into and 
duration in the center of the arena, and no significant difference in overall locomotion as 
denoted by total distance traveled (n = 20–21). *P < 0.05, **P < 0.01. All panels 
represent one representative experiment of at least two separate trials. BM transplant data 
were acquired from one large experiment. 
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Fig. S7. MIA does not affect levels of activated or total CD11b+ 
microglia/macrophages in the brains of adult offspring. (A) There is no significant 
difference in levels of total CD11b+ cells or MHCI+ cells in the cerebellum, cortex, or 
hippocampus of adult poly(I:C) versus saline mice. (B) Representative flow cytometry 
plots of the separation of brain CD11b+ and MHCI+ cells. (C) There is no significant 
difference in the percentage of CD11b+ MHCII+ CD68+ cells from the cerebellum, 
cortex, or hippocampus of adult poly(I:C) versus saline mice. (D) Representative flow 
cytometry plots of the separation of brain MHCII+ and CD68+ cells. (n = 4 for each brain 
region). 
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Fig. S8. MIA offspring retested for anxiety in the open field at 9 mo of age retain 
behavioral deficits of similar intensity to those seen at 2 mo of age. This result applies 
to the number of entries into the center of the open field (Left) and duration of time spent 
in the center of the open field (Center). No significant difference is observed between 
saline and poly(I:C) offspring in total distance traveled in the open field arenas (Right), 
as is typically observed in the MIA model (n = 17–19). *P < 0.05 
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Fig. S9. The abnormal behaviors of MIA offspring are not maintained after 
irradiation and BM transplant. (A) Saline and poly(I:C) offspring irradiated and 
transplanted with poly(I:C) BM exhibit no difference in social preference for a novel 
mouse over a familiar mouse, as indicated by chamber duration (Left) and chamber 
frequency (Right). (B) MIA and control offspring irradiated and transplanted with 
poly(I:C) BM exhibit levels of repetitive marble burying that are comparable to those 
observed in transplanted control and untransplanted saline offspring. (C) There is no 
significant difference in level of anxiety in the open field between saline and poly(I:C) 
offspring irradiated and transplanted with saline or poly(I:C) BM, as measured by 
duration spent in the center of the open arena (Left) and number of entries into the center 
arena (Center). However, irradiated and BM-transplanted mice exhibit increased overall 
activity in the open field compared with untreated mice, as seen in elevated total distance 
traveled (Right). [n = 11–16 animals for saline and poly(I:C) groups, 4–5 animals for 
BM-transplant groups]. *P < 0.05, **P < 0.01, n.s., not significant. BM-transplant data 
were acquired from one large experiment. 
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Abstract 
 
Although autism spectrum disorder (ASD) is defined by core behavioral impairments, 
gastrointestinal (GI) symptoms are commonly reported. Subsets of ASD individuals 
display dysbiosis of the gut microbiome, and some exhibit increased intestinal 
permeability. Here we demonstrate GI barrier defects in a mouse model of an important 
ASD risk factor, maternal immune activation (MIA). Remarkably, oral treatment of MIA 
offspring with the human commensal Bacteroides fragilis corrects gut permeability and 
ameliorates defects in communicative, stereotypic, anxiety-like and sensorimotor 
behaviors. MIA offspring also display an altered serum metabolomic profile, and B. 
fragilis modulates levels of several of the serum metabolites. We show that treating naïve 
mice with a metabolite that is induced by MIA and restored by B. fragilis treatment 
causes some behavioral abnormalities, suggesting that repair of gut permeability 
ameliorates behavior. Taken together, these findings support a gut-microbiome-brain 
connection in autism, and identify a potential probiotic therapy for ASD. 
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Introduction 
Autism is a serious neurodevelopmental disorder characterized by stereotypic 
behavior and deficits in language and social interaction. The incidence of autism has 
rapidly increased to 1 in 88 births in the United States(CDC, 2012), representing a 
significant medical and social burden in the coming decades. However, therapies for 
treating the core symptoms of autism are limited, and reproducible molecular diagnostics 
have not been developed. Much research into autism spectrum disorder (ASD) has 
focused on genetic, behavioral and neurological aspects of the illness, but primary roles 
for environmental risk factors(Hallmayer et al., 2011), immune dysregulation(Onore, 
Careaga, & Ashwood, 2012) and additional peripheral disruptions(Kohane et al., 2012) in 
the pathogenesis of ASD have recently gained significant attention. Of several potential 
contributions to ASD, gastrointestinal (GI) distress is of particular interest, given its 
prevalence and correlation with the severity of core autism behavioral 
abnormalities(Adams, Johansen, Powell, Quig, & Rubin, 2011; Buie et al., 2010). A 
significant subset of ASD children display GI abnormalities, including abdominal 
cramps, chronic diarrhea or constipation and increased intestinal permeability(D'Eufemia 
et al., 1996; de Magistris et al., 2010). Moreover, antibiotic treatment and restricted diet 
are reported to provide behavioral improvements for some autistic children(Buie et al., 
2010). The causes of these GI problems are unclear, but may be linked to gut bacteria, as 
the intestinal microbiome is altered in ASD individuals(Finegold, Downes, & 
Summanen, 2012; Williams, Hornig, Parekh, & Lipkin, 2012).  
Humans are colonized with a diverse gut microbiota, which plays a critical role in 
obesity and inflammatory bowel disease (IBD)(Kau, Ahern, Griffin, Goodman, & 
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Gordon, 2011). In animal models, the microbiota not only modulates the development 
and function of the enteric immune system, but also impacts neuroinflammation(Hooper, 
Littman, & Macpherson, 2012; Ochoa-Reparaz et al., 2010). In particular, the human 
commensal Bacteroides fragilis exhibits therapeutic properties in mouse models of both 
colitis and multiple sclerosis (MS)(Ochoa-Reparaz et al., 2010; Round & Mazmanian, 
2010). Recent studies have revealed that commensal bacteria also affect a variety of 
behaviors, including emotional, nociceptive and anxiety-like behaviors(Amaral et al., 
2008; Bravo et al., 2011; Heijtz et al., 2011), and contribute to brain development and 
function in mice(Al-Asmakh, Anuar, Zadjali, Rafter, & Pettersson, 2012; Collins, 
Surette, & Bercik, 2012; Cryan & Dinan, 2012). Based on an emerging appreciation of a 
gut-brain connection(Mayer, 2011), we asked whether commensal bacteria, and B. 
fragilis in particular, could affect behaviors relevant to ASD.  
Maternal immune activation (MIA) is an important environmental risk factor for 
ASD. Several large epidemiological studies link maternal viral and bacterial infection 
with increased autism risk in the offspring(Atladottir et al., 2010; Lee et al., 2012). We 
have shown that modeling this risk factor in mice by injecting pregnant dams with the 
viral mimic poly(I:C) yields offspring that exhibit the core behavioral symptoms of 
autism, as well as a common autism neuropathology(Malkova, Yu, Hsiao, Moore, & 
Patterson, 2012; Shi et al., 2009). MIA offspring also display altered peripheral immune 
responses(Hsiao & Patterson, 2011), which aligns well with recent studies highlighting a 
role for immune dysregulation in ASD(Onore et al., 2012). Although several 
environmental and genetic risk factors have been investigated in mice, GI abnormalities 
have not been reported in preclinical models of ASD. We show herein that MIA offspring 
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have defects in intestinal integrity and that treatment of MIA offspring with B. fragilis 
improves gut barrier function and ameliorates autism-related behaviors. Consistent with 
the finding that gut bacteria impact the serum metabolome(Bercik et al., 2011; Nicholson 
et al., 2012), B. fragilis treatment restores levels of specific serum metabolites that are 
altered by prior MIA exposure. Injection of the most prominently affected metabolite into 
naïve mice causes a behavioral impairment related to ASD. Thus, modulating serum 
metabolites by B. fragilis provides a potential pathway for its beneficial effects and may 
represent a novel approach for treatment of human autism. 
 
B. fragilis treatment ameliorates ASD-related behaviors 
As previously reported(Malkova et al., 2012), maternal poly(I:C) injection yields 
offspring with increased anxiety in the open field, increased stereotyped marble burying, 
decreased number and duration of ultrasonic vocalizations, deficient prepulse inhibition 
(PPI) of acoustic startle, and low sociability and social preference (Fig. 1; compare saline 
(S) to poly(I:C) (P)). Remarkably, oral treatment with B. fragilis ameliorates many of 
these ASD-associated behavioral abnormalities in MIA offspring. Probiotic-treated 
poly(I:C) offspring are protected from anxiety-like behavior in the open field (Fig. 1a) 
and also exhibit significantly decreased levels of stereotyped marble burying and restored 
number of ultrasonic vocalizations, with the duration per call exceeding that observed in 
control offspring (Fig. 1b, d; compare poly(I:C) (P) to poly(I:C)+B. fragilis (P+BF)). B. 
fragilis treatment also improves sensorimotor gating as indicated by the restoration of PPI 
to levels comparable to controls, with no significant effect on the intensity of startle to the 
acoustic stimulus (Fig. 1c). Interestingly, behavioral improvement in response to B. 
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fragilis treatment is not associated with changes in systemic immunity in MIA offspring 
(Supplementary Fig. 1) and is not dependent on polysaccharide A (PSA), the capsular 
component identified to confer immunomodulatory effects of B. fragilis in experimental 
autoimmune encephalomyelitis (EAE) and colitic mice (Supplementary Fig. 2)(Ochoa-
Reparaz et al., 2010; Round & Mazmanian, 2010). Furthermore, amelioration of behavior 
is not specific to B. fragilis, as similar treatment with Bacteroides thetaiotaomicron also 
significantly improves anxiety-like, repetitive and communicative behavior in MIA 
offspring (Supplementary Fig. 3). While we cannot exclude the possibility of a tissue-
specific effect of B. fragilis on immunity, these data suggest a novel beneficial effect of 
B. fragilis in the autism model as compared to models of MS or IBD. Notably, B. fragilis 
does not significantly alter baseline behavior in saline offspring (Fig. 1; compare saline 
(S) to saline+B. fragilis (S+BF)) in all tests but PPI, suggesting that the diseased state 
elicits a physiological response to B. fragilis that differs from that found in treated control 
mice.  
Although B. fragilis-treated poly(I:C) offspring exhibit improved communicative, 
repetitive, anxiety-like and sensorimotor behavior, they retain deficits in sociability, as 
indicated by decreased preference for a novel mouse versus a novel toy, and in social 
preference for an unfamiliar versus familiar mouse (Fig. 1e). Interestingly, this parallels 
the inability to improve social behavior by administration of risperidone to ASD 
individuals(Canitano & Scandurra, 2008) or CNTNAP2 knockout mice, a genetic mouse 
model for ASD(Penagarikano et al., 2011), and by irradiation and bone marrow 
transplant of MIA offspring(Hsiao & Patterson, 2011). These data suggest that there are 
fundamental differences in the circuitry or circuit plasticity governing social behavior as 
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compared to the other behaviors, and that B. fragilis modulates specific pathways during 
amelioration of ASD-related behavioral defects in MIA offspring. 
 
B. fragilis improves intestinal barrier integrity in offspring of immune-activated 
mothers 
There is growing evidence that subsets of autistic children display GI 
abnormalities, including increased intestinal permeability or “leaky gut”(Buie et al., 
2010; Ibrahim, Voigt, Katusic, Weaver, & Barbaresi, 2009). Remarkably, we find that 
MIA offspring display a significant deficit in intestinal barrier permeability, as reflected 
by increased translocation of orally administered FITC-dextran across the intestinal 
epithelial layer and into the circulation (Fig. 2a, left panel). A similar deficit is present in 
3-week-old MIA offspring (Fig. 2a, right panel), demonstrating that this abnormality is 
established early during development and prior to B. fragilis treatment. Notably, B. 
fragilis treatment restores this MIA-associated increase in intestinal barrier permeability 
to levels comparable to those observed in saline controls (Fig. 2a, left panel). These data 
demonstrate that, in addition to improving autism-related behaviors, B. fragilis 
ameliorates leaky gut in MIA offspring. The presence of GI defects prior to probiotic 
administration suggests that B. fragilis may treat, rather than prevent, this ASD-related 
pathology in MIA offspring.  
To assess the molecular basis for increased intestinal permeability in MIA 
offspring, we examined the colons of MIA offspring for levels of the tight junction 
components ZO-1, ZO-2, ZO-3, occludin and claudins 1, 2, 3, 4, 7, 8, 12, 13 and 
15(Holmes, Van Itallie, Rasmussen, & Anderson, 2006). Consistent with the leaky gut 
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phenotype, colons from adult poly(I:C) offspring exhibit decreased expression of ZO-1, 
ZO-2, occludin and claudin 8, and increased expression of claudin 15 mRNA (Fig. 2b). 
Furthermore, B. fragilis treatment ameliorates MIA-associated changes in expression of 
claudin 8 and 15, but has no restorative effect on expression of ZO-1, ZO-2 or occludin 
mRNA. Similar changes in colon claudin 8 and 15, with restoration by B. fragilis 
treatment, are also observed at the protein level (Fig. 2c). Interestingly, both decreased 
claudin 8 and increased claudin 15 are associated with alterations in sodium paracellular 
permeability in the mouse intestine(Amasheh et al., 2009; Tamura et al., 2011), and 
sodium electrochemical gradients across the intestinal epithelia are known to regulate 
sodium-dependent ion and nutrient absorption as well as GI motility(Turner, 2009). No 
such effects of B. fragilis on tight junction expression are observed in small intestines 
from MIA offspring (Supplementary Fig. 4), consistent with reports showing that B. 
fragilis colonizes the colonic mucosa and that Bacteroides species are predominantly 
found in the colon(Huang, Lee, & Mazmanian, 2011). Collectively, discovery of GI 
defects in MIA offspring recapitulates intestinal co-morbidities found in subsets of ASD 
individuals, and correction of leaky gut and behavioral abnormalities by B. fragilis 
supports emerging evidence for a gut-brain link in autism.  
 
B. fragilis modulates an MIA-associated cytokine in the gut 
Cytokines are signaling molecules used widely by both the immune and nervous 
systems. Levels of a variety of cytokines, including interleukin-6 (IL-6), are altered in the 
serum and cerebrospinal fluid of autistic individuals(Onore et al., 2012; Patterson, 2011), 
but whether they also exhibit altered gut expression patterns is unknown. Remarkably, 
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colonic tissues of adult MIA offspring contain increased levels of IL-6 mRNA and 
protein, and B. fragilis treatment restores elevated IL-6 to levels found in control mice 
(Supplementary Fig. 5). Levels of other cytokines are also altered in both colons and 
small intestines of MIA offspring (Supplementary Fig. 4 and Supplementary Fig. 5), but 
these are not affected by B. fragilis treatment, revealing specificity for IL-6. This is 
interesting in light of a previous study showing that induction of IL-6, but not other 
cytokines, in response to MIA is required for the development of behavioral deficits in 
the offspring(S. E. Smith, Li, Garbett, Mirnics, & Patterson, 2007). Nonetheless, altered 
intestinal cytokines may be the basis for the increased intestinal permeability observed in 
MIA offspring, as several cytokines including IL-6 regulate tight junction expression and 
intestinal barrier integrity(Suzuki, Yoshinaga, & Tanabe, 2011; Turner, 2009). Consistent 
with the notion that IL-6 affects intestinal permeability in MIA offspring, we find that 
recombinant IL-6 treatment can modulate colon levels of both claudin 8 and claudin 15 in 
in vivo and in in vitro colon organ cultures (Supplementary Fig. 6). This suggests that B. 
fragilis-mediated restoration of colonic IL-6 levels regulates changes in colon tight 
junction protein expression. Overall, these findings demonstrate that MIA offspring 
exhibit defective GI barrier integrity, with corresponding changes in colon tight junction 
and cytokine profiles, which are reversed by B. fragilis treatment.  
 
The serum metabolome is modulated by MIA and B. fragilis 
Metabolomic studies have shown that gut microbial products are found in many 
extra-intestinal tissues, and molecules derived from the microbiota may influence 
metabolic, immunologic and behavioral endophenotypes in mice and humans(Bercik et 
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al., 2011; Blumberg & Powrie, 2012; Hooper et al., 2012; MacFabe, 2012; Matsumoto et 
al., 2012; Nicholson et al., 2012). Given that MIA offspring display altered intestinal 
permeability and tight junction expression, we utilized liquid chromatography/gas 
chromatography with mass spectrometry (LC/GC-MS)-based metabolomic profiling to 
identify MIA-associated changes in serum metabolites. 2400 metabolites were assayed 
and of these, 322 metabolites, spanning amino acid (94), peptide (15), carbohydrate (22), 
energy (10), lipid (128), nucleotide (23), xenobiotic (19) and cofactor and vitamin (11) 
super pathways were detected in sera from adult mice. Interestingly, MIA leads to 
statistically significant alterations in 8% of all serum metabolites detected 
(Supplementary Table 1). Furthermore, postnatal B. fragilis treatment has a significant 
effect on the serum metabolome, altering 34% of all metabolites detected (Supplementary 
Fig. 7 and Supplementary Data 1). The majority (72%) of B. fragilis-mediated changes 
are found in MIA offspring and not in control mice, demonstrating that the particular 
effects of postnatal B. fragilis treatment on the serum metabolome depend on the disease 
status of the host. This is consistent with our finding that B. fragilis-mediated 
improvement of many ASD-related behaviors is specific to MIA offspring and is not 
observed in controls (Fig. 1). In particular, B. fragilis treatment lowers serum levels of 
several fatty acids and increases levels of molecules associated with purine catabolism 
(Supplementary Fig. 7 and Supplementary Data 1). In light of our finding that B. fragilis 
itself does not permanently colonize the GI tracts of treated MIA and control offspring 
(Supplementary Fig. 8), these widespread changes suggest that B. fragilis disrupts the 
composition and/or functional activity of the resident intestinal microbiota. Moreover, 
that vehicle-treated MIA offspring do not display many of these changes in fatty acid and 
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purine metabolites suggests that these disruptions do not play a significant role in the 
onset of autism-related symptoms in the MIA model. Whether B. fragilis-mediated 
changes in fatty acid uptake and purine salvage serve a protective role in ameliorating 
MIA-induced autism-related behaviors remains to be investigated.  
 
B. fragilis corrects levels of MIA-induced serum metabolites 
In line with the notion that increased gut permeability leads to leakage of 
metabolites into the bloodstream, we hypothesized that B. fragilis-mediated improvement 
of intestinal barrier integrity prevents alterations in serum metabolite levels. We therefore 
focused on serum metabolites that are significantly altered by MIA treatment and 
completely restored to control levels by B. fragilis treatment (Fig. 3). MIA offspring 
display a striking, 45-fold increase in serum levels of a recently identified metabolite, 4-
ethylphenylsulfate (4EPS), which is dramatically reduced by B. fragilis treatment (Fig. 
3a). This metabolite is of particular interest because of the reported production of 4EPS 
by GI microbes and proposed role of 4EPS in communication by mice(Lafaye et al., 
2004). Moreover, we find that, compared to conventionally colonized mice, germ-free 
mice display nearly undetectable levels of serum 4EPS, indicating that serum 4EPS is 
derived from or critically modulated by the commensal microbiota (Fig. 4e). 
Interestingly, 4EPS is suggested to be a uremic toxin, as is p-cresol (4-methylphenol), a 
metabolite identified as a possible urinary biomarker for human autism(Altieri et al., 
2011). MIA offspring also exhibit elevated levels of serum p-cresol, though the increase 
does not reach statistical significance (Supplementary Data 1). That 4EPS shares such 
structural similarity to the toxic sulfated form of p-cresol (4-methylphenylsulfate) is 
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intriguing in its suggestion that the two metabolites may exhibit functional overlap and 
link metabolite abnormalities seen in the MIA model to those observed in human autism.   
 
In addition to 4EPS, MIA offspring display significantly increased levels of serum 
indolepyruvate, a key molecule of the tryptophan metabolism pathway, which is restored 
to control levels by B. fragilis treatment (Fig. 3b). Indolepyruvate is generated by 
tryptophan catabolism and, like 4EPS, indolepyruvate is known to be produced by gut 
microbes(E. A. Smith & Macfarlane, 1997). Moreover, the elevation in serum 
indolepyruvate observed in MIA offspring is analogous to the increase in another major 
tryptophan metabolite observed in human autism, indolyl-3-acryloylglycine (IAG), which 
was suggested to be a urinary biomarker for ASD(Bull et al., 2003). Interestingly, IAG is 
involved in GI homeostasis and is produced by bacterial tryptophan 
metabolism(Keszthelyi, Troost, & Masclee, 2009). Although IAG was not detected in our 
metabolomic screen, it is notable that MIA offspring exhibit increased levels of serum 
serotonin (0.05 < P < 0.10; Supplementary Data 1), which reflects an alteration in another 
pathway of tryptophan metabolism and is reminiscent of the hyperserotonemia 
endophenotype of autism(Mulder et al., 2004). Importantly, the commensal microbiota is 
known to impact serum levels of indole-containing tryptophan metabolites and 
serotonin(Wikoff et al., 2009). MIA also leads to altered serum glycolate, imidazole 
propionate and N-acetylserine levels (Fig. 3c-e), which are corrected by B. fragilis 
treatment. How changes in these metabolites may be relevant to ASD or GI dysfunction, 
however, are unclear. Overall, we demonstrate that MIA elevates, and B. fragilis 
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treatment normalizes, serum levels of 4EPS and indolepyruvate, two molecules 
modulated by the intestinal microbiota with potential relevance to autism. 
 
A serum metabolite induces some ASD-related behaviors 
MIA-induced increases in the systemic bioavailability of specific metabolites and 
restoration by B. fragilis treatment suggests that these molecules may play a causative 
role in the development of autism-related behaviors in MIA offspring. To test this 
hypothesis, we examined whether experimental increase in serum 4EPS, the most 
dramatic of all MIA-induced and B. fragilis-restored metabolite changes, is sufficient to 
cause autism-related behavioral abnormalities in mice. We chemically synthesized 4EPS 
by treatment of 4-ethylphenol with sulfur trioxide-pyridine complex, which following ion 
exchange, provided the 4EPS potassium salt (Supplementary Fig. 9a)(Burlingham et al., 
2003; Grimes, 1959). Mice were intraperitoneally treated with 4EPS daily, from 3 weeks 
of age (when increased intestinal permeability is detected in MIA offspring, Fig. 2a) to 6 
weeks of age (when behavior testing begins). Remarkably, systemic administration of 
4EPS to naïve mice is sufficient to induce anxiety-like behavior that is similar to that 
observed in MIA offspring (Fig. 4a). In addition, 4EPS-treated mice exhibit an abnormal 
PPI response characterized by increased startle to the primary acoustic stimulus (Fig. 4b). 
There are no significant differences, however, between 4EPS-treated versus saline-treated 
mice in marble burying or USV behavior (Fig. 4c, d), suggesting that elevating serum 
4EPS levels specifically promotes anxiety-like behavior. It will be interesting to assess 
whether continued 4EPS administration through the behavioral testing period influences 
communicative and stereotyped behavior. More likely, complex behavioral conditions 
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may be mediated by combinations of serum metabolites, in addition to pathology 
unrelated to metabolome changes. In line with a GI involvement in modulating the serum 
metabolome and behavior in MIA offspring, we find that serum 4EPS levels are 
modulated by the commensal microbiota (Fig. 4e) and that elevating serum 4EPS in naïve 
mice is sufficient to induce anxiety-like behavior. This indicates that metabolomic 
changes can contribute to the onset and/or persistence of autism-related behavioral 
abnormalities in MIA offspring, and suggests that B. fragilis-mediated modulation of 
serum 4EPS levels leads to the correction of anxiety-like behavior in MIA offspring. 
Overall, our studies reveal that metabolomic changes may cause some ASD-related 
behavioral abnormalities in mouse models, suggesting that inhibition of specific serum 
metabolites represents a novel approach to autism therapies.  
 
Conclusion 
While the impact of the microbiota on immunologic and metabolic disease is 
profound, little is known regarding a link to behavioral disorders. We propose that 
commensal bacteria of the microbiota can influence the gut-brain connection by 
modulating metabolites that alter behavior. We find that postnatal B. fragilis treatment 
corrects abnormal intestinal permeability and ameliorates communicative, stereotyped, 
sensorimotor and anxiety-like behavior in a mouse model for ASD. While a number of 
microbes, including Lactobacillis rhamnosus(Bravo et al., 2011) and Bifidobacterium 
longum(Bercik et al., 2011), are known to alleviate anxiety and depressive behavior in 
animal models, our current findings represent the first evaluation of a microbial effect on 
core autism-related behaviors. We further demonstrate that, in addition to displaying 
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cardinal behavioral and neuropathological symptoms of ASD(Malkova et al., 2012; Shi et 
al., 2009), offspring of immune-activated mothers exhibit altered serum metabolites and 
deficient GI integrity that is analogous to that seen in subsets of ASD individuals(Buie et 
al., 2010; D'Eufemia et al., 1996; de Magistris et al., 2010). Thus, the MIA model 
exhibits face and construct validity for particular co-morbid GI symptoms found in 
human autism. Consistent with the well-established role of GI microbes in regulating 
intestinal permeability and metabolic homeostasis(Ewaschuk et al., 2008; Matsumoto et 
al., 2012; Nicholson et al., 2012; Resta-Lenert & Barrett, 2009; Turner, 2009; Wikoff et 
al., 2009), we show that B. fragilis treatment corrects GI permeability and restores MIA-
associated changes in blood metabolites. By this means, B. fragilis may prevent the 
leakage of deleterious molecules from the GI lumen and/or promote the synthesis of 
protective compounds in the periphery. In a proof-of-concept test of this idea, the 
microbially-modulated metabolite 4EPS, which is elevated in circulating blood by MIA 
and restored by B. fragilis treatment, is sufficient to induce anxiety-like behavior in 
wildtype mice. Although core autism behaviors are not affected by 4EPS alone, this 
finding warrants the study of several other blood metabolites affected by B. fragilis 
treatment for their potential to impact particular autism-related behaviors. It is intriguing 
that B. fragilis exerts beneficial behavioral and metabolomic effects in a disease-specific 
manner. This observation contributes to a growing number of studies emphasizing that 
microbial composition and function is critically influenced by differences in host 
genotype and environment(Campbell et al., 2012; Gulati et al., 2012; P. Smith et al., 
2012). Taken together, we provide a novel mechanism by which B. fragilis treatment can 
improve autism-related behavioral abnormalities and present compelling evidence for a 
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probiotic-based therapy for ASD-associated symptoms. Validation of a specific 
metabolomic profile specific in human autism subjects with GI complications may serve 
as a novel molecular diagnostic and the basis for microbiome-mediated therapies.  
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Methods Summary 
Maternal immune activation was induced by injection of 20 mg/kg poly(I:C) sodium salt 
(Sigma Aldrich) into pregnant E12.5 C57Bl/6N females. Offspring were treated with 
three doses of 10^10 cfu B. fragilis in applesauce or 1.5% sodium bicarbonate vehicle in 
applesauce at weaning. Mice were behaviorally tested from 6-10 weeks of age in prepulse 
inhibition, open field exploration, repetitive marble burying, sociability, social preference 
and adult ultrasonic vocalization. In vivo intestinal permeability assays were conducted 
by oral gavage with 4kD FITC-dextran (Sigma Aldrich) and serum fluorescence 
detection at 521 nm using an xFluor4 spectrometer (Tecan). Colon lysates from adult 
mice were used for 20-plex cytokine arrays (Luminex) or processed for gene expression 
analysis by RNA extraction with Trizol (Invitrogen) and RNeasy mini column isolation 
(Qiagen) with DNase treatment (Qiagen), cDNA synthesis with iScript kit (Biorad) and 
SYBR Green qRT-PCR with Rox passive reference dye (Roche) using tight junction and 
cytokine-related primers. Metabolomics screens were conducted by GC/LC-MS 
(Metabolon Inc.) using a Waters ACQUITY UPLC and Thermo-Finnigan LTQ mass 
spectrometer, with a linear ion-trap front-end and a Fourier transform ion cyclotron 
resonance mass spectrometer back-end. 4EPS was measured by LC-MS at Caltech using 
an Agilent 110 Series HPLC system equipped with a photodiode array detector and 
interfaced to a model G1946C single quadrupole expectospray mass spectrometer.     
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Figure 1. B. fragilis treatment ameliorates autism-related behaviors in MIA 
offspring. a, Poly(I:C) offspring exhibit anxiety-like behavior, as measured by decreased 
entries into and duration spent in the center of an open field, which is restored to control 
levels by B. fragilis treatment. There is no difference between experimental groups in 
total distance traveled. n = 35-75. b, B. fragilis treatment corrects deficits in 
communicative behavior, as indicated by the total number and duration of ultrasonic 
vocalizations produced by adult male poly(I:C) offspring in response to a female. n = 7-
10. c, B. fragilis-treated poly(I:C) and saline offspring display increased prepulse 
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inhibition (PPI) of an acoustic startle, indicating improved sensorimotor gating (PPI5, 5 
db prepulse; PPI15, 15 db prepulse). n = 35-75. d, Poly(I:C) offspring engage in elevated 
stereotypic marble burying, and this phenotype is corrected by B. fragilis treatment. n = 
16-45. e, B. fragilis is not effective in treating social abnormalities in MIA offspring, 
having no impact on the decreased preference for a novel mouse versus novel toy 
(sociability) or the decreased preference for an unfamiliar versus familiar mouse (social 
preference) observed in MIA offspring. n = 10. *P < 0.05, **P < 0.01, ***P < 0.001, n.s. 
= not significant. S=saline+vehicle, S+BF= saline+B. fragilis, P=poly(I:C)+vehicle, 
P+BF=poly(I:C)+B. fragilis 
 
 
 
 
 521 
 
Figure 2. MIA offspring exhibit a deficit in GI barrier function and expression of 
tight junction components, which are corrected by B. fragilis treatment. a, Left 
panel: Adult poly(I:C) offspring display increased serum FITC fluorescence intensity 
after oral FITC-dextran gavage, indicating elevated intestinal permeability. This is 
restored to levels comparable to saline controls by B. fragilis treatment. DSS-treated 
colitic mice are used as a positive control for leaky gut. n= 12-13 for poly(I:C) and saline, 
n = 6 for DSS and poly(I:C)+BF. Right panel: 3 week old MIA offspring also exhibit 
increased intestinal permeability, demonstrating that this GI barrier abnormality is 
present prior to probiotic treatment. n = 4. b, The abnormal intestinal barrier integrity in 
MIA offspring corresponds to altered colon tight junction expression of ZO-1, ZO-2, 
occludin, claudin 8 and 15 mRNA. The changes in claudin 8 and 15 expression are 
ameliorated by B. fragilis treatment. n = 8. Asterisks within bars indicate significance 
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compared to saline control (normalized to 1, as denoted by the black line), whereas 
asterisks to the right of bars denote significance between poly(I:C) and poly(I:C)+B. 
fragilis. c, Similar alterations in colon claudin 8 and 15 are seen at the protein level, with 
trending decreases in claudin 8 and significant increases in claudin 15, which are both 
corrected by B. fragilis treatment. n = 3. # P < 0.07, φ P = 0.05, *P < 0.05, **P < 0.01, 
n.s. = not significant. DSS=dextran sodium sulfate, S=saline+vehicle, 
P=poly(I:C)+vehicle, P+BF=poly(I:C)+B. fragilis. 
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Figure 3. B. fragilis treatment corrects MIA-induced alterations in serum 
metabolites. a, Adult MIA offspring display a striking 45-fold increase in serum 4-
ethylphenylsulfate levels, which is reduced to levels comparable to controls by B. fragilis 
treatment. MIA offspring also exhibit significantly increased serum indolepyruvate (b), 
glycolate (c) and imidazole propionate (d) levels, and decreased serum N-acetylserine 
levels (e), which are each corrected by B. fragilis treatment. n = 8. Ψ P =0.08, *P < 0.05, 
**P < 0.01, a.u.=relative arbitrary units. S=saline+vehicle, S+BF= saline+B. fragilis, 
P=poly(I:C)+vehicle, P+BF=poly(I:C)+B. fragilis. 
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Figure 4. Elevating serum 4-ethylphenylsulfate (4EPS) levels is sufficient to induce 
anxiety-like behavior. a, 4EPS-treated mice exhibit anxiety-like behavior in the open 
field, as indicated by significantly decreased duration spent in the center arena, but no 
difference in total distance traveled, compared to saline-treated control mice. n = 10. b, 
4EPS treatment also induces an altered PPI response characterized by significantly 
elevated startle to the 120 db acoustic tone, despite no significant difference in percent 
PPI. There is no significant effect of 4EPS treatment in the marble burying task (c) and in 
adult male ultrasonic vocalizations in the response to a female (d). n = 10 (n = 5 males 
for USV). e, Germ-free (GF) mice display dramatically reduced levels of serum 4EPS 
compared to conventional specific-pathogen-free (SPF) controls, demonstrating that the 
commensal microbiota modulates serum 4EPS levels. UD=undetectable. n=1, where each 
represents pooled sera from 3-5 mice. *P < 0.05 
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Methods 
Animals and MIA 
Pregnant C57BL/6N (Charles River; Wilmington, MA) were injected i.p. on E12.5 with 
saline or 20 mg/kg poly(I:C) according to methods described in ref. (Hsiao & Patterson, 
2011). All animal experiments were approved by the Caltech IACUC.  
 
B. fragilis treatment 
At 3 weeks of age, saline and poly(I:C) offspring were weaned and treated with B. 
fragilis freshly prepared every other day for 3 days: 10^10 cfu B. fragilis was mixed with 
4 ml sugar-free applesauce and spread over four standard food pellets. Control saline and 
poly(I:C) animals were fed 1.5% sodium bicarbonate vehicle in applesauce over food 
pellets. Applesauce and pellets were completely consumed by mice of each treatment 
group by 48 hours after administration. The same procedure was used for treatment with 
mutant B. fragilis lacking PSA and B. thetaiotaomicron.  
 
Behavioral testing 
Adult MIA and control offspring were behaviorally tested as in refs. (Hsiao & 
Patterson, 2011) and (Malkova et al., 2012). Mice were tested beginning at 6 weeks of 
age for prepulse inhibition, open field exploration, marble burying, social interaction and 
adult ultrasonic vocalizations, in that order with at least 5 days between behavioral tests. 
Behavioral data for B. fragilis treatment and control groups (Fig. 1) represent cumulative 
results collected from multiple litters of 3-5 independent cohorts of mice for PPI and 
open field tests, 2-4 cohorts for marble burying, 2 cohorts for adult male ultrasonic 
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vocalization and 1 cohort for social interaction. Discrepancies in sample size across 
behavioral tests reflect differences in when a particular test was implemented.   
Prepulse inhibition. PPI tests are used as a measure of sensorimotor gating and 
were conducted and analyzed as in refs (S. E. Smith et al., 2007) and (Geyer & 
Swerdlow, 2001). Briefly, mice were acclimated to the testing chambers of the SR-LAB 
startle response system (San Diego Instruments) for 5 min, presented with six 120 db 
pulses of white noise (startle stimulus) and then subjected to 14 randomized blocks of 
either no startle, startle stimulus only, 5 db prepulse with startle or 15 db prepulse with 
startle. The startle response was recorded by a pliezo-electric sensor, and the percent PPI 
is defined as [((startle stimulus only – 5 or 15 db prepulse with startle)/startle stimulus 
only)*100]. 
Open field exploration. The open field test is widely used to measure anxiety-like 
and locomotor behavior in rodents (Bailey & Crawley, 2009). Mice were placed in 50 x 
50 cm white Plexiglas boxes for 10 min. An overhead video camera recorded the session, 
and Ethovision software (Noldus) was used to analyze the distance traveled, and the 
number of entries and duration of time spent in the center arena (central 17 cm square).  
Marble burying. Marble burying is an elicited repetitive behavior in rodents 
analogous to those observed in autistic individuals(Silverman, Yang, Lord, & Crawley, 
2010). This test was conducted and analyzed according to methods described in refs. 
(Thomas et al., 2009) and (Malkova et al., 2012). Mice were habituated for 10 min to a 
novel testing cage containing a 4 cm layer of chipped cedar wood bedding and then 
transferred to a new housing cage. 18 glass marbles (15 mm diameter) were aligned 
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equidistantly 6 x 3 in the testing cage. Mice were returned to the testing cage and the 
number of marbles buried in 10 min was recorded.  
Sociability and social preference. Social interaction tests were conducted and 
analyzed according to methods adopted from refs. (Sankoorikal, Kaercher, Boon, Lee, & 
Brodkin, 2006) and (Yang, Silverman, & Crawley, 2011). Briefly, testing mice were 
habituated for 10 min to a 40 x 60 cm Plexiglas three-chambered apparatus containing 
clear interaction cylinders in each of the side chambers. Sociability was tested in the 
following 10 min session, where the testing mouse was given the opportunity to explore a 
novel same-sex, age-matched mouse in one interaction cylinder (social object) versus a 
novel toy (green sticky ball) in the other interaction cylinder of the opposite chamber. 
Social preference was tested in the final 10 min session, where the testing mouse was 
given the opportunity to explore a now familiar mouse (stimulus mouse from the 
previous sociability session) versus a novel unfamiliar same-sex, age-matched mouse. In 
each session, the trajectory of the testing mouse was tracked with Ethovision software 
(Noldus). Sociability data is presented as preference for the mouse over the toy: percent 
of time in the social chamber percent of time in the nonsocial chamber, and social 
preference data is presented as preference for the unfamiliar mouse over the familiar 
mouse: percent of time in the unfamiliar mouse chamber – percent of time in the familiar 
mouse chamber. Similar indexes were measured for chamber entries, and entries into and 
duration spent in the contact zone (7 x 7 cm square surrounding the interaction cylinder).  
Adult ultrasonic vocalizations. Male mice produce USVs in response to female 
mice as an important form of communication(Portfors, 2007). We measured adult male 
USV production in response to novel female exposure according to methods described in 
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refs. (Grimsley, Monaghan, & Wenstrup, 2011; Malkova et al., 2012; Scattoni, Ricceri, & 
Crawley, 2011). Adult males were single-housed one week before testing and exposed for 
20 min to an unfamiliar adult female mouse each day starting four days prior to testing in 
order to provide a standardized history of sexual experience and to adjust for differences 
in social dominance. On testing day, mice were habituated to a novel cage for 10 minutes 
before exposure to a novel age-matched female. USVs were recorded for 3 min using the 
UltraSoundGate microphone and audio system (Avisoft Bioacoustics). Recordings were 
analyzed using Avisoft’s SASLab Pro software after fast Fourier transformation at 512 
FFT-length and detection by a threshold-based algorithm with 5 ms hold time. Data 
presented reflect duration and number of calls produced in the 3 min session.  
 
In vitro immune assays 
Methods for Treg and Gr-1 flow cytometry and CD4+ T cell in vitro stimulation are 
described in ref. (Hsiao, McBride, Chow, Mazmanian, & Patterson, 2012). Briefly, cells 
were harvested in complete RPMI from spleens and mesenteric lymph nodes. For 
subtyping of splenocytes, cells were stained with Gr-1 APC, CD11b-PE, CD4-FITC and 
Ter119-PerCP-Cy5.5 (Biolegend). For detection of Tregs, splenocytes were stimulated 
for 4 h with PMA/ionomycin in the presence of GolgiPLUG (BD Biosciences), blocked 
for Fc receptors and labeled with CD4-FITC, CD25-PE, Foxp3-APC and Ter119-PerCP-
Cy5.5. Samples were processed using the FACSCalibur cytometer (BD Biosciences) and 
analyzed using FlowJo software (TreeStar). For CD4+ T cell stimulation assays, 10^6 
CD4+ T cells were cultured in complete RPMI with PMA (50 ng/ml) and ionomycin 
(750 ng/ml) for 3 d at 37C with 5% (vol/vol) CO2. Each day, supernatant was collected 
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for ELISA assays to detect IL-6 and IL-17, according to the manufacturer’s instructions 
(eBioscience).  
 
Intestinal permeability assay 
Adult mice were fasted for 4 hours before oral gavage with 0.6 g/kg 4 kDa FITC-dextran 
(Sigma Aldrich). 4 hours later, blood samples were collected by cardiac puncture and 
spun through SST vacutainers (Becton Dickinson). FITC-dextran standards and 3X-
diluted sera were immediately read for FITC fluorescence intensity at 521 nm using an 
xFluor4 spectrometer (Tecan). Mice were fed 3% dextran sulfate sodium salt (DSS; MP 
Biomedicals) in drinking water for 7 days to chemically induce colitis.   
 
Intestinal qRT-PCR, Western blots, and cytokine profiles 
1 cm regions of the distal, medial and proximal colon and small intestine were washed in 
HBSS and either a) homogenized in ice-cold Trizol for RNA isolation and reverse 
transcription according to ref. (Hsiao & Patterson, 2011) or b) homogenized in Tissue 
Extraction Reagent I (Invitrogen) containing EDTA-free protease inhibitors (Roche) for 
protein assays. For SYBR green qRT-PCR, validated primer sets were obtained from 
Primerbank (Harvard). For cytokine profiling, mouse 20-plex cytokine arrays 
(Invitrogen) were run on the Luminex FLEXMAP 3D platform by the Clinical 
Immunobiology Correlative Studies Laboratory at the City of Hope (Duarte, CA). 
Western blots were conducted according to standard methods and probed with rabbit anti-
claudin 8 or rabbit anti-claudin 15 (Invitrogen) at 1:88 dilution.  
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IL-6 oral gavage and in vitro colon culture 
For in vivo assays, adult mice were gavaged with 5 ug carrier-free recombinant mouse 
IL-6 (eBioscience) in 1.5% sodium bicarbonate. At 4 hours post-gavage, 1 cm regions of 
distal, medial and proximal colon were dissected, washed in HBSS and processed for 
qRT-PCR, as described above. For in vitro assays, adult mice were sacrificed and 1 cm 
regions of distal, medial and proximal colon were dissected, washed and bisected for 
colon culture with 0-80 ng/ml IL-6 in complete RPMI media. After 4 hours of culture, 
colon pieces were harvested and processed for qRT-PCR, as described above.  
 
B. fragilis colonization assay 
Fecal samples were sterilely collected from MIA and control offspring at 1, 2 and 3 
weeks after the start of treatment with B. fragilis or vehicle. Germ-free mice were treated 
with B. fragilis as described above to serve as positive controls. DNA was isolated fecal 
samples using the QIAamp DNA Stood Mini Kit (Qiagen). 50 ng DNA was used for 
qPCR with B. fragilis-specific primers, 5’ TGATTCCGCATGGTTTCATT 3’ and 5’ 
CGACCCATAGAGCCTTCATC 3’, and universal 16S primers 5’ 
ACTCCTACGGGAGGCAGCAGT 3’ and 5’ ATTACCGCGGCTGCTGGC 3’ 
according to ref. (Odamaki et al., 2008).  
 
Metabolome screening 
Sera were collected by cardiac puncture from behaviorally validated adult mice. Samples 
were extracted and analyzed on GC/MS, LC/MS and LC/MS/MS platforms by 
Metabolon, Inc. Protein fractions were removed by serial extractions with organic 
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aqueous solvents, concentrated using a TurboVap system (Zymark) and vacuum dried. 
For LC/MS and LC/MS/MS, samples were reconstituted in acidic or basic LC-compatible 
solvents containing >11 injection standards and run on a Waters ACQUITY UPLC and 
Thermo-Finnigan LTQ mass spectrometer, with a linear ion-trap front-end and a Fourier 
transform ion cyclotron resonance mass spectrometer back-end. For GC/MS, samples 
were derivatized under dried nitrogen using bistrimethyl-silyl-trifluoroacetamide and 
analyzed on a Thermo-Finnigan Trace DSQ fast-scanning single-quadrupole mass 
spectrometer using electron impact ionization. Chemical entities were identified by 
comparison to metabolomic library entries of purified standards. Following log 
transformation and imputation with minimum observed values for each compound, data 
were analyzed using two-way ANOVA with contrasts. 
 
4EPS synthesis and detection 
Potassium 4-ethylphenylsulfate was prepared using a modification of a procedure 
reported for the synthesis of aryl sulfates in refs. (Burlingham et al., 2003; Grimes, 1959). 
4-ethylphenol (Sigma-Aldrich, 5.00 g, 40.9 mmol) was treated with sulfur trioxide-
pyridine complex (Sigma-Aldrich, 5.92 g, 37.2 mmol) in refluxing benzene (20 ml, dried 
by passing through an activated alumina column). After 3.5 h, the resulting solution was 
cooled to room temperature, at which point the product crystallized. Isolation by filtration 
afforded 7.93 g of crude pyridinium 4-ethylphenylsulfate as a white crystalline solid. 1.00 
g of this material was dissolved in 10 mL of 3% triethylamine in acetonitrile and filtered 
through a plug of silica gel (Silicycle, partical size 32-63 µm), eluting with 3% 
triethylamine in acetonitrile. The filtrate was then concentrated, and the resulting residue 
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was dissolved in 20 mL of deionized water and eluted through a column of Dowex 
50WX8 ion exchange resin (K+ form), rinsing with 20 mL of deionized water. The ion 
exchange process was repeated once more, and the resulting solution concentrated under 
vacuum to afford 618 mg (55% overall yield) of potassium 4-ethylphenylsulfate as a 
white powder (Supplementary Fig. 9a).  
1H and 13C NMR spectra of authentic potassium 4-ethylphenylsulfate were 
recorded on a Varian Inova 500 spectrometer and are reported relative to internal DMSO-
d5 (1H, δ = 2.50; 13C, δ = 39.52). A high-resolution mass spectrum (HRMS) was acquired 
using an Agilent 6200 Series TOF with an Agilent G1978A Multimode source in mixed 
ionization mode (electrospray ionization (ESI) and atmospheric pressure chemical 
ionization (APCI)). Spectroscopic data for potassium 4-ethylphenylsulfate are as follows: 
1H NMR (DMSO-d6, 500 MHz) δ 7.11 – 7.04 (m, 4H), 2.54 (q, J = 7.6 Hz, 2H), 1.15 (t, J 
= 7.6 Hz, 3H); 13C NMR (DMSO-d6, 126 MHz) δ 151.4, 138.3, 127.9, 120.6, 27.5, 16.0; 
HRMS (Multimode-ESI/APCI) calculated for C8H9O4S [M–K]201.0227, found 
201.0225. 
Authentic 4EPS and serum samples were analyzed by LC/MS using an Agilent 
110 Series HPLC system equipped with a photodiode array detector and interfaced to a 
model G1946C single quadrupole expectospray mass spectrometer. HPLC separations 
were obtained at 25°C using an Agilent Zorbax XDB-C18 column (4.6 mm x 50 mm x 5 
um particle size). The 4EPS ion was detected using selected ion monitoring for ions of 
m/z 200.9 and dwell time of 580 ms/ion, with the electrospray capillary set at 3 kV. 
Authentic potassium 4EPS was found to possess a retention time of 6.2 minutes when 
eluted in 0.05% trifluoroacetic acid and acetonitrile, using a 10-minute linear gradient 
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from 0-50% acetonitrile. For quantification of 4EPS in mouse sera, a dose-response curve 
was constructed by plotting the total ion count peak area for known concentrations of 
authentic potassium 4EPS against the analyte concentration (R^2=0.9998; Supplementary 
Fig. 9b). Mouse serum samples were diluted four-fold with acetonitrile and centrifuged at 
10,000 g at 4°C for 3 minutes. 10 ul of supernatant was injected directly into the HPLC 
system. 
 
4EPS sufficiency experiments 
Wildtype mice were injected i.p. with saline or 30 mg/kg 4EPS potassium salt daily from 
3 to 6 weeks of age. A dose-response curve was generated by measuring serum 4EPS 
levels at various times after i.p. injection of 30 mg/kg 4EPS (Supplementary Fig. 9c). 
Mice were behaviorally tested as described above from 6 to 9 weeks of age.   
 
Statistical Analysis 
Statistical analysis was performed using Prism software (Graphpad). Data were assessed 
for normal distribution and plotted in the figures as mean ± SEM. Differences between 
two treatment groups were assessed using the Student t test, and differences among 
multiple groups were assessed using one-way ANOVA with Bonferroni post hoc test. 
Two-way repeated measures ANOVA with Bonferroni post hoc test was used for analysis 
of PPI and CD4+ T-cell stimulation data. Two-way ANOVA with contrasts was used for 
analysis of the metabolite data. Significant differences emerging from the above tests are 
indicated in the figures by *P<0.05, **P<0.01, ***P<0.001. Notable near-significant 
differences are indicated in the figures by φ P=0.05, # P<0.07 and Ψ P=0.08. Notable 
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non-significant (and non-near significant) differences are indicated in the figures by 
“n.s.”. 
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Supplementary Figure 1. B. fragilis treatment has no effect on systemic immune 
dysfunction in MIA offspring. a, After B. fragilis treatment, adult poly(I:C) offspring 
retain deficits in splenic Foxp3+ CD25+ Tregs. b, B. fragilis treatment also has no impact 
on the elevated levels of Gr-1+ and CD11b+ neutrophilic and monocytic cells observed 
in spleens of adult MIA versus control offspring. c, B. fragilis also has no effect on the 
hyper-responsivity of splenic CD4+ T cells observed in MIA offspring, as indicated by 
comparably elevated production of IL-6 and IL-17 after stimulation of CD4+ T cells 
derived from poly(I:C) versus B. fragilis-treated poly(I:C) offspring. d, Similarly, there is 
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no difference after B. fragilis treatment in production of IL-6 or IL-17 by CD4+ T cells 
derived from the mesenteric lymph nodes of MIA offspring. n = 5. *P < 0.05, **P < 0.01, 
***P < 0.001, n.s. = not significant. S=saline+vehicle, S+BF= saline+B. fragilis, 
P=poly(I:C)+vehicle, P+BF= poly(I:C)+B. fragilis. 
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Supplementary Figure 2. B. fragilis-mediated amelioration of autism-related 
behaviors is not dependent on polysaccharide A (PSA). a, MIA offspring treated with 
mutant B. fragilis lacking PSA exhibit decreased anxiety-like behavior in the open field, 
with increased entries into and duration spent in the center arena comparable to that seen 
with wildtype B. fragilis treatment. There is no difference between treatment groups in 
general locomotion as measured by total distance traveled. b, Deletion of PSA has no 
effect on B. fragilis-mediated reduction in stereotyped marble burying behavior in adult 
MIA offspring. n= 17-75. *P < 0.05, **P < 0.01, ***P < 0.001. S=saline+vehicle, 
S+BF= saline+B. fragilis, P=poly(I:C)+vehicle, P+BF= poly(I:C)+B. fragilis, 
P+BFΔPSA=poly(I:C)+B. fragilis with PSA deletion. 
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Supplementary Figure 3. Amelioration of autism-related behaviors in MIA 
offspring is not specific to B. fragilis treatment. a, MIA offspring treated with B. 
thetaiotaomicron exhibit decreased anxiety-like behavior in the open field, with increased 
entries into and duration spent in the center arena comparable to that seen with B. fragilis 
treatment. There is no difference between treatment groups in general locomotion as 
measured by total distance traveled. n= 30-75. b, B. thetaiotaomicron treatment leads to a 
trending decrease in stereotyped marble burying, similar to that observed with B. fragilis 
treatment. n= 30-45. c, Treatment of MIA offspring with B. thetaiotaomicron restores 
communicative behavior as measured by adult production of ultrasonic vocalizations, 
with a statistically significant increase in total number of calls produced and a trending 
increase in average duration per call. n= 7-10 males. d, B. thetaiotaomicron treatment 
significantly improves sensorimotor gating as measured by prepulse inhibition in adult 
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MIA offspring. n= 30-75. #P < 0.07, *P < 0.05, **P < 0.01, ***P < 0.001. 
S=saline+vehicle, P=poly(I:C)+vehicle, P+BF= poly(I:C)+B. fragilis, 
P+BT=poly(I:C)+B. thetaiotaomicrom. 
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Supplementary Figure 4. B. fragilis treatment has little effect on tight junction 
expression and cytokine profiles in the small intestine. a, MIA offspring display 
significantly decreased expression of ZO-1 and a trending increase in expression of 
claudin 1 in the small intestine. n = 8 b, MIA offspring treated with B. fragilis retain their 
deficit in small intestine ZO-1 expression, and exhibit significantly increased small 
intestine claudin 1 expression. n = 8 c, MIA offspring display significantly elevated 
levels of FGF-basic, IL-1a, IL-2, IL-6, IP-10 and KC protein in the small intestine, 
compared to controls. B. fragilis treatment has no effect on these cytokine changes. 
Asterisks within bars denote significance compared to saline control (normalized to 1, as 
denoted by the black line in (b) and (c)), whereas asterisks to the right of bars denote 
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statistical significance between poly(I:C) and poly(I:C)+B. fragilis. n = 8-10. *P < 0.05, 
n.s. = not significant. S=saline+vehicle, S+BF= saline+B. fragilis, P=poly(I:C)+vehicle, 
P+BF=poly(I:C)+B. fragilis. 
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Supplementary Figure 5. IL-6 expression is elevated in colons from MIA offspring 
and is normalized by B. fragilis treatment. a, Compared to controls, adult MIA 
offspring exhibit increased expression of IL-6 mRNA in the colon, but no difference in 
colon IL-1b, TNFa, IL-10, NOS2 and SOCS3 expression. n = 6-21 b, B. fragilis 
treatment reduces levels of colon IL-6 mRNA to levels observed in saline controls. c, The 
increase in colon IL-6 is also seen at the protein level and is similarly reduced by B. 
fragilis treatment. Asterisks within bars denote significance compared to saline control 
(normalized to 1, as denoted by the black line in (c)). n = 10; # P < 0.07, *P < 0.05. 
S=saline+vehicle, P=poly(I:C)+vehicle, P+BF= poly(I:C)+B. fragilis. 
 543 
    
 
Supplementary Figure 6. IL-6 modulates colon expression of claudin 8 and 15. a, 
Oral gavage of recombinant mouse IL-6 leads to numerically increased claudin 8 and 15 
expression at 4 hours post-gavage. b, IL-6 induces a dose-dependent increase in colon 
claudin 8 and 15 expression after 4 hours of culture. c, Changes in colon claudin 8 and 15 
expression in response to IL-6 in culture are influenced by the duration of culture. 
Significant decreases in claudin 8 and 15 expression are observed after 12 hours of 
culture. n = 3 animals 
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Supplementary Figure 7. B. fragilis treatment causes statistically significant 
alterations in 109 serum metabolites, with widespread changes in biochemicals 
relevant to fatty acid metabolism (green outline) and purine salvage pathways (red 
outline). n = 8. That MIA offspring display significantly decreased serum 3-
hydroxybutyrate levels, a marker of liver beta-oxidation of fatty acids suggests that the 
widespread decrease in fatty acids is due to deficient uptake by the intestinal epithelium. 
Since treated offspring exhibit significantly lower levels of serum urate, an end product 
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of purine catabolism, the elevated levels of purine nucleosides and nucleobases likely 
reflect enhanced purine salvage. 
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Supplementary Figure 8. There is no evidence for persistent colonization of B. 
fragilis after probiotic treatment of MIA or control offspring. a, Cecal samples 
collected from MIA and control offspring at 1, 2, and 3 weeks after probiotic or vehicle 
treatment exhibit negligible qPCR signals (cycling threshold [C(t)] > 34) from B. fragilis-
specific primers, despite showing robust signal from universal 16S primers (15<C(t)<20; 
translucent gray bars). As a positive control, cecal samples from germ-free mice treated 
with B. fragilis exhibit high B. fragilis signal (C(t)~20). b, Similarly, fecal samples 
collected from MIA and control offspring display negligible B. fragilis levels, despite 
being positive for universal 16S signal. S=saline+vehicle, S+BF= saline+B. fragilis, 
P=poly(I:C)+vehicle, P+BF=poly(I:C)+B. fragilis, GF+BF=germ-free+B. fragilis. 
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Supplementary Figure 9. 4-ethylphenylsulfate (4EPS) synthesis, detection and in 
vivo experiments. a, 4EPS was synthesized by treating 4-ethylphenol with sulfur 
trioxide-pyridine in refluxing benzene to generate the pyridinium salt followed by ion 
exchange over K+ resin to generate the potassium salt. b, A dose-response curve was 
generated by analyzing known concentrations of potassium 4EPS by LC/MS. Linear 
regression analysis results in a correlation coefficient (R^2) of 0.99983. c, After a single 
i.p. injection of 30 mg/kg potassium 4EPS, mice experience an acute elevation in serum 
4EPS that peaks by 30 min post-injection and lasts over 3 hours post-injection. 
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Supplementary Table 1. MIA leads to statistically significant alterations in 26 serum 
metabolites. Fold change compared to saline controls is indicated in parentheses. 
Increases are denoted by red font and decreases are denoted by green font. n = 8. 
 
Supplementary Data 1 (Dataset online). Compiled data from LC-GC/MS-based 
metabolomic screening.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 549 
Supplementary Data and Discussion 
 
 
We find that B. fragilis treatment does not lead to persistent colonization of B. 
fragilis or to any expected effects of B. fragilis on immunity. However, we observe 
lasting effects of B. fragilis treatment on behavior, GI permeability and the serum 
metabolome, suggesting that B. fragilis treatment induces long term changes in the 
composition of the intestinal microbiome. To evaluate this, we utilized 454 
pyrosequencing to examine microbial community composition from fecal samples of 
adult MIA and control offspring treated with or without B. fragilis at 10 weeks of age.  
 Interestingly, we find that MIA itself sufficiently leads to global alterations in the 
composition of the microbiota, characterized by decreased firmicutes (Lacnospiraceae), 
slightly increased Bacteroidetes (includes Bacteroidales, decreased Bacteroidaceae), 
decreased proteobacteria (Alcaligenaceae and Alphaproteobacteria) and increased 
Actinobacteria. Surprisingly, however, B. fragilis does not induce global changes in the 
microbiota, but rather causes considerable specific reductions in the Tenericute phylum 
(Eryspipelotrichaeceae) and selective loss of Betaproteobacteria in poly(I:C) offspring. 
Together, these data suggest that specific changes to particular species may mediate 
effects of B. fragilis treatment on host physiology and behavior.  
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 Consistent with the notion that the beneficial effects of B. fragilis treatment on GI 
physiology and behavior are mediated by long-term changes in the composition of the 
microbiome, we find that the ability to restore autism-related behaviors in MIA offspring 
by microbial treatment is not specific to B. fragilis itself. Rather, treatment with B. 
thetaiotaomicron also corrects for the autism-related communicative, sensorimotor, 
stereotyped and anxiety-like behavior in MIA offspring. We further assessed the ability 
to utilize other microbes to treat MIA offspring, and the data are summarized here. 
Overall, we see that disparate species can impart specific effects on particular behavioral 
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phenotypes. The mechanisms underlying these discrepancies are entirely unknown; 
however, it suggests that microbe treatments can be utilized to alter specific phenotypes 
in mice.  
Finally, we begin to assess the ability to extend the beneficial effects of B. fragilis 
treatment to additional genetic and environmental models for autism. For this, we utilized 
the valproic acid (VPA) model which is founded on strong epidemiological links between 
maternal VPA exposure and the development of features of autism in the offspring. In 
mice, maternal i.p. injection with VPA on E12.5 has been shown to elicit autism-related 
behaviors in the adult offspring. We also utilize BTBR strain mice, which researchers 
find exhibit decreased social interaction and elevated stereotyped behaviors when 
compared to particular strains of mice, such as the C57Bl/6. We further utilize transgenic 
mice harboring a knockout allele of the CNTNAP2 gene, which encodes a synaptic 
protein found to be altered in human autism and to be associated with language 
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production. The CNTNAP2 knockout mouse was recently validated to exhibit core 
autism related behaviors, by researchers from the Geschwind lab at UCLA.  
Results from our preliminary analysis indicate that B. fragilis treatment has 
variable effects on prepulse inhibition, open field and ultrasonic vocalization behavior 
across different mouse models for autism. However, in many cases we were unable to 
replicate reported autism-related phenotypes in the mouse models. For example, in the 
VPA model, no autism-related behaviors were observed in VPA offspring versus 
controls. Also, in the CNTNAP model, only trending changes at most were observed as 
compared to those reported in primary research papers using similar sample sizes. Further 
experiments need to be performed to optimize mouse models for autism and to gain 
insight into whether B. fragilis 
treatment can be translated.   
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Abstract 
 
Maternal immune activation (MIA) increases the risk for schizophrenia and symptoms of 
autism spectrum disorders (ASD) in humans and mice. In pregnant mice, MIA can be 
induced by respiratory infection or by the administration of poly(I:C), a synthetic, 
double-stranded RNA that triggers an anti-viral inflammatory response (Shi et al., 2003). 
The offspring of mothers injected with poly(I:C) at E12.5 exhibit peripheral immune 
dysregulation and behavioral deficits associated with schizophrenia and autism. In 
addition, Smith et al. revealed that the pro-inflammatory cytokine IL-6 is both necessary 
and sufficient to induce behavioral and transcriptional changes in the offspring (Smith et 
al, 2007). As IL-6 can cross the placenta and as E12.5 marks the onset of placental 
hematopoietic stem cell (HSC) expansion (Mikkola et al.,2006), we sought to determine 
whether the placenta could be a site of early peripheral immune dysregulation in an MIA 
mouse model. Our studies show that MIA upregulates IL-6 in the E13.5 placenta and that 
HSCs in the placenta at this time express TLR3. Thus, HSCs could respond to MIA 
induced IL-6 through cytokine receptors and/or to poly(I:C) directly through the TLR3 
receptor. Real-Time PCR on CD34 dim c-Kit high HSCs isolated from E13.5 and E15.5 
embryos of pregnant mothers injected with poly(I:C) reveals MIA induced trends in gene 
expression among saline versus poly(I:C) groups. This finding was supported by 
methylcellulose cultures in which the introduction of poly(I:C) to primary cells led to 
increased numbers of myeloid colonies. This data would suggest that poly(I:C) induced 
MIA may alter the fate of HSCs and progenitors in vivo. However, the observed changes 
in these populations may be temporary; examination of overall cell populations in the 
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spleens of adult mice whose pregnant mothers were injected with poly(I:C) or saline 
revealed no differences in abundance of general cell types between poly(I:C) and saline 
groups. Thus, it appears that HSCs and progenitors are resistant to transiently induced 
changes in gene expression. 
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Introduction 
Schizophrenia and Autism Spectrum Disorders (ASD) include severe behavioral 
and developmental deficits (DSMIV TR). Schizophrenia affects roughly 1.0% of the 
population over the age of eighteen while the diagnoses of ASD cases are rising at an 
alarming rate. Also of concern are the high annual costs of these disorders. There is 
therefore a great need to further our understanding of the development of schizophrenia 
and ASD in order to provide better treatment and/or prevention of these disorders. 
While there are a number of factors that have been shown to contribute to the 
pathology of ASD and schizophrenia, a significant environmental influence is the 
infection of mothers during pregnancy (Togichi et al., 2004). In humans, infection during 
the second trimester increases the risk for schizophrenia and symptoms of ASD in the 
offspring. Epidemiological studies show that there is increased incidence of 
schizophrenia following outbreaks of influenza with the second trimester being especially 
significant (Brown and Susser, 2002; Brown et. al, 2004; Brown, 2006,). In mice, 
poly(I:C) induced MIA is used as a model of influenza infection (Smith et al, 2006; 
Patterson, 2009; Urs et al, 2008, Shi et al, 2003). A single intraperitoneal injection of 
poly(I:C) on embryonic day E12.5 induces behavioral deficits in the offspring that are 
associated with schizophrenia and ASD. Shortly after MIA, cytokine levels in the 
placenta, maternal serum, amniotic fluid and fetal brain are altered. The cytokine IL-6 is 
induced in maternal serum by MIA and is critical for mediating the behavioral and 
transcriptional changes observed in these offspring (Smith et al., 2007).  
In addition to behavioral deficits, the adult offspring display dysregulated 
peripheral immunity. Elevated levels of IL-17 and IL-6 are produced by CD4+ T cells 
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from lymph nodes and spleens of adult MIA offspring. Similar abnormalities are 
observed in CD4+ T cells isolated from spleens of young and newborn MIA 
offspring. Likewise, T cell dysregulation has been reported in humans with autism. 
Mostafa et al. showed that children with autism have lower levels of CD4+CD25+ T cells 
with a positive correlation between the severity of symptoms and the deficiency of this 
cell population (Mostafa et al., 2010). In addition, it has been shown that children with 
ASD have altered levels of naïve CD8+ cells (CCR7+ CD45Ra+), CD8+ effector 
memory (EM) cells (CCR7-/CD45RA-$), and CD4+ terminally differentiated (TD) cells  
(CCR7-$/CD45RA+) (Sarsella et al., 2009). 
While the above studies shed further light on the complexities of ASD and 
schizophrenia, there is much information that remains to be discovered about the etiology 
of these disorders. We have investigated the effects of MIA on the development of HSCs 
in the placenta and fetal liver as well as possible subsequent alterations in myeloid and 
lymphoid populations. The development of HSCs is of particular interest as several 
reports demonstrate that the time of poly(I:C) injection, E12.5, marks the onset of 
placental hematopoietic stem cell (HSC) expansion (Mikkola et al., 2005) as well as HSC 
seeding of the fetal liver (Mikkola et al., 2006). In addition, embryonic HSCs express 
cytokine and toll-like receptors and may therefore respond to poly(I:C) directly or to 
poly(I:C)-induced proinflammatory cytokines (Dorner et al., 2009; McKinstry et al., 
1997; Nagai et al., 2006). Thus, MIA may initiate the dysregulation of peripheral 
immunity in the offspring by affecting the development of the immune system at key 
sites during embryogenesis.  
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Pregnant mice were injected with poly(I:C) at E12.5, and IL-6 levels were 
evaluated at 24 and 72 hours post-injection in the placentas and fetal livers. HSCs were 
then isolated from placentas and fetal livers of E13.5 and E15.5 embryos. Real-Time 
PCR of these cells revealed that HSCs express TLR3 and could therefore be responding 
directly to poly(I:C). To examine aberrations in lineage potential, expression of 
transcription factors for myeloid and lymphoid progenitors were evaluated in the isolated 
HSCs. This data shows trending differences in gene expression of GATA-1 and IL-7Rα 
placental and fetal liver HSCs from poly(:C) versus saline injected mothers. 
Methylcellulose assays were also used to examine effects of poly(I:C) in vitro on lineage 
potential of fetal liver cells. To further evaluate alterations of lineage potential in vivo, 
abundance of adult MIA offspring spleen cell populations was evaluated for differences 
in saline and poly(I:C) groups.  
 
Results 
MIA elevates IL-6 levels in the Placenta and Fetal Liver 
As IL-6 has was previously shown to be crucial in mediating the effects of MIA, 
we examined overall levels of IL-6 in the tissues and supernatant of E13.5 and E15.5 
fetal livers and placentas of poly(I:C) or saline injected pregnant mothers. IL-6 is 
significantly upregulated in the placentas of poly(I:C) embryos at E13.5. The fetal liver 
shows a similar trend, but the results are not significant. By E15.5 these changes are no 
longer apparent in either the placenta or the fetal liver (figure 1).  
           
MIA has no Effect on IL-17 levels in the E13.5 and E15.5 Placenta or Fetal Liver   
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We were also interested in examining IL-17 levels in the placenta and the fetal 
liver as IL-17 has been implicated in the dysregulated peripheral immunity of MIA in 
mice. ELISA was used to assess IL-17 levels in whole placenta and fetal liver tissues, and 
expression was normalized to total protein of the tissues. No significant differences were 
observed in IL-17 levels at E13.5 or E15.5 in either the placenta or the fetal liver.  
                                                           
HSCs express toll-like receptor 3 
HSCs have various cytokine receptors, including the receptor for IL-6 (McKinstry 
et al, 1997). Thus, HSCs can respond directly to IL-6 through the IL-6 receptor. In 
addition, HSCs have various toll-like receptors (Nagai et al., 2006). As poly(I:C) signals 
through toll-like receptor 3, we were interested in whether or not placental CD34 dim c-
Kit high HSCs have toll-like receptor 3. We used the markers CD34 and c-Kit as opposed 
to SLAM family markers, because Daley et al showed that while the placenta contains a 
large number of HSCs at E12.5, these cells most likely lack the SLAM family markers 
CD48 and CD150 as evidenced by repopulation assays (Daley et al., 2009). After cell 
sorting Real-Time PCR was used to evaluate TLR3 expression. TLR3 expression was 
observed in both fetal liver and placental HSCs. Although not significant, the TLR3 
expression is lower in HSCs embryos from poly(I:C) versus saline injected mothers. This 
difference suggests that poly(I:C) may be inducing a downregulation of TLR3 in HSCs, 
perhaps through a negative feedback mechanism (figure 3). In order to visualize TLR3 in 
the placenta, we performed IHC on E13.5 saline tissues (figure 4). 
 
MIA has no Effect on the Abundance of HSCs in the Placenta or Fetal Liver 
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As IL-6 is upregulated at E13.5 and as HSCs express TLR3, we examined 
potential effects of MIA on abundance of HSCs in the placenta and fetal liver 24 hours 
post-poly(I:C) injection. Previous studies have shown that IL-6 and poly(I:C) alters the 
differentiation and/or proliferative capacities of HSCs (Essers et al., 2009; Suzuki et al., 
1989). HSCs were isolated from the placenta and fetal liver using fluorescence activated 
cell sorting (figure 5). HSCs were CD34 dim c-Kit high and progenitors were single 
positive for either CD34 or c-Kit. Percent totals of cell populations reveals no differences 
in saline versus poly(I:C) samples (figure 5). IHC for the nascent HSC and progenitor 
marker CD41 also reveals no differences in saline versus poly(I:C) tissues (figure 6). 
 
Poly(I:C) Induces Myeloid Lineage Potential In Vitro but not In Vivo 
To evaluate potential effects of poly(I:C) on differentiation potential, colony 
forming methylcellulose assays for myeloid potential were done in the presence or 
absence of increasing concentrations of poly(I:C). E12.5 fetal liver were roughly minced 
and left overnight at 37°C with the indicated concentrations of poly(I:C) or vehicle. 
Single cell suspensions were prepared on E13.5, and cells were plated on methylcellulose 
(Stem Cell Technologies) supplemented TPO (5ng/mL). Myeloid colonies were scored 
on day 5 according to morphological differences. The results indicate that in vitro, 
poly(I:C) enhances the lineage potential of fetal liver cells (figure 7A). These results then 
led us to investigate the effects of poly(I:C) in vitro over a longer time. For this 
experiment we used the same procedure, but poly(I:C) was only added at the 
concentration of 25ug/mL, and colonies were scored at day 12. The effect of poly(I:C) on 
total colony count was no longer apparent by day 12 (figure 7B). We then repeated a 
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similar experiment, but poly(I:C) was administered in vivo by i.p. injection of E12.5 
pregnant mothers rather than being added to the culture medium. On E13.5, fetal liver 
cells were made into single cell suspension and plated on myeloid promoting 
methylcellulose. However, no differences in total colony counts were observed at days 5 
or 12 (figure 8). 
 
Alterations in Gene Expression of MIA HSCs and Progenitors 
The in vitro assays with poly(I:C), the upregulation of IL-6, and the alterations in 
TLR3 expression led us to further investigate if MIA causes changes in HSC lineage 
potential in vivo. Pregnant mice were injected with 20mg/kg poly(I:C) or vehicle at 
E12.5. On E13.5 placental and fetal liver HSCs and progenitors were isolated by FACS 
as previously described. Real-Time PCR was used to evaluate gene expression levels of 
the common myeloid marker GATA-1 and the common lymphoid marker IL-7Rα. HSCs 
are CD34 dim c-Kit high and progenitors are either CD34+ or c-Kit+. We also sorted the 
CD34 high c-Kit high population. There are some trends that indicate MIA induced 
alterations in gene expression. However, these changes are not significant. The figures 
below show if expression of GATA or IL-7Rα is higher in the saline or poly(I:C) groups. 
N/A indicates that no expression level was detected. Consistencies among time points are 
highlighted in red. 
 
Spleen Cell Populations in Adult MIA Offspring  
The observed changes in GATA-1 and IL-7Rα is not significant as there is high 
variation among the samples. In some cases, the fold induction of the relative expression 
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of poly(I:C) over saline for a sample is 20 fold and in other instances there is no 
difference. Thus, in order to determine if these gene expression changes were leading to 
long-term alterations in cell populations, we evaluated overall cell populations in the 
adult offspring of mothers that were injected with either saline or poly(I:C) at E12.5. 
Again, these results are not significant. 
 
Discussion 
Poly(I:C) induced MIA is a useful model for studying symptoms of ASD and 
schizophrenia in mice. However, the mechanisms by which these disorders develop 
remain unclear. Previous studies have linked poly(I:C) induced MIA to behavioral 
deficits associated with ASD and schizophrenia and to dysregulated peripheral immunity. 
As the cytokine IL-6 is crucial to poly(I:C) induced MIA and as IL-6 can cross the 
placenta, we hypothesized that MIA could aberrantly affect the development of HSCs 
during embryogenesis. ELISAs confirmed the transient upregulation of IL-6 following 
MIA in the placenta at E13.5. In addition, we were able to observe that TLR3 is 
expressed in placenta tissue, and more specifically in HSCs. Thus, it is possible that 
placental HSCs can respond not only to the effects of MIA induced IL-6 but also to the 
introduction of poly(I:C) via TLR3. Furthermore, methylcellulose assays in which 
poly(I:C) was introduced into the media for a 24 hour period prior to plating revealed that 
poly(I:C) can influence the lineage potential of HSCs for up to 5 days in vitro. We did not 
observe similar results in the “in vivo” methylcellulose experiments. However, as there 
are many inconsistencies between cell culture experiments and in vivo work, we decided 
to investigate potential differences in lineage potential of HSCs and progenitors isolated 
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from E13.5 and E15.5 placentas and fetal livers. While alterations in gene expression for 
the myeloid marker GATA-1 and the lymphoid marker IL-7Rα were revealed, these 
changes were transient and insignificant. Likewise, no differences in spleen cell 
populations of adult MIA offspring were observed. Thus, it appears that while MIA is 
capable of inducing short-term changes in HSCs and progenitors, the significance of 
these changes is highly variable among samples. It may also be that HSCs harbor 
resistance to transient changes as they migrate between niches, as suggested by Kiel et 
al., 2005. Their study revealed that unlike stem cells of the nervous system, HSCs do not 
retain phenotypic, functional, or gene expression differences as they migrate between 
various niches (Kiel et al, 2005). Mikkola et al. showed that while the placenta supports 
HSCs, it does not promote their differentiation. However, the fetal liver does promote the 
differentiation of HSCs. Thus, a more significant injection time might be at E15.5, when 
the fetal liver HSC population reaches its peak (Mikkola et al., 2005). Another possibility 
is that while overall cell type is not affected, cell functioning may remain altered. Such 
deficiencies may not become apparent without additional insult, and further investigation 
would be needed to fully explore these possibilities. 
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Methods 
Mice  
Female C57BL/6 mice were maintained at the in-house breeding facility at Caltech 
University. All mice were weighed and were randomly assigned to either poly(I:C) or 
control groups. At E12.5, mice were injected i.p. with 20mg/kg poly(I:C) (potassium salt; 
Sigma, St. Louis, MO) dissolved in saline or with saline alone. Mice were sacrificed by 
i.p. injection with 200uL of sodium pentobarbital (Nembutal).  
 
ELISAs for IL-6 and IL-17 
ELISAs were performed on fetal liver and placenta tissues and serum from E13.5 and 
E15.5 embryos whose mothers were injected with either saline or poly(I:C) at E12.5. 
Serum refers to supernatant collected during the HSC isolation described below. 
Cytokine levels of serum samples were normalized to cell count of the suspension. 
Tissues were frozen in liquid nitrogen, and cytokine levels were normalized to total 
protein of the tissues with BCA assay.  
 
Immunohistochemistry 
Whole Placentas from E13.5 embryos were fixed in 4.0% PFA for 2 hours at 4°C. 
Tissues were then washed with PBS and left overnight at 4°C covered in 30.0% sucrose. 
Sucrose was removed and OCT added, and tissues were left for 1 hour at 4°C to 
equilibrate. Tissues were removed and placed into plastic molds, covered with OCT, 
frozen in liquid nitrogen, and stored at -80°C until sectioning.  
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For TLR3 staining, tissues were cut into 20um sections. Antigen retrieval and 
endogenous peroxidase blocking was performed prior to blocking in normal goat serum. 
Primary antibody was then added at a final concentration of 1ug/mL diluted in blocking 
buffer, and tissues were left overnight at 4°C in a humidified chamber. The following day 
the slides were washed, and a 1/400 dilution of the secondary antibody goat anti-rabbit 
IgG was added. Slides were incubated with the primary antibody for 1 hour at room 
temperature. The slides were washed and the substrate was added (ABC solution, CAT) 
and left to develop for 30 minutes at room temperature. 
For HSC staining, we followed the procedure described in Current Protocols (Mikkola et 
al., 2008). 
 
Serum Collection and Isolation of Fetal Liver HSCs 
Mice were injected with either poly(I:C) or saline on E12.5 as previously described. At 
E13.5 and E15.5 mice were sacrificed with 200uL Nembutal. Conceptuses were removed 
and washed in HBSS with Calcium and Magnesium and 5%FBS and DNase (Sigma 
9003-98-9). Fetal livers were then removed from the embryos and placed in falcons 
containing the above media. For the E13.5 time point, 6 saline livers from one mouse 
were placed into a tube with 6 livers from another mouse for a total of 12 tissues per tube. 
For the E15.5 time point, 5 saline livers from one mouse were placed into a tube with 5 
livers from another mouse for a total of 10 tissues per tube. Only 10 tissues total were 
used per E15.5 group because of the expected higher HSC yields at this time (Mikkola et 
al., 2005). Single cell suspensions were prepared by filtering the tissues through sterile 
mesh filters into new falcons. All falcons were centrifuged 10’at 1200rpm at 4°C. 
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Supernatant was removed and stored at -80°C for ELISAs. RBC lysis was then 
performed on the cells, and the remaining cells were washed and filtered. Cell counts 
were done using 0.25% trypan blue. Cells were then incubated in FC Block and dead and 
lineage positive cells were depleted using Miltenyi Biotec cell columns and reagents. The 
remaining lineage negative cells were again incubated with FC block and stained with 
various antibodies diluted in PBS with Magnesium and Calcium at 50uL final volume. 
Cells were filtered immediately before sorting, and 20uL 7ADD was added to the cell 
solution. Cells were gated into 4 groups: CD34high, Ckithigh, CD34dim Ckit high, and 
CD34high Ckithigh. Sorted cells were stored in RNase/DNase free eppendorfs with 0.5mL 
RNA Cell Protect at -80°C. 
 
Serum Collection and Isolation Placental HSCs 
Mice were injected with either poly(I:C) or saline on E12.5 as previously described. At 
E13.5 or E15.5 mice were sacrificed with 200uL Nembutal. Conceptuses were removed 
and washed in HBSS with Calcium and Magnesium and 5%FBS and DNase (Sigma 
9003-98-9). Placentas were separated and the deciduas and spongiotrophoblasts were 
removed. Placentas were then placed in falcons containing the above media: 6 
saline/poly(I:C) placentas from one mouse were placed into a tube with 6 saline/poly(I:C) 
placentas from another mouse for a total of 12 tissues per tube. All falcons were 
centrifuged 10’at 300xg at 4C, and the supernatant removed. Cells were then resuspended 
in 5.0mL of a 0.1%(w/v) collagenase solution diluted in PBS with 10%FBS and 1%P/S. 
Mechanical dissociations were performed on the cells using a 16G needle followed by an 
18G needle. The cell suspensions were then incubated 30’ at 37°C. Following the 
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incubation, the cells were centrifuged 10’at 1200rpm and resuspended in 2.0mL HBSS. 
The cells were then mechanically dissociated using a 20G needle, 2.0mL 0.25% trypsin 
was added, and the cells were incubated 10’ at 37°C. HBSS with 5%FBS was added to 
the cell solutions to deactivate the trypsin, and cells were centrifuged 10’at 1200rpm and 
resuspended in HBSS with 5% FBS. The cells were then dissociated further with 22G 
and 25G needles, centrifuged, and the supernatant was stored at -80°C for ELISAs. RBC 
lysis, cell counts, and dead cell removal was then performed as described above. The 
lineage depletion was also done as previously described with the exception of an 
additional incubation with a cytokeratin Ab to deplete trophoblasts. Cell staining and 
sorting was done as described above. 
 
Antibodies and Reagents for FACS 
CD34/Alexa Fluor 647 1/75 dilution (eBioscience #51-0341), Terr119/PerCPCy5.5 1/250 
(Biolegend #116227), SA/PerCPCy5.5 1/100 (Biolegend #116227), CkitACK45/PE 1/75 
for livers (BD Pharmingen #553869 clone ACK45,), Ckit2B8/PE 1/50 for placentas (BD 
Biosciences clone 2B8 #553355, BD Biosciences), CD41/FITC 1/150 (CAT), 7AAD 
(BD Pharmingen #559925), Cytokeratin 18/Biotin (abcam #ab27553), CD16/32 
(eBioscience #14-0161), Lineage Cell Depletion Kit (Miltenyi Biotec #130-090-858), 
Dead Cell Removal Kit (Miltenyi Biotec 130-090-101) 
 
RTPCR 
Total RNA was isolated with the RNeasy QIAGEN kit, and cDNA was 
synthesized with the iscript cDNA synthesis kit (Biorad). cDNA was purified with PCR 
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purification kit (Qiagen). Real-Time PCR was done using SYBR green with ROX 
(Roche) on the ABI Prism 4300.  
Primer Sequences: 
GATA-1 sense, TCCTCTGCATCAACAAGCCCA 
GATA-1 anti-sense GTTGAGCAGTGGATACACCTG  
β-actin sense AGAGGGAAATCGTGCGTGAC 
β-actin anti-sense CAATAGTGATGACCTGGCCGT 
IL-7Rα sense GGATGGAGACCTAGAAGATG  
Il-7Rα anti-sense GAGTTAGGCATTTCACTCGT  
TLR3 sense ACCTTTGTCTTCTGCACGAACCT  
TLR3 anti-sense AGTTCTTCACTTCGCAACGCA 
 
GEMM Methylcellulose Assays  
GEMM methylcellulose assays refer to lineage potential assays for colony forming units 
of granulocytes, erythrocytes, monocytes, and macrophages. Two types of 
methylcellulose assays were performed. The first assay will be referred to as the in vitro 
assay. In this assay, fetal liver tissues were isolated from E12.5 C57BL/6 mice and 
roughly minced. Equal numbers of tissues from 2 mice were combined on a 6cm petri 
and left overnight at 37°C with IMDM supplemented with 2%FBS and 1%P/S. Half of 
the dishes also had 25ug/mL poly(I:C) added to the media while other dishes half of the 
dishes had extra media. After 24 hours, tissues were mechanically dissociated to make 
single cell suspensions. Cells were plated on 35mm petris (Stem Cell Technologies 
#27110) with methylcellulose (Methocult 3434, Stem Cell Technologies) supplemented 
 579 
with 5ng/mL TPO (recombinant mouse TPO #488-TO, R&D Systems) at the density of 
2x10^4 cells per plate. Colonies were scored at days 5 and 12. 
The second type of assay will be referred to as the in vivo assay. In this assay, pregnant 
C57BL/6 mice were injected at E12.5 with 20mg/kg saline or poly(I:C). Mice were 
sacrificed at E13.5, and single cell suspensions were made from fetal livers. Cells were 
then plated as described above and scored at days 5 and 12. 
 
Flow Cytometry  
Flow Cytometry was performed on cells isolated from spleens of C57BL/6 adult mice 
whose pregnant mothers were injected at E12.5 with saline or with poly(I:C). Spleens 
were removed, and single cell suspensions prepared by mashing the spleens through 
0.2um cell filters and washing with CLB buffer. RBC lysis was performed, and cells 
were fixed and stained at a final count of 2x10^6 cells per trial. 
 
Antibodies for Flow Cytometry 
IL-17A/APC (eBioscience #17-7177-81), CD62L/APC (Biolegend # 104411), CD44/PE 
(Biolegend #103007), CD4/FITC (Biolegend # 100405), CD4/PE (Biolegend # 100407), 
CD8/FITC (Biolegend # 100705), Gr-1/APC (Biolegend # 108411), CD11b/APC 
(Biolegend # 101211), B220/FITC (Biolegend # 103205), NK1.1/PE (Biolegend # 
108707) 
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Figure 1. MIA Induced IL-6 in the Placenta and Fetal Liver: (A) IL-6 levels in the E13.5 
placental and fetal liver supernatants collected from HSC isolation preparations. IL-6 is 
significantly upregulated in the placenta, but the upregulation in the fetal liver is not 
significant. (B) E15.5 IL-6 levels in placenta and fetal liver tissues. There are no longer 
any differences in IL-6 levels between saline and poly(I:C) groups. 
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Figure 2. MIA has no effect on Il-17 levels in the placenta or fetal liver  
(A) IL-17 levels in the placenta and fetal liver at E13.5  (B) IL-17 levels in the placenta 
and fetal liver at E15.5    
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Figure 3. TLR3 expression in E13.5 Placenta and Fetal Liver HSCs (A). Fold induction 
of TLR (poly(I:C)/saline) in E13.5 placental HSCs (B) Fold induction of TLR 
(poly(I:C)/saline) in E13.5 fetal liver HSCs 
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Figure 4. TLR3 staining in E13.5 Placenta, 10X objective (A). TLR3 in the decidua (B) 
TLR3 in the labyrinth  
 
 
 
 
 
 
 
 
 
 
 584 
 
 
Figure 5. (Top) Representative FACS plots of HSCs (CD34 dim c-Kit High) and 
progenitors (CD34+ or c-Kit+) in the placenta and fetal liver 
(Bottom) Percent total HSC and progenitor placenta and fetal liver cells sorted at E13.5.  
Percent of cells sorted refers to the percent of a specific cell type within the parent 
population.  
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Figure 6. (Left) Red dash indicates a CD41+ HSC in the placental labyrinth at E13.5. 
HSCs range in size from about 8-12um, and the dash represents 10um.  CD41 also stains 
platelets, but these are relatively smaller in size than HSCs. (Right) E13.5 CD41+ HSCs 
in the placental labyrinth of saline and poly(I:C) tissues.  There is no difference in the 
abundance of HSCs in these tissues as indicated by IHC. 
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Figure 7. (A) Total Myeloid Colonies of Fetal Liver Primary Cells In Vitro Day 5. (B) 
Total Myeloid Colonies of Fetal Liver Primary Cells In Vitro Day 12  
CFU-E (Erythroid), CFU-GM (granulocyte, macrophage), CFU-GEMM (granulocyte, 
erythroid, monocyte, macrophage) 
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Figure 8. (A) Total Myeloid Colonies of Fetal Liver Primary Cells In Vivo Day 5. (B) 
Total Myeloid Colonies of Fetal Liver Primary Cells In Vivo Day 12  
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GATA Fetal Liver E13.5 E15.5 
HSC same Same 
CD34 Same Poly(I:C) up 
c-Kit Same Same  
CD34 high c-Kit high Same Same 
   
GATA Placenta   
HSC Poly(I:C) up Same 
CD34 Saline up Saline up 
c-Kit Poly(I:C) up Saline up 
CD34 high c-Kit high Saline up Saline up 
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IL-7Rα  Fetal Liver E13.5 E15.5 
HSC same same 
CD34 Poly(I:C) up Saline up 
c-Kit Poly(I:C) up Saline up 
CD34 high c-Kit high same same 
   
IL-7Rα  Placenta   
HSC Saline up Poly(I:C) up 
CD34 N/A N/A 
c-Kit N/A Poly(I:C) up 
CD34 high c-Kit high N/A Saline up 
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Introduction 
In considering the mechanism underlying how maternal immune activation (MIA) 
leads to behavioral and neuropathological features of autism and schizophrenia in the 
adult offspring, the cytokine IL-6 is a key target. It was previously shown that IL-6 is 
necessary for mediating the effects of MIA; that is, injection of poly(I:C) into pregnant 
IL-6 KO mice leads to normal behavioral development in the offspring. Similarly, co-
injection of poly(I:C) with a neutralizing antibody against IL-6 into wild-type pregnant 
mice also blocks the effects of poly(I:C) on fetal development. Furthermore, recombinant 
IL-6 injection into pregnant mice is sufficient to induce MIA-associated changes in 
offspring behavior. Thus, tracing IL-6 action shortly after maternal poly(I:C) injection 
offers the opportunity to elucidate the early molecular mechanisms that trigger 
downstream events leading to autism and schizophrenia-related endophenotypes in the 
offspring. 
In chapter 6, we evaluate the role of IL-6 in the placenta shortly after MIA. We 
find that IL-6 is dramatically increased, at levels 17-fold greater than those seen in non-
MIA controls. Furthermore, we demonstrate that IL-6 plays an important role in 
regulating endocrine function in the placenta in response to maternal poly(I:C) injection, 
altering levels of hormones and lactogens that play key roles in embryonic development.  
 Another potential site of IL-6 action, however, is in the fetal brain itself. Some 
reports point to the ability of maternal cytokines to cross the placenta and enter the fetus 
directly. Also, it is possible that the fetal brain itself responds to MIA by production of 
cytokines. Here we evaluate fetal brains from embryos of mothers injected with poly(I:C) 
versus controls to assess cytokine production shortly after MIA. Specifically, we utilize 
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qRT-PCR to detect IL-6 transcript in RNA derived from whole fetal brain lysate. We 
further utilize Luminex multiplex arrays to detect cytokine protein, including IL-6, from 
whole fetal brain lysate.  
 
Results 
IL-6 expression is induced in the fetal brain shortly after maternal poly(I:C) injection.  
Fetal brains from MIA mothers experience a significant upregulation of IL-6 
transcript by 3 hours post maternal poly(I:C) injection (Figure 1). This induction is 
transient, decreasing to levels that are not statistically different from those seen in saline 
controls by 6 hours post injection. Similarly, there is no significant difference between 
poly(I:C) and saline control embryos in the level of fetal brain IL-6 expression at 24 
hours post maternal injection. Similar induction of IL-6 is observed at the protein level in 
poly(I:C) fetal brains compared to controls, as assessed by Luminex multiplex cytokine 
array (Figure 2). Overall, that IL-6 is induced in the fetal brain itself, albeit transiently, 
after maternal poly(I:C) injection indicates that IL-6 action directly in the fetal brain may 
manifest is detrimental downstream consequences on neurodevelopment.  
 
IL-4 is dramatically induced in the fetal brain shortly after maternal poly(I:C) injection.  
Interestingly, in addition to IL-6, the cytokine IL-4 is dramatically upregulated in 
the fetal brain at 3 hours post matmernal poly(I:C) injection as measured by Luminex 
array (Figure 2). In addition, this induction requires maternal IL-6 signaling as indicated 
by the lack of IL-4 induction in fetal brain when poly(I:C) is maternally injected into IL-6 
knockout mice. Furthermore, basal levels of fetal brain cytokines are dependent on 
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maternal IL-6 signaling (Figure 2). There is a significant decrease in levels of all 
cytokines detected by Luminex array in fetal brains from poly(I:C) injected IL-6 KO 
mothers versus those detected in fetal brains from poly(I:C) injected WT mothers.   
 
Discussion 
 We show here that shortly after maternal poly(I:C) injection, IL-6 is induced not 
only in the placenta, but in the fetal brain as well. The fetal brain induction of IL-6 (less 
than 2 fold that seen in controls) is considerably mild compared to that seen in poly(I:C) 
placentas (17-fold that seen in controls). In addition, the IL-6 induction in the fetal brain 
is more transient, lasting between 3 and 6 hours post maternal poly(I:C) injection, 
whereas the placental response to poly(I:C) leads to IL-6 induction that lasts over 24 
hours post injection. It will be interesting to evaluate whether fetal brain IL-6 induction 
requires a placental IL-6 response.  
 We also demonstrate here that maternal IL-6 is critical in regulating fetal brain 
cytokine induction and as well as basal fetal brain cytokine levels. Thus, it is likely that 
maternal IL-6 reflects the pool of IL-6 that is particularly important in mediating MIA 
effects on offspring development. Further studies utilizing conditional IL-6R knockout 
mice will be necessary to confirm this notion.  
 
Methods 
Generation of animals.  
Female C57BL/6N mice (Charles River; Wilmington, MA) were obtained from the 
Caltech breeding facility and housed under standard laboratory conditions. Mice were 
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mated overnight and the presence of a vaginal plug on the following morning was noted 
as day E0.5. 
 
IL-6 KO mice.  
IL-6 KO mice, strain B6.129S2-IL6tm1Kopf/J, were obtained from Jackson Laboratory 
(Bar Harbor, ME). IL-6 -/- females were mated with IL-6 +/+ males. 
 
MIA.  
Pregnant C57BL/6J or IL-6 KO mice were injected on E12.5 with saline, poly(I:C), or 
recombinant IL-6 (rIL-6). For poly(I:C) injections, poly(I:C) potassium salt (Sigma 
Aldrich; St. Louis, MO) was freshly dissolved in saline and administered i.p. at 20 mg/kg 
based on the weight of the poly(I:C) itself, not including the total weight of the potassium 
salts. Control mice were injected with saline alone at 5 ml per gram body weight.  
Measurement of fetal brain cytokines. After injection on E12.5, wild type (WT) and IL-6 
KO mice were sacrificed at 3 hours post injection by an overdose of sodium pentobarbital 
(Nembutal). Fetal brains were microdissected from the embryo and washed in PBS prior 
to snap-freezing in liquid nitrogen and storage at -80°C. To generate cell lysates, each 
fetal brain was placed in 1 ml of cell lysis buffer (50 mM Tris-HCl (pH 7.4) with 0.6 M 
NaCl, 0.2% Triton X-100, 1% BSA, and 1 EDTA-free protease inhibitor cocktail 
tablet/10 ml buffer) (Roche Applied Sciences; Indianapolis, IN). Each tissue was 
homogenized on ice using a syringe fitted with an 18G needle and then sonicated for 5 
seconds at 10 mV. Total protein was measured by BCA assay (Thermo Scientific; 
Rockford, IL) according to the manufacturer’s instructions. For cytokine profiling, mouse 
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20-plex cytokine arrays (Invitrogen) were run on the Luminex FLEXMAP 3D platform 
by the Clinical Immunobiology Correlative Studies Laboratory at the City of Hope 
(Duarte, CA). 
 
Measurement of fetal brain gene expression by real-time PCR.  
Fetal brains were quickly dissected from the embryo and washed in PBS prior to 
preservation in 1 ml TRIzol solution (Invitrogen; Carlsbad, CA). Tissues were passed 
through an 18G needle and sonicated for two rounds of 3 seconds at 10 mV separated by 
incubation on ice. Homogenates were processed by chloroform extraction and washing 
with 70% ethanol according to standard procedures. RNA was further purified by 
applying the cleared lysate to an RNeasy mini column (Qiagen; Valencia, CA), and an 
on-column DNA digestion was performed according to the manufacturer’s protocols. 
Samples were assayed using the 2100 Bioanalyzer (Agilent Technologies; Santa Clara, 
CA) and confirmed to contain high integrity RNA (RIN > 8). 5 mg RNA per sample was 
reverse-transcribed using the iScript cDNA synthesis kit (Biorad; Hercules, CA). 
Resultant cDNA was purified using a PCR purification kit (Qiagen) and eluted in 50 ml 
PCR-grade water (Roche). Gene expression was measured using SYBR Green master 
mix with Rox passive reference dye (Roche) on the ABI 7300 Real Time PCR system. 
Target gene expression was normalized against beta-actin transcript, and data are 
expressed as ratios of gene expression of poly(I:C) to saline samples. The primers used 
were adapted from the Primerbank database (Spandidos et al., 2010).  
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Figure 1. MIA elevates IL-6 expression in the fetal brain. At 3 hours post injection, 
fetal brains from mothers injected with poly(I:C) exhibit elevated levels of IL-6 mRNA 
compared to saline controls. This IL-6 induction is transient, as no significant differences 
are seen in fetal brain IL-6 levels at 6 hours and 24 hours post injection in E12.5 
poly(I:C) versus saline offspring.  
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Figure 2. MIA elevates IL-4 and IL-6 protein in the fetal brain, which is dependent 
on maternal IL-6 signaling. At 3 hours post injection, fetal brains from offspring of 
poly(I:C)-injected mothers exhibit significantly elevated levels of IL-4 and IL-6 protein 
compared to controls. This induction was dependent on maternal IL-6 signaling, as 
cytokine levels are dramatically reduced in offspring of IL-6 KO mothers injected with 
poly(I:C).  
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Introduction 
 
Findings presented in chapter 11 demonstrate that maternal immune activation (MIA) 
induces long-term changes in offspring immunity. The persistent abnormalities are 
characterized by systemic deficits in T regulatory cells, hyper-active production of IL-6 
and IL-17 by CD4+ T cells and increased levels of Gr-1+ monocytotic and neutrophilic 
cells. To evaluate whether MIA offspring exhibit additional changes in overall B cell and 
NK cell function, we measure levels of major immunoglobulin isotypes in sera of adult 
poly(I:C) versus control offspring and we evaluate cytotoxicity by NK cells isolated from 
spleens of poly(I:C) versus control offspring. In addition, we characterize levels of 
splenic memory CD4+ and CD8+ T cell subtypes. We further demonstrate that adult 
MIA offspring do not display primary changes in regional microglial abundance or 
activation. Here we explore whether fetal brains exhibit changes in microglial levels or 
status.  
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Results 
There is no difference in levels of major immunoglobulin subtypes in sera from adult MIA 
offspring compared to controls.  
Adult offspring of poly(I:C)-injected mothers display levels of serum IgM, IgG, 
IgA and IgE that are comparable to those observed in adult offspring of saline-injected 
mothers (Figure 1). This suggests no major change to B cell function.   
 
There is no difference in cytotoxicity of NK cells isolated from spleens of adult poly(I:C) 
versus saline offspring.  
NK cells derived from spleens of MIA offspring display similar levels of 
cytotoxicity against Yac-1 murine lymphoma cells in culture as compared to those 
derived from spleens of saline offspring (Figure 2). This suggests no primary abnormality 
in NK cell reactivity or function.  
 
Adult MIA offspring exhibit decreased levels CD4+ effector memory cells and increased 
levels of CD4+ naïve T cells.  
Interestingly, adult offspring of poly(I:C)-injected mothers display selective 
decreases in CD4+ CD44hi CD62Llo effecter memory cells and increased levels of 
CD4+ CD44lo CD62Lhi naïve T cells, but no difference in central memory cells (Figure 
3). Altered levels of CD4+ and CD8+ memory subtypes are also observed in MLN cells 
from poly(I:C) versus saline offspring. In contrast, there is no significant difference in the 
level of CD4+ CD44hi CD62Lhi central memory cells, or splenic CD8+ CD44hi CD62Llo 
effector memory cells, CD8+ CD44hi CD62Lhi   central memory cells, or CD8+ CD44lo 
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CD62Lhi naïve T cells. Overall, MIA leads to abnormal distribution of CD4+ memory 
cells in adult offspring, consistent with reports of altered T cell memory subtypes 
observed in autistic individuals (Ferrante et al., 2003; Gupta et al., 1998). This indicates 
that primary alterations are observed in CD4+ T cells from MIA offspring, consistent 
with findings of decreased CD4+ T regulatory cells and hyper-responsiveness of CD4+ T 
cells to stimulation.  
 
There is no significant difference in levels of fetal brain CD11b+ cells in response to 
poly(I:C).  
To examine whether poly(I:C) offspring exhibit evidence of early microglial 
activation or proliferation compared to controls, we isolated whole fetal brain and 
generated single cell suspensions. We further applied flow cytometry using the 
macrophage/microglia marker CD11b and early activation marker CD69 to examine 
brain immune status. There is no difference in total levels of CD11b+ cells from fetal 
brains of poly(I:C) versus control offspring on E12.5. In addition, there is no significant 
difference in CD69+ activation in these CD11b+ cells (Figure 4). This suggests that 
maternal poly(I:C) injection does not induce global changes in microglial levels or 
activation.   
 
Methods 
Mice.  
C57BL/6J mice (Charles River; Wilmington, MA) were housed under specific pathogen-
free conditions in Caltech’s Broad animal facility. Mice were mated overnight and the 
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presence of a vaginal plug on the following morning was noted as day E0.5. All 
experiments were performed under the approval of Institutional Animal Care and Use 
Committee.  
 
MIA.  
Pregnant C57BL/6J mice were injected on E12.5 with saline or poly(I:C). For poly(I:C) 
injections, poly(I:C) potassium salt (Sigma Aldrich; St. Louis, MO) was freshly dissolved 
in saline at 4 mg/ml and administered i.p. at 20 mg/kg based on the weight of the 
poly(I:C) itself, not including the total weight of the potassium salt. Control mice were 
injected with saline alone at 5 ml per g body weight.  
 
Detection of Serum Immunoglobulins. 
Sera were harvested from adult poly(I:C) and saline offspring by cardiac puncture, and 
allowed to clot for 30 minutes in Vacutainer SST tubes (BD Biosciences). Tubes were 
spun at 1500 xg for 10 minutes, and serum was collected above the separator gel, 
aliquoted, and stored at -80°C. Aliquots were used for endpoint ELISA assays for mouse 
IgM, IgG, IgA, and IgE (Biolegend) according to the manufacturer’s protocols. 
 
NK cell cytotoxicity assay.  
Splenic single cell suspensions were isolated as described above. CD49+ microbeads 
(Miltenyi Biotec) were used for positive selection of NK cells. 105 effector NK cells were 
incubated, 5:1, with DiO-labeled Yac-1 murine lymphoma cells (ATCC; Manassas, VA) 
for 1 hour at 37°C, alongside effector-only and target-only controls. Cells were then 
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counterstained with propidium iodide (PI) and assayed by flow cytometry according 
protocols from the LIVE/DEAD cell-mediated cytotoxicity kit (Invitrogen; Carlsbad, 
CA). Data presented are [[(% effector-killed cells (DiO+ PI+) - % spontaneously dead 
cells (DiO+ PI+) from effector-only control)] / % total DiO+ target cells] x 100.  
 
Flow cytometry.  
Splenic and MLN single cell suspensions were generated as described above. For brain 
suspensions, adult mice were sacrificed by CO2 gas exposure and frontal cerebral cortex, 
cerebellum, and hippocampus were carefully dissected in ice cold PBS. Single cell 
suspensions were generated using the Neural Dissociation kit (Miltenyi Biotec) according 
to the manufacturer’s protocol. For extracellular staining, cells were treated with anti-
mouse CD16/CD32 Fc block (eBioscience) for 10 minutes on ice prior to staining in 
CBSS buffer with subsets of these antibody conjugates: Ter119-PerCP-Cy5.5, CD4-
FITC, CD8-FITC, CD11b-APC (eBioscience), CD69-PE, CD62L-APC, CD44-PE 
(Biolegend; San Diego, CA). Samples were processed using the FACSCalibur cytometer 
(BD Biosciences) alongside appropriate isotype, single-stain, and unstained controls. 
Data were analyzed using FlowJo software (TreeStar Inc.; Ashland, OR) and presented as 
percent frequency of the parent population (non-erythroid (Ter119-) cells). 
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Figure 1. There is no significant difference in levels of total IgM, IgG, IgA and IgE 
in blood sera from adult poly(I:C) versus saline offspring [n=8 saline, 8 poly(I:C)]. 
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Figure 2. Splenic NK cells from adult poly(I:C) versus saline offspring exhibit 
similar levels of cytotoxicity against stimulating Yac-1 murine lymphoma target 
cells [n=4 saline, 4 poly(I:C)]. 
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Figure 3. Compared to controls, spleens from poly(I:C) offspring exhibit decreased 
levels of CD4+ CD44hi CD62Llo effecter memory cells and increased levels of CD4+ 
CD44lo CD62Lhi naïve T cells (C, left). There is no difference in CD8+ memory cell 
subtypes from spleens of poly(I:C) versus saline offspring (C, right). [n=8 saline, 9 
poly(I:C); *p<0.05] 
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Figure 4. There is no difference in levels of CD11b+ cells in E12.5 fetal brains from 
poly(I:C) versus saline-injected mothers.  
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Introduction 
 Autism is one of the five “Autism Spectrum Disorders (ASDs)” (the other four 
being Asperger’s syndrome, Rett’s Disorder, Childhood Disintegrative Disorder, and 
Pervasive Developmental Disorder-Not Otherwise Specified (PDD-NOS)). According to 
the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision 
(DSM-IV-TR) and International Classification of Diseases, Tenth Revision (ICD-10), the 
three key characteristics of autism are: impairments in language or communication, 
deficits in social interaction, and the increased tendency towards repetitive behaviors 
(White, 2003). CDC currently estimates that 1 out of 110 US children have an ASD, 
making this disorder more common than childhood cancer, juvenile diabetes, and 
pediatric AIDS combined. 
The recent California Autism Twin Study conducted by Stanford University 
suggests that 58% of autism development risk can be attributed to non-genetic factors 
(Hallmayer et al., 2011). Within these non-genetic factors, the involvement of 
gastrointestinal symptoms is becoming more apparent. Historically, common 
gastrointestinal complaints reported in autism include chronic constipation and 
abdominal pain, and antibiotics have been seen to informally treat symptoms (Buie, 
2010). Autistic children also frequently show food intolerance, which has led many 
parents to enlist a gluten-free or casein-free (casein is the major protein in cow’s milk) 
diet (White, 2003). This “gfcf” diet commonly results in the amelioration of autistic 
behaviors: Lucarelli et al. (1995) showed marked behavioral symptom improvement in 36 
autistic patients after 8 weeks on a milk-elimination diet and Knivsberg et al. (2002) 
showed normalizing of previously abnormal urinary peptide levels in autistic individuals 
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on the “gfcf” diet. Furthermore, autistic patients have displayed significantly eroded and 
more ulcerated intestinal epithelium compared to controls, in addition to increased 
intestinal permeability (Ibrahim, 2009). According to de Madistris et al. (2010), autistic 
patients on a reported “gfcf” diet showed reduced abnormal intestinal permeability 
compared to autistic individuals on an unrestricted diet. 
Unfortunately, many of the current reports on the potential relationship between 
gastrointestinal symptoms and the onset of autism have not been able to be replicated or 
have had poor controls. The prevalence of recent interest in this research and 
identification of possible connections has led to the “leaky gut hypothesis”, which 
proposes the leakage of harmful toxins from the gut into the bloodstream, thus resulting 
in changes in the brain and behavior. More specifically, this hypothesis suggests that 
digestion products (such as those of wheat and milk) may be able to leak into the blood 
through leaky mucosal linings, initiating antigenic responses and possibly affecting the 
central nervous system, ultimately resulting in behavioral symptoms (White, 2003). 
One of the most widely used mouse models in autism research today is the Maternal 
Immune Activation (MIA) model, in which an injection of synthetic double stranded 
RNA poly(I:C) in a pregnant mouse induces an immune response, and the resulting 
offspring display characteristics of autism as tested through behavioral assays (Patterson, 
2011). It has been previously shown that poly(I:C) mouse exhibit leaky gut, providing 
further evidence for a relationship between gastrointestinal issues and the onset of autism. 
 Leaky gut is currently studied in mice through the use of dextran sulfate sodium 
(DSS), which when orally administered induces experimental colitis (inflammation of the 
large intestine) (Gaudio et al., 1999). Studies regarding DSS treatment have not 
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investigated any resulting behavioral abnormalities with respect to developmental 
disorders such as autism. Behavior studies that have been done include pain sensitivity 
assays which show that DSS-induced colitis correlates with mice exhibiting hyperalgesia 
in response to visceral capsaicin and restrain stress is related to the increased onset of 
DSS-induced colitis (Eijkelkamp et al., 2007, Milde and Murison, 2002). 
 In an effort to characterize the involvement of leaky gut in the onset of autism-
like symptoms in a mouse model, this study seeks to examine the behavior of mice with 
DSS-induced colitis, or “leaky gut”. By investigating behavior abnormalities using 
common autistic behavioral assays (pre-pulse inhibition, sociability, social interaction, 
open field test, marble burying assay) in non-poly(I:C) offspring with leaky gut, this 
research explores the sufficiency of leaky gut in development of the some of the core 
symptoms of autism (increased repetitive behavior and deficits in social interaction). 
 
Results 
Following DSS treatment, mice were monitored twice daily for weight gain 
(Figure 1). As expected, mice treated with 2% DSS showed diminished weight gain after 
approximately 1 week. 1%-DSS-treated mice did not show this diminished weight gain, 
and continued to gain weight normally, similar to the control mice. Mice were also scored 
for intestinal bleeding according to Table 1. Results show that 2%-DSS treated mice 
frequently displayed rectal bleeding, a hallmark of DSS-induced colitis (Figure 2).  
To confirm existence of leaky gut in the DSS-treated mice, mice were gavaged 
with fluorescent compound FITC-dextran, and serum fluorescence was subsequently 
measured. Leaky gut assay results show that DSS-induced colitis yields a comparable 
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measure of serum fluorescence to that of poly(I:C) offspring (Figure 3). Furthermore, 
colon lengths of 2% DSS-treated mice were significantly shorter than control and 1% 
DSS-treated mice, which is a sign of successfully induced inflammation of the gut 
(Figure 4).  
Real-time PCR was done on colon tissue to measure gene expression of various 
tight junction proteins. The proteins examined (clauidin 8, claudin 15, ZO-1, ZO-2, 
occludin) were chosen based upon previously seen differences in poly(I:C) gene 
expression. Colon tissue of 4-week-old mice showed no significant differences in tight 
junction protein transcript levels (Figure 5), despite existence of leaky gut. This finding 
suggests that leaky gut may be localized or that DSS-induced colitis results in the loss of 
proteins other than those examined in the current study. 
 Real-time PCR was again performed on adult mice colon tissue, and deficits were 
seen in both claudin 15 and occludin (Figure 6). These results parallel abnormalities seen 
in poly(I:C) transcript levels, and support the notion that leaky gut is localized to certain 
areas of the colon.  
To visualize leaky gut in the DSS-treated mice, colon tissue was sectioned and 
stained with hematoxylin and eosin (H&E) markers (Figure 7). Control mice colon tissue 
show fully intact intestinal crypts. 1% DSS-treated mice display slightly disrupted crypts, 
whereas 2% DSS-treated mice clearly show atrophy. Images support molecular findings 
for the basis of leaky gut existence in 2% DSS-treated mice. 
Behavioral assays were used to characterize the behavior of DSS-treated mice. 
Unlike poly(I:C) offspring behavior, the results of the DSS-treated mice assays showed 
no difference in PPI (Figure 8), social interaction (Figure 9), or marble-burying (Figure 
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10). The open field test showed no difference in the frequency of entering the center of 
the box, but a mild deficit in duration spent in center was seen (Figure 11). Upon closer 
examination, the deficit was seen to be significant in 2% males compared to control 
males, but not in females.  
A leaky gut assay was performed on adult DSS-treated mice to confirm 
persistence of leaky gut into adulthood. Results showed that DSS-treated mice continued 
to exhibit decreased colon length and increased serum fluorescence (Figures 12, 13). 
 
Discussion 
DSS was first administered to PND 21 mice in 0%, 1% and 2% DSS by volume in 
drinking water to determine the optimal dosage. DSS is normally administered to adult 
mice, and monitored by observation of weight loss. Since autism is a developmental 
disorder (symptoms appear by the age of three in humans), and poly(I:C) mice were seen 
to exhibit leaky gut as early as 3 weeks, DSS was administered to 3 week old mice. 
Furthermore, since young mice are still growing, a diminished weight gain was noted for 
instead of weight loss. Weight monitoring, in addition to stool scoring, indicated 
successful induction of leaky gut in 2% DSS mice. Results were confirmed with the leaky 
gut assay: 2% DSS-treated mice showed a 1.6 fold increase in serum fluorescence 
compared to control mice; poly(I:C) offspring also show 1.6 fold increase in serum 
fluorescence compared to offspring of mothers injected with saline. 
Real-time PCR was employed to examine loss of tight junction proteins in mice with 
leaky gut, using beta-actin as a “housekeeping gene”. The housekeeping gene is stably 
expressed, and varies only due to cell density differences, allowing for normalization 
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against potential transcript level differences due to tissue size, or other outlying factors. 
No significant differences were seen in tissue of the first leaky gut assay performed, 
suggesting the possibility that DSS-induced colitis involves the loss of tight junction 
proteins not examined in this study, or that the leaky gut is localized to certain areas of 
the colon that were not observed in the present samples. The second leaky gut assay 
done, on adult tissue, confirmed the persistence of leaky gut into adulthood and showed 
significant losses in claudin 8 and occludin proteins. This further suggests that leaky gut 
is localized and that the extensiveness of DSS-colitis-induced leaky gut and poly(I:C) 
leaky gut is similar, in that poly(I:C) offspring also show a loss in occludin and claudin 8 
tight junction proteins. 
The PPI assay, which measures the startle response of a mouse to a loud noise, 
showed no difference in the DSS-treated mice. Compared to controls, poly(I:C) mice 
display a deficit in PPI, but this was not seen in the DSS-treated mice, which suggests 
that leaky gut is not sufficient to produce this effect. Similar results were seen in the 
marble burying, sociability, and social preference assays, as differences seen in poly(I:C) 
mice were not replicated in DSS-treated mice. This further suggests that leaky gut is not 
sufficient for the onset of repetitive behavior and social interaction impairments. The 
open field center duration results displayed a mild deficit, and identified a sexual 
dimorphism, showing a potential correlation of DSS-treatment and development of 
anxiety in young mice. However, results obtained require substantiation through further 
research. 
Overall, the findings of this study suggest that leaky gut is not sufficient to induce the 
core symptoms of autism in mice. Accordingly, continued research should be done in this 
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field to investigate if leaky gut is necessary for autism-like symptoms, which could be 
done by treating the leaky gut of poly(I:C) mice and observing if autistic behavior is 
ameliorated. It would also be interesting to research the molecular pathways behind why 
and how an injection of poly(I:C) in a pregnant mouse yields offspring with autistm-like 
symptoms. This research would shed light on the molecular basis for studies that have 
shown maternal immune system activation is correlated with the onset developmental 
disorders in the offspring. 
 
Methods 
Dextran Sulfate Sodium (DSS) Administration and Weight Monitoring 
C57 mice from the Caltech breeding facility were housed under standard laboratory 
conditions. Mice from different litters were organized randomly into 0% DSS, 1% DSS, 
and 2% DSS treatment groups. Mice were orally administered DSS in 0%, 1%, and 2% 
concentrations by volume in drinking water and weight was monitored twice daily as a 
measure of ensuring mouse health. Stool samples were also scored according to Table 1 
as measurement of leaky gut severity. 
 
Leaky Gut Assay 
Mice used for the leaky gut assay were separated from food and water for four hours 
before gavaging with FITC-dextran fluorescence at a concentration of 60ug FITC-dextran 
per 100g mouse (FITC-dextran stock solution was 100ug/ml). Four hours following 
gavaging, mice were sacrificed using CO2. Blood was collected using cardiac puncture 
and blood was allowed to clot in a vacutainer for 30 min before spinning down in a 
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centrifuge. Serum fluorescence was then measured against aliquots of a FITC-dextran 
standard solution using a Safire II spectrophotometer. Colon lengths were also measured 
following sacrifice and stored in paraformaldehyde for fixation before transferring to 
30% sucrose overnight and flash-frozen in liquid nitrogen for storage at -80°C. Three 
5mm sections of colon from each mouse were isolated for RNA extraction and placed in 
Trizol after washing in PBS and stored at -80°C. 
 
Immunohistochemistry 
Colons were dissected and fixed in 4% paraformaldehyde before storing overnight in 
30% sucrose at 4°C. After equilibrating in the OCT (optimal cutting temperature) 
compound for 1 hour, colons were flash-frozen in liquid nitrogen and stored at -80°C. 
The tissue was sectioned into 12um slices using a microtome and then stained with 
hematoxylin and eosin to visualize gut morphology (hematoxylin stains for nuclei and 
eosin is a marker for cytoplasm). Stained slides were coverslipped using Vectamount 
aqueous solution and visualized under a microscope using bright light. 
 
Measurement of Tight Junction Protein Levels through Real-Time PC 
Colon tissue for RNA isolation was sonicated at 5-second intervals of 10mV until 
homogenized. By spraying the workspace and all involved materials with RNAse-Zap, 
RNases were eliminated, optimizing conditions for RNA extraction. The addition of 
chloroform to the homogenized samples in trizol and 4°C centrifugation following 
incubation and shaking yielded phase separation. Subsequent 70% ethanol (made with 
Diethylpyrocarbonate (DEPC) water) washes in RNeasy mini columns (Qiagen) allowed 
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for purification of RNA. Washes were performed according to standard manufacturer 
protocol and RNA was eluted using RNase-free water. Concentration of isolated RNA 
was then measured using a Nanodrop. 
Using an iScript cDNA synthesis kit (composed of 5x iScript Reaction Mix, iScript 
Reverse Transcriptase, Nuclease-free water, and RNA template), 2ug of RNA per sample 
was reverse-transcribed into cDNA for real-time PCR (qPCR). Control samples with no 
reverse transcriptase, as well as with no RNA template were also created. Resulting 
cDNA levels were measured using a Nanodrop and cDNA was diluted in PCR water to a 
concentration of approximately 350ng/ul for qPCR. Gene expression was measured with 
a SYBR Green master mix (with Rox as a passive reference dye). Beta-actin was used as 
a housekeeping gene and transcript levels were measured for tight junction proteins 
claudin 8, claudin 15, ZO-1, ZO-2, and occludin. 
 
Behavioral Assays 
 Five commonly used behavioral assays in autism-like symptoms diagnosis were 
employed to characterize the behavior of DSS-treated mice: pre-pulse inhibition (PPI), 
sociability, social interaction, open field test, and marble burying. Mice were tested for 
PPI at 6 weeks, sociability and social interaction at 7 weeks, marble burying and open 
field test at 8 weeks of age. 
 The PPI assay tests the startle response of a mouse to a loud noise. After 5 
minutes of habituation to the testing chambers, mice are subjected to randomized blocks 
of no startle, startle (120db pulse), startle with a 5db prepulse, or startle with a 15db 
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prepulse. PPI is defined to be (startle stimulus only – (5 or 15 db prepulse + 
startle))/startle stimulus only. 
 The sociability and social preference assays measure for deficits in social 
interaction. In the sociability assay, the mouse is habituated in a three-chamber construct 
for 10 minutes. The mouse is then placed in the center chamber and given the choice to 
interact with a novel mouse or a novel toy. Its movement is tracked for 10 minutes; 
chamber frequency data describes the number of times the mouse enters the respective 
chamber, and contact frequency describes the number of times the mouse has contact 
with the toy or novel mouse. Chamber duration and contact duration delineate time spent 
in the respective chamber or interacting with the contact. The social preference assay 
tracks the mouse for 10 minutes, with a choice given between interacting with a familiar 
or unfamiliar mouse (of the same gender). 
 The open field test assay measures a mouse’s anxiety and willingness to enter or 
spend time in the center of a box. Open field testing consists of a 10 minute habituation 
period of mice singularly placed in an empty rectangular box. Mouse movement is then 
tracked for 10 minutes, specifically noting for number of times the mouse enters the 
center of the box (frequency) and time spent in center of the box (duration). 
 The marble burying assay identifies repetitive behavior in mice. After 10 minutes 
of habituation in the testing cages, mice are given 18 marbles (arranged equidistantly in 3 
columns by 6 rows) for 10 minutes. The number of marbles buried was noted such that a 
marble covered in >50% bedding was considered buried. 
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Figure 1. Early life treatment with 2% DSS induces mild colitis symptoms and leaky 
gut but no differences in autism-related behaviors. (A). Treatment of 3 week old mice 
with 2% DSS in water for 5 days leads to decreased weight gain versus wildtype controls. 
(B) DSS-treated mice exhibit decreased colon length and colitis-related symptoms (C). 
(D) 5 day treatment of 3 week old mice with 2% DSS leads to mild leaky gut symptoms 
similar to those seen in 3 week old poly(I:C) offspring, as measured by FITC-dextran 
translocation into the bloodstream after oral gavage. (E) 10 week old adult DSS-treated 
mice retain the increased intestinal permeability observed at 4 weeks of age. (F) Adult 
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DSS-treated mice exhibit decreased colon occludins and claudin 8 levels versus controls, 
similar to the phenotype observed in adult MIA offspring, as described in Chapter 12. (G) 
Adult DSS-treated mice display trending decreases in open field center entries, 
suggestive of increased anxiety-like behavior, but no differences in center duration of 
total distance traveled in the open arena. (H). DSS-treated mice do not show differences 
in social interaction behavior, stereotyped marble burying (I), or prepulse inhibition (J).  
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Introduction  
While commensal microbes are known to regulate a vast array of biological 
processes, including immune development, energy utilization and metabolism, they are 
only recently being appreciated for their important roles on the central nervous system. 
Commensal microbes play important roles in the production of neuroactive molecules, 
including neurotransmitters and neuropeptides, and in the development of complex 
behaviors, such as anxiety-like, emotional and nociceptive behavior. Modifying the 
composition of the microbiota in animal models affects circulating and brain levels of 
neurotransmitters such as serotonin and GABA, and germ-free mice which lack 
microbiota are known to exhibit several abnormal behaviors, including increased 
locomotion and decreased anxiety. Alterations in the composition of the microbial 
communities that inhabit us are further implicated in a variety of neurological and 
neurodevelopmental diseases, including multiple sclerosis, depression and autism. 
 In Chapter 12, we show that modulating the composition of the intestinal 
microbiota ameliorates autism-related behaviors in a mouse model of autism. We provide 
evidence that commensal bacteria of the microbiota can influence the gut-brain 
connection by modulating metabolites that alter behavior, and that in a mouse model of 
autism, a microbe-based therapy improves GI pathologies in conjunction with behavior. 
To further evaluate whether commensal microbes normally contribute to autism-related 
behaviors in wildtype mice, we assessed behavioral performance in germ-free versus 
conventionally colonized (specific pathogen free, SPF) mice in tasks measuring 
communication, stereotyped/repetitive behavior, and social interaction, among others.  
Results 
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The commensal microbiota modulates the development of behaviors relevant to ASD 
The microbiota is known to modulate a variety of behaviors, including motor, 
sexual, nociceptive and anxiety-like behaviors, but whether it also affects the 
development of behaviors relevant to ASD is unknown. We therefore tested GF and SPF 
mice for social interaction, stereotyped/repetitive behaviors, communication, pre-pulse 
inhibition and open field exploration to assess the core behavioral symptoms of autism 
along with additional ASD-associated behaviors. Based on findings that same-strain mice 
from different commercial vendors harbor distinct microbial populations, we utilized SPF 
C57Bl/6 mice from Taconic Farms (SPF-T) and from Charles River Laboratories (SPF-
CR) for testing. 
 Consistent with previous reports, GF mice exhibit hyperactivity in the open field, 
as measured by increased total distance traveled and center entries, when compared to 
both SPF-T and SPF-CR mice (Fig 1A). This hyperactivity is similarly observed across 
all three trials (habituation, sociability and social preference) of social interaction testing. 
Interestingly, GF mice also display altered performance in a number of autism-related 
behavioral tasks. Adult male GF mice exhibit significantly fewer ultrasonic vocalizations 
in the presence of a novel female mouse (Fig 1B) than do SPF controls. Moreover, the 
individual calls emitted by GF mice are of significantly shorter duration compared to 
those from both SPF-T and SPF-CR mice suggesting a deficit in not only the quantity but 
also the quality of calls produced. This decrease in communication is not due to a lack of 
exploratory interest, since there is no significant difference between GF and SPF-CR 
mice in the time spent interacting with the novel mouse during the ultrasonic vocalization 
task (Fig 1C). Moreover, the decrease in communication observed in GF mice is not due 
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to confounding abnormalities in olfaction, as GF mice exhibit normal olfactory 
discrimination compared to SPF-CR controls (Fig 1D). In addition to altered 
vocalizations, GF mice also display disrupted sensorimotor gating as measured by 
decreased inhibition of an acoustic pre-pulse at 5 or 15 db above background noise (Fig 
1E), with no difference in startle response intensity. This phenotype is consistent with 
symptoms observed in human autism, as well as other neurodevelopmental disorders such 
as schizophrenia.          
To assess additional core symptoms of autism, we tested GF versus SPF-CR and 
SPF-T mice in repetitive/stereotyped behavior and social interaction. There is no 
difference between GF versus SPF mice in stereotyped marble-burying behavior (Fig 
2A). However, GF mice engage in significantly elevated levels of self-grooming 
compared to SPF-CR, but not SPF-T mice (Fig 2C), highlighting an underlying 
difference in a repetitive/stereotyped behavior between SPF mice derived from Taconic 
Farms versus Charles River Laboratories that is statistically significant by Student’s t-test 
(p=0.03) but not by one-way ANOVA with Bonferroni post-hoc test. An additional 
vendor-based difference is observed in social interaction testing: while mice typically 
display a preference for social novelty, as reflected by increased interest in an unfamiliar 
mouse versus a familiar mouse, SPF-T lack this social preference, exhibiting a notable 
preference for the familiar mouse rather than unfamiliar mouse (Fig 2D). There is no 
difference, however, between performance of GF, SPF-T or SPF-CR mice in the 
sociability task, which measures a mouse’s preference to explore a social object (novel 
mouse) versus a non-social object (novel toy) (Fig 2B). Together these findings 
demonstrate that differences in microbial composition can lead to altered social, 
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stereotyped, communicative and sensorimotor behavior. These findings further suggest 
that disruptions to the normal microflora may initiate changes that manifest in alterations 
in behavioral development.  
   
The commensal microbiota modulates the development of communicative behavior in 
diverse paradigms 
 We show in figure 1 that germ free mice emit dramatically fewer adult ultrasonic 
vocalizations of significantly shorter duration compared to both Taconic and Charles 
River SPF controls. To further evaluate communication-related behavior in germ-free 
mice we tested adult mice in the scent-marking paradigm. These tests measure the 
propensity for mice to engage in the placement of chemical signals used as a means to 
communicate with other mice. There was no difference in the level of scent marks 
produced by male GF versus SPF mice after one hour of habituation to a novel cage (Fig 
3). This indicates no difference in scent marking response to novelty in the absence of 
stimulation. Interestingly however, GF males produce significantly fewer scent marks in 
response to both female urine and male urine (Fig 4), indicating a primary deficit in 
another mode of adult communicative behavior.  
 To gain insight into whether the communication abnormalities in GF mice 
compared to SPF controls are established early on during development, we assessed the 
level of USV production in pups from postnatal day 6 through 14 in response to brief 
maternal isolation. Remarkably, GF pups emit significantly more USVs after isolation 
from the mother compared to SPF controls (Fig 5). This increase in number of USVs 
produced corresponds to a great total duration of calls, but there is no difference in 
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average duration per single call, suggesting no overt differences in quality of USVs 
produced between GF and SPF mice. Overall, we find that GF mice exhibit a core 
abnormality in communicative behavior across several experimental paradigms, and that 
these impairments may be established by early postnatal development.  
 
Effects of conventionalization on behavior of GF mice 
 To determine whether these behavioral abnormalities are reversible during 
adulthood, we conventionalized GF mice with either Taconic or Charles River microbiota 
and assessed behavioral performance. Mice were confirmed to be conventionalized by 
plating and qPCR (data not shown). However, there was no restoration in PPI or open 
field behavior (Fig 6). Interestingly, there was trending amelioration of adult USV 
behavior in response to adult conventionalization, but more studies are needed to confirm 
this phenotype. The inability to restore behavior is similarly seen with adult 
conventionalization with B. fragilis, indicating that effects B. fragilis alone on immunity 
or metabolism are not sufficient to alter behavior (Fig 7). Futhermore, B. fragilis 
monocolonized mice, born from B. fragilis monocolonized dams, also retain deficits in 
PPI and open field behavior (Fig 8). Interestingly, there is again a trending improvement 
in adult communicative behavior as measured by abundance and duration of vocalization. 
This phenotype, like that seen in adult conventionalized mice, requires further 
investigation.  
 To determine whether there is a developmental component to microbiota-
mediated restoration of behavioral abnormalities in GF mice, we mated adult 
conventionalized males and females, to evaluate behavioral performance of ex-GF 
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offspring, which are born conventionalized from parent males and females that were 
conventionalized during adulthood. Ex-GF mice exhibit a statistically significant 
improvement in pup USV, but the effect is mild in that levels of pup USV in ex-GF still 
significantly differ form those observed in conventional SPF mice (Fig 9). As adults, ex-
GF mice again retain deficits in PPI and open field behavior compared to SPF controls. 
These abnormalities are equivalent to those observed in adult conventionalized and GF 
mice (Fig 10). The adult ex-GF mice further retain deficits in scent marking behavior, at 
levels similar to those seen in GF mice (Fig 11).  It will be interesting to assess whether 
adult USVs are impaired in these ex-GF mice. These measurements are in progress. 
Overall, these experiments suggest that adult USVs may be ameliorated by 
conventionalization and potentially reversible by microbiota manipulation during 
adulthood. However, that PPI and open field behaviors are not restored by 
conventionalization suggests that there may be underlying genetic alterations between GF 
and SPF mice of the same background strain but from different vendors. Both of these 
notions will be explored further in future studies.  
 
 Methods 
Generation of animals.  
Specific pathogen-free (SPF) C57BL/6 mice were purchased from Charles River 
Laboratories (Wilmington, MA) or Taconic Farms and housed under standard laboratory 
conditions in Caltech’s animal facility. Germ-free (GF) mice were obtained originally 
from University of North Carolina and housed in sterile isolators in Caltech’s animal 
facility.   
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Behavioral testing.  
At 6 weeks of age, offspring were behaviorally tested for PPI; at 7 weeks, for open field 
exploration, at 8 weeks, for self-grooming and marble burying, at 9 weeks for social 
interaction and at 10 weeks for scent marking and/or adult ultrasonic vocalizations, 
according to methods described by Hsiao et al., 2011 and Malkova et al., 2012. 
Additional details are provided in the supplementary methods. All equipment was 
sterilized with Process NPD and 70% ethanol before and after testing. GF mice were 
removed from the isolators at least two days prior to PPI testing and allowed to habituate 
to standard housing rooms. Immediately after PPI testing, GF mice were kept on water 
containing erythromycin and gentamycin to maintain GF status.  
 
Conventionalization.  
Fecal pellets were collected from SPF-Taconic or Charles River animals and 
homogenized in sodium bicarbonate. 100ul of the slurry was used for oral gavage into GF 
animals. On the same day, GF mice were transferred into a novel housing cage containing 
dirty bedding from respective SPF Taconic or Charles River mice.  
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Figure 1. Germ-free mice display abnormal anxiety-like, sensorimotor and 
communicative behavior.  
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Figure 2. GF mice do not consistently exhibit altered stereotyped/repetitive or social 
interaction behavior.  
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Figure 3. There is no difference in scent marking levels in response to spatial novelty 
in GF versus SPF mice.  
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Figure 4. GF mice exhibit significant deficits in scent marking in response to female 
or male urine.  
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Figure 5. GF pups exhibit significantly elevated levels of ultrasonic vocalizations in 
response to brief maternal isolation.  
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Figure 6. Adult conventionalization has no significant effect on prepulse inhibition 
or open field behavior, but elicits trending improvement of adult USV behavior.  
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Figure 7. Adult monocolonization with B. fragilis has no significant effect on the 
behavior of GF mice.  
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Figure 8. B. fragilis monocolonized mice exhibit behavioral abnormalities similar to 
those seen in GF mice, but trending improvement in adult USV.  
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Figure 9.  Conventional offspring of adult conventionalized mice exhibit mild 
improvements in pup USV in response to brief maternal isolation.  
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Figure 10. Conventional offspring (ex-GF) of adult conventionalized mice do not 
exhibit restored prepulse inhibition or open field behavior.  
 
 
 
 
 
 645 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11. Conventional offspring (ex-GF) of adult conventionalized mice do not 
exhibit restored scent marking behavior.   
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Introduction 
Autism and schizophrenia are neurodevelopmental disorders for which the precise 
causes are unknown. Both exhibit a high degree of genetic heritability; however, 
environmental factors have been identified that contribute to the development of each 
disorder. Of these, maternal immune activation (MIA) is of particular interest given the 
several large epidemiological studies indicating that maternal bacterial or viral infection 
during the first or second trimesters of pregnancy increase the risk for autism and 
schizophrenia in the offspring. As described in Chapters 2-4, several mouse models of 
MIA have been developed that recapitulate core behavioral and neuropathological 
features of both disorders. 
Interestingly, several immune-related susceptibility genes have been identified by 
genetic association and linkage studies of autistic and schizophrenic individuals. In 
particular, human HLA variants and short nucleotide polymorphisms, leading to impaired 
function of specific isotypes of human major histocompatibility complex (MHC), have 
been replicated as susceptibility genes. MHCI is canonically expressed on cells of the 
innate immune system, used to present unique antigenic components to T cells of the 
adaptive immune system. Recent studies reveal that MHCI also plays a key role in the 
brain, being expressed by neurons and glia alike. Neurons lacking MHCI display critical 
deficits in synaptic transmission, leading to impaired long term potentiation.  
 To explore a potential gene and environmental interaction between MHC and 
MIA, we ask whether MHC-deficient mice exhibit potentiated responses to the 
environmental factor MIA. In particular, we utilize beta-2-microglobulin (b2m) knockout 
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mice which lack a key component of mouse MHCI, in combination with maternal 
poly(I:C) injection mimicking viral infection.  
 
Results 
Heterozygous b2m KO mice exhibit expected responses to maternal poly(I:C) injection 
In order to preserve as much as possible the maternal immune response to poly(I:C), we 
utilized pregnant b2m +/- mice mated to b2m +/- males. In wildtype mice, we typically 
observe that mothers injected with poly(I:C) on E12.5 display significant weight loss at 
24 hours post injection, which restores to normal levels thereafter. We see a similar effect 
in pregnant b2m +/- mice, where maternal poly(I:C) injection leads to decreased maternal 
weight at 24 hours post injection (Figure 1). This indicates that b2m +/- mice experience 
a comparable immune response to poly(I:C), with associated sickness behavior and 
weight loss.  
 
There is no effect of b2m genotype on MIA-induced deficits in pre-pulse inhibition. Adult 
MIA offspring of +/+, +/- and -/- b2m genotype were behaviorally tested starting at 6 
weeks of age. In prepulse inhibition, there is no effect of b2m genotype on behavioral 
performance. However, the expected treatment effect of MIA on inducing deficits in PPI 
are observed regardless of genotypes (Figure 2).  
 
No MIA treatment or b2m genotype effects are observed in open field anxiety or 
stereotyped marble burying behavior. That b2m offspring of any genotype exhibit 
expected defects in PPI behavior in response to MIA suggest that b2m +/- mothers 
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experienced expected responses to poly(I:C) induction. This is consistent with the 
expected maternal weight loss observed in b2m +/- mice after poly(I:C) injection. 
Interestingly, however, b2m +/+ offspring of poly(I:C) injected b2m +/- mothers do not 
exhibit the expected behavioral abnormalities in open field exploration or stereotyped 
marble burying behavior. That is, there is no significant difference in behavioral 
performance between b2m+/+ poly(I:C) versus saline offspring (Figure 3 and 4). One 
possibility underlying this result may be discrepancies in the degree of immune activation 
experienced by b2m +/- mice in response to poly(I:C). Future studies evaluating MIA-
induced cytokine levels in the maternal sera in b2m+/- versus WT controls will provide 
insight into any potential differences in intensity of MIA experienced by the different 
strains of mice.  
 
Discussion 
That the experimental condition representative of our positive control (b2m+/+ offspring 
of b2m +/- mothers) do not exhibit expected abnormalities in open field exploration and 
marble burying after maternal poly(I:C) injection suggests disparity between the b2m+/- 
maternal response to poly(I:C) compared to that experienced by wildtype b2m+/+ 
controls. This confounding factor precludes the ability to use this transgenic line to 
evaluate gene x environmental interactions in the development of autism and 
schizophrenia-related behavior. Future studies assessing the poly(I:C)-induced antiviral 
response in b2m +/- versus wildtype mice should be performed; specifically, levels of the 
cytokines IL-6, IL-1b and TNFa can be measured in maternal sera in poly(I:C)-injected 
b2m+/- and wildtype mice as an indication of poy(I:C)-induced immune response.  
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Figure 1. Heterozygous b2m mice exhibit expected maternal weight loss after 
poly(I:C) injection. Maternal poly(I:C) injection into wildtype mice leads to transient 
weight loss seen at 24 hours post injection, compared to saline-injected controls. 
Heterozygous b2m females mated with heterozygous b2m males display a comparable 
decrease in weight after poly(I:C) injection.  
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Figure 2: There is no effect of b2m genotype on MIA-induced deficits in PPI. B2m 
+/+, +/- and -/- offspring display no difference in percent PPI after 5 or 15 db prepulse.  
However, maternal poly(I:C) injection into pregnant b2m +/- mice induces a significant 
treatment effect of lowering PPI, consistent with that observed after MIA in WT mice.  
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Figure 3. There is no effect of MIA treatment or b2m genotype on open field 
exploration. B2m+/+ offspring of MIA versus control mothers exhibit no difference in 
open field performance as measured by center entries or center duration into the center of 
the open field. This is in contrast to the expected effect of MIA on inducing anxiety-like 
behavior in the open field.  
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Figure 4. There is no effect of MIA treatment or b2m genotype on stereotyped 
marble burying behavior. B2m+/+ offspring of MIA versus control mothers exhibit no 
difference in stereotyped marble burying. This is in contrast to the expected effect of 
MIA on inducing repetitive behavior in the marble burying task. 
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